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The presence of lymph node metastases and/or extracapsular spread (ECS) 
has a significant impact on patient survival in Head and neck squamous cell 
carcinoma (HNSCC). Little is known about the molecular mechanisms 
associated with metastasis. A marker that could predict metastasis from 
primary tumour sampling could be of great clinical benefit for patients. 
Similarly in oropharyngeal squamous cell carcinoma (OPSCC), the 
molecular changes associated with human papilloma virus are incompletely 
understood. The impact of viral load has not been well explored and could 
help identify molecular markers associated with Human papillomavirus 
(HPV)-driven OPSCC. 
METHODS 
Tissue samples were identified from Leeds Pathology Archive and nucleic 
acid extracted from these. This was processed into sequencing libraries and 
analysed for copy number alteration (CNA) and microRNA (miRNA) profiles 
in clinicopathologic groups relating to metastasis and HPV viral load. 
RESULTS 
A panel of 14 CNAs was identified as associated with nodal metastasis and  
loss of 18q21.1-q21.32 was associated with ECS. The fraction of genome 
altered (FGA) was also increased in metastatic primary tumours. A panel of 
19 CNAs was identified as associated with no detectable viral load and the 
FGA was found to be increased in this group of OPSCC. Twelve miRNAs 
were identified as associated with nodal metastasis.  
DISCUSSION 
The CNA and miRNA profile of primary tumours was found to be largely 
similar, though not identical, highlighting the need to use metastatic tissue to 
attempt discovery of metastatic molecular markers. Integrating miRNA and 
CNA data suggested miRNA expression is not governed by CNA. Potentially 
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Chapter 1  
INTRODUCTION AND AIMS OF THESIS 
1.1 Head and neck squamous cell carcinoma 
1.1.1 Epidemiology 
Head and neck squamous cell carcinoma (HNSCC) is the sixth most 
common cancer worldwide and affects over 600 000 people annually (Ferlay 
J, 2013). In 2012, in England the overall age-standardised incidence of head 
and neck cancer was 26.9 per 100 000 for men and 10.9 per 100 000 for 
women per annum (see Table 1-1) (Statistics, 2012). 
 
Sub-site Total new cases  (2009) Age-standardised rate per 
100,000 per year 
Male Female Male Female 
Oral, Lip & 
Pharynx 
4335 2274 18.9 8.8 
Nasal Cavity & 
Middle Ear 
153 125 0.7 0.5 
Paranasal 
sinuses 
94 59 0.4 0.2 
Larynx 1521 355 6.9 1.4 
Table 1-1: New cases and age-standardised incidence in 2012 in England (Office of 
National Statistics, 2012) 
 
HNSCC is often described as a heterogeneous group of cancers, in that they 
are biologically similar (approximately 95% are squamous cell carcinoma) 
but they are clinically distinct dependent on the primary tumour subsite. 
HNSCC refers to malignant squamous disease of any subsite of the upper 






due to their location and the often disfiguring and functionally destructive 
treatments, whether surgical or chemoradiotherapy (and frequently both). 
The anatomical classifications of the various subsites are demonstrated in 
Table 1-2.  
 
Subsite Anatomical areas within subsite 
Oral Cavity Lip 





Oropharynx Soft palate 
Palatine tonsils  
Tonsillar fossa and pillars 
Base  (posterior 1/3) of tongue 
Posterior wall pharynx 
Nasopharynx Superior, posterior and lateral walls 




Hypopharynx Pyriform sinus/fossa 
Postcricoid area 
Posterior pharyngeal wall 









Table 1-2: Subsites and the anatomical areas within each subsite 
 
There is a wide geographic variation in the incidence of HNSCC 
(approximately 20-fold). High incidence areas include South and Southeast 
Asia (e.g. India, Taiwan), parts of Eastern Europe, Latin America, the 
Caribbean and Pacific regions (e.g. Papua New Guinea) (Warnakulasuriya, 
2009). In high risk countries, such as India, HNSCC is the most common 
cancer in men and contributes up to 25% of all new cancers 
(Warnakulasuriya, 2009). This variation is attributed to the high incidence of 
betel nut chewing in addition to potential dietary factors and social 






Trends in survival in HNSCC have shown little improvement over the last 
three decades as demonstrated in the Oxford Cancer Intelligence Unit report 
(Price G, 2009). Improvements that have been achieved are put down to 
generally more aggressive treatments, at the cost of increased toxicity to the 
patient. Treatment failures most commonly manifest as distant metastases 
(Ferlito et al., 2001). The ability to stratify patients and their disease to 
identify those most at risk of recurrence or requiring combined modality 
therapy has been at the forefront of HNSCC research for decades with little 
progress. 
 
Figure 1-1: Bar chart to show the global variation in incidence/prevalence of 
HNSCC, produced from WHO GLOBOCAN 2012 data (reproduced with kind 







The most well known source of carcinogenic exposure in HNSCC is 
cigarette smoking and alcohol consumption. The relative risk of developing 
HNSCC is 3 to 12 times higher for smokers than non-smokers (Lewin et al., 
1998). The risk increases with the amount of tobacco smoked and the 
duration of smoking (Elwood et al., 1984). Alcohol and smoking have a 
synergistic effect in inducing malignancy, though in populations who have 
never smoked there is no conclusive evidence that alcohol is an 
independent risk factor for HNSCC (though this particular patient group is 
always small in epidemiological studies on HNSCC) (Licitra et al., 2006, 
Brennan et al., 2004, Menvielle et al., 2004a).  
In non-Western populations, local habits such as betel quid chewing are 
responsible for a great deal of HNSCC (e.g. India). The betel nut (also 
known as the areca nut) is harvested from the tropical palm, Areca catechu, 
which is widely cultivated throughout India, Sri Lanka, Thailand and the 
Philipines and consumed throughout Asia (Croucher and Islam, 2002). The 
fruit is harvested and the hard, dry buts removed. The nut is often cut into 
small pieces and chewed either alone or mixed with a variety of additives, 
which are often wrapped in the leaf of the Piper betle plant and referred to as 
betel quid. The additives vary from region to region and can include tobacco, 
slaked lime amongst other herbs, fruits and perfumes (Sharan et al., 2012). 
Betel nut chewing is a socially acceptable and widespread practice amongst 
Asian and Arabic populations (even in children) and is highly addictive 
(Yusuf and Yong, 2002). 
There is a strong, causal association between betel nut chewing (with and 
without tobacco) and HNSCC, as well as the precancerous conditions oral 
leukoplakia, erythroplakia and oral submucous fibrosis (Sharan et al., 2012, 
Yusuf and Yong, 2002). The betel nut represents a significant cash crop. It is 
commercially prepared both as a fresh or dried preparation, separately or 
within mixed preparations. The nut is exported from Asia and available for 






within immigrant communities. Other uses such as toothpaste or shampoo 
have also been developed (Croucher and Islam, 2002). 
A diet deficient in fruit and vegetables is also a recognised risk factor for 
HNSCC (Esteve et al., 1996). A reduced risk of HNSCC has been 
associated with high intake of vitamins A, C, E and a high 
polyunsaturated/saturated fatty acids ratio (Esteve et al., 1996, Brennan et 
al., 2004). 
Social inequalities have long been recognised in these cancers. Significantly 
elevated risks have been observed amongst lower socioeconomic groups, 
with some evidence suggesting socioeconomic deprivation also has a 
significant detrimental impact on survival in patients with head and neck 
cancer (Elwood et al., 1984, Hwang et al., 2013). Explanations for this have 
often cited alcohol and tobacco consumption though a proportion could also 
be attributable to occupational exposures (Menvielle et al., 2004b). 
In addition to these traditional risk factors human papilloma virus  (HPV) has 
emerged as an independent risk factor for developing HNSCC  (particularly 
HPV-16). HPV-positive HNSCC is genomically, histologically and clinically 
distinct from HPV-negative HNSCC (Hennessey et al., 2009). Authors have 
reported cancers from the oral cavity and oropharynx as collectively being 
“oral cancer”. This has led to confusion in interpreting both the incidence of 
these cancers as well as the incidence of HPV in these cancers (da Silva et 
al., 2011, Chaturvedi et al., 2008). This subtype of HNSCC is most prevalent 
in the oropharynx, where there is a preponderance of lymphoid tissue 
relative to other sub-sites. Subsites outside the oropharynx appear to have a 
low incidence of HPV-driven disease (Upile et al., 2014).  
Epstein Barr virus (EBV) is implicated in the pathogenesis of 
nasopharyngeal cancer (NPC). EBV has been detected in dysplastic lesions 
and invasive NPC. Antibodies to EBV are reported as prognostic in EBV-
associated cancer (Licitra et al., 2006, Lin et al., 2004). 
A large body of cancer research has focused on the ability to identify 






significance. The aim of this work is to stratify patients into different risk 
groups and tailor their treatment accordingly. 
1.1.3 Prognostic features of the primary tumour 
Increasing size of primary tumour is well recognised to be associated with 
poorer outcome and as such forms the basis of both the Union for 
International Cancer Control (UICC) and American Joint Committee on 
Cancer (AJCC) staging classifications for head and neck cancer according 
to the Tumour Nodes Metastases (TNM) system (Sobin LH, 2009). This 
varies according to site and subsite of primary tumour but ultimately size is 
the important factor (see Table 1-3). 
 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour 2cm or smaller in greatest dimension 
T2 Tumour larger than 2cm but 4cm or smaller in greatest dimension 
T3 Tumour larger than 4cm in greatest dimension 
T4a Tumour invades the larynx, deep/extrinsic muscles of the tongue, 
medial pterygoid, hard palate or mandible 
T4b Tumour invades lateral pterygoid muscle, pterygoid plates, lateral 
nasopharynx, or skull base or encases carotid artery 
Table 1-3: T-staging for oral squamous cell carcinoma  (OSCC) 
 
The histological differentiation of the primary tumour (well, moderate or poor) 
is a standard pathological diagnostic parameter described by Broders in 
1920 (Broders, 1920). This is based on the resemblance of the tumour to the 
tissue of origin with well-differentiated tumours resembling their tissue of 
origin more closely than poorly differentiated tumours. Well-differentiated 
tumours contain orderly stratified cells and heavy keratinisation in a pear 
formation whilst moderately differentiated tumours have prickle cells, some 






prominent nuclear pleomorphisms and atypical mitoses though they are still 
recognisable as a squamous cell carcinoma (SCC) (Mao et al., 2004).  
Though the histologic differentiation is a necessity for every histology report 
its prognostic significance has been analysed with varying results. This may 
be due to the subjective nature of the grading system. As scoring methods 
have been introduced to minimise this subjectivity and improve accuracy, 
studies have shown a trend towards worsening differentiation being 
associated with worse overall survival and higher risk of metastases (Roland 
et al., 1992, Janot et al., 1996).  
Depth of tumour invasion has been shown to be associated with a higher 
risk of locoregional recurrence and nodal metastasis (Alkureishi et al., 2008, 
Shah et al., 1976). Other negative histological prognosticators of the primary 
tumour include the presence of perineural invasion, blood vessel invasion 
and lymphatic vessel invasion (Miller et al., 2012, Yilmaz et al., 1998, 
Michikawa et al., 2012). These have all been shown to be associated with 
poorer overall survival and increased locoregional recurrence, though none 
of these is an absolute solitary indicator for adjuvant radiotherapy. 
1.1.4 Prognostic features of lymph nodes 
A lymph node is defined as an encapsulated collection of lymphoid tissue, of 
any size, which possesses a peripheral sinus (Ferlito et al., 2002). The UICC 
and AJCC have developed staging classifications for nodal disease (see 
Table 1–4) (Wittekind and Oberschmid, 2010).  
For decades the single most important negative prognostic indicator has 
been considered to be the presence of cervical lymph node metastases. 
Finding this at the time of initial presentation is traditionally described to 
reduce the 5-year survival by approximately 50% regardless of the primary 
sub-site (Hahn et al., 1987). This is of huge importance considering that 
lymph node metastasis can be demonstrated in 30–60% of patients with 






30% who present with no clinical or radiological evidence of disease (Snow 
et al., 1982, Coatesworth et al, 2002). 
 
NX Regional Lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in a single ipsilateral lymph node, 3cm or less in greatest 
dimension 
N2a Metastasis in a single ipsilateral lymph node, more than 3cm but not more 
than 6cm in greatest dimension 
N2b Metastasis in multiple ipsilateral lymph nodes, none more than 6cm in 
greatest dimension 
N2c Metastasis in bilateral or contralateral lymph node, none more than 6cm in 
greatest dimension 
N3 Metastasis in a lymph node more than 6cm in greatest dimension 
 
Table 1-4: N-staging for regional lymph nodes 
 
This high risk of occult cervical lymph node metastasis has meant that many 
patients require treatment to their cervical lymph nodes even if 
preoperatively their clinical nodal stage is N0. This most commonly takes the 
form of surgery to remove the cervical lymph nodes at risk (referred to as a 
neck dissection). This surgery is not without considerable morbidity to the 
patient including risk of facial, vagus, phrenic, hypoglossal and accessory 
nerve injury, shoulder weakness, chylous fistula, infection and haemorrhage 
(Ferlito et al., 2006a, Ferlito et al., 2006b, Ferlito et al., 2006c). 70% of those 
with a preoperatively N0 neck do not have any pathological evidence of 
metastases after surgery. Combining this with the risks of surgery means 
that a considerable number of patients are undergoing surgery without any 
tangible benefit.  
Adopting an approach of observation for those with an N0 neck has been 
investigated in the past with significantly improved survival being 
demonstrated in patients with clinically N0 neck who have undergone neck 
dissection compared to those who did not receive treatment for the cervical 
nodes (Haddadin et al., 1999, Mashberg and Meyers, 1976, Kligerman et al., 






patients deemed to have a risk of occult cervical node metastases of 20% or 
more (i.e. neck dissection or radiotherapy).  
Approximately 30% of lymph nodes containing metastatic SCC have been 
found to be 3mm or less in diameter. Given that pathologists often use 
techniques that only allow them to comment on lymph nodes 3mm or more 
in diameter there is potential for microscopic disease to be missed even in 
patients who are undergoing neck dissection (Buckley and MacLennan, 
2000, Coatesworth and MacLennan, 2002). 
Pathological features of the lymph nodes have also been examined for 
prognostic features. Numerous studies have found that increasing size of 
largest node is associated with decreased survival (Sessions, 1976, Richard 
et al., 1987, Spiro et al., 1974). Similar trends have been demonstrated with 
increasing number of positive nodes and anatomical level of nodal 
metastasis (Noone et al., 1974, Snow et al., 1982). These findings have not 
been uniform across all studies: neither Schuller et al nor Johnson et al 
found any significance in the impact of number of positive nodes or size of 
largest metastatic node (Schuller et al., 1980, Johnson et al., 1981). Survival 
in patients with HPV-positive OPSCC has been shown to be significantly 
better than those with HPV negative disease (Ang et al., 2010). Previous 
studies contained tumours of mixed subsites and do not stratify by HPV-
status, which may be responsible for the conflicting reports.  
A vital feature of cervical lymph node metastases in HNSCC and arguably 
the most important marker for aggressive disease is the presence of 
extracapsular spread (ECS) in lymph node metastasis.  
1.1.5 Extracapsular spread (ECS) 
ECS refers to the extension of cervical lymph node metastasis beyond the 
capsule of the lymph node (see Figure 1-2) (Coatesworth and MacLennan, 
2002). Willis first described this in HNSCC in 1930 (Willis, 1930). Though 
this was subsequently well recognised as a finding in cervical metastases 






that resulted in ECS, it was not until 1971 that Bennett et al first described 
an association between the presence of extranodal spread and reduction in 
patient survival (Toker, 1963, Bennett et al., 1971) 
 
 
       Lymph node with ECS  (arrows)       Lymph node without ECS 
Figure 1-2 – Haematoxylin and eosin histological slide image of extracapsular 
spread 
  
Since then a number of studies have demonstrated the strong association 
between extracapsular spread and reduced overall survival (Noone et al., 
1974, Sessions, 1976, Shah et al., 1976, Kalnins et al., 1977, Schuller et al., 
1980, Johnson et al., 1981, Snow et al., 1982). The incidence of ECS in 
cervical lymph node metastases varies considerably in the literature from 
21% to 85% (Carter et al., 1987, Jose et al., 2003, Hirabayashi et al., 1991, 
Mamelle et al., 1994). There is also evidence of interobserver variation 
between pathologists in assessing the presence of ECS. Brekel et al found 
inter-observer variability kappa of 0.44 between pathologists  (indicating 
moderate agreement) (van den Brekel et al., 2012). This is likely due to the 
lack of a universally accepted definition for ECS. In the last 15 years a 
proposed definition, which appears to be widely accepted is: tumour 
extension beyond the lymph node capsule with a desmoplastic stromal 
response (Coatesworth and MacLennan, 2002). The acknowledgement of 






positives due to mechanical handling of the lymph nodes during surgery or 
subsequent processing in the pathology department.  
The variation in incidence and assessment is thought to be strongly related, 
once again, to the lack of a universally accepted definition for ECS (van den 
Brekel et al., 2012). Similarly, though several studies have suggested the 
likelihood of ECS increases with increasing nodal stage and nodal size this 
relationship is also not universally described (Jose et al., 2003, Brannan et 
al., 2011, Hirabayashi et al., 1991, Mamelle et al., 1994). A large study 
utilising the Surveillance, Epidemiology and End Results  (SEER) database 
did not find a linear relationship between ECS and nodal size (Brannan et 
al., 2011). This may also be related to variation in definition and agreement 
but it may also be due to mixing HPV-16 positive and negative disease.  
Many studies have either included oropharyngeal cancers in their analysis or 
not clearly distinguished oral from oropharyngeal primary tumours. More 
recent studies evaluating prognostic factors in HPV-16 positive 
oropharyngeal cancer have found that ECS does not appear to have a 
negative impact on disease-specific survival or overall survival (Sinha et al., 
2012, Lewis et al., 2011, Haughey and Sinha, 2012). Larger, more recent 
studies of oral cavity primary tumours (a subsite recognised to have a very 
low incidence of HPV) show ECS to have the largest negative impact on 
patient outcome (including overall and disease-free survival and distant 
metastases) (Shaw et al., 2010, Goldstein et al., 2013). 
The impact of ECS on survival is so marked that when studies have stratified 
patients into those that are pathologically N0  (pN0), those with node 
metastases (N+) without ECS and those N+ with ECS a clear difference is 
seen. Survival in pN+ patients without ECS is worse than pN0 patients but 
significantly better than patients found to be pN+ with ECS (see Figure 1-3) 
(Jose et al., 2003, Shaw et al., 2010). ECS also closely correlates with other 
adverse histological parameters such as perineural invasion and poor 
differentiation, though not closely enough to be accurately predictive of ECS 







Figure 1-3 - Kaplan-Meier plot of survival comparing patients with HNSCC and 
differing pathological neck nodal status. (Reproduced with kind permission 
Jose et al, 2003) 
 
The histological approach may also impact on the reported incidence of 
ECS. Macroscopic ECS has been shown to be associated with significantly 
reduced survival (Johnson et al., 1981). Microscopic extracapsular spread 
(defined as that which is not visible macroscopically) was initially regarded 
as insignificant (Brasilino de Carvalho, 1998). Jose et al and Coatesworth et 
al suggested that it could be as important as macroscopic ECS reducing 5-
year survival, putting patients at a higher risk of loco-regional recurrence and 
distant metastases (Coatesworth and MacLennan, 2002, Jose et al., 2003). 
Greenberg et al and Woolgar et al demonstrated clearly that microscopic 
ECS had as significant negative impact on survival as macroscopic ECS 
(see Figure 1-4) (Woolgar et al., 2003, Greenberg et al., 2003).  
Variations in specific laboratory protocols for processing the neck dissection 
specimens may be responsible for the fact that previously microscopic ECS 
was found to be insignificant. Some advocate the palpation of the specimen 
for lymph nodes and subsequent dissection of these palpable lymph nodes 
from the specimen to be examined. In the Leeds studies, the entire 
specimen was embedded and sliced for examination (Jose et al., 2003, 






of missing smaller lymph nodes and potentially increases the sensitivity for 
microscopic extracapsular spread but is more labour intensive as it produces 
more sections for examination. Despite using the palpation and dissection 
pathologic technique, in the largest, more recent series Shaw et al also 
found no significant difference between 5-year overall survival in patients 
with macroscopic or microscopic ECS (Shaw et al., 2010). Indeed the Royal 
College of Pathologists advises there is no need to differentiate between 
microscopic and macroscopic ECS when reporting on HNSCC specimens 
(Helliwell T, 2013). 
 
 It is 
important to remember that ECS is seen in small, single lymph nodes 
(including macroscopic ECS) and therefore that this is not purely a sign of 
late disease; it is a sign of aggressive disease. This also reflects a failing of 
the UICC and AJCC cancer staging system, which does not include it at all 
in the nodal staging system. The fact that patients in whom ECS is identified 
are at higher risk of local recurrence again suggests that this is a sign of 
biologically aggressive disease.  
Figure 1-4 - Kaplan-Meier survival classified by presence and extent of 







Again it should be highlighted that the risk of occult neck node metastasis in 
patients with HNSCC is the reason that the cervical lymph nodes are 
treated. Where the primary tumour is to be treated with radiotherapy then the 
neck can also be treated with radiotherapy. Though this has the advantage 
of only subjecting the patient to a single modality of treatment it is also 
associated with considerable life-long morbidity (Bentzen et al., 2001, 
Silverman Jr, 2003). When the primary tumour is treated surgically, the 
lymph nodes are generally treated surgically (a neck dissection is 
performed). This has the added advantage of allowing pathologic 
examination of the lymph nodes enabling the identification of patients with 
ECS. The latter has been established as an absolute indication for 
postoperative adjuvant therapy (radiotherapy with or without chemotherapy) 
as these patients are at double the risk of local recurrence and have triple 
the incidence of regional relapse (Shaw et al., 2010, Bartelink et al., 1983, 
Peters et al., 1993). However, this does mean that the majority of patients 
with a preoperatively N0 neck are undergoing surgery due to the inability to 
recognise a primary tumour that will metastasise causing ECS.  
Several studies have attempted to assess the utility of imaging in detecting 
ECS. These have involved computed tomography (CT) and magnetic 
resonance imaging (MRI). Overall they suggest these imaging modalities to 
be moderately accurate in terms of sensitivity and specificity (Yousem et al., 
1992, Zoumalan et al., 2010, Souter et al., 2009, Kimura et al., 2008, Hao 
and Ng, 2000, King et al., 2004, Lodder et al., 2013). Across a number of 
studies the CT has been found to have a sensitivity ranging from 50–100% 
and specificity of 85–100% (Yousem et al., 1992, Souter et al., 2009, King et 
al., 2004, Lodder et al., 2013). MRI has been found to have a sensitivity 
ranging from 50–77% and specificity of 90–93% (King et al., 2004, Yousem 
et al., 1992, Kimura et al., 2008). This may improve as the quality of images 
produced by newer generations of scanners improves, but is not currently at 
an acceptable, consistent level for images to be used to guide treatment in 
this way. More recently 18-fluorodeoxyglucose positron emission 






HNSCC. This has been found to have a sensitivity of 80% and specificity of 
74–88% (Joo et al., 2013b, Joo et al., 2013c, Joo et al., 2013d).  
In terms of predicting occult cervical node metastases a meta-analysis by 
Liao et al comparing different imaging modalities, including CT, MRI, PET 
and ultrasound found that all had similar diagnostic accuracy (Liao et al., 
2012). All were found to have higher negative predictive probabilities 
compared to positive probabilities but again none were consistently high 
enough to warrant widespread acceptance of using this as a method to 
avoid treating the clinically N0 neck. The situation of having to upstage a 
radiologically N0 patient to pN+ with ECS transitioning them from the most 
favourable prognostic group to the least favourable is well recognised (Shaw 
et al., 2010). 
It could be advantageous to recognise or predict ECS accurately with a 
molecular marker because imaging is not sufficiently sensitive and specific. 
The poor prognosis of patients with ECS makes them ideal candidates to be 
targeted for neoadjuvant treatments or for additional biological therapies. 
Conversely being able to reliably identify those without any clinically or 
radiologically occult nodal metastases could spare those patients 
unnecessary surgery.  
1.1.6 Genomic alterations in HNSCC 
Cancer is considered to be a genetic disease with carcinogenesis being a 
multistep process that reflects genomic alterations that underlie the 
transformation of normal cells into malignant cells (Hanahan and Weinberg, 
2000). These genomic alterations are considered the key drivers behind the 
cancerous cell gaining the characteristics deemed to be hallmarks of cancer. 
These include: resisting cell death, evasion of growth suppressors, induction 
of angiogenesis, sustenance of proliferative signalling, replicative immortality 
and activation of invasion and metastasis (Hanahan and Weinberg, 2000). 
Foulds demonstrated the progressive development of cancer via a number 






Vogelstein established the morphological development of colorectal cancer 
occurring in parallel with a stepwise, progressive accumulation of genetic 
alterations (Fearon and Vogelstein, 1990). Vogelstein et al also suggested 
that carcinogenesis is a result of the accumulation of the genetic alterations 
rather than the specific order in which they occur. Califano et al produced a 
similar study in HNSCC (see Figure 1-5) (Califano et al., 1996). This work 
used microsatellite analysis to determine which chromosomal losses are 
associated with different steps of carcinogenesis. Loss of 9p21 or 3p21 was 
one of the earliest detectable events leading to dysplasia en route to 
invasive HNSCC.  
 
Figure 1-5 - Above is the genetic model for colorectal tumourigenesis and below the 
HNSCC model  (Reproduced with kind permission Fearon and Vogelstein, 
1990 and Califano et al, 1996). 
 
Subsequent technological advances in the ability to understand and 






understood with much greater resolution. The concept of sequential genomic 
alterations rather than isolated events have been substantiated by the wide 
field of work in cancer genomics (Tamborero et al., 2013). Since the first 
somatic mutation in a human cancer gene (G12V in HRAS in human bladder 
carcinoma) over 660 cancer genes have been curated and included in the 
Cancer Gene Census (Forbes et al., 2015). Though this is only a fraction of 
the 20 000 genes in the human genome, a challenge has been the 
identification of genes that drive tumourigenesis as the overall list of genes 
altered in cancer may be in the thousands (Ezkurdia et al., 2014). “Driver” 
genes endow the tumour with a growth advantage over surrounding cells 
when altered whilst the remaining alterations can be regarded as being 
within “passenger” genes (Vogelstein and Kinzler, 2015).  
Single nucleotide variants and copy number alterations of chromosomal 
regions have been identified as two of the primary alterations in human 
cancer (Schroeder et al., 2014). The genes affected by these alterations are 
termed oncogenes (genes that increase or change their function upon 
somatic variants) and tumour suppressor genes (genes whose product tend 
to lose function) dependent on their role in cancer development. Copy 
number gain or loss may heighten or reduce the function of these and this 
may highlight a way of identifying driver genes in cancer.  
1.1.7 Oncogenes and tumour suppressor genes in HNSCC 
Some of the specific genes associated with the hallmarks of cancer listed 
below have been elucidated.  
1.1.7.1 Replicative immortality 
The p53 and Rb pathways have been demonstrated to be crucial to this 
characteristic of HNSCC. TP53 is an established tumour suppressor gene in 
HNSCC, with mutations being identified in over 85% of HPV-negative 
HNSCC and inactivation of TP53 being found in HPV-positive tumours, via 
HPV-16 E6 oncoprotein (Poeta et al., 2007, Stransky et al., 2011, Agrawal et 






it is one of the few driver genes identified as altered in a high proportion of 
HNSCC. In health p53 is produced in response to cellular insult or 
deoxyribonucleic acid (DNA) damage and induces cell cycle arrest and/or 
apoptosis (Gleich and Salamone, 2002). Inducing overexpression of a 
dominant-negative mutant of TP53 or inducing inactivation via ectopic HPV-
16 E6 in cell lines has been shown to extend lifespan (Opitz et al., 2001, 
Rheinwald et al., 2002). p53 can be inactivated by HPV-16 E6, which binds 
p53 and targets it for degradation, upregulation of MDM2, which also target 
p53 for degradation or loss of CDKN2A, which downregulates MDM2 
(Rothenberg and Ellisen, 2012). CCND1 lies on 11q13. Its product 
phosphorylates Rb leading to cell cycle progression (Gleich and Salamone, 
2002). 11q13 is one of the most commonly amplified regions in HNSCC. 
CDKN2A encodes for p16, which slows G1/S phase progression (Nobori et 
al., 1994). It is frequently inactivated by genetic (e.g. mutation or deletion) or 
epigenetic alterations (e.g. methylation) in HNSCC. These genes act within 
the Rb pathway and these abnormalities contribute to HNSCC cell 
immortalisation (Smeets et al., 2011). 
1.1.7.2 Evasion of growth suppression and sustenance of proliferation 
EGFR is an important gene in HNSCC. It encodes the protein EGFR which 
is involved in the MAPK signalling and PI3K/PTEN/AKT signalling pathways 
as well as inducing CCND1 (Leemans et al., 2011). EGFR is amplified in up 
to 30% of HPV-negative HNSCC, whilst mutations are rare (Seiwert et al., 
2015, Sheu et al., 2009). Overexpression of EGFR has been reported in up 
to 80% of HNSCC, though reported figures vary (Zimmermann et al., 2006).  
Ectopic expression of EGFR in vitro transforms oral keratinocytes (Goessel 
et al., 2005). Once activated EGFR initiates several downstream signal 
transduction cascades modulating DNA synthesis, cell adhesion, migration 
and proliferation (Zimmermann et al., 2006). The pleiotropic nature of EGFR 
may underlie the fact is commonly expressed (Leemans et al., 2011). 
TGFβ is another signalling pathway responsible for inhibiting cell growth. 






apoptosis (White et al., 2010). These receptors have been reported to be 
downregulated in HNSCC (White et al., 2010). 
1.1.7.3 Resisting cell death 
Apoptosis is an essential natural barrier for cells to overcome in order to gain 
a malignant phenotype (Hanahan and Weinberg, 2011). The 
PI3K/PTEN/AKT signalling pathway has been suggested to be critical to 
carcinogenesis. PIK3CA and PTEN are components of this pathway that 
function as oncogenes (Qiu et al., 2006). Mutations or deletions of these 
genes increase the activity of this pathway, allowing cells to resist apoptosis. 
EGFR is also an upstream mediator of this pathway.  In HNSCC mutations 
of PIK3CA have been identified in up to 20% of cases, with this incidence 
rising to 33% of HPV-positive tumours (Lui et al., 2013). Multiple mutations 
of genes within the PI3K pathway have been associated with advanced 
stage HNSCC, whilst in a subset of HPV-positive tumour mutations of 
PIK3CA have been found to be the only mutated cancer gene (Lui et al., 
2013). 
Loss of TP53 function effectively removes a critical DNA damage detector 
and allows cells to evade apoptosis (Hanahan and Weinberg, 2011). BCL2 
also regulates apoptosis. Gain of function results in antiapoptotic cellular 
activity (Danial and Korsmeyer, 2004). Overexpression of BCL2 has been 
reported in HNSCC and associated with chemotherapy resistance (Trask et 
al., 2002, Sharma et al., 2005).  
1.1.7.4 Activation of invasion and metastasis 
Concrete evidence for specific genes in metastasis in HNSCC is wanting, 
though many have been purported to be associated with metastasis. 
Roepman et al described a 102-gene panel associated with lymph node 
metastasis derived using microarray gene expression profiling (Roepman et 
al., 2005). This high number of genes may reflect both the high level of inter-
tumour heterogeneity and the complexity of epithelial-mesenchymal 
transition (EMT), which is thought to underpin the metastatic phenotype. 






expression profiling. One subtype was classified as mesenchymal in light of 
an association with elevated expression of genes associated with EMT 
including TWIST1 and BMI1 (Walter et al., 2013). TWIST1 is activated via 
the PI3K/AKT, RAS and WNT signalling pathways. It has been shown to 
induce EMT in HNSCC cell lines and associated with poor outcome and 
chemotherapy resistance (Way et al., 2014, Wu and Yang, 2011, Wu, 2011). 
BMI1 has been shown to act co-operatively with TWIST1 to repress levels of 
E-cadherin and p16INK4a, both of which have tumour suppressor function 
(Way et al., 2014). 
1.1.7.5 Angiogenesis 
Neo-angiogenesis is essential to the growth of solid tumours and must be 
sustained in order to continue growth (Hanahan and Weinberg, 2011). 
Vascular endothelial growth factor (VEGF) is a member of the platelet-
derived growth factor super family and a potent stimulator of new blood 
vessel growth (Vassilakopoulou et al., 2015). This has been found to be 
overexpressed in HNSCC and associated with aggressive disease and 
decreased survival (Kyzas et al., 2005a, Kyzas et al., 2005b). Angiogenesis 
is induced by different mechanisms, highlighted by a study where anti-VEGF 
treatment had little effect on tumour growth in those with low levels of VEGF 
expression (Hasina et al., 2008). Other cytokines including IL-8 and HGF 
have also been implicated in angiogenesis in HNSCC (Hasina et al., 2008). 
1.1.8 The host response in cancer 
The concept of host immune surveillance protection against cancer was first 
postulated by Ehrlich (1909) and further adapted in the 1960s (P., 1909, 
Bhardwaj, 2007, Burnet, 1964). More recently, evidence that 
immunodeficient mice were at increased risk of spontaneous tumour 
development gave further credence to this theory (Shankaran et al., 2001). 







(i) Elimination – during this phase tumour cells are destroyed by 
elements of the innate and adaptive immune system. Tumour cells 
express antigens that can be recognised by host T cells, which 
can lyse tumour cells (Gajewski et al., 2012, Badoual et al., 2010). 
CD8+ cytotoxic T lymphocytes are capable of directly killing 
tumour cells. CD4+ T helper type 1 lymphocytes are essential to 
activating C8+ lymphocytes and type 2 lymphocytes stimulate 
humoral immunity and eosinophils (Gooden et al., 2011).  
(ii)  Equilibrium – in this period the tumour cells persist but do not 
expand due to “equilibration” by the immune system. A population 
of immune-resistant cells appears whilst a consistent, effective 
immunological response is ongoing against non-resistant tumour 
(Gooden et al., 2011). This phase can last for years (Kim et al., 
2007). 
(iii) Escape – the tumour cells actively disable immune recognition 
and evade immune destruction by co-opting immune cells for 
growth, angiogenesis and invasion (Bhardwaj, 2007). These 
escape mechanisms include loss of antigen-presenting machinery, 
tolerisation of immune cells, induction and recruitment of 
regulatory immunosuppressive cells (e.g. CD4+ T regulatory 
lymphocytes actually suppress effector T lymphocytes and are 
trafficked to tumours by chemokines released by tumour cells) and 
activation of proinflammatory cytokines that stimulate 
angiogenesis (Badoual et al., 2010, Gooden et al., 2011). This 
phase enables processes not just key to cancer development but 
also to metastasis. 
Evasion of immune destruction is regarded as a emerging hallmark of 
cancer (Hanahan and Weinberg, 2011). Immunosuppressed patients are 
more likely to develop HNSCC, than immunocompetent patients, as well as 
more likely to respond poorly to treatment (Engels et al., 2011). In 
established HNSCC, an endogenous immune response is prognostic. In 






as CD4+ and CD8+ lymphocytes have been found to be prognostic (Ward et 
al., 2014). The immune response, reflected by the presence of tumour 
infiltrating lymphocytes has a important role in the improved survival seen in 
most HPV-positive tumours. Correlation has also been found between the 
presence of tumour infiltrating immune cells and circulating immune cells, 
suggesting promise for a peripheral biomarker to be developed in the future 
(Green et al., 2013). 
1.1.9 Copy number markers for metastasis and ECS in HNSCC 
CNAs are a form of structural variation of the genome. The “normal” human 
genome is considered to have a copy number of two (in that it is diploid). 
CNA has been defined as a segment of DNA 1 kb or larger that is present at 
a variable copy number compared to the reference genome (though smaller 
CNAs have been reported) (Feuk et al., 2006). This can result from 
duplication or insertion (gain) or a deletion (loss). These regions of gain and 
loss can represent insertions, deletions and duplications.  
Early studies utilised cytogenetic techniques that are often limited to 
evaluating changes in targeted areas of a chromosome and the breadth of 
the whole genome is not considered. Loss of heterozygosity (LOH) only 
enabled assessment of changes in the ratio of length of DNA between 
normal and cancerous tissue. This was therefore dependent on a candidate 
driven approach. Though inferences can be made LOH cannot directly 
discover gain or loss of DNA (copy number alteration, CNA) (Patmore et al., 
2005).  Newer technologies such as comparative genomic hybridisation 
allow discovery of CNA. 
Traditionally fluorescence in situ hybridisation (FISH) was used to 
demonstrate CNAs (Stankiewicz and Beaudet, 2007). However FISH has a 
relatively low resolution (approximately 5-10 Mbp) (Duan et al., 2013). 
Quantitative real time polymerase chain reaction (qRT-PCR) can be used to 
evaluate genomic regions, however this requires sequence-specific primers 
to be designed. Not all regions of DNA will lend themselves to optimal primer 






Microarrays can provide higher resolution (array comparative genomic 
hybridisation (aCGH) or single nucleotide polymorphism (SNP) arrays). The 
resolution of microarrays are dependent on the number of probes embedded 
in the array and therefore directly related to cost (Duan et al., 2013). 
Advantages of these methods include the fact that high resolution can be 
obtained and that its limitations are well established. These include bias due 
to the poor sensitivity for detecting copy number gains compared to losses, 
the inability to detect copy neutral alterations  (balanced translocations or 
inversions) and the fact that only CNAs targeted by the array probes can be 
interrogated (Stankiewicz and Beaudet, 2007). 
The CNA profile of HNSCC is complex. Older studies, using low resolution 
CGH, identified an average number of alterations per HNSCC sample of 16 
compared to 11 in lung carcinoma and 8 for colorectal carcinoma (Gebhart 
and Liehr, 2000). The chromosomal aberrations associated with metastasis 
in HNSCC are not well characterised. Though several studies have been 
conducted into this area variations in findings are common. This is likely due 
to differing methodologies, heterogeneity of primary tumour subsite and 
often small numbers of samples affecting individual studies over the years. A 
summary of the findings of studies into CNA associated with an increased 
risk of metastasis is shown in Table 1-5. All of these studies have used 
technology that is limited to discovering alteration on targeted areas. The 
concept of using an untargeted, less-biased technology could reveal a more 
consistent or novel pattern for metastasis and ECS. 
The literature on molecular markers for extracapsular spread in HNSCC is 
relatively sparse. Using FISH, epidermal growth factor receptor (EGFR) 
gene copy number aberrations (both gain and loss) were found to be 
associated with ECS in OSCC (Michikawa et al., 2011). Another study found 
EGFR overexpression in 81% of primary tumours associated with ECS, 
though this study took place in a betel quid prevalent area (Chen et al., 
2003a). Correlations to ECS have been found with overexpression of 
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(Fendri et al., 
2009) 
NPSCC 88/FF qRT-PCR  3q26.3 








(Myo et al., 
2005) 
OSCC 45/FFPE FISH  11q13 
(Miyaguchi et 
al., 2012) 
OSCC 60/FF SNP array 8p21.2  
(Bhattacharya 
et al., 2011) 






OSCC 54/FF aCGH 
qRT-PCR 
 11q13 
(Chiang et al., 
2008) 
OSCC 42/FFPE qRT-PCR  7p11.2 





33/FF qRT-PCR  3q26.3 
 
(Xia et al., 
2007) 
OSCC 33/FFPE qRT-PCR  11q13.3 
 
(Freier et al., 
2007)  
OSCC 296/FFPE FISH  17q25.3 
(Noutomi et 
al., 2006) 
OSCC 35/FF aCGH 4p  
(Lin et al., 
2005) 
OSCC 66/unclear qRT-PCR  3q26.32, 
3q26.33 
(Bockmuhl et 



















et al., 2000) 










8/FF SB  8q24.21 
Table 1-5: DNA copy number gain and loss associated with increased risk of 







CNA has been used to delineate prognostic subgroups in breast cancer as 
well as lung cancer (Curtis et al., 2012, Kim et al., 2013). These demonstrate 
that though CNA has been investigated for many years it still presents an 
exciting avenue of biomarker discovery. This is also in part due to newer 
technologies, which have ben little explored in this area, such as next 
generation sequencing (NGS).  
1.1.10 Next generation sequencing 
The advent of NGS technology represented an epochal moment in cancer 
genomics. The first major studies in the use of NGS in HNSCC were 
published in 2011 (Agrawal et al., 2011, Stransky et al., 2011). Together 
these performed whole exome sequencing on 106 patients with oral, 
oropharyngeal, laryngeal, hypopharyngeal and sinonasal tumours (both 
HPV-positive and negative). These studies confirmed the findings of 
previous genomic work that TP53 was the most commonly mutated gene in 
HNSCC (found in 60% of patients) and also discovered the second most 
commonly mutated gene was NOTCH1 (in around 15% of patients) 
(Stransky et al., 2011, Agrawal et al., 2011). This was the first time NOTCH1 
had been implicated in HNSCC. 
Interestingly these studies also found that HPV-positive tumours had 
approximately half the mutation rate of HPV-negative tumours (Agrawal et 
al., 2011, Stransky et al., 2011). On analysing subgroups they also found 
smokers had a higher rate of guanosine to thymidine point mutations, in 
addition to having a higher rate of mutations. On average they found 130 
mutated genes per sample. This compares favourably to the TCGA report on 
178 lung SCC samples where they found an average of 360 exonic 
mutations (Cancer Genome Atlas Research, 2012). The surprisingly low 
proportion of recurring mutations could be related to the mix of subsites 
reducing the number in each group, but gives a picture that each head and 
neck tumour is genomically quite different to the next. 
In a follow up publication by Lui et al in 2013 a further 45 tumours had 






set (Lui et al., 2013). Again a large number of mutated genes were identified 
per sample and a high degree of inter-tumour mutational heterogeneity 
observed. Developing their analysis, they focused on specific functional 
pathways that had previously been identified as targetable in cancer. PI3K 
pathway mutations were identified in 31% of their cohort. This signalling axis 
has been shown to have a role in cancer cell growth, survival, motility and 
metabolism (Samuels et al., 2004, Engelman et al., 2006, Courtney et al., 
2010). Lui et al found that PI3K-pathway mutated HNSCC contained a 
higher rate of mutations in known cancer genes and that those with 
concurrent mutations in PI3K pathway genes were all advanced tumours 
implicating his pathway in HNSCC progression (Lui et al., 2013). This study 
highlighted the potential for NGS to identify possible therapeutic targets and 
biomarkers in HNSCC. 
Pickering et al combined exome sequencing with SNP array copy number, 
gene expression, miRNA expression and methylation data in 40 OSCC 
patients (Pickering et al., 2014). Using this integrated approach, they 
identified four major driver pathways in OSCC including mitogenic signalling, 
Notch, cell cycle and p53.  
The Cancer Genome Atlas (TCGA) has reported preliminary findings from 
comprehensive genomic sequencing of 279 HNSCC patients. This included 
whole exome sequencing, whole genome sequencing and whole 
transcriptome sequencing as well as miRNA, DNA methylation and copy 
number profiling (Cancer Genome Atlas, 2015). The vast majority were 
HPV-negative tumours (243/279) and majority of subsites oral cavity and 
larynx (244/279). They found HPV-positive and negative tumours had 
different mutation profiles, with HPV-positive tumours exhibiting infrequent 
mutations in TP53, CDKN2A, FAT1 and AJUBA. TP53 mutations were 
present in 86% of HPV-negative tumours but only 1 of 36 HPV-positive 
tumours. PIK3CA was mutated in both tumour types but a specific mutation 
of the helical domain of PIK3CA was predominant in HPV-positive tumours – 
an important finding when considering targetable events. EGFR was found 






tumours (Cancer Genome Atlas, 2015). This could have serious implications 
regarding the use of EGFR-inhibitors in these patients.  
As the numbers of HNSCC tumours sequenced increases, therapeutic 
subgroups may be discovered. As the cost of sequencing and bioinformatics 
drops the concept of truly “personalised medicine” will become widely 
accessible. NGS is driving a shift away from purely pathological 
classification of tumours towards integrating clinically relevant genomic 
subgroups. Gross et al utilised TCGA data to identify loss of 3p as a marker 
for decreased survival. This effect was enhanced by concurrent presence of 
TP53 mutation and miR-548k expression (Gross et al., 2014). This 
demonstrates the importance of CNA, even in the setting of much more 
detailed mutational data. 
Another recent study performed whole exome sequencing on 16 younger 
non-smokers with oral tongue cancer (< 45 years old) and 28 older smokers 
(Pickering et al., 2014). The two groups were genomically similar, but on 
interrogating TCGA data for lung adenocarcinoma, bladder urothelial 
carcinoma and HNSCC, a smoking mutation signature was generated. Both 
young and older oral tongue cancers were found to be most similar to a non-
smoking mutation profile. Though a small number of patients it demonstrates 
the accumulative power of NGS. 
NGS also has applications for the determination of HPV-status by detecting 
copies of HPV DNA/RNA within the sample being sequenced. It also has the 
advantage that all sub-types of HPV can be screened for simultaneously 
(Conway et al., 2012). This can be achieved with low-coverage and relatively 
low-cost NGS technology and can be performed as an additional analysis of 
the same sequencing data being obtained for other purposes at no extra 
cost. Issues with the use of this technology relate to the fact that detection of 
a single copy of HPV DNA within the sample does not mean the tumour was 
driven by HPV and there is no accepted standard for the number of 
detectable copies that should be regarded as a positive result. Conway et al 






immunohistochemistry with excellent sensitivity and specificity (Conway et 
al., 2012). It has also been used to screen a large number of oral verrucous 
carcinoma samples establishing the scarcity of HPV in this type of oral 
cancer (Samman et al., 2015). 
Parfenov et al used NGS to investigate the tumour-host interaction in HPV16 
positive HNSCC (Parfenov et al., 2014). They examined whole genome 
sequencing and DNA methylation profiles in 35 HPV positive tumours and 
compared these to 270 HPV negative samples from the TCGA cohort. By 
doing this they were able to identify cancer genes at the sites of HPV DNA 
integration that were potentially disrupted and involved in the carcinogenic 
mechanism in virally driven HNSCC. 
Intra-tumour heterogeneity has gained increasing prominence recently with 
landmark studies in renal cell carcinoma using NGS to demonstrate 
significant mutational difference in different samples from the same tumour 
(Gerlinger et al., 2012, Gerlinger et al., 2014). Three samples from a single 
oropharyngeal tumour and two samples from its corresponding cervical 
metastasis underwent whole genome sequencing in a study by Zhang et al 
(Zhang et al., 2013). This found only 41% of all somatic point mutations were 
shared across all five samples. Wood et al used exome and copy number 
sequencing to demonstrate complex clonality within five patients with 
HNSCC. The clinical picture of these patients varied widely from a patient 
with multiple tumours over many years to a patient with a single tumour and 
lymph node metastasis. The recurrent or metastatic clone was identified and 
traced using their techniques (Wood et al., 2015). This has significant 
implications for the use of targeted therapies. 
The concept of integrative genomics (combining different methods of 
genomic analysis) is relatively novel. Large scale efforts using only a single 
genomic method such as exome sequencing analyses have not revealed a 
universal molecular marker.  This likely reflects the complex RNA-genome 






that could be valuable in the discovery of biomarkers are microRNAs 
(miRNAs). 
1.1.11 MicroRNAs in HNSCC 
miRNAs are a class of noncoding RNAs. They are approximately 18-25 
nucleotides in length, and modulate gene expression by interacting with 
messenger RNA (mRNAs) post-transription (Almeida et al., 2011). 
miRNAs can bind to the 3’untranslated region (UTR), coding sequences or 
5’UTR of the target mRNA and can inhibit translation or target mRNA for 
degradation (Filipowicz et al., 2008).  Since being discovered in 1993 in 
Caenorhabditis elegans, miRNAs have been found to regulate approximately 
30% of mRNA transcripts in humans influencing functions such as 
apoptosis, proliferation and metabolism (Bartel, 2009, Ambros, 2008). 
miRNAs were first documented to be conserved in the human genome in 
2000 (Pasquinelli et al., 2000) and since then there has been an exponential 
increase in the rate of discovery of miRNAs, though this may now be 
slowing. 
1.1.11.1 miRNA Biogenesis 
miRNAs are encoded in the genome as longer primary transcripts called 
primary-miRNAs (pri-miRNAs). These are embedded either as separate 
transcriptional units or within the introns of protein coding genes. These are 
processed by the RNase III endonuclease Drosha together with DGCR8  
(microprocessor complex) in to a structure 60-110nt long called precursor-
miRNA (pre-miRNA). These are imperfect stem loop (or ‘hairpin’) structures 
that are exported to the cytoplasm by an Exportin-5-dependent mechanism, 
where the RNase III enzyme DICER-1 cleaves it. This produces a short 
double-stranded miRNA duplex. A helicase then unwinds this duplex to form 
the mature miRNA, which is then loaded into the multi-protein structure 
referred to as RNA-induced silencing complex  (RISC). Binding of the RISC 
to the target mRNA (usually to partly complementary sequences with the 
3’UTR) silences its expression (Bartel, 2009, Siomi and Siomi, 2010, 






In the normal state miRNAs play a role in biofeedback. They have been 
shown to figure in differentiation pathways such as skin and smooth muscle 
(Yi et al., 2009, Yi et al., 2008, Cordes et al., 2009). As a single miRNA can 
target several hundred mRNAs deregulation of miRNA expression could 
affect many different signalling pathways and drive cells towards cancerous 
transformation (Jansson and Lund, 2012). These targets may reside within 
the same functional pathway or not.  
Dysregulation of miRNAs has been widely reported in a plethora of 
diseases. The exact function of many miRNAs is unclear. Model system 
studies tend to focus on individual targets and often multiple miRNAs are 
found have altered expression in different disease states. For instance, 
miRNA-29 (miR-29) is downregulated in lung cancer whilst it is upregulated 
in breast cancer (Fabbri et al., 2007, Gebeshuber et al., 2009). 
1.1.11.2 miRNAs implicated in HNSCC 
Though there has been an exponential increase in the number of miRNAs 
that have been discovered in the last decade, accurate reports of their 
function are emerging more slowly (Castoldi et al., 2006). The same miRNA 
has been found to be up or downregulated in the same cancer in different 
studies (see Table 1-6). There may be methodological and statistical 
variations causing this discrepancy and only by performing functional 
experiments alongside highly robust profiling studies can we be certain of 
the true significance of each specific miRNA.  
1.1.11.3 Oncogenic miRNAs 
miR-21 was the first miRNA to be termed an “oncomiR” due to the fact it is 
found to be overexpressed in many different cancers including lung, breast, 
pancreatic, brain, lymphoma and colon (Medina et al., 2010, Meng et al., 
2008, Papagiannakopoulos et al., 2008, Guo et al., 2008, Frankel et al., 
2008, Dillhoff et al., 2008). It has also been identified in many studies related 
to HNSCC and seems to be the most consistent miRNA (in that it is most 
commonly identified and always upregulated) (Yu et al., 2010, Reis et al., 






al., 2010, Hui et al., 2010, Childs et al., 2009, Chang et al., 2008, Avissar et 
al., 2009a, Cervigne et al., 2009, Rentoft et al., 2011, Gombos et al., 2013). 
miR-21 upregulation has been significantly associated with poor prognosis in 
HNSCC patients (Li et al., 2009, Avissar et al., 2009b). A large number of 
significant, oncogenic and tumour suppressor targets have been identified 
for miR-21 in head and neck and other cancers including RAS, PDCD4, 
PTEN, RECK and HNRPK (Reis et al., 2010, Chen et al., 2003b, Jung et al., 
2012, Darido et al., 2011, Zhang et al., 2010, Papagiannakopoulos et al., 
2008). Other studies have suggested downregulating miR-21, using short-
interfering-RNAs (siRNAs), in OSCC cell lines sensitises them to cisplatin 
(Wang et al., 2012, Bourguignon et al., 2012, Yu et al., 2010).  
miR-155 has been recognised as overexpressed in several cancers 
including HNSCC (Wong et al., 2008b, Kikkawa et al., 2010, Hui et al., 2010, 
Chang et al., 2008, Cao et al., 2013, Saito et al., 2011, Wang et al., 2010, 
Gombos et al., 2013). It is involved in haematopoiesis, inflammation and 
immunity.  
Studies on OSCC cell lines have suggested miR-155 promotes proliferation 
and invasion by down-regulating the CDC73 gene as well as suppressing 
the cytokine signalling 1 (SOCS1)-STAT3 pathway (Rather et al., 2013, 
Zhao et al., 2013). Other important targets of miR-155 include TP53INP1, 
HIF and MAP3K7IP1 (Faraoni et al., 2009). 
miR-106b-25 refers to a cluster of miRNAs that includes miR-106b, -93 and -
25, which have been found to be overexpressed in HNSCC (Cao et al., 
2013, Hui et al., 2010, Ramdas et al., 2009). Knockdown of this cluster has 
been demonstrated to reduce cell proliferation (Hui et al., 2010). This effect 
is mediated via targeting the p21/CDKN1A pathway (Ivanovska et al., 2008). 
miR-130b has been consistently found to be upregulated in HNSCC (Liu et 
al., 2010, Kikkawa et al., 2010, Avissar et al., 2009a, Cao et al., 2013). Its 
role in HNSCC is yet to be elucidated but it is related to EMT in endometrial 
carcinoma (Li et al., 2013). It has also been identified as regulating the 
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Table 1-6: miRNA profiled when comparing tumour tissue to normal. Reproduced 
with kind permission, Sethi et al, 2014. 
 
miR-223 has been found to be overexpressed in profiling studies of HNSCC 
(Hui et al., 2010, Lajer et al., 2011). It is recognised as oncogenic in gastric 
cancer whilst in breast cancer it has been associated with increased cell 
death and decreased migration (Pinatel et al., 2014, Chen et al., 2012). 
1.1.11.4 Tumour suppressor miRNAs 
Though miR-31 has been described as upregulated in HNSCC it appears 
that this relationship is cancer-type specific (Li et al., 2009, Liu et al., 2010, 
Cao et al., 2013, Scapoli et al., 2010). It has also been observed to be 
upregulated in hepatocellular carcinoma and colorectal cancer but 
downregulated in breast, prostate and ovarian cancer (Bandres et al., 2006, 
Motoyama et al., 2009, Wong et al., 2008a, Yan et al., 2008, Schaefer et al., 
2010, Creighton et al., 2010). In pancreatic cancer under and over-
expression of miR-31 lead to inhibited migration and invasion in different cell 
lines, dependent on their endogenous levels of miR-31 (Laurila et al., 2012). 
As mentioned earlier miR-31 activates the HIF pathway suggesting an 
important role in the development of HNSCC, however upregulation of miR-
31 in breast cancer models causes regression of metastases (Valastyan et 
al., 2011). This is a prime example of the complicated nature and function of 
miRNAs. 
The miR-99 family consists of miR-99a, -99b and -100. Dysregulation of this 
family has been reported in prostate and cervical cancer as well as HNSCC 
(Tsukamoto et al., 2010, Sun et al., 2011, Chen et al., 2012, Kikkawa et al., 
2010, Hui et al., 2010, Wong et al., 2008b). miR-99a has been shown to be 
downregulated contributing to survival of OSCC cells(Yan et al., 2012). 
Forced restoration of miR-99a and -100 results in suppressed cell 
proliferation and migration in HNSCC cell lines (Chen et al., 2012). 
Functionally miR-99a directly targets mTOR, an important signalling pathway 
in cell survival and growth (Yan et al., 2012). 
Low levels of expression of miR-375 correlate to decreased survival and 
metastasis in HNSCC (Harris et al., 2012). This effect may be mediated via 
the metadherin pathway, levels of which inversely correlate to miR-375 as 
well as miR-375 mediated regulation of MYC expression (Hui et al., 2011, 
Jung et al., 2013). Loss of miR-125b has been suggested to play an 
important role in the development of HNSCC (Nakanishi et al., 2014, 
Henson et al., 2009). This downregulation has also been implicated in 
radioresistance by inducing inhibition of ICAM2. Forced expression of miR-
125b has been shown to decrease proliferation and enhance radiosensitivity 
of OSCC cells (Shiiba et al., 2013). High levels of ERBB2, the proto-
oncogene, have been linked to suppression of miR-125b (Scott et al., 2007).  
The Let-7 family (the largest) of miRNAs are reported to be downregulated in 
HNSCC (Maclellan et al., 2012, Kikkawa et al., 2010, Hui et al., 2010, Childs 
et al., 2009, Yang et al., 2013). Let -7 has been demonstrated to be a direct 
regulator of RAS expression in humans (Johnson et al., 2005). Loss of 
miRNA-mediated suppression can promote oncogenesis. Let-7a 
downregulates genes associated with stemness in tumour-initiating cells (Yu 
et al., 2011). Let-7d has been shown to negatively modulate EMT in OSCC 
cell lines (Chang et al., 2011). Low levels of Let-7d expression have also 
been associated with poorer prognosis inpatients with HNSCC (Childs et al., 
2009). 
1.1.11.5 Mixed role miRNAs 
miR-7 has been reported as up and downregulated in HNSCC (Kikkawa et 
al., 2010, Maclellan et al., 2012, Liu et al., 2009). It has been suggested to 
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play a role in the keratinisation of OSCC cell lines (Jung et al., 2012). 
However, it has been demonstrated to inhibit EGFR expression and 
downstream AKT activity in lung and breast cancer reducing cell proliferation 
and survival (Kefas et al., 2008, Webster et al., 2009). HNSCC cell lines 
have shown the same pattern of EGFR regulation and miR-7 has been 
reported to inhibit erlotinib-resistant cells, highlighting the therapeutic 
potential of miRNAs (Kalinowski et al., 2012). Tumour-suppressor genes 
IGF1R and RECK have also been shown to be regulated by miR-7 in OSCC 
(Jiang et al., 2010, Jung et al., 2012). 
miR-34b is widely reported to be upregulated in HNSCC (Wong et al., 
2008b, Ramdas et al., 2009, Liu et al., 2010, Cervigne et al., 2009). This is 
perhaps counter-intuitive as miR-34b has been shown to act as a tumour-
suppressor in a feedback loop with the proto-oncogene MET (Wang et al., 
2013). Over-expression of the MET-axis has been correlated with 
progression and metastases in HNSCC (Xu and Fisher, 2013). 
The first miRNA mimic is currently in early phase trial  (a miRNA-34 mimic) 
in liver cancer demonstrating the potential for miRNA markers to be 
translated to therapeutic targets in cancer. 
1.1.12 Summary and Impact 
We know that cancer is a disease characterised by progressive genetic and 
epigenetic alterations (Hahn and Weinberg, 2002, Jones and Baylin, 2002). 
The diversity of outcomes in HNSCC is an indicator of the intrinsic biological 
heterogeneity of the individual tumours (Chung et al., 2006). Evidence that 
genomic changes drive tumour development through various methods (e.g. 
mutations, oncogenes, LOH etc.) has accumulated (Hanahan and Weinberg, 
2000). Identifying copy number alteration has been shown to be a highly 
successful method of stratifying a patient’s risk of metastasis and overall 
survival (Desouki et al., 2011). This can be performed at high resolution, 
without being restricted to known targets, using NGS technology. miRNAs 
have been shown to be aberrantly expressed in cancer and show great 
potential for biomarkers and therapeutic targets in cancer management. By 
examining matched pairs of primary tumours and lymph node metastases 
(with and without ECS) we may be able to identify a molecular signature in 
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the primary tumour for lymph node metastasis and ECS. This means we 
would be able to distinguish between the patient with high-risk lymph node 
disease (with ECS) and the patient with low-risk lymph node disease 
(without ECS). This would enable risk stratification of the patient at initial 
biopsy without the need for cervical node surgery and allow better 
management planning and reduce morbidity for the patient. 
1.1.13 Aim 
It is known that cervical lymph nodes with ECS act as an indicator of 
tumours with a more aggressive phenotype and a poor prognosis. I 
hypothesised this phenotype is driven by underlying molecular changes and 
that these should be detectable in the primary tumour. This would provide a 
biomarker of tumour aggressiveness without the need for cervical node 
surgery. I planned to use next generation sequencing at low coverage to 
identify CNA’s as a reflection of the molecular changes in cancer and 
metastasis. I intended to analyse changes at specific chromosomal loci, 
compare the total number of breakpoints between different groups and apply 
algorithms to analyse the karyogram complexity (e.g. GISTIC) (Mermel et 
al., 2011).  I then wanted to apply the skills gained from analysing metastatic 
and non-metastatic molecular profile to evaluating CNA data for 
oropharyngeal tumours with and without any detectable HPV-viral load. I 
also set out to obtain miRNA profile data for metastatic and non-metastatic 
tumours evaluating any differential expression patterns associated with 
metastasis as well as integrating this with copy number data. 
I aimed to answer the following questions with my study: 
1. Is the molecular signature, identified in the lymph nodes containing 
metastatic SCC, a reflection of that in the matching primary tumour 
samples of individual patients? 
2. In patients with a primary head and neck tumour, do the metastatic 
cervical lymph nodes have a molecular signature that differs from 
non-metastatic primary tumours?  
3. In patients with a primary head and neck tumour, do the metastatic 
cervical lymph nodes with ECS have a molecular signature that differs 
from patients in whom metastatic nodes show no ECS? 
4. Do patients with a detectable HPV-viral load have a molecular 
signature that differs from tumours with no detectable HPV-viral load?  
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Chapter 2  
Materials and Methods 
2.1 Introduction 
Methods used throughout this project are detailed here. Room temperature 
(RT) is taken to be 21-24 ̊C. Supplier addresses and e-mail addresses are 
presented in Appendix 8.1. Figure 2-1 below displays an overview of this 
project.  
 
Figure 2-1: General overview of study design 
 
Ethical approval was obtained from Leeds (East) Research Ethics 
Committee (REC – 07/Q1206/30) for this work. 
2.2 Patients 
I designed three groups to compare tissue samples as shown in Table 2-1. 
Helene Thygesen (CRUK Biostatistician) was contacted to determine the 
minimum sample size large enough to detect statistically significant 
difference between groups for this study. Performing simulations (based 
upon digital karyograms produced by previous CNA studies on HNSCC 































approximately 20 patients per group should be sufficient to identify CNAs 
that have excess frequencies of 30% in one group relative to the other. 
Previous studies by Prof Rabbitts’ group had found a background rate of 
CNAs to be at least 5% (gain and loss) and an average of 100 segments per 
sample were obtained. Using this as the background assumed background 
CNA rate, Fisher’s Exact test was used in the simulations to compare gains 
to non-gains and losses to non-loss. These simulated p-values were then 
converted to false discovery rates (or q-values) for multiple testing. Based on 
these figures CNAs with an excess frequency of 30% were shown to be 
identifiable with a significant FDR set at < 0.10. This did not mean that CNAs 
with a lower excess frequency could not be evaluated but should be 
regarded with a higher degree of caution. 
 
Primary Site Lymph node status Tissue to be used 
Anterior 2/3 tongue pN0 Primary and 1 negative 
node 
Anterior 2/3 tongue pN1-3 no ECS Primary and 1 positive 
node 
Anterior 2/3 tongue pN1-3 with ECS Primary and node with 
ECS 
Table 2-1 - Patient groups 
 
Potential patients were identified from the hospital tissue archive using the 
CoPath database used by the pathology department in Leeds. This 
produced a list of over 3000 specimens between 2005 and 2012. The 
Patient Pathway Manager (PPM) database was then used to identify 
appropriate patients (many were not HNSCC) from this list that had been 
diagnosed with squamous cell carcinoma of the anterior two-thirds of the 
tongue who had undergone surgical resection of their primary tumour with 
an accompanying cervical lymph node dissection as primary treatment. This 
search identified potential patients as described in Table 2-1.  
These patients were all assigned a study code (e.g. ECS001, ECS002 etc.) 
and thenceforth treated anonymously. Exclusion criteria included a past 
medical history of autoimmune disease or drug history of 
immunosuppressants. These two conditions are known to be associated with 
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an increased risk of developing cancer and were excluded to attempt to 
reduce heterogeneity. 
Formalin-fixed paraffin embedded (FFPE) tissue blocks for primary tumour 
and lymph node were obtained (via Andy Clarke, Chief Biomedical Scientist 
in Bexley Wing Pathology Department) using the block numbers identified 
from the formal histopathology reports and a file of all histopathology reports 
was compiled.  
Upon receiving the tissue blocks these were then recorded and stored 
according to block number and study code in accordance with the Human 
Tissue Act 2004. 
2.3 Identification of appropriate tumour and lymph samples 
2.3.1 Haematoxylin and eosin staining 
The relevant FFPE blocks were stored at 4oC overnight prior to sectioning. 
They were then placed on ice ten minutes prior to cutting. The water bath 
was set at 45oC and hot plate set at 60oC. The manual rotatory microtome 
and forceps were cleaned with Histo-Clear and a new blade inserted.  
Sections from each block were cut at 5μm in the vertical position. Slides for 
these were labelled with the study ID, block number, section number, stain 
type and thickness. Slides were then placed on the hot plate for 2 hours and 
either stored overnight at 4oC or immediately stained for haematoxylin and 
eosin (H & E).  
Staining took place on level 4, Wellcome Trust Brenner Building. This 
involved deparaffinisation in xylene (Sigma-Aldrich, USA), serial rehydration 
in graded ethanol (Sigma-Aldrich, USA), staining and dehydration shown in 
Table 2-2. Mayer’s Haematoxylin (Sigma-Aldrich, USA) and Eosin (BDH, UK) 
were used for staining. 
At completion of the staining protocol a coverslip was mounted onto each 







Xylene 3 min x 4 
100% ethanol 3 min 
90% ethanol 3 min 
70% ethanol 3 min 
Tap water 2 min 
Mayer’s Haematoxylin 2.5 min 
Tap water 1 min 
Scott’s tap water 2 min 
Tap water 1 min 
0.5% Eosin Y 2 min 
Tap water 1 min 
100% ethanol 15 seconds 
100% ethanol 1 min 
100% ethanol 5 min x 2 
Xylene 3 min x 3 
Table 2-2: Protocol followed for H & E staining of FFPE sections. 
 
2.3.2 Slide marking 
For each slide, the target areas for dissection (e.g. primary tumour, 
metastasis) were marked out by a consultant head and neck histopathologist 
(Dr Preetha Chengot or Professor Kenneth MacLennan). The areas of 
highest tumour cell content were specifically marked with a visually 
determined minimum tumour cell content of approximately 70%. The slides 
with the highest tumour cell content were then selected and tumour-lymph 
node patient pairs were identified for micro-dissection and nucleic acid 
extraction. 
2.4 Tissue micro-dissection 
Seven 10 μm sections were cut from each selected FFPE block for tissue 
dissection. A further, single 5 μm section was cut immediately after obtaining 
the seven tissue slides for H & E staining. These were left to air-dry 
overnight. They were then prepared for dissection by placing on a hot plate 
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at 600C for 5 minutes and then dewaxing and rehydrating the slides by serial 
immersion in Coplin jars according to the following protocol: 
 
Xylene 5 min 
100% Ethanol 3 min 
90%  Ethanol 3 min 
70% Ethanol 3 min (and keep each slide 
immersed until dissection) 
Table 2-3: Dewaxing and rehydration protocol for tissue dissection for RNA. 
 
The initial marked H&E slide was used as a guide for dissection. By placing 
this underneath the rehydrated slides the targeted areas were dissected off 
precisely using either a size 11 disposable scalpel or a pair of 21 gauge 
needles. The dissected tissue was immediately placed into a fresh 1.5 ml 
micro-centrifuge tube. The slide taken following harvesting of the seven 
sections for dissection was stained with H&E and preserved for marking to 
ensure accuracy of dissection and if the tissue block was used again. DNA 
and RNA extraction protocols were then followed as below. 
2.5 DNA extraction 
According to the area being sampled for extraction one of two Qiagen DNA 
extraction kits (Qiagen, UK) were used: 
2.5.1 Tissue area sampled per slide <5 mm2 
The Qiagen QIAamp DNA micro kit reagents and columns were used for 
these samples. After transferring the dissected tissue to a 1.5 ml micro-
centrifuge tube, 30 μl Buffer ATL and 10 μl Proteinase K solution was 
immediately added to the tissue. This was then mixed by pulse-vortexing for 
15 seconds before spinning down the contents and then incubating the tube 
in a heat block at 56oC. They were incubated until the sample was 
completely lysed with daily agitation (up to a maximum of 72 hours with new 
addition of 10μl Proteinase K solution every 24 hours if visible tissue 
fragments remained in the tube). After lysis was achieved the sample was 
then incubated at 90oC for 1 hour on a heat block. Next, 10 μl Buffer ATL 
and 50 μl Buffer AL were added to the sample, which was mixed by pulse-
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vortexing for 15 seconds. Then 50 μl 100% ethanol was then added and 
mixed thoroughly with pulse vortexing for 15 seconds. This was then 
incubated at 15-25oC (room temperature) for 5 minutes. The lysate was then 
transferred and centrifuged through a QIAamp MinElute column at 6,000 x g 
(8,000 rpm) for 1 minute. The column was then placed in a fresh 2 ml 
collection tube and 500 μl Buffer AW1 added. This was centrifuged at 6,000 
x g (8,000 rpm) for 1 minute and the flow through discarded. 500 μl of AW2 
buffer was then added to the column and centrifuged at 20,000 x g (14,000 
rpm) for 3 minutes. The flow-through was discarded and the column placed 
in a fresh 1.5 ml microcentrifuge tube (labelled with the sample’s study ID, 
block ID, DNA, tissue type and date). The DNA was then eluted by adding 
30 μl Elution Buffer (EB) to the column. This was incubated for 5 minutes at 
room temperature before being centrifuged at 20,000 x g (14,000 rpm). The 
eluate was then reloaded in the same column, allowed to incubate for 5 
minutes at room temperature and centrifuged at 20,000 x g (14,000 rpm). 
This was then stored at -200C. 
2.5.2 Tissue area sampled per slide 5-10 mm2 
The Qiagen QIAamp DNA micro kit reagents and columns (Qiagen, UK) 
were used for these samples in a similar protocol to that described above. In 
these dissected tissue samples, 180 μl Buffer ATL and 20 μl Proteinase K 
solution was immediately added and mixed by pulse-vortexing for 15 
seconds. This was then incubated at 56oC until the sample was lysed (with 
addition of 20 μl Proteinase K solution every 24 hours if tissue fragments 
remained visible). After lysing was completed the sample was then 
incubated at 90oC for 1 hour. A further 200 μl Buffer AL and 200 μl 100% 
ethanol was then added and mixed thoroughly by pulse-vortexing. This was 
then incubated for 5 minutes at room temperature. The entire lysate was 
then transferred to a Qiamp MinElute Column and centrifuged in a 2ml 
collection tube at 6,000 x g (8,000 rpm) for 1 minute. The flow-through was 
discarded and the bound DNA washed with 500 μl Buffer AW1 and 500 μl 
Buffer AW2 as in section 2.5.1. The DNA was then eluted in 30 μl of EB as 
in section 2.5.1 and stored at -200C. 
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2.5.3 Tissue are sampled per slide >10 mm2 
The Qiagen QIAamp DNA mini kit reagents and columns (Qiagen, UK) were 
used for these dissected tissue samples. After dissection, 180 μl Buffer ATL 
and 20 μl proteinase K were added and mixed by pulse-vortexing for 15 
seconds. These were incubated until tissue lysis achieved as in section 
2.5.2. After completion of lysis the sample was incubated at 900C for 1 hour. 
Then 200 μl Buffer AL was added and mixed by pulse-vortexing for 15 
seconds. This was then incubated for 10 minutes at 700C. Following this, 
200 μl 100% ethanol was added and mixed by pulse-vortexing for 15 
seconds. The sample was then incubated at room temperature for 5 
minutes. The entire lysate was then transferred to the QIAamp Mini spin 
column and centrifuged at 6,000 x g (8,000 rpm). The flow-through was 
discarded and 500 μl Buffer AW1 added to the column and centrifuged at 
8,000 x g (6,000 rpm) for 1 minute. The flow through was discarded and 500 
μl Buffer AW2 added to the column and centrifuged at 20,000 x g (14,000 
rpm) for 3 minutes. The column was then transferred to a fresh 1.5 ml 
microcentrifuge tube (labelled with the sample’s study ID, block ID, DNA, 
tissue type and date) and 70 μl EB added to the column. This was incubated 
for 5 minutes at room temperature and centrifuged at 20,000 x g (14,000 
rpm) for 1 minute. The eluate was reloaded, incubated for 1 minute at room 
temperature and centrifuged at 20,000 x g for 1 minute. The DNA was then 
stored at -200C. 
2.6 Total RNA including microRNA extraction 
The Qiagen miRNA FFPE kit reagents and columns (Qiagen, UK) were used 
for these dissected tissue samples. Prior to beginning extraction all 
equipment and surfaces were cleaned with RNase AWAY (Sigma-Aldrich, 
USA).  
After transferring the dissected tissue to a fresh 1.5 ml micro-centrifuge tube, 
the sample was placed in a heat block at 550C for 3-5 minutes to dry the 
tissue. Immediately following this, 150 μl Buffer PKD were added and mixed 
by pulse-vortexing for 15 seconds. 10 μl proteinase K was then added and 
mixed by pipetting. The sample was then incubated at 560C for up to 2 hours 
(vortexing every 20 minutes and adding a further 10 μl proteinase K after 1 
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hour if visible tissue remains). The sample was then incubated at 800C for 
15 minutes, before being immediately placed on ice for 3 minutes. The 
sample was then centrifuged at 20,000 x g (14,000 rpm) for 20 minutes. The 
resulting supernatant was transferred to a fresh 2 ml micro-centrifuge tube, 
taking care not to disturb the pellet. Following this, 1/10th volume of DNA 
Booster Buffer (approximately 16 μl) and 10 μl DNase I stock solution was 
added. This was mixed by inverting the tube and then incubated at room 
temperature for 15 minutes. Then, 320 μl Buffer RBC was added and mixed 
by pulse-vortexing for 15 seconds followed by 1120 μl 100% ethanol and 
mixed by pipetting. The entire lysate was then transferred to an RNeasy 
MinElute spin column in a 2 ml collection tube and centrifuged at 8,000 x g 
for 15 seconds. The flow-through was discarded and the column placed in a 
fresh 2 ml collection tube. Then, 500 μl Buffer RPE was added to the column 
and centrifuged at 8,000 x g for 15 seconds. The flow through was discarded 
and wash repeated. The column was then placed in a fresh 2 ml collection 
tube and centrifuged with the lid open for 5 minutes at full speed. The 
column was then placed in a fresh 1.5 ml micro-centrifuge tube (labelled with 
the sample’s study ID, block ID, RNA, tissue type and date) and 23 μl 
RNase-free water added to the column. This was incubated for 1 minute on 
ice and centrifuged for 1 minute at full speed. Following elution the RNA was 
stored at -800C, if not used immediately. 
2.7 Nucleic acid quantification 
After extracting the nucleic acid this was then quantified in two ways: 
2.7.1 Fluorometry 
This used the Qubit dsDNA BR assay kit and Qubit fluorometer (Life 
Technologies, UK). Initially 1 μl of 200x Qubit dsDNA BR Reagent is diluted 
to 1x concentration using the BR Buffer provided. Both calibration of the 
fluorometer and quantification was carried out using the concentrations of 
standard DNA and sample DNA shown in Table 2-4. For RNA quantification 
the Qubit RNA BR assay kit (Life technologies, UK). The Qubit RNA BR 
Reagent 200x concentration provided was diluted to 1:200 in Qubit RNA BR 
Buffer as with the dsDNA kit. The same Qubit fluorometer was used with the 
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same concentrations of standard and sample nucleic acid as shown in Table 
2-4.  
 Standard DNA 1 and 2 
(provided with kit) 
Sample DNA 
Volume of DNA 10 μl 1 μl 
Volume of 1x BR Reagent 
(in BR Buffer) 
190 μl 199 μl 
Total Volume 200 μl 200 μl 
Table 2-4: DNA quantification using Qubit dsDNA BR assay kit. 
 
By following the on-screen instructions the Qubit fluorometer was calibrated 
each use with the nucleic acid standards provided and 1 μl of the nucleic 
acid sample was used to determine the concentration within the sample. 
This concentration was then used to calculate the input for downstream 
experiments such as sequencing library preparation. 
2.7.2 Spectrophotometry 
The Nanodrop-1000 was used to determine the concentration of DNA within 
the sample as well as to give an indication of any protein or chemical 
contamination using the ultra-violet (UV) radiation absorption. For DNA 
samples the concentrations were measured against the EB Buffer (Qiagen, 
UK) the DNA was eluted in whilst for RNA sample the concentration was 
measured against the RNase-free water provided in the Qiagen miRNA 
FFPE kit (Qiagen, UK). For each nucleic acid sample 2 μl was used. As well 
as concentration, the absorbance and the ratio of absorbance at 230 nm, 
260 nm and 280 nm (A260:A280 and A260:A230) were also recorded. 
2.8 DNA Copy number sequencing library preparation 
The NEBNext DNA Library Prep Master Mix Set for Illumina and NEBNext 
Singleplex Oligos for Illumina (New England Biolabs, UK) were used to 
prepare DNA libraries for sequencing. The protocol described was modified 





Figure 2-2 - Flow chart of steps within DNA sequencing library preparation 
2.8.1 Sample preparation 
The input amount of DNA for each sample was approximately 50 – 200 ng. 
This was obtained by diluting an aliquot from each sample with a 
concentration >200 ng/μl. The diluent was 1x TE buffer, made up from 100x 
TE Buffer (Sigma-Aldrich, USA) and nuclease-free water (Life technologies, 
UK). This input amount was required in a volume of 250 μl and was 
calculated as per Table 2-5. Each sample input volume was prepared in a 
Covaris microTUBE (Covaris Ltd, UK) ready for shearing. 























3GL 1 48.8 4 246 195   
Table 2-5: Example of calculation table for input DNA amount and volume for DNA 

























Sonic Shearing of DNA 
End repair of sheared DNA 
dA-tailing of end repaired DNA 
Adaptor ligation 
PCR enrichment of uniquely 
tagged DNA 
Quality control of DNA 
sequencing library 
Sequencing of pooled libraries 
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2.8.2 Shearing 
The Covaris S2 Focused-ultrasonicator was used to shear the DNA at 19oC 
in batches of 25 cycles for each sample using the settings shown in Table 
2-6. 
 
 Duty Cycle Intensity Cycles/burst 
1000bp 19.9% 9.9 1000 
500cpb 15% 8 500 
Table 2-6 - Covaris S2 batch settings 
 
2.8.3 Clean up protocol 
This sample was then cleaned using Qiagen MinElute columns with Qiagen 
PB (binding) buffer and Qiagen PE (wash) buffer (Qiagen, UK). Adding the 
sonicated DNA sample to 5x volume of PB binding buffer, each sample was 
added to a Min Elute column and centrifuged at 13,000 rpm for 1 minute, 
followed by adding 750 μl of PE Buffer to the column and centrifuging this at 
13,000 rpm for 1 minute. Following this the flow-through was discarded and 
the column centrifuged with lid open at 13,000 rpm for 1 minute. The DNA 
was then eluted by adding 10 μl of EB buffer and centrifuging the column at 
13,000 rpm.  
2.8.4 Agilent 2200 Tapestation confirmation 
Successful shearing was then confirmed using the Agilent 2200 Tapestation 
D1K Standard Screentape and reagents on the Agilent 2200 Tapestation 
(Agilent technologies Inc., USA). This was performed using optical tube 
strips (Agilent technologies Inc., USA). Firstly, 3 μl of D1K ladder was 
aliquoted into the first tube and mixing 3 μl of D1K Sample Buffer and with 1 
μl of each DNA sample in the remaining tubes. These were mixed by 
pipetting and loaded onto the 2200 Tapestation, which was then run using 
preloaded software. The resulting digital gel image and electropherogram for 
each sample are used to confirm successful shearing before continuing with 
the protocol. 
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2.8.5 End-repair of fragmented DNA 
The fragmented DNA then underwent end-repair to form blunt-ended, 5’-
phosphorylated DNA. A master mix was made as shown in Table 2-7. 
 
 Volume per DNA sample/ μl 
NEBNext End repair reaction buffer (x10) 5 
NEBNext End repair enzyme mix 2.5 
Nuclease-free water 33.5 
Table 2-7 - End-repair master mix 
 
41 μl of the master mix was added to the 9 μl DNA sample from the section 
2.8.4 and incubated at room temperature for 30 minutes. The sample was 
then cleaned using the Qiagen QiaQuick column with PB buffer and PE 
buffer (Qiagen, UK), using the same volumes of buffer as proscribed in 
section 2.8.3. The column was then placed in a fresh 1.5 ml micro-centrifuge 
tube and the DNA eluted by adding 21 μl EB buffer (Qiagen, UK) to the 
column and centrifuging this at 13,000 rpm for 1 minute. 
2.8.6 dA-Tailing of end-repaired DNA 
This step incorporated a tail of deoxyadenosine monophosphate to the 3’ 
ends of blunted dsDNA from the section 2.8.5. A master mix was made as 
shown in Table 2-8. 
 
 Volume per DNA sample/ μl 
NEBNext dA-Tailing Reaction Buffer 2.5 
Klenow (3’>5’ exo) 1.5 
Table 2-8 - dA-Tailing master mix 
 
4 μl of the master mix was added to the 21 μl of DNA from section 2.8.5 and 
incubated in a heat block at 37oC for 30 minutes. This was then cleaned 
using a fresh Qiagen MinElute column (Qiagen, UK) according to the 
protocol in section 2.8.3. The column was then placed in a new 1.5 ml 
 53 
microcentrifuge tube. The DNA was then eluted by adding 12.5 μl to the 
column and centrifuging this at 13,000 rpm for 1 minute.   
2.8.7 Adaptor ligation to dA-tailed DNA 
Adaptors were then ligated to the DNA sample. A master mix was made as 
shown in Table 2-9. 
12.5 μl of master mix was added to the 12.5 μl dA-tailed DNA from section 
2.8.6 and incubated at room temperature for 15 minutes. 3 μl of USER 
enzyme mix (New England Biolabs, UK) was added to the sample and 
incubated at 37oC for a further 15 minutes. This was then made up to 50 μl 
by adding 23 μl of EB Buffer (Qiagen, UK). 
 
 Volume per DNA sample/ μl 
Quick Ligation Reaction Buffer (x5) 5 
NEBNext Adaptor 2.5 
Quick T4 Ligase 2.5 
Nuclease-free water 2.5 
Table 2-9 - Adaptor ligation master mix 
This was then cleaned and smaller fragments of DNA were removed using 
Solid-Phase Reversible Immobilisation (SPRI) beads as described below. 
2.8.8 Size-selection 
 Solid-Phase Reversible Immobilisation (SPRI) beads (Beckman Coulter, 
UK) were used to perform size selection (removal of smaller, non-target 
fragments of DNA) on the DNA sample from section 2.8.7.   40 μl (0.8x 
concentration) of suspended SPRI beads were added to the DNA solution to 
bind larger fragments of DNA. This was mixed by pipetting and incubated for 
5 minutes at room temperature. Then the micro-centrifuge tube was placed 
in a magnetic tube rack (Life technologies, UK) for 5 minutes to separate the 
beads. The supernatant was transferred to a new 1.5 ml micro-centrifuge 
tube and 18 μl (0.2x concentration) SPRI beads were added to bind the DNA 
targets (approximately 200bp in length). This was mixed by pipetting and 
then placed in the magnetic rack for 5 minutes. The supernatant was 
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removed and discarded. The beads containing the bound DNA were washed 
whilst still in the magnetic rack by adding 200 μl 80% ethanol and incubating 
for 30 seconds. The ethanol was then removed and the wash repeated with 
200 μl fresh 80% ethanol. The ethanol was removed and discarded and the 
beads allowed to dry for 10 minutes at room temperature. The DNA was 
then eluted by adding 22 μl of EB buffer (Qiagen, UK) and mixing the beads 
by pipetting. The magnetic rack was used to separate the beads and the 
supernatant removed and transferred to a clean 200 μl PCR tube. At this 
point the sample was split, by storing 10 μl at -200C in a 200 μl PCR tube 
(labelled with study code, DNA, tissue type and date). The remaining 10 μl 
was used in the following PCR enrichment.  
2.8.9 PCR target enrichment 
The target adaptor-ligated DNA was then enriched using a 15-cycle PCR 
protocol. A master mix was made up as per Table 2-10. 
 Volume per DNA sample/ μl 
NEB High Fidelity 2x PCR master mix 12.5 
Universal PCR Primer (25uM) 1.25 
Table 2-10 - PCR enrichment master mix 
13.75 μl of the master mix was added to remaining 10 μl of DNA from 
section 2.8.8. 1.25 μl of a separately purchased indexed primer (from a 
panel of 96 custom-designed primers each containing a unique identifying 
6bp tag designed by Dr Henry Wood, Precancer genomics group) was then 
added (Integrated DNA Technologies, USA). The sample was then 
transferred to the thermal cycler and cycles of PCR were carried out as 
described in Table 2-11. 
Following 15 cycles the thermal cycler is set to hold the samples at 40C, until 
the samples are cleaned using SPRI beads. 
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Number of cycles Time Temperature 
1 30 seconds 980C 
15 10 seconds 980C 
30 seconds 650C 
30 seconds 720C 
5 minutes 720C 
Table 2-11: PCR enrichment cycle protocol 
 
2.8.10 Post-PCR SPRI bead clean up 
The post-PCR sample from section 2.8.9 was then cleaned by adding 2.5x 
concentration of SPRI beads (Beckman Coulter, USA) in a fresh 1.5 ml 
microcentrifuge tube to bind the enriched DNA targets. This was mixed by 
pipetting and incubated at room temperature for 5 minutes. The tube was 
then placed in the magnetic rack to separate the beads and the supernatant 
was then collected and discarded. The beads were then washed with 200 μl 
80% ethanol and incubated for 30 seconds. The beads were then separated 
using the magnetic rack and the ethanol removed and discarded. The wash 
with ethanol was then repeated. The beads were then left to air-dry from 10 
minutes. The DNA was then eluted by adding 40 μl EB buffer (Qiagen, UK) 
and mixing this by pipetting. After incubating for 2 minutes and separating 
the beads on the magnetic rack, the supernatant containing the eluted DNA 
was transferred to a fresh 1.5 ml micro-centrifuge tube (labelled with the 
sample’s study ID, block ID, DNA, tissue type and date). 
2.8.11 Library quality control 
The DNA libraries were quantified using the Qubit fluorometer (Life 
Technologies, UK) as detailed in section 2.7.1. They were quality assured 
for size using the Agilent Tapestation (Agilent technologies Inc., USA). 1 μl 
of the eluted DNA library sample was examined on the Agilent Tapestation 
using the D1K Screentape (Agilent technologies Inc., USA). The protocol is 
identical to that in section 2.8.4. In addition to concentration, the Tapestation 
also allows confirmation that all excess adaptor oligonucleotide has been 
removed from the sample (with the appearance of a peak at approximately 
115 bp on the electropherogram). If there was contaminating adaptor of an 
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amount greater than 10% of the target library concentration then the library 
sample was re-cleaned using as per section 2.8.12. If there was no concern 
over adaptor contamination then the library sample was stored at -200C 
awaiting sample pooling and sequencing. Details of the library stored on our 
server.  
2.8.12 Post PCR sample re-clean with SPRI beads 
Firstly 2.5x concentration of SPRI beads (Beckman Coulter, UK) was 
prepared according to the volume of the sample from section 2.8.11 (38 μl). 
The beads are prepared as follows: 95 μl of beads are mixed well using 
vortexing with 38 μl nuclease-free H2O (Life technologies, UK). This was 
then added to the DNA library sample and mixed well. The sample was 
incubated for 5 minutes with continuous shaking. The tube was then placed 
in the magnetic rack for 5 minutes to separate. The supernatant was then 
removed and discarded. The beads were then washed in 200 μl 70% 
ethanol and incubated at 30 seconds. The magnetic rack was used to 
separate the beads and remove the ethanol. The ethanol wash was then 
repeated. The beads were then air-dried for 10 minutes before eluting the 
DNA in 42 μl EB buffer (Qiagen, UK). The sample was then quantified and 
quality assured using the Qubit fluorometer (Life Technologies, UK) and 
Agilent Tapestation (Agilent technologies Inc., USA) as detailed in sections 
2.7.1 and 2.8.11. If there was insufficient DNA in the library sample to 
proceed this then the pre-PCR sample was removed from -20oC storage 
(see section 2.8.9) and the post-PCR enrichment clean up process was 
repeated using this sample.  
2.8.13 DNA copy number library sample pooling 
To obtain the depth of sequencing coverage required, 40 samples per flow-
cell lane. Once 40 samples with unique 6 bp tags had been accrued in 
storage they were pooled for sequencing.  
The DNA concentrations (as measured by the Tapestation) of all the 
samples to be pooled were compared and a mutually convenient amount to 
pipette was determined – typically 20 ng, or a volume between 1 and 30 μl. 
 57 
The samples were then pooled in equal concentrations before being 
submitted to the sequencing team for running on the sequencer.  
The pooled library samples were run on the Illumina HiSeq 2000. This offers 
200 million reads per lane. The Illumina HiSeq 2000 produces a FASTQ file. 
This contains information about each read (including location, size and 
quality of read) in addition to the raw sequence. 
2.9 Copy number analysis data processing 
2.9.1 Alignment 
The Illumina HiSeq 2000 produces sequencing data in the form of FASTQ 
files. These are text files that contain the raw nucleotide sequences 
(sequencing reads) as well as a Phred quality score for each read.  Each 
sample that had been multiplexed in a single sequencing lane was 
individually tagged with an indexed primer. This tag was identified at the 
ends of the sequencing reads produced. Using this individual tag the 
samples were separated into unique files by the sequencing facility prior to 
delivering the files to our research group.  
The adaptor sequences were then removed (or ‘trimmed’) from the ends of 
all sequencing reads in all files using software called Cutadapt 
(http://code.google.com/p/cutadapt/). After removing the adaptor sequences, 
any remaining nucleotide sequence that was 20 bp or less in length was 
removed from further analysis (due to inherently poor alignment). 
The remaining reads were then aligned to the human reference genome 
(University of California Santa Cruz version GRCh37/hg19, 
http;//genome.ucsc.edu) using Burrows Wheeler Alignment (BWA) and to all 
known HPV subtypes using data downloaded from the National Centre for 
Biotechnology Information 
(http://www.ncbi.nlm.nih.gov/genomes/GenomesHome.cgi?taxid%20=%201
039) (Li et al, 2010). The resulting data is stored in the binary alignment map 
(BAM) format.  
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2.9.2 Copy number analysis using CNAnorm 
CNAnorm is a freely available software package designed specifically for the 
analysis of copy number data from tumour samples sequenced at low-
coverage (approximately 0.01 – 0.5x) (Berri, 2014, Gusnanto et al., 2012). 
As 40 samples per lane were run on the Illumina HiSeq 2500 in this project, 
this resulted in approximately 0.033x – 0.33x coverage. The input for this 
software is the sample BAM file. It divides the reference genome into 
genomic “windows”. These windows can be of a specified length (in base 
pairs) or can be assigned according to the number of sequencing reads 
aligned to each window. In this case we instructed CNAnorm to divide the 
genome into identical length windows (800 Kbp long) for the purposes of 
downstream analysis.  
The normal control sequencing data for this copy number analysis was 
obtained as a pooled normal sample from 20 individuals available from the 
1000 Genomes Project ((ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp). CNAnorm 
also performs guanine-cytosine (GC) correction of the sequencing reads 
prior to normalising the sample to normal read ratio (on a window by window 
basis).   
CNAnorm then uses a separate software package called DNAcopy to 
perform circular binary segmentation of the normalised data (Venkatraman 
and Olshen, 2007). This designates windows to a segment of genome at the 
same estimated sample to normal ratio. This essentially estimates changes 
in copy number. The segmented data is stored as text in a .bed file. 
As reads are aligned by genome position the structure of the genome can be 
analysed. The number of aligned reads per window relative to the number of 
aligned reads in the same window of the normal control allow inference of 
the relative copy number of that window. Where segments of DNA change in 
copy number represent the genomic breakpoints.  
2.9.2.1 Determination of HPV status using low-coverage NGS 
Conway et al, described the method used to determine viral load (Conway et 
al., 2012). Briefly, this involves counting the number of reads that align to the 
human reference genome and those that align to genomes of all HPV-
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subtypes. Depth of sequencing is equal to the number of aligned reads per 
kilobase of the human reference genome. The number of HPV genome 
reads detected per sample allows the viral load per genome to be calculated 
using Conway et al’s equation: 
(no. of viral reads) x 6 109 bp diploid human genome) 
(7900 bp viral genome x number of human reads) 
2.9.2.2 Visual assessment of digital karyograms 
2.9.2.2.1 Individual karyogram 
CNAnorm produces a digital karyogram (see Figure 2-1) as a graph with the 
chromosomal position represented on the x-axis and the sample to normal 
ratio on the y-axis. The normalised ratio (relative copy number) of each 
segment is represented by a black line. Each window is represented by a 
dot. Those windows with an increased sample to normal ratio (copy number 
gain) are coloured red. Those with a decreased sample to normal ratio (copy 
number loss) are coloured blue. 
 
Figure 2-3: Example of digital karyogram produced by CNAnorm. 
 
When visually inspecting these it is possible to estimate both ploidy and 
tumour cell content of the sample by analysing the karyogram and 
determining the ratio of loss that represents loss of one copy. By then 
visually determining the maximum number of copies that are lost at any any 
genomic region the ploidy can be inferred (e.g. if four copies are lost at a 
particular point in one sample it must at least tetraploid).  
The ratio that represents loss of one copy can then be compared to the ratio 
that would represent loss of one copy in a homogeneous diploid sample of 
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100% tumour cell purity and the tumour DNA content (of the dominant clonal 
population) be inferred from this (see Table 2-12). 
 
Estimated Ploidy Copy Gain/Loss Tumour/normal ratio Tumour DNA  Content 
2n 1 1.5 100% 
2n 1 1.38 75% 
2n 1 1.25 50% 
2n 1 1.23 25% 
2n -1 0.5 100% 
2n -1 0.63 75% 
2n -1 0.75 50% 
2n -1 0.88 25% 
3n 1 1.3 100% 
3n 1 1.27 75% 
3n 1 1.2 50% 
3n 1 1.11 25% 
3n -1 0.66 100% 
3n -1 0.72 75% 
3n -1 0.8 50% 
3n -1 0.89 25% 
4n 1 1.25 100% 
4n 1 1.21 75% 
4n 1 1.17 50% 
4n 1 1.1 25% 
4n -1 0.75 100% 
4n -1 0.78 75% 
4n -1 0.83 50% 
4n -1 0.9 25% 
Table 2-12: List of assigned ratios to represent loss/gain of 1 copy and inferred 
tumour DNA content of dominant clone from this. 
 
2.9.2.2.2 Cumulative frequency karyograms 
These were created using a script written by Dr Henry Wood (Bioinformatics, 
Precancer Genomics Group) called seg_compare. This produces a 
cumulative karyograms of all specified .bed files. This allows estimation of 
the proportion of samples that have CNA on a genome-wide view as well as 
a specific individual chromosome view. This analyses the segmented data 
for each sample and presents a frequency plot. A threshold for designating a 
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segment as representing a gain or loss must be assigned. This can be done 
either on a generic basis for all samples or on an individual sample basis.  
2.9.2.3 Genomic Identification of Significant Targets in Cancer (GISTIC 
2.0) 
GISTIC 2.0 is open access software developed by the Broad Institute, USA 
to provides systematic analysis of CNA, specifically in cancer (Mermel et al., 
2011). It provides rapid CNA profiles allowing both broad and focal analysis 
simultaneously, providing frequency, significance values and heat maps.  
GISTIC can be found at www.genepattern.broadinstitute.org. Before running 
GISTIC the CNAnorm text data files (containing the text data for each 
sample’s genomic windows with raw and segmented copy number data) 
were converted to the input form using an R script, cnaNorm2.GISTIC.R (Dr 
Stefano Berri, Precancer Genomic group). This also produced a markers file 
for each sample based on the genomic co-ordinates. The converted 
segmented data files were then grouped according to the clinicopathologic 
parameters set out previously (e.g. metastatic primary tumour, metastasis 
etc.) and uploaded along with the markers file (which was identical for all 
samples).  
The parameters used when running GISTIC were consistent for all analyses. 
The algorithm was set to calculate the significance of deletions at a gene 
level rather than a marker level. All other parameters were left as the default, 
recommended setting. Of note, the amplification and deletion thresholds 
were set at 0.1 for all samples (meaning regions with a log2 ratio above or 
below this were considered amplifications or deletions) as it was not possible 
to assign an individual sample threshold and the q-value threshold was set 
to 0.25. 
2.10 miRNA sequencing library preparation 
The total ribonucleic acid (RNA) samples from section 2.6 were used as 
input for this protocol. The Illumina TruSeq Small RNA Sample Prep kit 
(Illumina, USA) was used to create small RNA sequencing libraries. All 
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equipment and surfaces were wiped with RNase AWAY (Sigma Aldrich, 
USA) prior to commencement. RNA samples were kept on ice throughout.  
2.10.1 Sample preparation 
500 ng to 1 μg of the RNA samples from section 2.6 were prepared in 5 μl of 
RNase-free water (Qiagen, UK) using Table 2-13. It is worth noting that 
ribosomal depletion is not recommended by Illumina for this protocol. My 
experience was that samples with < 1 μg of input RNA did not yield a viable 


























47D 1 224 2 3 448 1  
Table 2-13: Example of calculation of input RNA concentration and volume for small RNA 
library preparation. 
2.10.2 3’ Adaptor ligation 
Adaptors specific for the 3’-hydroxyl group on miRNAs are ligated to the 
sample by adding 1 μl of RNA 3’ adaptor, mixing by pipetting and incubating 
this at 700C for 2 minutes before placing on ice immediately. A master mix 
(see Table 2-14) was prepared in a 200 μl PCR tube on ice (adding 10% for 
multiple samples). This required T4 RNA Ligase 2 deletion mutant (Cambio, 
UK) and mixing by pipetting. 4 μl of this mix was added to the RNA + 3’ 
adaptor sample and mixed by pipetting. This was incubated at 280C for 1 
hour. At completion, leaving the tube on the thermal cycler, 1 μl Stop 
Solution was added and incubated for 15 minutes at 280C. The tube was 
then immediately placed on ice. 
 Vol per sample (μl) 
5x HM Ligation buffer 
(HML) 
2 
RNase Inhibitor 1 




Table 2-14: Master mix for 3' adaptor ligation. 
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2.10.3 5’ Adaptor ligation 
5’ adaptors were then added by aliquoting 1.1 x n μl (where n = number of 
RNA samples) of RNA 5’ adaptor in a separate 0.2 μl PCR tube. This was 
incubated at 700C for 2 minutes and then placed on ice. 1.1 x n μl of 10 mM 
ATP was then added to the aliquoted RNA 5’ adaptor tube and mixed by 
pipetting. A further 1.1 x n μl of T4 ligase was added to the aliquoted RNA 5’ 
adaptor tube and mixed by pipetting. 3 μl of this mix were then added to the 
sample from section 2.10.2. This was then incubated at 280C for 1 hour and 
then immediately placed on ice. 
2.10.4 Reverse transcription 
In a separate 200 μl PCR tube 25 mM dNTP was diluted by adding 0.5 μl 
Ultra Pure Water to 0.5 μl 25 mM dNTP. This was then mixed by pipetting 
and placed on ice. Then 1 μl of RNA RT Primer was added to the 5’ and 3’ 
adaptor-ligated RNA sample from section 2.10.3. This was incubated at 
700C for 2 minutes and then placed on ice.  
In a separate 200 μl PCR tube on ice the master mix shown in Table 2-15 
was prepared (adding 10% for multiple samples). This required Superscript 
II Reverse Transcriptase and 10 mM DTT (Life Technologies, UK) in addition 
to the other reagents provided in the library kit. It was mixed by pipetting. 5.5 
μl of this master mix was added to the adaptor ligated RNA sample and 
incubated at 500C for 1 hour and then placed immediately on ice. 
 
 Vol per sample (μl) 
5x First strand buffer 2 
12.5 mM dNTP mix 0.5 
100 mM DTT  1 
RNase Inhibitor 1 
Superscript II Reverse Transcriptase 1 
Total 5.5 






2.10.5 PCR Amplification 
In a separate 200 μl PCR tube a PCR master mix was prepared (see Table 
2-16). Separate mixes were prepared for each indexed primer. This master 
mix was then added to the complementary DNA (cDNA) sample from 2.10.4. 
 
 Volume per DNA sample/ μl 
Ultra Pure Water 22.5 
5x Phusion HF Buffer 10 
RNA PCR Primer (RP1)  2 
RNA PCR Primer Index (RPIX) 2 
25mM dNTP  0.5 
Phusion DNA Polymerase 0.5 
Total 37.5 
Table 2-16: PCR amplification master mix. 
 
The sample was mixed by pipetting and then placed on ice. The thermal 
cycler was used with the conditions shown in Table 2-17. Upon completion of 
this protocol the thermal cycler was set to hold the sample at 40C. 
 
Time Temperature Number of cycles 
30 seconds 980C 1 
10 seconds 980C 11 
30 seconds 600C 
15 seconds 720C 
10 minutes 720C 1 
Table 2-17: Thermal cycler protocol for PCR amplification. 
2.10.6 Size selection 
The cDNA construct was purified using polyacrylamide gel size selection. 
Using stock 5x Novex TBE Buffer (Life Technologies, UK). 1l of 1x 
concentration TBE Buffer was prepared. Pre-cast Novex TBE 6% 
polyacrylamide gels (Life Technologies, UK) were used in the XCell 
SureLock Mini-Cell electrophoresis unit (Life Technologies, UK).  The 
ladders were prepared by adding 1 μl of high resolution ladder to 1 μl of 6x 
DNA loading dye (Life Technologies, UK). 2 μl of Custom ladder was mixed 
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with 2 μl 6x DNA loading dye. The entire amplified cDNA construct from 
section 2.10.5 was mixed with 10 μl 6x DNA loading dye. Once the gels 
were secured in position and the Mini-Cell filled with 1x TBE Buffer 
(approximately 500 ml), the wells were filled according to Figure 2-4. The 
cDNA construct for each sample was divided between two adjacent wells 
(approximately 30 μl in each). Two wells were left empty in between different 
patient samples to reduce the risk of cross-contamination. The gel was then 
run at 146 V until the dye front exited the gel (approximately 45 minutes).  
The cassette containing the polyacrylamide gel was then opened whilst 
submerged in 400 ml of 1x TBE Buffer (Life Technologies, UK). Once 
opened, add 20 μl of 10 mg/ml ethidium bromide (Life Technologies, UK) 
was added to the container (to create a 0.5 μg/ml concentration of ethidium 
bromide solution) and mixed gently for 5 minutes. The gel was then carefully 
transferred to a UV transilluminator and the bands representing 145–160 bp 
identified on the High resolution and Custom Ladders. These area within 
these bands were excised from the lanes containing the patient samples.  
 
Figure 2-4: Diagrammatic representation of allocation of wells in polyacrylamide 
gel. 
 
The excised bands from both lanes for each patient sample were transferred 
to 500 μl gel breaker tubes (Life Technologies, UK). These were placed in a 
fresh 2 ml collection tube and centrifuged at full speed from 2 minutes. To 
elute the DNA 200 μl Ultra Pure Water was added to the collection tube and 
shaken for 2 hours. The eluate was transferred to a new 5 μm filter tube (IST 
Engineering, USA) and transferred at 600 x g for 10 seconds. The DNA 

























Eppendorf Concentrator 5301 (Eppendorf, Germany) for 20-40 minutes at 
room temperature (the time needed to concentrate increases with the 
number of samples in the concentrator on the number of samples in the 
concentrator).  
2.10.7 Small RNA library quality assurance 
The concentrated library from section 2.10.6 was then assessed to confirm 
presence of the correct size nucleic acid chains (adaptor-ligated small RNAs 
with indexed primers) using the Agilent Bioanalyzer 2100 and Agilent High 
Sensitivity DNA kit (Agilent, UK).   
The kit reagents were allowed to equilibrate to room temperature for 30 
minutes. The gel dye mix is prepared by pipetting 15 μl of the blue dye 
concentrate into the High Sensitivity DNA gel matrix and vortexed for 10 
seconds. The gel-dye mix was then transferred to a spin filter in a 1.5 micro-
centrifuge tube and centrifuged at 6000 rpm for 10 minutes at room 
temperature. The filter is then discarded and the tube labelled (Gel-dye mix).  
A new High Sensitivity DNA chip (Agilent, UK) was place in the chip priming 
station and 9 μl of gel-dye mix was pipetted into the well marked G . The 
priming station is then closed and the syringe plunger depressed and held 
for 1 minute before being released. The priming station was opened and 9 μl 
of the gel-dye mix pipetted into each well marked G. Then 5 μl of High 
Sensitivity DNA marker was pipetted into the remaining 12 wells. 1 μl of High 
Sensitivity DNA ladder was pipetted into the well marked with the ladder 
symbol and 1 μl of library sample from section 2.10.6 into each of the 
remaining 11 wells. The chip was then vortexed for 1 minute at 2400 rpm. 
The chip was then placed in the Agilent Bioanalyzer 2100 and the computer 
set to run the dsDNA High Sensitivity assay.  
The output from the Agilent Bioanalyzer 2100 was used to confirm the 
presence of sequencing library at 145-160 bp and assess the quantity of 
adaptor dimer or concantamer at 120-138 bp in the library. If excess adaptor 
contamination is present then the library protocol should be repeated with a 
new input RNA sample. I found that re-attempting gel size selection of the 




2.10.8 Small RNA library quantification 
Each small RNA library sample from section 2.10.6 was then quantified 
using the Qubit fluorometer and Qubit dsDNA BR assay kit (Life 
technologies, UK) as detailed in section 2.7.1. This concentration was used 
when pooling library samples for sequencing. 
2.10.9 Small RNA library sample pooling and sequencing 
The quantified small RNA library samples were separated into two groups of 
12 to ensure that there was no duplication of the indexed primers used to 
label each sample. Then 8 ng of each library was pooled in a new 200 μl 
PCR tube (labelled with my name, miRNA library and sequencing lane 
number). This amount was chosen to ensure that there was sufficient library 
left in the sample with the lowest concentration that a repeat pooling could 
be performed in the event of a fault with running the Illumina HiSeq 2500 
sequencer. 
These were then run on the Illumina HiSeq 2500 Genome Sequencer 
operating in “Rapid Run Mode”, using 50 bp single-end reads (capable of 
generating 135 million sequencing reads per lane). 
2.10.10 miRNA sequencing data processing and analysis 
The FASTQ files generated by the sequencer containing the raw sequencing 
read data were downloaded. Cutadapt was used to remove the adaptor 
sequences from the ends of each read (http://code.google.com/p/cutadapt/). 
An open access software called CAP-miRSeq (Comprehensive Analysis 
Pipeline – microRNA Sequencing) was then used to process the data (Sun 
et al., 2014). This automatically aligned the trimmed reads to the human 
reference genome (University of California Santa Cruz version 
GRCh37/hg19, http://genome.ucsc.edu). After trimming all reads less than 
17 bp in length were removed. All RNA types contained in the sequencing 
library were quantified. CAP-miRSeq generated raw count data for each 
uniquely mapped miRNA and performed normalisation of these for the 
number of aligned reads per sample. 
CAP-miRSeq then implemented another open access software package 
called edgeR (Bioconductor, US) to perform further normalisations steps. 
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These include scaling of the libraries for the number of aligned reads per 
sample and the dispersion of reads in each sample. It then generated 
differential expression data according to defined clinicopathologic (Robinson 
et al., 2010).  
2.11 miRNA Nanostring nCounter Expression Assay 
The nCounter system (Nanostring Technologies, USA) is a relatively new 
commercial method for performing expression analysis. It is based on the 
hybridisation of target molecules to colour-coded, biotinylated probes that 
are then digitally detected with a raw molecule count being provided, which 
can allow fold change between samples (Geiss et al., 2008). The nCounter 
miRNA Expression Assay (Nanostring Technologies, USA) was used to 
provide an alternative method of miRNA profiling of the samples selected for 
miRNA sequencing. This was performed to provide validation of any 
sequencing findings and was specifically chosen as it allowed much a much 
larger number of miRNAs to be profiled compared to other methods such as 
qRT-PCR. 
Access to the nCounter system was kindly provided by Dr Tudor Fulga 
(Weatherall Institute of Molecular Medicine, University of Oxford) and 
training in the protocol was provided by Bruno Steinkraus (PhD Student). 
Materials and reagents contained in the nCounter Human miRNA 
Expression Assay Kit and the nCounter Master kit (Nanostring Technologies, 
USA) were used. All RNA samples were kept on ice throughout this protocol.  
2.11.1 Sample preparation 
All samples were normalised to 33 ng/μl using RNase-free H2O (Qiagen, 
UK) in a volume of 5 μl. All stock RNA samples were immediately returned 
to -800C storage, whilst the diluted RNA samples were kept on ice. Twelve 
RNA samples were processed at a time.  
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2.11.2 Annealing protocol 
A 1:500 dilution of the miRNA Assay Controls (Nanostring Technologies, 
USA) was prepared in a new 1.5 ml microcentrifuge using 499 μl RNase-free 
H2O (Qiagen, UK). 
An annealing master mix was prepared by combining 13 μl of Annealing 
Buffer, 26 μl of nCounter miRNA Tag Reagent and 6.5 μl of the diluted 
miRNA Assay Controls. This was mixed well by pipetting. Into 12 new 200 μl 
PCR tubes, 3.5 μl annealing master mix was pipetted. 3 μl of each RNA 
sample was added to each tube and mixed by flicking. The tubes were then 
placed in a thermocycler (see Table 2-18). After completion of this protocol 
the samples were held at 480C until the ligation protocol was initiated. 
 
Temperature Time Cycle 
940C 1 minute 1 
650C 2 minutes 1 
450C 10 minutes 1 
Table 2-18: Annealing thermocycler protocol 
 
2.11.3 Ligation protocol 
A ligation master mix was prepared by combining 24 μl PEG and 16 μl 
Ligase Buffer in a fresh 200 μl PCR tube. 2.5 μl of this master mix was then 
added to the RNA samples held at 480C and mixed by flicking. These were 
then returned to the thermocycler and incubated at 480C for 5 minutes.  
 
Temperature Time Cycle 
480C 3 minutes 1 
470C 3 minutes 1 
460C 3 minutes 1 
450C 5 minutes 1 
650C 10 minutes 1 
Table 2-19: Ligation thermocycler protocol 
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Following this 1 μl Ligase was added directly to each RNA sample without 
removing them from the thermocycler. The ligation protocol was then 
initiated on the thermocycler (see Table 2-19). At completion of this protocol 
the samples were held at 40C on the thermocycler for the purification 
protocol. 
2.11.4 Purification protocol 
After completion of the ligation protocol 1 μl Ligation Clean-Up Enzyme was 
added to each RNA sample from section 2.11.3 and mixed by flicking. The 
tubes were then returned to the thermocycler and the purification protocol 
initiated (see Table 2-20). After completion of this, 40 μl RNAse-free H2O was 
added to each sample. 
 
Temperature Time Cycle 
370C 2 hours 1 
700C 10 minutes 1 
Table 2-20: Purification thermocycler protocol 
 
2.11.5 Hybridisation protocol 
A master mix was created using 130 μl of the Reporter Codeset and 130 μl 
of Hybridisation Buffer and mixed by inverting. 20 μl of this master mix was 
added to the strip of 12 sample tube provided in the nCounter Human 
miRNA Expression Assay Kit. The RNA samples from section 2.11.4 were 
denatured at 850C for 5 minutes before immediately being placed on ice. An 
aliquot of 5 μl was transferred from each to a new 200 μl PCR tube (also on 
ice). The thermocycler was preheated to 650C. 5 μl of Capture Probeset was 
added to each 5 μl aliquot RNA sample and then immediately placed on 
650C. This was incubated for at least 12 hours before proceeding to post-
hybridisation processing. 
2.11.6 nCounter prep station protocol 
This step was performed by Bruno Steinkraus (Weatherall Institute of 
Molecular Medicine, University of Oxford) and required the components of 
the nCounter Master Kit (Nanostring Technologies, USA). After allowing 
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them to equilibrate to room temperature for 30 minutes the sample tubes 
from section 2.11.5 were loaded on the prep station, along with the prep 
plate and cartridge provided. The station was programmed to run on high 
sensitivity mode and allowed to process the samples. On completion all 
tubes, plates and waste reagents were disposed of. 
2.11.7 Processing and Analysis of nCounter data 
The nCounter system produces raw counts of molecules for each sample. 
These files are immediately input into a software package called nSolver 
(Nanostring, USA). This is specifically designed to perform quality control 
and normalisation of each sample. It also performs normalisation to internal 
positive and negative controls (including five housekeeping genes included 
in the assay cartridge). The normalised data was then input to the edgeR 
software used by CAP-miRSeq to perform differential analysis as per 
designated clinicopathologic groups. 
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Chapter 3  
Clinicopathologic analysis of tissue samples 
3.1 Introduction 
Head and neck cancer is a non-specific term that can refer to any 
extracranial malignancy above the level of the clavicles. It is generally used 
to describe malignant tumours of the upper aerodigestive tract. This extends 
from the lips and nasal cavity to the trachea and cervical oesophagus.  
As has been mentioned previously these tumours are therefore 
heterogeneous in that they are clinically different but histologically similar in 
that over 90% of all tumours at all subsites are squamous cell carcinoma. 
There is also some heterogeneity regarding the aetiological factors most 
strongly related to each subsite. For instance, in nasopharyngeal squamous 
cell carcinoma (SCC), the Epstein-Barr virus is implicated as a critical 
aetiologic agent in the majority of cases (Lo et al., 2004). Smoking tobacco 
is associated with a significantly increased risk of all head and neck cancer 
subsites (Ansary-Moghaddam et al., 2009). Smokeless tobacco are all 
associated with an increased risk of oral and pharyngeal SCC (Stockwell 
and Lyman, 1986). Even the betel nut is recognised to be an independent 
risk factor for oral cancer (Merchant et al., 2000). 
In most countries (including England), the oral tongue is the most commonly 
affected subsite of the oral cavity representing up to 42% of OSCC (Krishna 
Rao et al., 2013, Statistics, 2012). This is most strongly associated with 
smoking and alcohol use (Ansary-Moghaddam et al., 2009). Floor of mouth 
SCC is less common than oral tongue cancer in England though is 
associated with similar risk factors. Trends in the different methods of using 
tobacco (and related substances) result in variation in the incidence of 
different subsites, even within the oral cavity. In North America and Western 
Europe, buccal squamous cell carcinoma accounts for approximately 10% of 
OSCC, whilst in Southeast Asia buccal SCC is the most common form of 
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OSCC due to the endemic practice of chewing betel nut (Lubek et al., 2013, 
Chhetri et al., 2000). Despite these subtle variations there is little difference 
found in outcomes from subsites of OSCC (Camilon et al., 2014, Shaw et al., 
2009).  
HNSCC of different subsites do vary somewhat in their behaviour, relating to 
their local anatomy. For example, laryngeal SCC tend to metastasise to 
cervical node level II – IV, whereas oral SCC tends to metastasise to levels I 
– III (Candela et al., 1990a, Candela et al., 1990b, Shah, 1990, Shah et al., 
1990, Robson, 2001). The risk of cervical metastases from different stages 
of different subsites also varies slightly and therefore management for each 
subsite varies slightly, as does the impact of treatment on the patient.  
Despite the general similarities, in order to reduce potential heterogeneity, 
patients with oral tongue cancers were primarily targeted for this research. 
These patients are predominantly managed with surgery to remove the 
primary tumour as well as the cervical lymph nodes. This meant that the 
histopathology archive should have matched tissue samples for each patient 
that underwent surgical treatment for oral tongue SCC, making it ideal for 
obtaining tissue and nucleic acid for analysis from both primary tumour and 
matched lymph node metastasis.  
The initial statistical analysis utilised an estimation of background copy 
number alteration of 5% gain and 5% loss based on previous analysis from 
Professor Rabbitts’ Precancer Genomics group. Simulations based on this 
and that an average of 100 segments per sample was obtained in previous 
studies indicated that 20 patients per groups would be sufficient to reliably 
identify CNA with an excess frequency of 0.3 in one group compared to the 
other. This did not mean any CNA with a lower excess frequency was not 
worthy of analysis but must be regarded with greater caution.  This minimum 
number of patients also appeared an obtainable number of patients from the 
Leeds histopathology archive.  
3.2 Aim 
The objective of this study was to describe the results of conducting an 
extensive retrospective search for suitable patients for this project as well as 
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their clinicopathologic features. This is important to establish the phenotypic 
features of the patients included in this study in order to identify any potential 
bias or flaws in subsequent genomic analysis. 
3.3 Results 
3.3.1 Sample Identification and procurement 
An important aspect of searching for suitable patients was understanding the 
system currently used in Leeds to catalogue tissue samples (CoPath). This 
enables a search to be performed between defined dates for certain 
keywords.  
It is also important to remember that tissue samples from the same disease 
can be described in a multitude of different terms and therefore repeated 
searches needed to be performed using the keywords listed in Table 3-1. The 
searches were performed for samples between 01/01/2005 and 31/12/2011. 
These dates were selected to try and ensure that patients included in the 
study would have undergone sufficient follow-up to provide a minimum of 2 
years follow up data. 
 
CoPath search keywords used: Tongue carcinoma 
 Oral carcinoma 
 Glossectomy 
 Neck dissection 
 Level 1/Level I 
 Cervical lymph node 
Table 3-1:  Search terms used on CoPath system 
 
This produced numerous lists, which in total came to over 3000 patients. 
These required close inspection of the final diagnosis to determine the site of 
primary tumour. This provided a list of 91 patients that required further 
interrogation using the clinical Patient Pathway Manager (PPM) system.  
PPM is used to record details of treatment and follow-up for all oncology 
patients treated at Bexley Wing, St James’ Institute of Oncology. Using this 
system allowed review of each patients clinical background as well as review 
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of their full histopathology and management to ascertain whether they met 
the inclusion criteria specified in Chapter 2.2. A number of patients were 
excluded due to a history of previous HNSCC (n = 5), previous head and 
neck radiotherapy (n = 1) and a history of autoimmune disease for which 
they were on immunosuppressants at the time of their diagnosis and 
treatment (n = 2). This resulted in 71 eligible patients being identified with 
primary oral tongue cancer that were treated with surgery to the primary 
tumour and neck dissection. These were assigned to groups according to 
histopathologic nodal status (N0, N+ECS-, N+ECS+). 
A full, anonymised histopathology report of both primary tumour and neck 
dissection specimens was obtained for every patient. This allowed 
identification of the specific FFPE tissue blocks within each report that 
should contain cancerous and metastatic tissue. This is a vital part of the 
process as a single patient with oral cancer regularly has upwards of twenty 
tissue blocks created for clinical purposes. Requesting all blocks and 
subsequently creating H & E slides for examination would have been an 
unnecessary waste of time and energy. 
A pipeline between our research group and Bexley Wing Histopathology 
Department was established with the approval of Professor MacLennan and 
Dr Alec High. Andy Clarke, Chief Biomedical Scientist, at Leeds 
Histopathology department kindly handled all requests for specific tissue 
blocks via email. These were then retrieved from the archive at which point I 




Figure 3-1: Chart to show sample identification and procurement 
 
A significant problem became apparent after requesting several batches of 
tissue blocks: missing or unobtainable blocks. These missing blocks were 
either the primary tumour or matched metastasis, or both. Unfortunately, 
beyond contacting the last person recorded to have possession of the blocks 
there was little that could be done to overcome this issue. This resulted in 
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insufficient patient numbers for the patients groups. In order to overcome 
this issue the original inclusion criteria was broadened from oral tongue to 
oral cavity. This was carried out as the tissue blocks for several patients in 
both the ECS+ group and the N+ECS- group appeared to be potentially 
reducing numbers significantly in these groups. The final numbers of 
patients obtained are detailed in Figure 3-1. 
3.3.2 Clinicopathologic characteristics of samples 
In total 75 patients were included in the study for clinicopathologic and 
subsequent CNA analysis. The diagnosis of SCC and the nodal status was 
confirmed using the H & E by Dr Preetha Chengot (consultant head and 
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Table 3-2: Summary of clinical characteristics of sample population 
 
All of these cases had DNA successfully extracted for copy number analysis, 
from both the primary tumour and matched metastasis, as well as a further 
sub-group being selected for miRNA extraction and sequencing. The clinical 
and histopathologic characteristics of these patients were summarised in 
Table 3-2 and Table 3-3. More detailed tables of individual patient samples 
can be found in Appendix 8.2. 
The distribution of tumour subsites according to nodal status is shown in 
Figure 3-2. There male to female ratio was 2.3:1. The preponderance of male 
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2.5 – 45 
Table 3-3: Histopathologic characteristics of sample population 
 
Figure 3-2: Distribution of primary tumour subsite across nodal status grouping 
 
The distribution of T-staging across nodal status groups is shown in Figure 













shown in Figure 3-4. These show a trend towards smaller tumours associated 
with N0 nodal status, whilst larger tumours tend to have positive nodes and 
the largest tumours more likely to have ECS. However, 14 patients with ECS 
(52%) had T1/T2 primary tumours. In terms of N-staging, though disease 
with ECS is associated with more advanced staging (indicating either greater 
number or size of nodal metastases), 3 patients (11%) with ECS were 
staged at N1. This is again consistent with the knowledge that ECS indicates 
aggressive disease rather than late disease.  
 
 
Figure 3-3: Distribution of T-staging across nodal status grouping 
 
 
Figure 3-4: Distribution of N-staging according to presence or absence of ECS 
 
Depth of invasion of primary tumour is a histopathological characteristic, 
previously associated with poorer outcome and metastasis in OSCC 
(Asakage et al., 1998). In this group of patients depth of invasion was 
recorded for 64 of 75 patients. The average depth of tumour was higher in 



























tumour in the N+ECS- was higher than the N0 group. This association was 
statistically significant using the ANOVA test (p = 0.015). 
Univariate analysis was performed of histopathologic variables and their 
relationship to the presence of ECS or cervical metastases. The chi-squared 
test was used, except where only two groups were present where Fisher’s 
Exact test was used. Tumour differentiation, lymphatic invasion, perineural 
invasion and vascular invasion were analysed (see Table 3-4). 
 
Table 3-4: Univariate analysis of histologic variable and metastasis and ECS 
 
Univariate analysis was performed of histopathologic characteristics and 
their relationship to recurrence. This was done using chi squared test (and 
Fisher’s Exact test where both variables had only two groups). There was a 
strong statistically significant relationship between the presence of ECS and 
locoregional recurrence of disease. Interestingly there was no difference 
between the N0 group and N+ECS- groups in the rate of locoregional 
recurrence (p = 0.6).  For characteristics such as tumour differentiation, 
lymphatic invasion, perineural invasion and vascular invasion the 





No. of patients 
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Table 3-5: Univariate analysis of histopathologic variables and recurrence 
 
3.3.3 Survival Analysis 
The range of length of follow-up for any patient alive at the end of the study 
period was 34 – 111 months (mean – 68.5 months). The presence of ECS 
was found to have a significant adverse effect on both disease-free survival 
(p = < 0.0001) and overall survival (p = < 0.0001) (see Figure 3-5 and Figure 
3-6). There was no statistically significant difference in survival between the 
pN0 and pN+ without ECS groups. 
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Figure 3-5: Kaplan-Meier disease-free survival curve for pN0, pN+ with and without 
ECS 
 
Figure 3-6: Kaplan-Meier overall survival curve for pN0, pN+ with and without ECS 
 83 
3.4 Discussion 
HNSCC is regularly described as a heterogeneous group of cancers. In 
choosing a group of patients to study I attempted to create as homogeneous 
a group as possible by targeting a specific primary tumour subsite. The 
compromise that had to be made with this decision is that the pool of 
patients from which patients can be selected is reduced, therefore obtaining 
numbers that could provide statistical significance later became a significant 
challenge in this study.  
A long, laborious search through massive lists of potentially candidates from 
the CoPath system was required. An important consideration was that prior 
to 2008, the histopathology department used a number of different systems 
to catalogue tissue samples due to there being separate IT systems at both 
Leeds General Infirmary and St James’ University Hospital. These have 
since been unified at Bexley Wing, St James’ University Hospital. Samples 
prior to 2005 have not been transferred to CoPath and whether all samples 
between 2005 and 2008 have been reliably transferred to the CoPath is 
unknown. I was unable to gain access to the older systems to search these 
independently. This did hinder my ability to get more patients. 
Tissue blocks that were missing from the Pathology archive had a significant 
impact on the numbers of patients with oral tongue primary tumours I was 
able to obtain. In order to combat this I decided to include patients with any 
subsite of OSCC in order to obtain the minimum group size targeted. 
Though subtle variation in aetiology has been reported (e.g. smoking 
tobacco for oral tongue vs. chewing tobacco for buccal) there are conflicting 
reports regarding the impact of subsite on the clinical behaviour and 
outcomes of these tumours in terms of survival and recurrence (Camilon et 
al., 2014, Lubek et al., 2013, Chhetri et al., 2000). In this respect, I needed 
to bear in mind in later analysis that 13 patients in my study had primary 
tumour subsites other than oral tongue, particularly in that buccal cancers 
were only in the ECS+ group. Little work has been reported on subsite-
specific molecular signatures in HNSCC. An immunohistochemistry study 
found simultaneous downregulation of p16 and p21 was found in 47% of oral 
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tongue against 28% of buccal SCC, suggesting some molecular differences, 
though these were by no means exclusive (Sathyan et al., 2006). 
The number of patients obtained in the original CoPath search per year is 
shown in Figure 3-7. This demonstrates a fairly even spread of patients 
between 2006 and 2011, though in 2005 only four patients were obtained. 
This suggests that not all patients from this time were entered on to the 
CoPath system, likely contributing to the issues in obtaining samples. 
 
 
Figure 3-7: Chart to show distributions of patients over time 
 
None of the histologic characteristics analysed in Table 3-4 demonstrated 
any significant association with ECS. Though grade of differentiation, 
perineural invasion and vascular invasion all showed a significant 
association with metastasis, it is important to recognise that 20 patients had 
no perineural invasion yet still were found to have cervical metastases. More 
patients were found to have cervical metastases in the absence of vascular 
or lymphatic invasion. These findings highlight the lack of clinical reliability in 
these histologic characteristics in predicting metastases or ECS. This is in 
keeping with previous studies examining the relationship of these variables 
in relation to patient outcome. In a study of 142 patients with mixed subsite 
HNSCC Fagan et al found cervical metastases in 73% of patients with 
perineural invasion. However they also found metastases present in 43% of 
patients without perineural invasion (Fagan et al., 1998). Soo et al found no 
association between perineural invasion and cervical metastases (Soo et al., 
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found associations with metastasis in HNSCC, which are statistically 
significant but not 100% predictive of metastases (Close et al., 1989, Close 
et al., 1987, Okada, 2010).  
In terms of disease recurrence the absence of lymphatic invasion was 
associated with absence of recurrence of disease on the limits of statistical 
significance. Though one would expect a strong link between this and poorer 
outcome this finding is consistent with other studies in OSCC showing some 
potential association but certainly not as a foolproof marker of recurrence 
(Goldstein et al., 2013, Olsen et al., 1994). As with many other studies 
previously discussed the strong link between ECS and recurrence was again 
shown in this study (p = 0.0001).  
This group of patients is a very small population and therefore it is difficult to 
draw any significant conclusions from analysis of the histologic variables of 
these samples. However, it is reassuring that in terms of both overall and 
disease-free survival a massive difference was clearly demonstrated 
between those patients with and without ECS. In this respect it provides 
evidence that these patients behaved clinically as would be expected of 
patients with their histopathologic findings and therefore were a suitable 
group to utilise in further genomic analysis. 
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Chapter 4  
Copy number analysis of HNSCC and matched cervical 
metastases to identify characteristics of metastatic and non-
metastatic HNSCC and of tumours associated with ECS 
4.1 Introduction 
The management and prognosis for patients with HNSCC of any subsite is 
significantly affected by firstly the presence of cervical metastases and in 
particular by the presence of ECS (Shaw et al., 2010, Coatesworth and 
MacLennan, 2002). Patients with a clinically N0 neck represent a group in 
whom treatment to the neck is often warranted on the basis of the risk of 
occult cervical nodal metastases. Cervical metastases are present in 
approximately 30% of patients with clinically N0 disease (van den Brekel et 
al., 1993, Weiss et al., 1994, Alvi and Johnson, 1996, Haddadin et al., 1999). 
Approximately 60% of these occult cervical metastases have been shown to 
contain ECS (Coatesworth and MacLennan, 2002). This means that 18% of 
patients with clinically N0 disease actually have ECS. This would change 
them from being considered in the group at lowest risk of disease recurrence 
or progression to the group at highest risk instantly. Patients with clinically 
undetectable nodal metastases and ECS represent a group that could 
benefit from being targeted specifically with systemic therapies. However, 
due to the absence of a reliable marker to identify metastases and ECS, 
many patients undergo neck dissection to provide histological staging of the 
neck or have prophylactic radiotherapy to the neck. This means that up to 
70% of patients have unnecessary treatment, which is associated with 
considerable morbidity. 
A decision analysis by Weiss et al concluded that when the probability of 
occult metastasis is more than 20% then elective neck treatment would be 
preferable (Weiss et al., 1994). This benchmark is used widely in clinical 
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practice and therefore the majority of HNSCC patients with clinically N0 
disease undergo treatment to the cervical nodes. Only small T1 oral and 
glottic carcinomas can potentially avoid this. Retrospective studies 
comparing observation to elective neck dissection in clinically N0 disease 
have been performed. Haddadin et al found 5-year survival reduced from 
80.5% to 44.8% when patients with T1/T2 N0 OSCC were observed instead 
of undergoing elective neck dissection (Haddadin et al., 1999). Similar 
findings were reported by Kligerman et al (Kligerman et al., 1994).  
The only prospective randomised trial with sufficient power regarding the 
issue of elective neck dissection in early oral cancer was recently published 
in 2015. This found an absolute 5-year survival benefit in those patients 
having undergone elective neck dissection as opposed to therapeutic neck 
dissection (where a watch and wait approach was taken) of 12.5% (D'Cruz 
et al., 2015). This survival benefit was likely due to the fact that 30% of 
clinically N0 necks treated with elective neck dissection were found to 
contain occult metastases, as the neck was the most common site of 
disease progression/recurrence in the group having undergone therapeutic 
neck dissection. It is likely that the group of patients with occult cervical 
metastases with ECS represent those in greatest need of elective treatment. 
In highlighting the need to treat patients who may have occult cervical 
metastases we have to remember the patients that undergo treatment who 
do not have any nodal metastases. These are still the majority receiving 
treatment. 
As discussed in the previous chapter, histopathologic studies for metastasis 
have failed to produce a reliable marker in the primary tumour for nodal 
metastases. Genomic studies could provide such a marker. Copy number 
alterations (CNA) are known to disrupt a larger proportion of the cancer 
genome than any other type of somatic genetic alteration (Beroukhim et al., 
2010, Zack et al., 2013). CNA studies led to the discovery of distinct clinical 
subsets of cancer patients in lung cancer and significant disrupted pathways 
in acute lymphoblastic leukaemia (Chitale et al., 2009, Mullighan et al., 
2007). CNA studies can allow the identification of the positions of oncogenes 
and highlight putative targetable pathways (Weir et al., 2007, Zender et al., 
2006). 
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Previous studies in HNSCC have utilised technologies such as FISH, PCR 
and comparative genomic hybridisation to demonstrate commonly occurring 
areas of chromosomal gain mapped to 1q, 2q, 3q, 5p, 8q, 11q and areas of 
chromosomal loss mapped to 1p, 3p, 4p, 11q, 13q, 14q, 17q and 20q (Chen 
and Chen, 2008, Smeets et al., 2006, Struski et al., 2002). Despite this, 
relatively little is know about the genomic changes that lead to metastasis. 
Few studies have specifically aimed to evaluate CNA markers for metastasis 
in HNSCC primary tumours. A study by Patmore et al compared 23 HNSCC 
primary tumours to matched nodal metastases using CGH, finding no 
markers for metastasis (Patmore et al., 2004). This was limited by the small 
number of patients, lack of non-metastatic controls and mixing of primary  
tumour subsites (in particular mixing oropharyngeal SCC with non-
oropharyngeal SCC). Yoshioka et al profiled 25 patients with OSCC and 
their matched nodal metastasis using array-based CGH (Yoshioka et al., 
2013). This study found gains of 7p, 8q and 17q were more common in 
lymph node metastases compared to non-metastatic primary tumours 
implying they could be involved in metastasis. Though this did include a 
group of patients that were pN0 there was still a smaller number of patients 
and they did not take into account those tumours that produced metastases 
with ECS. 
Single nucleotide polymorphism (SNP) arrays have been demonstrated to 
provide high resolution analysis of CNA within cancer cells, though they 
have limited power to detect CNA in regions not targeted by the array and 
any study is limited by the resolution of the array being used (Bignell et al., 
2004). NGS can provide copy number data in a way analogous to arrays 
(Wood et al, 2010). Each genomic window consists of 200-900 sequencing 
reads that uniquely align to that genomic region (using a reference genome 
to align). Each genomic window can be considered equivalent to one array 
probe (Wood, 2013). This represents a genomic signal corresponding to a 
specific genomic location (Zhang and Gerstein, 2010). Whilst array data is 
calculated from log-ratios of normalised intensity of signal from the test 
sample to the reference sample, NGS copy number data is calculated from 
sequencing read counts after accounting for depth of sequencing (Zhang 
and Gerstein, 2010). Copy number sequencing (CNSeq) has been 
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demonstrated to be reproducible and reliable (Schweiger et al., 2009, Wood 
et al., 2010). Wood et al demonstrated that the data produced had a very 
high correlation to an array with an equivalent number of probes (Wood et 
al., 2010).  Hayes et al also reported a 100% concordance between CNSeq 
and aCGH for identifying pathogenic copy number variants, with CNSeq 
identifying one purported pathogenic variant not detected by aCGH (Hayes 
et al., 2013). 
NGS offers significant advantages in terms of CNA analysis. These include 
the ability to estimate the tumour-to-normal copy number ratio by counting 
the read number at specific loci, resolution that can be chosen (pre-
sequencing according to aim and cost) but can be manipulated post-hoc. In 
addition to offering comparable resolution to array-based technologies, 
CNSeq can be performed reliably and consistently with nanogram quantities 
of DNA. It can also use degraded sources of DNA such as FFPE tissue 
avoiding the need for extra preprocessing steps that are often required with 
arrays (Wood et al., 2010, Gusnanto et al., 2012, Hayes et al., 2013, 
Gusnanto et al., 2014). The sequencing library can also be reused in 
multiple experiments at varying depths of sequencing, which can be tailored 
to budget (Wood, 2013). 
One of the most striking features of the literature evaluating CNAs relating to 
an increased risk of metastasis, is the lack of concordance amongst the 
different studies (see Table 1-5). Differences in approach could explain 
some of these discrepancies, particularly when comparing genome-wide 
approaches to more targeted approaches such as FISH or PCR. Even when 
comparing apparently the same genome-wide technique, the age of the 
study (as a surrogate marker of technology generation), issue of resolution, 
source tissue type (FFPE vs fresh-frozen vs. cell-line) need to be considered 
as confounding factors. Though the subsite of HNSCC could influence 
findings it is more likely that the aetiology of the tumour would have a more 
significant effect on genomic findings for example smoking tobacco, HPV, 
chewing betel nut. The aetiology could be heavily influenced by the 
epidemiological background of the samples i.e. betel nut chewing is 
uncommon in the UK and western Europe but endemic in the Indian 
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subcontinent. The issue of inter and intra-tumour heterogeneity may affect 
the concordance of genomic findings between studies. 
Beroukhim et al, highlighted the disagreement between studies analysing 
genomic alterations in the same cancer as a serious issue suggesting 
differing analytical methods as a potential cause for this (Beroukhim et al., 
2007). They also raised the issue that many potential regions of interest put 
forward by studies could be random events of no biological significance as 
the background rate of random chromosomal aberrations is not clearly 
accounted for in many studies. For this reason they developed a systematic 
approach to analysing chromosomal aberrations in cancer called Genomic 
Identification of Significant Targets in Cancer (GISTIC) which has been 
found to significantly improve concordance in genomic alterations found in 
glioma studies. 
This was since updated to a second version (GISTIC 2.0) to provide 
estimation of focal and broad-level CNAs. Segmented data files are 
presented to GISTIC 2.0 of identical window size. The copy number profile is 
then deconstructed into underlying CNAs and GISTIC 2.0 models the 
background rate of CNAs separating focal and arm-length CNAs on the 
basis of length. A G-score is then calculated for each CNA (a log ratio of 
probability of specific CNA to the background rate of CNAs). A “peel-off 
algorithm” is then applied by GISTIC 2.0, that subtracts segments covering 
each peak until no significant segments remain on the chromosome. This 
defines the independent genomic regions undergoing significant CNA. 
Finally, the G-score is used to define the boundaries of the focal CNAs 
(Mermel et al., 2011). In addition to providing a standardised, reproducible 
approach to analysis GISTIC was also produced with the aim of identifying 
driver genomic event in cancer and ideally using CNA data to localise 
specific driver genes (Beroukhim et al., 2007). 
Though not the only software available to analyse CNA, GISTIC 2.0 has 
been utilised by all TCGA sub-groups and can be applied to both 





The work described in this chapter aimed to: 
1. Use NGS CNA data to compare genomic features of OSCC primary 
tumours and their matched cervical node metastases. 
2. Use NGS CNA analysis to identify genomic damage patterns within 
OSCC metastatic and non-metastatic primary tumours. 
3. Use NGS CNA analysis to identify genomic damage patterns that are 
specific to OSCC primary tumours associated with nodal 
extracapsular spread. 
 92 
4.2.1 Results 1: Comparison of CNA profiles of OSCC primary 
tumours to matched cervical node metastases 
4.2.1.1 Summary of patient cohort 
This initial analysis planned to compare the DNA copy number profile of 
primary tumours and their matched nodal metastasis. This included 49 
patients with a OSCC primary tumour and a paired nodal metastasis (see 
Table 4-1). In each patient the archived FFPE tissue blocks were obtained. A 
5 μm haematoxylin and eosin section was cut from each sample. Professor 
Kenneth MacLennan or Dr Preetha Chengot (consultant head and neck 
histopathologists) used this section to confirm the diagnosis and mark out 
the area of highest tumour cell content. DNA was successfully extracted 
from all 98 samples (49 tumour-metastasis pairs). These were all processed 
to copy number libraries (see Chapter 2.8) and multiplexed on the Illumina 
HiSeq 2500 at 40 samples per lane. The mean number of reads obtained 
per sample was 10,865,175 (range: 1,448,220 – 86,693,194). Only one 
sample had a detectable viral load (ECS066-L) which had a barely 







Buccal Alveolar Total 
No. of 
patients 
36 9 3 1 49 
Table 4-1: Table of all OSCC tumour (with matching nodal metastasis) subsite 
 
4.2.1.2 Individual karyograms of metastatic primary tumours 
The DNA sequencing libraries were multiplexed on the Illumina HiSeq 2500 
at 40 samples per lane. The resulting data was processed to a digital 
karyogram for each patient (see Chapter 2.9). The karyograms produced 
using CNAnorm allow a genome wide view of CNA in each sample. Even in 
visual inspection of the karyograms it is important to exclude specific areas 
of the genome from analysis. CNAs have been found to be overrepresented 
in genomic regions close to centromeres and close to telomeres (within 2 
Mb) as CNAs do not appear to arise uniformly throughout the genome and 
are overrepresented in these regions (Nguyen et al., 2006). This is thought 
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to be related to the repetitive nature of the nucleotide sequence in these 
regions, which results in reads aligning with poorer quality scores to these 
regions, making interpretation of them unreliable. As such, CNAs incorrectly 
appear the be enriched in these regions. Similarly chromosome (chr) 19 has 
long been regarded as unreliable when assessing CNA and was also 
interpreted with caution (Kallioniemi et al., 1994). This is due to the wider, 
normal individual variation existing in chr 19 and the reference genome 
therefore not being reliable. 
For each karyogram an assessment of the tumour cell DNA fraction of the 
sequenced sample is possible. Though a pathological estimate was made of 
all tissue blocks to try and obtain the highest dissected tumour cell fraction, 
this may not be identical to the fraction of DNA obtained from the dissected 
sample that is actually tumour, and that is subsequently sequenced. Firstly, 
each individual karyogram was inspected and the segments at which 
loss/gain of one copy of a genomic region is to be called at for that sample 
identified, as opposed to background noise due to mixed tumour clone 
sampling (see Figure 4-1). Simultaneously, an estimation of ploidy can be 
made from inspecting the karyogram. Once identified, the specific change in 
ratio of minimum gain/loss to normal can be obtained from the individual 
.bed file. This threshold can then be used to estimate the sample tumour 
DNA content by scaling the figure to that which would be produced by a 
gain/loss of one copy in a sample with 100% tumour DNA content (i.e. +1/-
1), accounting for ploidy. The CNA call threshold for each sample is needed 
for downstream analysis. 
Due to a pooled normal being used that was made up of 10 men and 10 
women (therefore containing a mean pooled 1.5 chr X and 0.5 chr Y), it was 
not possible to assess the copy number status of the X and Y chromosomes. 
This is because every male sample would automatically erroneously be 
labelled as having loss of chr X and gain of Y and every female sample 
assigned gain of chr Y and loss of X. In addition to this the level of coverage 
obtained with my sequencing was arguably not sufficient to reliably 
determine the status of these chromosomes as they contain large, repetitive 
regions. 
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Initial visual inspection of the individual karyograms of the primary tumours 
obtained from patients with nodal metastases show a number of CNAs in the 
majority. Losses were most frequently mapped to 3p, 4p, 5q, 8p, 9p, 11q 
and 18q.  Gains were most frequently seen on 3q, 5p, 7p, 8q, 12p, 14q, 20p 
and 20q. Two samples showed a dramatically reduced number of CNAs. 
All individual sample karyograms are shown in Appendix 8.3. 
 
Figure 4-1: An example of a karyogram from an OSCC primary tumour associated 
with nodal metastasis. Genomic windows with copy number gain are red and 
those with loss are blue. The tumour DNA fraction of the sample can be 
estimated from the ratio of the minimum gain/loss to normal. In this case the 
tumour DNA fraction is approximately 75%. 
 
 
Figure 4-2: The karyogram produced from the matching nodal metastasis from the 
same patient as fig. 4-1. The difference in height of gains and losses when 
compared to the primary tumour is due to a lower tumour DNA fraction. 
The digital karyograms from the matched nodal metastasis of each primary 
tumour were also inspected. An example is shown in Figure 4-2. All CNAs 
and genomic breakpoints within this nodal metastasis were shared with the 
matched primary tumour suggesting that the clonal cell population sampled 
from the metastasis was identical to the dominant clonal population sampled 
from the primary tumour. The level of similarity varied widely amongst 
tumour-metastasis pairs. Visual inspection and counting of CNAs and 
ECS040-T 
ECS040-L 
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breakpoints remained a slow method of demonstrating and measuring this 
across the group and so other methods of comparing the primary tumours 
and varied metastases were evaluated. 
4.2.1.3 Cumulative frequency CNA plots of metastatic primary tumours 
and paired nodal metastases 
In order to be able to compare the primary tumours to their matched 
metastasis as groups cumulative frequency plots were produced. Initial 
creation of these using seg_compare (Dr Henry Wood, Precancer Genomics 
group) was attempted using a group-wide minimum threshold for calling 
areas of gain or loss. This produced cumulative frequency plots that 
appeared to include a lot of spurious CNAs (e.g. in centromeric or telomeric 
regions) as well as appearing not to include areas that appeared to be 
significant on individual karyogram inspection (e.g. loss of 3p) and therefore 
falsely reducing the proportion of patients with certain regions of gain or loss 
(see Figure 4-3). 
In these plots chromosomal regions of gain are represented in red and 
regions of loss are highlighted blue. Along the y-axis is the frequency which 
each gain or loss is seen across the group (as opposed to the tumour to 
normal ratio presented on the y-axis in the individual karyograms). By 
assessing each karyogram individually and estimating the tumour DNA 
fraction and ploidy the minimum threshold for each sample was set for each 
sample. Cumulative frequency plots were then generated taking into account 
the individual sample thresholds (see Figure 4-4). This method of generating 
cumulative frequency plots reduced spikes of CNA in spurious regions (i.e. 
close to centromeres and telomeres) and therefore appeared to present a 
“cleaner” image.  
As can be see in Figure 4-4 there are few chromosomal arms where no gain 
or loss is seen in any sample. Despite this the majority of chromosomal 
instability is only seen in a minority of samples. For initial assessment I 




Figure 4-3: Cumulative frequency plot of OSCC primary tumours associated with 
nodal metastasis. Created using an arbitrary identical CNA threshold for all 
samples. Regions of gain are represented by red and loss by blue. In this plot 
approximately 50% of patients are demonstrated to have loss of 3p. This was 




Figure 4-4: Cumulative frequency plot of OSCC metastatic primary tumours. This 
was created after determining the minimum gain/loss threshold for each 
sample included in the group. This resulted in approximately 78% of samples 
having loss of 3p, an accurate reflection of individual karyogram assessment. 
It also contains far fewer spurious spikes of gain and loss in centromeric and 
telomeric regions making the overall plot easier to interpret. 
 
The most common CNAs were loss of 3p and gain of 8q, both found in 38/49 
(78%) of samples. Gain of 3q was demonstrated in 30/49 (61%) similar to 
gain of 5p (29/49 (60%)). These are quintessential genomic changes well 
recognised to be associated with HNSCC and lung SCC (to be expected 
given the unifying common aetiology is tobacco smoking). Loss of 18q was 
also shown in 25/49 (50%) of patients. 
Regions of gain and loss occurring at lower rates in this group include gain 
of 11q (21/49 (43%)), loss of 7p (20/49 (40%)), loss of 5q (18/49 (37%)), 
gain of 20p (18/49 (37%)), loss of 11q (17/49 (34%)), gain of 17p (17/49 
(34%)) and gain of 12p (17/49 (34%)). 
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The seg_compare scipt (Dr Henry Wood, Precancer genomics group) also 
generates cumulative frequency plots for each chromosome, as well as the 
genome-wide view above. This allows more specific observations to be 
made about regions of gain and loss (see Figure 4-5). These images suggest 
that most CNAs are broad. This is in keeping with studies of CNAs across a 
range of human cancers (Beroukhim et al., 2010). However this provides a 
challenge when trying to identify foci of minimally-altered regions to 
nominate candidate oncogenes or tumour suppressor genes as broad-level 
CNAs encompass thousands of genes. For this type of analysis the 
cumulative frequency karyograms are limited and required different software 
to be used at a later point. The cumulative individual chromosome plots 
allow a low resolution view of cytobands and the frequency of CNAs 
associated with the, across the whole group.  
As described above, individual karyograms were generated for each DNA 
sample obtained from the matching nodal metastasis of each primary tumour 
in this group (n = 49). This was done using the copy number gain/loss 
threshold individually determined for each sample as outlined previously 
(see Figure 4-6). This demonstrated a very similar pattern to the cumulative 
frequency plot generated for their respective primary tumours (see Figure 









Figure 4-5: Cumulative frequency plots of each chromosome for OSCC primary tumours 
associated with nodal metastasis.  
 
Visible differences included gain of 6p seen in 13/49 (26%) of metastatic 
primary tumours compared to 5/49 (11%) of paired metastases. Gain of 12p 
was seen in 15/49 (31%) of metastatic primary tumours but only in 7/49 
(14%) of paired lymph node metastases. Smaller differences were also seen 
such as loss of the distal portion of 14q, apparent in 2/49 (5%) of primary 
tumours but absent in their matched metastasis.  
 
 
Figure 4-6: Cumulative frequency plot generated from DNA samples from a matching nodal 
metastasis for each primary tumour in this group. 
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4.2.1.4 Comparison of CNA between metastatic primary tumours and 
lymph node metastases 
Though visually the cumulative frequency plots for these two groups were 
very similar a more objective measure of their similarity was needed to 
establish whether or not a significant genomic difference was present. 
4.2.1.4.1 Concordance 
Firstly  concordance rates for the presence of gain or loss in each window 
between matched pairs of metastatic primary tumours and their nodal 
metastasis were calculated. This was done by assigning a binary value to 
the presence of gain or loss (according to the individual threshold for each 
sample) in each window in each sample. These were then compared. Each 
metastatic primary tumour was compared to every other lymph node 
metastasis as well as every other metastatic primary tumour (see Figure 4-7). 
Discrepancies between tumour and paired metastasis could often be 
ascribed to differences in clonal sampling. In pair ECS040 (see Figure 4-7), 
though gain of 5p occurs along the whole arm it is not homogeneously 
gained in both samples. This would not affect the concordance as I have 
calculated it according to whether gain or loss was present and not the 
precise level of gain or loss. However, in chr 7 a focal segment of gain is 
identified in the primary tumour (represented by the black dot). This is not 
identified in the paired metastasis, though a genomic window of gain is 
present (represented by red dots). CNAnorm would require > 1 window of 
gain in the same region to be present in order to then be then assigned a 
segment (with a black dot/line). Variation like this is responsible for the < 
100% concordance. In other samples this may be more obvious when 
genomic segments are larger. 
As expected when compared with itself all samples had 100% concordance 
of genomic windows. Interestingly the concordance rates between paired 
tumour and metastasis varied widely from 90% to 10% with a mean of 51% 
(see Figure 4-8). In no tumour-lymph node pair was 100% concordance 
found. This is to be expected as variation in factors such as tumour DNA 
content or mixed clonal sampling could affect concordance. 28/49 (57%) of 
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pairs had concordance of 50% or greater and only 3 samples had 




Figure 4-7: (a) Bar chart to show the concordance of copy number alterations for all 
metastatic primary tumours and all metastases when compared to the primary 
tumour ECS040. When compared to itself (T) 100% concordance is found. 
The paired metastasis (L) for ECS040 has a high concordance of 90%. (b) 
The karyogram from the ECS040 primary tumour and (c) the karyogram from 
its matched metastasis. The black arrows highlight the minor differences 
between the two karyograms. 
 
Though tumour DNA content is attempted to be accounted for by assigning 
each sample a CNA call threshold, clonal heterogeneity is not. However, 
CNAs contained in small clonal populations may be removed from the 
analysis by the individual threshold if the levels of gain and loss within this 
population do not reach the minimum threshold. Larger sub-populations, 









Figure 4-8: Chart of concordance of metastatic primary tumours to their paired 
nodal metastases. 
 
In 37 of 49 pairs (78%) the paired metastasis had the highest concordance 
rate of any metastasis compared to it’s paired tumour. However, in 12 cases 
the paired metastasis was not the most concordant sample. Of these 12 
tumours, four were within 10% of being  the most concordant metastasis. 
The number of unrelated metastases with higher concordance ranged from 1 
to 48. In one case (ECS013) actually had the lowest concordance (10%) of 
all metastases compared (see Figure 4-9). The variation seen in concordance 
likely reflects the fact that though certain CNAs are characteristic of SCC 
there is no universal CNA seen in 100% of samples.  
On inspecting the individual karyograms produced such genomic differences 
are generally apparent. In 6 out of the 12 cases where the matched 
metastasis was not the most concordant sample, the paired metastasis 
demonstrated a greatly reduced number of CNA as in ECS013 (see Figure 
4-9). This could represent a sampling error due to different clonal 
populations being present in the metastasis. This could mean that a non-
dominant clone was sampled in the metastasis or that the differing 
environmental selective pressures surrounding the metastasis have led to a 
different clonal population becoming dominant. It is also possible that the 
lack of CNAs is due to error in tissue dissection including an excess of non-
cancerous cells leading to poor tumour DNA content. Reviewing the size of 
each metastasis showed that 3 out of 6 were < 5 mm in diameter, which can 
Primary Tumour Samples 
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be more technically demanding to dissect, however 3 of 6 were > 1 cm in 




Figure 4-9: (a) Bar chart to show copy number concordance for all metastatic 
primary tumours and metastases when compared to ECS013 primary tumour. 
When compared to itself (T) concordance is 100%. The paired metastasis (L) 
for ECS013 actually has the lowest concordance out of all metastases. (b) 
Karyogram for the ECS013 primary tumour and (c) karyogram for the ECS013 
metastasis. The stark differences in copy number profile are clear. 
 
In 5 out of 12 pairs with poor concordance, the metastasis showed a similar 
number of CNAs though a different overall genomic profile was seen. This 
could also be a resulting of ongoing evolution of the clonal population either 
at the primary tumour or the metastasis. It is also possible that the 
metastatic clone is dominant in the metastasis but is not in the primary 
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In the remaining tumour-metastasis pair (ECS068) with poor concordance 
(27%) closer inspection of the individual karyograms led to a different 
conclusion (see Figure 4-10). As can be seen, though the tumour DNA 
content is lower in the primary tumour karyogram the areas of gain and loss 
can still be discerned. The metastasis karyogram demonstrated a completely 
different CNA profile with almost no regions of chromosomal loss. This is 
particularly unusual for HNSCC.  
An insight into how CNAnorm works is useful here. CNAnorm operates by 
setting the most common copy number detected as the ‘normal’. In the 
ECS068 metastasis sample, it is apparent that the most common copy 
number detected is actually a loss and therefore has mistakenly ‘reset’ the 
normal baseline masking the segments in blue. The normal baseline for this 
was manually reset by subtracting the ratio 0.245 from all values in the 
ECS068-L .bed file to shift the baseline upwards. When concordance was 
re-calculated using these values it resulted in a concordance of 66% and the 
paired metastasis had the highest concordance of any sample. 
It is still important to note the range in concordance rates calculated in the 
37 cases where the primary tumour and paired metastasis had the highest 
concordance (range: 90% - 35%, mean: 57%). This could be interpreted as 
showing genomic changes are continually ongoing at either the metastasis 
or the primary tumour, or that heterogeneity of clonal populations is a factor 
when sampling.  It is also interesting that attempting to use an objective 
measure of similarity between primary tumour and metastasis highlighted 
one case of potential error in the CNAnorm karyograms. An alternative 
method of objectively measuring similarity between pairs could be to use 






Figure 4-10: (a) Bar chart to show concordance of all metastatic primary tumours 
and metastases when compared to ECS068 primary tumour. Comparison to 
itself (T) and its matched metastasis (L) are highlighted (b) Individual 
karyogram for ECS068 primary tumour and (c) ECS068 paired metastasis. 
 
4.2.1.4.2 Correlation 
The correlation of CNA between samples can be calculated by assigning a 
value to each segment for the presence or absence of CNA for each sample 
(i.e. -1, 0, 1). This approach was chosen over giving a quantitative value for 
each CNA was in order to try and reduce noise in the results as well as the 
fact that the level of gain or loss was not deemed as important as the simple 
presence of gain or loss in terms of CNA profile. The correlation between the 
presence or absence of gain or loss can be calculated using Pearson’s 
product moment correlation coefficient (r). 
The data produced agreed closely with the concordance data above. In 
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correlation whilst it did not have the highest concordance. In these the rates 
of CNA on either the primary tumour or the metastasis were significantly 
reduced. Though visual similarities can be seen on their individual 
karyograms the differences are clear (see Figure 4-11). It is also worth noting 
that in these cases the matched metastasis was only marginally more 
closely correlated to the primary tumour than the next closest metastasis.  
It is of interest that the ECS068 tumour-metastasis pair discussed earlier, 
potentially highlighted a flaw in the CNAnorm programme, was found to have 
closest correlation in complete contrast to their concordance. This is likely 
due to the assignation of gain or loss to each segment is related to its 
position relative to the previous segment and therefore the changes in 
segment relative to one another are detected rather than the absolute 
position as assigned by CNAnorm. This may also be the reason why 
correlation figures appear higher in many cases compared to the 
concordance rate. This could suggest that, as an isolated measure, 
correlation may provide a better indication of genomic similarity, rather than 
concordance. 
Otherwise the same tumour-metastasis pairs were found to have closest 
correlation as with concordance rates. Correlation therefore acted as a 
second objective technique of comparing how genomically similar primary 
tumour and matched metastasis were. Advantages and disadvantages of 
both approaches exist and it seems sensible to suggest using correlation in 
combination with visual inspection of karyograms will provide a reliable 
indication of genomic CNA differences between primary tumour and 
metastasis. Concordance on the other hand allows for genomic regions of 
high or low concordance to be identified. Ultimately, the majority of tumour-







Figure 4-11: (a) Individual karyogram for primary tumour of ECS054 and (b) its 
matched metastasis. (c) Bar chart comparing correlation of CNA in ECS054 primary 
tumour (T) to all other tumours and metastases. The closest correlate is the 
matched metastasis (L). (d) Bar chart comparing concordance rates of CNA in 
ECS054 primary tumour to all other tumours and metastases. Here the matched 
metastasis (L) has a poor concordance. 
 
4.2.1.4.3 Use of GISTIC 2.0 for focal analysis 
CNAs in cancer are frequently found to encompass the entire length of a 
chromosomal arm (Zack et al., 2013, Beroukhim et al., 2010). The samples 
included in this study concur with this finding as seen in the individual and 
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2.0 is an open access algorithm developed by the Broad Institute that 
provides a systematic method for analysing chromosomal aberrations in 
cancer (Mermel et al., 2011). It provides accurate identification of the copy 
number profile in each sample, providing an indication of significant focal 
copy number aberrations across a group of samples. It analyses the 
frequency and amplitude of the CNA as well as assesses the statistical 
significance of the CNA assigning a q-value to each. GISTIC has been used 
across numerous cancer studies providing an objective method of analysing 
samples correlating CNA with clinical outcome and identifying driver CNAs 
and potentially the driver genes within these regions (Zack et al., 2013, 
Beroukhim et al., 2010, Bass et al., 2009, Frankel et al., 2014, Xie et al., 
2012). 
Though cumulative frequency karyograms can be produced at good 
resolution with CNAnorm files high frequency broad events can mask the 
lower frequency focal event on the images produced. GISTIC simultaneously 
runs a focal and broad analysis separately removing any potential masking 
of focal CNAs. GISTIC also provides lists of amplified and deleted genes 
within the altered regions as well as heat maps of the copy number data. 
The GISTIC parameters used are in Chapter 2.9.2.3. 
Firstly, an analysis was performed to identify focal chromosomal events. The 
focal amplification and deletion profiles of the nodal metastases paired to the 
metastatic primary tumours revealed a strong similarity. It was still important 
to regard event occurring close to centromeres and telomeres as potentially 
spurious.  
In terms of focal amplifications (see Figure 4-12). The most common shared 
amplification was gain of 8q24.13, identified in 38/49 (78%) of metastatic 
primary tumours and 24/49 (49%) of nodal metastases (see Table 4-2). This 
is closely followed by similar gains of 3q26.2 (present in 57% of metastatic 
primary tumours and 53% of nodal metastases), 5p14.3, 11q13.3 and 
7p11.2. 
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Figure 4-12: Genome-wide focal amplification plots for all metastatic primary 
tumours (left) and their matched nodal metastases (right). The chromosomes 
are numbered along the y-axis. The bottom x-axis indicates the q-value with 
the green line marking the significance threshold (0.25). The top x-axis shows 
the G-score for the CNAs calculated by GISTIC. 
 
Slight variation was present between groups, in the focal CNA cytobands 
produced by GISTIC, for example: gain of 7q22.2 reported in primary 
tumours but gain of 7q22.1 for nodal metastases. The wide peak 
boundaries, also provided by GISTIC, for these amplifications showed they 
were very closely overlapping. This was confirmed on inspection of the 
cumulative frequency plots. 
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Cytoband Number of samples in 
each group (%) 
Cytoband Number of samples in 





(n = 49) 
Nodal 
Metastases 




(n = 49) 
Nodal 
Metastases 
(n = 49) 
8q24.13 38 (78) 24 (49) 3p14.2 38 (78) 35 (71) 
3q26.2 28 (57) 26 (53) 3p26.1 34 (69) 31 (63) 
5p14.3 26(53) 23 (47) 18q21.1 24 (49) 29 (59) 
11q13.3 23 (47) 22 (45) 5q33.1 19 (39) 18 (37) 
7p11.2 20 (41) 26 (53) 11q24.2 17 (35) 22 (45) 
17q23.2 17 (35) 15 (31) 11q21 17 (35) 22 (45) 
9p13.3 13 (27) 9 (18) 9p24.3 16 (33) 15 (31) 
13q34 12 (24) 9 (18) 8p23.2 14 (29) 14 (29) 
7q22.2 11 (22) 9 (18) 4p14 11 (22) 7 (14) 
2q11.2 8 (16) 4 (8) 15q26.2 8 (16) 10 (20) 
2q31.1 7 (14) 5 (10) 7q36.1 7 (14) 7 (14) 
4p15.1 6 (12) 5 (10) 2q34 6 (12) 4 (8) 
   19p12 4 (8) 6 (12) 
Table 4-2: Frequency of focal CNAs identified by GISTIC 2.0. 
 
Amplifications identified by GISTIC as present in the metastatic primary 
tumours, but absent in the nodal metastases included gain of 2q31.1, 
4p15.1, 5p14.3. When the cumulative frequency karyograms were inspected 
these CNAs were observed in both groups at similar frequencies (see Table 
4-2). Gain of 2q31.1 was present in 7/49 (14%) metastatic primary tumours 
and 5/49 (10%) nodal metastases. Gain of 4p15.1 was present in 6/49 (12%) 
metastatic primary tumours and 5/49 (10%) nodal metastases. These were 
present at low frequencies in both groups, but marginally lower in the nodal 
metastases, which is likely the reason GISTIC did not identify them as focal 
CNAs in this group.  
Gain of 5p14.3 was present in 26/49 (53%) metastatic primary tumours and 
23/49 (47%) of nodal metastases. Despite this much higher and similar 
frequency in both groups GISTIC only identified this as a focal CNA in the 
primary tumours. On inspecting the individual karyograms, it is clear that 
amplifications on 5p occur on a broad level (> half the length of 
chromosome) in both groups. In the nodal metastases 16/23 amplification on 
5p occur across the entire arm, thus reducing the number in which a focal 
alteration can be identified. The nine focal amplifications common to both 
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groups, tended to occur at similar frequencies. Gain of 8q24.13 was present 
in 78% of metastatic primary tumours and 49% of nodal metastases. Seven 
of the remaining amplifications occur with 8% or less difference between 
groups. Only gain of 7p11.2 occurred with a higher frequency in the nodal 
metastases (53% vs. 40% in the metastatic primary tumours).  
         
Figure 4-13: Genome-wide focal deletion plots for all metastatic primary tumours 
(left) and their matched nodal metastases (right). The chromosomes are numbered 
along the y-axis. The bottom x-axis indicates the q-value with the green line 
marking the significance threshold (0.25). The top x-axis shows the G-score 
calculated by GISTIC. 
 
In terms of focal deletion profiles (see Figure 4-13) the primary tumour and 
their matched metastases are again very similar. The most common shared 
focal deletion is loss of 3p14.1, occurring in 38/49 (78%) of primary tumours 
and 35/49 (71%) of nodal metastases. This is followed by loss of 18q21.1 in 
24/49 (49%) of primary tumours and 29/49 (59%) of nodal metastases. 
There is also variation in the focal CNAs reported by GISTIC between 
groups such as loss of 11q24.3 is present in the metastatic primary tumours, 
but loss of 11q24.2 in the nodal metastases.  
These regions were examined more closely using the individual 
chromosome cumulative frequency plots created using seg_compare (see 
Figure 4-14). The close proximity of these region were confirmed using the 
wide peak boundaries provided by GISTIC revealing these two regions are 






























































































































overlapping (see Table 4-3). This suggests that the same genes may be lost, 
though the actual region varies slightly in its co-ordinates. Similarly loss of 
4p14 is reported by GISTIC in the primary tumours but loss of 4p15.1 in the 
nodal metastases. This variation may be due to variation in the exact 
breakpoints between samples. Therefore slight variation in the exact co-
ordinates of overlapping regions in separate groups can occur. The generic 
CNA call threshold utilised by GISTIC means that alterations in some 
samples may not be recognised affecting the precise assignation of CNA.  
 
Figure 4-14: Cumulative frequency karyograms for (a) chr 11 in metastatic primary 
tumours and (b) in matched nodal metastases (c) chr 4 in metastatic primary 
tumours and (d) in matched nodal metastases. 
 
(a)      (b) 
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Table 4-3: Wide peak boundaries of adjacent focal CNAs reveal them to be in fact 
overlapping rather than adjacent. 
 
The nodal metastases contained four deletions not reported in the metastatic 
primary tumours by GISTIC. These were again all identified on the 
inspection of the individual karyograms in both groups at similar frequencies. 
These included loss of 3p26.1 (in 34/49 (69%) primary tumours and 31/49 
(63%) metastases), loss of 8p23.2 (in 14/49 (29%) primary tumours and 
14/49 (29%)  nodal metastases), loss of 15q26.2 (in 8/49 (16%) primary 
tumours and 10/49 (20%) nodal metastases) and loss of 2q34 (in 6/49 (12%) 
primary tumours and 4/49 (8%) nodal metastases). Inspection of the 
individual karyograms revealed 6/8 losses on 15q included the entire arm, 
whilst 28/34 losses of 3p and 10/14 losses on 8p also included the entire 
arm. The high frequency of these broad-level losses may have reduced the 
sensitivity of GISTIC in identifying focal CNAs in both groups. The generic 
CNA call threshold used by GISTIC is also a confounding factor when 
comparing it to CNAnorm karyograms produced using individual sample 
thresholds.  
Again there is a similar rate of focal deletion in both groups (see Table 4-2) 
with the nine common deletions having a difference of 10% or less in the 
proportion of samples the CNA is present. Four of the common deletions 
were more common in nodal metastases, and one was observed at identical 
rates in both groups.  
Overall it is of interest that the frequency with which focal deletions are 
observed similar to focal amplifications (see Table 4-2). In the metastatic 
primary tumours focal amplifications occur in from 6–38 patients (78%–12%, 
mean: 36%) whilst in nodal metastases they occur in 5–24 patients (49%–
10%, mean: 30%). Focal deletion occur in 4–38 metastatic primary tumours 
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(78%–8%, mean: 34%), whilst in the nodal metastases they occur in 6 - 35 
patients (71%–12%, mean: 35%). 
In both groups the majority of focal CNAs are seen in the minority of 
samples (see Table 4-2). In terms of focal amplifications only 3/12 (gain of 
8q24.13, 3q26.2 and 5p14.3) are present in more than 50% of metastatic 
primary tumours. Only gain of 8q24.13 and 3q26.2 are present in more than 
50% of nodal metastases. Similarly only two focal deletions were present in 
more than 50% of metastatic primary tumours (loss of 3p14.2 and 3p26.1) 
and only three present in more than 50% of nodal metastases (loss of 
3p14.2, 3p26.1 and 18q21.2). 
4.2.1.4.4 GISTIC 2.0 Broad-level analysis 
GISTIC generates genome-wide heat maps  of CNA on a broad level (see 
Figure 4-15). 
(a)       (b) 
   
Figure 4-15: GISTIC heat maps for regions of chromosomal gain (red) and loss 
(blue) are shown above for (a) metastatic primary tumours and (b) their 
matched nodal metastases. The intensity of colour indicates higher or lower 
relative CNA. 
 
The GISTIC heat maps are analogous to the cumulative frequency 
karyograms produced using CNAnorm. They offer a group-wide view and a 
low resolution individual sample view simultaneously. GISTIC also generates 
raw data giving the frequency of each arm-level CNA with an associated z-













































outside -1.96 to 1.96 are considered significant. The q-value threshold was 
set at <0.25, in relation to the false discovery rate due to background 
chromosomal alterations. GISTIC assigns each of these values to the 




 Metastatic primary tumours Nodal Metastases 
Chr Arm Frequency z-score q-value Frequency z-score q-value 
3q 0.45 3.44 0.00528 0.24 1.47 0.308 
5p 0.5 2.34 0.0628 0.39 2.52 0.0763 
7p 0.5 3.35 0.00528 0.26 1.17 0.474 
8p 0.33 0.527 0.583 0.34 2.07 0.126 
8q 0.64 5.73 1.92E-07 0.49 5.42 1.16E-06 
9q 0.36 2.03 0.119 0.2 0.947 0.609 
19p 0.29 0.785 0.496 0.29 2.15 0.123 
19q 0.26 1.83 0.145 0.23 2.72 0.0644 
20p 0.5 2.62 0.0345 0.36 2.25 0.118 
20q 0.45 2.75 0.0293 0.29 1.94 0.147 
Amplifications 
	 Metastatic primary tumours Nodal metastases 
Chr Arm Frequency z-score q-value Frequency z-score q-value 
3p 0.76 8.13 8.66E-15 0.7 10 0 
3q 0.29 0.897 0.655 0.39 4.28 0.00012 
5q 0.46 4.49 6.98E-05 0.36 4.84 1.24E-05 
8p 0.49 2.72 0.0426 0.45 3.86 0.00056 
9p 0.39 1.04 0.577 0.38 2.69 0.0247 
10p 0.27 -0.578 0.999 0.34 2.08 0.0911 
10q 0.16 -0.865 0.999 0.24 2.02 0.0946 
15q 0.33 2.03 0.167 0.21 1.62 0.188 
18p 0.36 0.266 0.999 0.37 2.12 0.0911 
18q 0.43 1.67 0.306 0.37 2.67 0.0247 
19q 0.28 2.18 0.142 0.13 0.521 0.629 
Table 4-4: List of broad level CNAs identified as significant by GISTIC (z-score 
outside -1.96-1.96 and q-value < 0.25) highlighted in red. 
The frequency of all arm-level CNAs identified by GISTIC is not identical to 
the rates at which they are identified using the CNAnorm karyograms. This is 
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due to the fact that GISTIC is unable to accept an individual CNA-calling 
threshold for each sample and can only assign a generic group-wide 
threshold. This could potentially include a lot of background “noise”, whilst if 
too high may exclude actual CNAs, and is therefore an important limitation of 
using GISTIC 2.0.  
Interestingly the GISTIC heat maps show similar trends of CNA to the 
cumulative frequency plots (see Figure 4-4 and Figure 4-6). The most frequent 
CNAs were loss of 3p (37/49 (76%) of metastatic primary tumours and 34/49 
(70%) of metastases) and gain of 8q (in 31 (64%) of metastatic primary 
tumours and 24/49 (49%) of metastases). Gain of 5p was present in 25 
(50%) of primary tumours and 19/49 (39%) of metastases.  
Gain of 11q was identified in 9/49 (19%) of primary tumours and 5/49 (10%) 
of metastases. In neither of these groups was this amplification found to be 
at a significant level (q = 0.989). This is a much lower frequency than found 
using the CNAnorm karyograms (43% in primary tumours). The 
inconsistency may be due to the fact that GISTIC utilises a generic group-
wide threshold, rather than an individual sample threshold, making it less 
sensitive, to samples with variable tumour DNA content. Gain of 20p was 
present in 25/49 (50%) of metastatic primary tumours analysed by GISTIC 
but 18/49 (37%) of tumours analysed using CNAnorm karyograms. This, is 
still likely due to variation produced by not using an individual sample CNA-
call threshold. 
Though the frequency of CNAs was similar for the majority of CNAs in 
primary tumours and metastases their significance level varied. 9/11 
Deletions occurred at rates within 10% of each other (see Table 4-4). Despite 
this six of them were only found at a level of significance            (q < 0.25) in 
one group. Loss of 18q was present in 18/49 (37%) of nodal metastases (q = 
0.00247). Though present at a higher frequency in primary tumours (21/49 
(43%)), this was not found to be significant (q = 0.306). This discrepancy 
may simply reflect that though a deletion on 18q was present in 25/49 (50%) 
of the individual karyograms, in 13/25 the deletion is focal, not covering the 
whole arm of the chromosome. 
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Broad amplifications appear to have more variation between primary 
tumours and metastases, for example gain of 3q is present in 22/49 (45%) of 
primary tumours and 12/49 (24%) of nodal metastases. This drop in 
frequency is likely the cause for it not to be found at a significant level in 
nodal metastases (q = 0.308). This may reflect the differences due to CNA-
call thresholds. However examination of the karyogram reveals gain of part 
of 3q to be present in 26/49 (53%) of all samples. In 19/26 primary tumours 
the amplification includes > 50% of the 3q arm whilst in only 7/26 
metastases does it cover > 50% of the arm.  These differences may also be 
due to clonal heterogeneity between primary tumour and metastasis. 
GISTIC broad analyses are similar to the focal analysis in that the majority of 
broad CNAs are again seen in the minority of samples. Only 4/10 
amplifications are present in ≥ 50% of primary tumours and none in the 
nodal metastases. Only 1/11 deletions is identified in the primary tumours or 
nodal metastases. This highlights the inter-tumour heterogeneity amongst 
HNSCC. An advantage of the heat maps is that they highlight the 
heterogeneity of CNA. Regions such as 2q are found to have a low 
frequency of CNA yet a small number of samples have a significant loss. As 
such GISTIC broad analyses have limitations and need to be interpreted 
with the value of individual karyograms. All broad CNAs of significance are 
identifiable on the CNAnorm cumulative frequency plots but GISTIC does 
provide an estimation of their significance with relation to background CNAs, 
which is valuable.  
4.2.2 Results 2: DNA copy number analysis of non-metastatic 
OSCC primary tumours  
4.2.2.1 Individual karyograms for non-metastatic primary tumours 
A total of 26 patients with OSCC were included in this group. All patients 
underwent surgical resection of both their primary tumour and regional 
cervical lymph nodes as treatment. The specimens were all examined under 
standard protocol  in Leeds Histopathology department and confirmed to 
have no lymph node metastases. Tissue blocks from the primary tumours 
were obtained and the diagnosis confirmed by Professor Kenneth 
MacLennan or Dr Preetha Chengot (consultant head and neck pathologists). 
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DNA extraction was carried out and then processed to copy number 
sequencing libraries as described previously. The samples were multiplexed 
on the Illumina HiSeq 2500 and the resulting data processed to an individual 
digital karyogram for each (see Figure 4-16). 
 
Figure 4-16: An example of an individual karyogram produced from OSCC non-
metastatic primary tumour. 
 
In general the karyograms generated from non-metastatic primary tumours 
showed a different pattern to those from metastatic primary tumours. Ten 
tumours showed very few, if any CNAs on their karyogram. The remainder 
demonstrated a lower degree of genomic damage, on visual inspection, 
compared to those from metastatic primary tumours. Though classical CNAs 
associated with both HNSCC and lung SCC such as loss of 3p and 5q were 
still seen this appeared to be in a much lower proportion of samples than in 
the nodal metastases. Group-wide analysis is easier using cumulative 
frequency plots. 
4.2.2.2 Cumulative frequency plots for non-metastatic primary tumours 
and comparison to metastatic primary tumours 
Cumulative frequency plots were created using seg_compare (Dr Henry 
Wood, Precancer genomics group). These highlighted the differences in 
genomic CNAs between non-metastatic primary tumours and the metastatic 
groups (see Figure 4-17). 
Though loss of 3p was seen in non-metastatic primary tumours, it was only 
apparent in 10/26 (39%) compared to 39/49 (80%) of metastatic primary 
tumours (using visual inspection of CNAnorm images). Similarly reduced 
rates of CNA were seen in other typical areas associated with SCC, such as 




gain of 3q and 5p and loss of 5q. More details could be discerned from 
cumulative individual chromosomes (see Figure 4-18). 
 












Figure 4-18: Individual cumulative chromosome plots for non-metastatic primary 
tumours. 
 
Though there were similarities in the regions of CNAs seen on the 
cumulative karyograms when compared to the metastatic primary tumours 
there were marked differences in the frequency. Loss of 3p was found in 
9/26 (35%) of non-metastatic primary tumours compared to 38/49 (78%) of 
metastatic primary tumours. Gain of 3q was present in 10/26 (38%) 
compared to 30/49 (61%) of metastatic primary tumours. Gain of 8q was 
present in 10/26 (38%) compared to 38/49 (78%) of metastatic primary 
tumours. Gain of 5p was present in 8/26 (31%) compared to 29/49 (60%) of 
metastatic primary tumours. Loss of 5q was present in 4/26 (15%) compared 
to 18/49 (37%) of metastatic primary tumours.  
Other CNA differences included loss of 18q, identified in 50% of metastatic 
primary tumours was only present in 1/26 (4%) of non-metastatic primary 
tumours and gain of 7p, which was found in 6/26 (23%) of non-metastatic 
primary tumours but 20/49 (40%) of metastatic primary tumours.  
The cumulative frequency plots demonstrated an overall reduced number of 
CNAs in the non-metastatic tumours compared to the metastatic tumours. 
They also showed that the CNAs were not uniform in their length and 
therefore a focal analysis could be more revealing. 
4.2.2.3 GISTIC focal analysis of non-metastatic primary tumours 
Surprisingly, no significant focal amplifications were identified by GISTIC 
(see Figure 4-19) in this group. Though numerous events were observed to 
occur in up to 40% of samples these were not shown to be significantly 
aberrant when compared to the background rate of alterations (i.e. they did 
not reach the q-value threshold of 0.25). 
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Figure 4-19: Genome-wide focal amplification (red, (a)) and deletion (blue, (b)) plots 
for non-metastatic tumours. The chromosomes are numbered along the y-
axis. The bottom x-axis indicates the q-value with the green line marking the 
significance threshold (0.25). The top x-axis shows the G-score calculated by 
GISTIC. 
 
In terms of focal deletions, in general the frequency across the group was 
much lower than the metastatic samples (see Table 4-5). The most common 
deletion present was loss of 3p14.3, in 10/26 (39%) non-metastatic primary 
tumours, compared to 38/49 (78%) of metastatic primary tumours. This was 
followed by loss of 5q32 in 4/26 (15%) non-metastatic tumour. The wide 
peak boundaries for this region reveal it to be present in 19/49 (39%) of  
metastatic tumours. Loss of 8p23.2 was present in 4/26 (15%) non-
metastatic primary tumours and 14/49 (29%) of metastatic primary tumours. 
Loss of 9p24.3 was present in 3/26 (12%) non-metastatic tumours and 16/49 
(33%) of metastatic primary tumours.  
The wide peak boundaries for loss of 18q12.2 revealed that this deletion 
overlapped between metastatic and non-metastatic primary tumours. 
However it was only present in 1/26 (4%) non-metastatic primary tumours, 





















































































Frequency in N0 
Tumours n = 26 (%) 
3p14.3 10 (39) 
5q13.1 5 (19) 
5q32 4 (15) 
8p23.2 4 (15) 
1p12 3 (12) 
9p24.3 3 (12) 
10q24.32 2 (12) 
18q12.2 1 (4) 
9q33.1 1 (4) 
Table 4-5: Frequency of focal deletions identified as reaching a level of significance 
in non-metastatic primary tumours (q = < 0.25). 
 
Four focal amplifications were identified by GISTIC as occurring at a 
significant level (q = < 0.25) across the non-metastatic primary tumours, 
which were not identified in the metastatic primary tumours or metastases. 
These included loss of 5q13.1, 1p12, 10q24.32 and 9q33.1. All of these 
were present in 3 or less non-metastatic primary tumours.  
Of note, GISTIC identified loss of 22q13.1 as a focal deletion just achieving 
significance (q = 0.248) in non-metastatic primary tumours. However on 
inspection of the CNAnorm karyograms no deletion is present in this region 
(see Figure 4-20). This is likely due to the generic CNA-call threshold that 
GISTIC uses, rather than an individual sample threshold. By generating the 
cumulative frequency plots using a generic threshold the deletion at 22q13.1 
is visible (see Figure 4-20), demonstrating it is a spurious finding. 
The absence of focal amplifications and low incidence of focal deletions 
suggests that these events are uncommon in non-metastatic tumours. As 
GISTIC calculates whether these events are likely to be significant in 
comparison to the background CNA rate, it could reflect the fact that a 10/26 
(38%) non-metastatic primary tumours have few or no CNAs. It could 
however reflect the lower number of samples included in this group. A larger 
number of samples could reveal more significant CNAs occurring at a low 




Figure 4-20: Comparison of cumulative individual chromosome plots for chr 22 
across non-metastatic primary tumours. A generic CNA threshold (a) shows a 
deletion of 22q13.1, whilst this is no longer present when applying an 
individual sample threshold (b). 
 
4.2.2.4 Identification of minimally altered genomic regions associated 
with metastasis 
The CNA profile of nodal metastases and their metastatic primary tumours 
have been shown to share similarities (see section 4.2.1.4). Disparities may 
be due to differences in clonal sampling between the two. The metastatic 
clone is likely to be the dominant clone in the nodal metastasis. Therefore 
when attempting to identify markers for metastasis it may be more useful to 
compare the profile of non-metastatic primary tumours to that of the nodal 
metastases. Any marker found is likely to be identifiable in the metastatic 
primary tumour as demonstrated by the correlation and concordance 
analysis.  
Though GISTIC identifies potential focal regions of relevance in known 
clinicopathologic groups, the wide peak boundaries for these are often 
extremely broad and in order to try and identify potential candidate genes of 
interest it is necessary to identify the smallest region that is being recurrently 
copy number altered (the minimally altered region). This is of particular 
importance when attempting to identify genes of interest, in order to reduce 
the number of potential candidates. By using open access software called 
pheatmap (Raivo Kolde, Harvard USA) and combining this with an R-based 
script called genomeHeat (Dr Henry Wood, Precancer genomics) I was able 
to create group-wide heatmaps for these samples, utilising the 
CNAnormout.txt files as input. This software provided greater resolution than 
(a) (b) 


























the CNAnorm-generated cumulative frequency plots when attempting to 
identify the minimally altered region, as well as allowing the ability to 
simultaneously count the number of samples that any region was altered in. 
As individual sample CNA thresholds were applied to the input files this was 
an ideal software. 
Firstly the focal region identified by GISTIC in nodal metastases and non-
metastatic tumours were analysed to identify the true minimally altered 
region, corresponding cytoband and frequency in each group. pheatmap 
was sued to produce sequential heatmaps with increasing resolution to 
identify the minimally altered region (see Figure 4-21). This process was then 
repeated for all focal CNAs identified by GISTIC. 
Comparison of the frequency of minimally altered regions in nodal 
metastases and non-metastatic primary tumours is shown in Table 4-6. The 
focal regions exclusively seen in the nodal metastases could suggest driver 
genes that play a key role in cellular events enabling metastasis. Focal 
CNAs shared between the non-metastatic tumours and nodal metastases 
could represent changes involved in cancer development rather than 
necessary for metastasis.  
 
 





Figure 4-21: Example of sequential heatmaps produced to identify minimally altered 
region. (a) shows a genome-wide view of the CNA profile of all nodal 
metastases. (b) demonstrates a view of chr 18q. (c) shows the focal deletion 
identified using GISTIC is highlighted with black brackets. The actual 
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Amplifications Frequency (%) 
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15 (31) 3 (12) 










































































6 (12) 1 (4) 
Table 4-6: Comparison of frequency of minimally altered regions in nodal 
metastases and non-metastatic primary tumours. 
There were no minimally altered amplifications unique to one group. This 
was surprising, given GISTIC did not identify any focal amplifications in the 
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non-metastatic primary tumours of significance (q = < 0.25). This was likely 
related the fact that 10/26 (38%) of this group contained a greatly reduced 
number of CNAs, leaving fewer samples for GISTIC to compare focal 
amplification rates to background CNAs. 
Several CNAs were found much more frequently in the nodal metastases. In 
terms of amplifications gain of 11q13.3-q13.2 is present in 22/49 (45%) of 
nodal metastases and only 2/26 (8%) of non-metastatic primary tumours. 
Gain of 7p12.1-11.2 is present in 26/49 (53%) of nodal metastases 
compared to 6/26 (23%) of non-metastatic primary tumours. Gain of 17q22-
q23.3 was present in 15/49 (31%) of nodal metastases and 5/26 (19%) of 
non-metastatic primary tumours. Gain of 9p21.1 was present in 9/49 (18%) 
of nodal metastases and 1/26 (4%) of non-metastatic primary tumours.  
The remaining focal amplification highlighted by GISTIC were found at rates 
within ≤15% in both groups. Two minimally altered regions were identified at 
occurring at high frequency in nodal metastases, using pheatmap alone. 
These were gain of 8q24.12-q24.13 and 8q11.21. They were found in 25/49 
(50%) and 28/49 (57%) of nodal metastases and 11/49 (42%) and 9/26 
(35%), respectively, of non-metastatic primary tumours. 
A number of minimally altered deletions presented a greater contrast 
between the groups compared to amplifications, with two being unique to the 
nodal metastases. Loss of 11q23.1-q25 was present in 22/49 (45%) of nodal 
metastases and absent in non-metastatic primary tumours. Loss of 18q21.1-
q21.32 was present in 30/49 (59%) of nodal metastases and only 1/26 (4%) 
of non-metastatic primary tumours. Loss of 3p14.1-p14.1 was present in 
35/49 (71%) of nodal metastases and 10/26 (38%) of non-metastatic primary 
tumours. Loss of 3p26.3-p26.1 was present in 31/49 (63%) of nodal 
metastases and only 35% of non-metastatic primary tumours. Loss of 
4p15.1 was present in 7/49 (14%) of nodal metastases and in 1/26 (4%) 
non-metastatic primary tumours. 
Out of 22 focal CNAs, pheatmap enabled identification of a minimally altered 
region (within the wide peak boundaries provided by GISTIC) in 20. In one 
case the minimally altered region was the same size and in one case it was 
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actually slightly bigger. This enabled a more focused analysis of potential 
gene candidates to be undertaken.  
4.2.2.5 Identification of genes  
The genomic co-ordinates of the minimally altered regions were input into 
the UCSC Genome Browser to produce lists of all genes contained within 
(Kent et al., 2002). These were then cross-referenced with gene lists known 
to be associated with HNSCC. These were comprised of 12 gene pathways 
from the Kyoto Encyclopaedia of Genes and Genomes (KEGG, 
http://www.genome.jp/kegg/), HNSCC genes from the  cancer  
gene census (http://cancer.sanger.ac.uk/cancergenome/projects/census) 
and a list of genes identified by Stransky et al and the TCGA HNSCC 
subgroup as harbouring a statistically significant frequency of somatic 
mutations in HNSCC (Stransky et al., 2011, Cancer Genome Atlas, 2015).  
In total 1116 genes were contained within the minimally deleted regions and 
641 genes within the minimally amplified regions. After cross referencing 
these to the lists above, 54 deleted genes and 50 amplified genes were 
identified (see Table 4-7 and Table 4-8). This is consistent with reports that 
CNA occur across broad regions suggesting the majority of genes are 
unlikely to be important in cancer or metastasis development. It also 
highlights the effectiveness of this process of identifying the minimally 
altered region. 
Interestingly, these deleted genes were identified 752 times in nodal 
metastases compared to 64 times in non-metastatic primary tumours. 
Amplified genes of interest were identified 688 times in nodal metastases 
compared to 173 non-metastatic primary tumours. This is consistent with the 
fact that these CNAs were found more frequently in nodal metastases. It 
also suggests that in nodal metastases tumour suppressor genes and 
oncogenes are affected by CNAs at a similar rate.  
The higher frequency of amplified genes in non-metastatic primary tumours 
may indicate that the loss of tumour suppressor genes play a more 
prominent role in metastasis. However, it is difficult to infer this as these 
CNAs were selected for their association with nodal metastases. Genomic 
analyses of HNSCC have suggested there is a surprisingly low level of 
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crossover in recurrently mutated genes between tumours (Lui et al., 2013, 
Stransky et al., 2011). For these reasons, pathway analysis rather than gene 
analysis is a potentially revealing approach to take to understand 
mechanisms involved in metastasis.  
Amplifications 
Cytoband Genes 
2q31.1 ITGA6, ZAK, CIR1, CHN1, ATF2 
3q26.2 
MECOM, TBL1XR1, ZMAT3, PIK3CA, 
GNB4 
4p15.2-p15.1 ANAPC4, SLC34A2, RBPJ, CCKAR 
5p14.1-p15.1 CDH12, PRDM9 
7p12.1-11.2 EGFR, PHKG1 
7q21.3-q22.3 
DBF4, ZNF804B, FZD1, AKAP9, AKAP9, 
GNGT1, GNG11, COL1A2, PPP1R9A, 
MCM7, GNB2, EPO, SERPINE1, RELN 
8q24.12-q24.13  
8q11.21 PRKDC, MCM4 
9p21.1 CNTFR, IL11RA, FANCG 
11q13.3-p13.2 LRP5, CCND1, FGF19, FGF4, FGF3 
13q33.1-q34 COL4A1, COL4A2 
17q22-q23.3 CLTC, RPS6KB1, PPM1D, BRIP1 
Table 4-7: List of amplified genes of identified in minimally altered regions 





ATIC, FN1, PLCD4, STK36, WNT6, 
WNT10A, FEV, IHH, PAX3, ACSL3, 
CUL3, IRS1, COL4A4, COL4A3 
3p14.3-p14.1 FHIT, PRICKLE2 
4p15.1-14  
3p26.3-p26.11 IL5RA, ITPR1 
5q33.1-q33.3 ITK 
7q31.1-q35 
MET, WNT2, WNT16, POT1, GRM8, LEP, 
FLNC, SMO, CHRM2, DGKI, CREB3L2, 




POU2AF1, PPP2R1B, SDHD, 
PAFAH1B2, PCSK7, IL10RA, DDX6, 
CBL, ARHGEF12, HSPA8, EI24, CHEK1, 
FLI1, KCNJ5, TP53AIP1 
15q26.2-q26.3 IGF1R 
18q21.1-q21.32 SMAD4, MALT1, PMAIP1 
19p12  
Table 4-8: List of deleted genes of identified in minimally altered regions associated 
with metastasis. 
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4.2.2.6 Analysis of gene pathways containing CNAs associated with 
metastasis 
Using the lists described in section 4.2.2.5 the distribution of pathways  
enriched by CNAs in these identified genes was evaluated (see Figure 4-22). 
Out of 12 signalling pathways included, 8 contained a higher number of 
amplified rather than deleted genes.  
The pathway containing the most copy number altered genes was the PI3K 
pathway, well recognised to be associated with proliferation, invasion and 
metastasis. The EGFR/PI3K/AKT pathway has been identified as an 
important pathway in oral cancer and immunohistochemistry studies have 
suggested changes in expression in markers in this pathway are predictive 
of survival (Chang et al., 2013). Lui et al found this to be the most frequently 
mutated pathway (31%) in whole exome sequencing data from 151 HNSCC 
tumours (Lui et al., 2013). CNAs in genes involved in the PI3K pathway were 
identified in 45/49 (92%) nodal metastases and only 16/26 (62%) non-
metastatic primary tumours. It is also worth  noting that the ten non-
metastatic primary tumours in which no PI3K pathway genes were identified 
contain very few CNAs. 
 
Figure 4-22: Distribution of copy number altered genes within pathways of interest 














The WNT signalling pathway contained the next highest frequency of copy 
number altered genes, though only 11 hits were obtained compared to 29 in 
the PI3K signalling pathway. Copy number altered genes were identified at a 
similar frequency in the MAPK signalling pathway (10), cell cycle pathway 
(10), JAK/STAT pathways (9) and the p53 signalling pathway (8). Genes 
identified from the cancer gene census as associated with HNSCC produced 
the second highest number of hits. This is encouraging that the data is 
accurately identifying genes involved in cancer. The fact that not all genes 
are identified within this database is consistent with the fact that the census 
is based upon mutated genes rather than copy number altered genes, and 
drawn from all cancer types rather than just HNSCC. 
 
4.2.3 Results 3: DNA copy number analysis of metastases 
associated with and without extracapsular spread 
A important subgroup of HNSCC patients with metastases is those in whom 
ECS is identified histopathologically. This remains the most significant 
indicator of biologically aggressive disease and poor outcome in patients. 
These patients were identified from the metastatic cohort of patients (see 
Table 4-9) and their low-coverage sequencing data (FASTQ files) processed 
into digital karyograms as outlined in Chapter 2.9. Cumulative frequency 
plots were then created from these using seg_compare (Dr Henry Wood, 
Precancer genomics). 
	 Metastasis without ECS Metastasis with ECS 
No. of patients 22 27 
Table 4-9: Table of patients with nodal metastases with and without ECS. 
4.2.3.1 Cumulative frequency CNA plots of metastases with and 
without ECS 
These were created as described in section 4.2.1.3 and inspected visually 
(see Figure 4-23).  
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Using this genome-wide view the CNA profile of the two metastatic groups  
contain a lot of similarities.  Gain of 3q was present in 12/22 (55%) of 
metastases without ECS and 14/27 (52%) of metastases with ECS. Gain of 
5p was present in 12/22 (55%) of metastases without ECS and 12/27 (44%) 
metastases with ECS. Loss of 5q was identified in 10/22 metastases without 
ECS and 10/27 (37%) metastases with ECS. Loss of 9p is present in 7/22 
(32%) of the ECS group and 7/27 (26%) in the ECS group.  
 
Figure 4-23: Cumulative frequency karyogram plots of (a) nodal metastases with 
ECS and (b) nodal metastases with ECS. 
 
No broad CNA was unique to one group. Loss of 18q was present in 9/22 
(41%) of metastases without ECS and 20/27 (74%) metastases with ECS. 
Similarly gain of 8q was present in 10/22 (45%) metastases without ECS 
and 19/27 (70%) in the ECS group. Gain of 7p was present in 8/22 (36%) 
metastases without ECS and 14/27 (52%) metastases with ECS. Loss of 8p 
was identified in 3/22 (14%) metastases without ECS and 11/27 (41%) in the 
ECS group. Loss of 6q was found in 1/22 (5%) metastases without ECS and 
5/27 (19%) metastases with ECS. Focal analysis was undertaken to 
elucidate differences at higher resolution. 
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4.2.3.2 GISTIC analysis of focal CNA in metastases with and without 
ECS 
Evaluation of focal CNA was performed using GISTIC 2.0 as described 
previously. GISTIC identified a number of focal amplifications common to  
both groups of metastases as occurring at a significant frequency (q = < 
0.25) (see Figure 4-24). These included gains of 3q26.2, 7p11.2, 8q24 and 
11q13.3. Gain of 7q22.1 was observed in the metastases with ECS, whilst 
gain of 2q11.2 and 9p13.3 were identified in the metastases without ECS by 
GISTIC. On inspection of the individual karyograms all focal amplifications 
were present in both groups, at differing frequencies (see Table 4-10). 
In terms of focal deletions GISTIC identified a number of differences in the 
focal alteration profile for these two groups (see Figure 4-25). Nodal 
metastases without ECS show fewer focal deletions overall (only loss of 
4p15.1, 9q24.2 and 18q21.2). Within metastases with ECS GISTIC 
highlighted losses at 3q26.1, 5q33.2, 11q24.2. Both sub-types of metastasis 
share loss of 18q21.2. Again the frequency of these focal alterations was 
evaluated using the individual sample karyograms (see Table 4-11). 
(a) Metastases without ECS  (b) Metastases with ECS 
            
Figure 4-24: GISTIC analysis of focal amplifications in (a) nodal metastases without 
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 (a) Metastases without ECS  (b) Metastases with ECS 
         
Figure 4-25: GISTIC analysis of focal deletions in (a) nodal metastases without 
ECS and (b) with ECS. 
 
Using the wide peak boundaries the frequency of all focal CNAs highlighted 
by GISTIC were evaluated in each group. pheatmap (Raivo Kolde, Harvard 
USA)  was used to identify the minimally altered region within the GISTIC 
co-ordinates and the frequency of these in each group of metastases was 
assessed (see Table 4-10 and Table 4-11). 
No CNA was found exclusively within one group of metastases, though 
several are identified at a higher frequency in one group. Gain of 8q24.12-
q24.13 was present in 17/27 (63%) of metastases with ECS and 8/22 (36%) 
of those without ECS. Gain of 8q23.3 was present in 16/27 (59%) of 
metastases with ECS and 9/22 (41%) of those without ECS. Out of nine 
minimally amplified regions, four were found at a slightly higher frequency in 
the metastases without ECS. Three of these CNAs (10q21.1-q21.3, 3q26.1-
q26.33 and 7q21.3-q22.3) were highlighted by GISTIC as occurring at a 
significant level (q = < 0.25) in the metastases with ECS. The fact they 
occurred at a slightly higher frequency in the group without ECS without 
being highlighted by GISTIC may be related to the lower number of samples 








































Amplifications  Frequency (%) 




























































8 (36) 14 (52) 
Table 4-10: Frequency of amplified minimally altered regions in metastases with 
and without ECS. The original GISTIC wide peak boundaries are shown next 
to the revised minimally altered region identified using pheatmap. The 
cytoband corresponds to the minimally altered region. 
 
Deletions Frequency (%) 



















9 (41) 9 (33) 




















9 (41) 21 (78) 
Table 4-11: Frequency of deleted minimally altered regions in metastases with and 
without ECS. The original GISTIC wide peak boundaries are shown next to 
the revised minimally altered region identified using pheatmap. The cytoband 
corresponds to the minimally altered region. 
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Notably, loss of 18q21.1 was present in 21/27 (78%) of metastases with 
ECS and 9/22 (41%) of metastases without ECS. Out of nine other focal 
deletions, seven were found at higher frequency in the metastases with 
ECS. One of these was identified by GISTIC in the non-ECS group only 
(loss of 9p24.3). The fact that this and loss of 5q33.1 were present at higher 
rates in the metastases without ECS suggests they represent genomic 
change not specifically associated with ECS. Losses at 15q26.2 and 
11q24.2 were present in higher frequencies in the ECS group (12% and 11% 
more respectively), though overall present in less than 50% of samples in 
each group. This suggests that despite the strong clinical phenotype of ECS 
(poor prognosis and reduced survival), there is still a large amount of 
genomic heterogeneity between patients. 
4.2.3.3 GISTIC analysis of broad regions of CNA in metastases with 
and without ECS 
As stated previously the GISTIC analysis produces both a focal and broad 
analysis simultaneously. Heat maps generated from this for nodal 
metastases with and without ECS are shown in Figure 4-26.  
(a)      (b) 
 
Figure 4-26: GISTIC heat maps for broad analysis of (a) nodal metastases without 
ECS and (b) with ECS. 
 
They show similar profiles of gain and loss to those seen in the cumulative 
















































and gain of 3q are visible. Loss of 11q and 18q and gain of 8q are seen to 
occur at higher frequency in the nodal metastases with ECS. It also apparent 
that two of the samples in the nodal metastases without ECS contain a 
greatly reduced number of CNAs overall as well as 3 samples which may 
contain a lower tumour DNA content (inferred from the lower intensity of 
colour across these samples). This could be due to these metastases being 
on average smaller than those with ECS. This effect would be reduced by 
using an individual sample CNA threshold rather than a generic one as used 
by GISTIC. 
4.2.3.4 Identification of genes in metastases with and without ECS 
The genes within the minimally altered regions were identified using the 




3q26.1-q26.33 SLITRK3, MECOM, TBL1XR1, ZMAT3, PIK3CA, GNB4, SOX2 
7p12.1-p11.2 EGFR, PHKG1 
7q21.3-q22.3 MCM7, GNB2, EPO, SERPINE1, RELN, ORC5 
8q23.3 CSMD3 
8q24.12-q24.13  
9p13.3 CNTFR, IL11RA, FANCG, CREB3 
10q21.1-q21.3 CDK1 
11q13.3-q13.4 CCND1, FGF19, FGF4, FGF3 
Deletions 
Cytoband	 Genes	
3p26.3	 IL5RA, ITPR1, OXTR, SRGAP3	





ATM, DDX10, POU2AF1, PPP2R1B, SDHD, PAFAH1B2, 
PCSK7, IL10RA, DDX6, CBL, ARHGEF12, HSPA8, EI24, 
CHEK1	
15q26.2	 IGF1R	
18q21.1	 SMAD4, MALT1, PMAIP1	
Table 4-12: Genes identified of potential significance within minimally altered 
regions associated with extracapsular spread. 
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These lists were then cross-referenced against the KEGG pathways and 
lists of genes associated with HNSCC (as described in section 4.2.2.5). The 
final list of genes of potential interest is shown in Table 4-12). 
4.2.3.5 Analysis of gene pathways containing CNAs in metastases with 
and without ECS 
This was generated using the same pathways selected for cross-referencing 
the gene lists produced from the minimally altered regions (see section 
4.2.3.4). The pathways enriched by CNAs in metastases with and without 
ECS are shown in Figure 4-27. In terms of signalling pathways there is a 
higher frequency of amplified genes in each pathways rather than deleted 
genes. This suggests that oncogenes are more frequently involved in CNAs 
relating to ECS, rather than tumour suppressor genes being lost. The 
Cancer Gene Census contained the highest number of hit overall and 
demonstrates a much higher frequency of deleted genes. This may reflect 
the fact that the Cancer Gene Census is based on known mutated genes in 
cancer rather than copy number altered genes.  
 
Figure 4-27: Number of genes cross-referenced to each pathway and gene lists. 
Across all pathways ECS positive metastases contained a higher number of 
copy number altered genes (see Figure 4-28). This is consistent with the fact 
















negative metastases, and even then only in a small number of samples. A 
similar trend across both types of metastases was seen in terms of 
frequency of copy number altered gene hits. The pathway most frequently 
enriched for copy number altered genes was the PI3K pathway (in both ECS 
positive and negative metastases). This was followed by the p53 signalling 
pathway, in contrast to the copy number altered gene pathways associated 
with nodal metastases. In those minimally altered regions the MAPK 
pathway was the next most highly enriched.  
  
 
Figure 4-28: Number of times a gene within each pathway was identified in 











However there is a small difference in the overall number of gene hits 
contained with 171 hits for the p53 signalling pathway (in both ECS positive 
and negative metastases) and 140 hits for the MAPK pathway. Again there 
is a similar level of enrichment across the JAK/STAT, MAPK, Cell Cycle and 
WNT signalling pathways. An important influence on the number of hits 
obtained per list is the number of genes in each list. The PI3K pathway is 
very large and this obviously increases the chance of genes being identified 
as of significance. 
4.2.4 A copy number panel associated with nodal metastasis 
Using visual inspection of the cumulative frequency karyograms and the  
minimally altered regions associated with metastases, a panel of CNAs 











Table 4-13: Selected panel of CNAs associated with nodal metastasis. 
All (both metastatic and non-metastatic) samples were then assessed for the 
presence of these CNAs using the pheatmap (Raivo Kolde, Harvard USA) 
software. Initially non metastatic primary tumours were compared to all nodal 
metastases (see Figure 4-29). This heatmap demonstrates the increased 
frequency of these minimally altered regions in the nodal metastases, but 
also highlights the fact that no CNA is truly mutually exclusive to one group. 
Assigning a score of 1 for each CNA present in each sample and 0 for each 
that is absent in each sample a score was generated. The scores for non-
metastatic primary tumours and nodal metastases were analysed using the 
Shapiro-Wilk test for normality, showing them to be not normally distributed. 
The Mann Whitney test was used to compare mean CNA scores for each 
group (see Figure 4-30). The mean CNA score of the nodal metastases was 




Figure 4-29: Heatmap of presence (red) or absence (white) of panel of CNAs 
associated with nodal metastases. The non-metastatic primary tumours are 
represented along the top in white and the nodal metastases in green.  
 
 
Figure 4-30: Box-plot of the mean CNA scores for non-metastatic primary tumours 
and nodal metastases. 
 
For clinical benefit, any marker for metastasis needs to be detectable in the 
primary tumour, in order to potentially spare patients unnecessary surgery. 
Using the same CNA panel, the non-metastatic primary tumours were 
compared to the metastatic primary tumours (see Figure 4-31).  
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The metastatic primary tumours were also scored for the presence and 
absence of the CNA markers as described above. The scores for the non-
metastatic primary tumours and metastatic primary tumours were then 
analysed (see Figure 4-32) using the Shapiro-Wilk test which revealed them 
to be not normally distributed. The mean scores for each group were then 
compared using the Mann Whitney test, which found the mean score of the 
metastatic primary tumours to be significantly higher than the non-metastatic 
primary tumours (p = 0.0001). 
 
 
Figure 4-31: Heatmap of presence (red) and absence (white) of CNA panel 
markers. Non-metastatic primary tumours are shown in white along the top 
and metastatic primary tumours are shown in green. 
 









































Figure 4-32: Box-plot comparing CNA-scores for non-metastatic primary tumours 
and metastatic primary tumours. 
4.2.5 Analysis of markers of genomic damage 
4.2.5.1 Comparison of breakpoints 
Though present, the differences in CNAs between the clinicopathologic 
groups are heterogeneous. Therefore I elected to use a more generic 
approach to separate samples. The number of segments in the .bed file for 
each sample reflects the number of breakpoints in each sample. As 
breakpoints are locations on chromosomes where DNA may be altered or 
damaged in a number of ways (e.g. amplification, deletion, inversion, 
translocation) this was hypothesised to be a reasonable estimation of the 
level of genomic damage contained in each sample. The mean number of 
segments in metastatic and non-metastatic samples was calculated and 
compared (see Figure 4-33). The Shapiro-Wilk test confirmed normality of 
data and an independent t-test showed no significant difference between 
non-metastatic tumour and metastatic primary tumours (p = 0.449). 
 




Figure 4-33: Box-plot to compare the number of breakpoints in non-metastatic 
primary tumours (Node_Negative) and metastatic primary tumours 
(Node_Positive). 
 
A similar comparison was performed using the ANOVA test (see Figure 4-34) 
to compare the number of breakpoints in node negative tumours to tumours 
associated with and without ECS, again finding no significant difference (p = 
0.752). Pearson’s correlation (2-tailed) was performed to evaluate any trend 
of increasing numbers of breakpoints and nodal status. No significant 
correlation was found (p = 0.513). 
 
 
Figure 4-34: Box-plot to compare the number of breakpoints in non-metastatic 
primary tumours to tumours associated with ECS and without ECS. 
Node Negative   Node Positive 
Nodal Status 
Node Negative  ECS Negative ECS Positive 
Nodal Status 
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4.2.5.2 Fraction of Genome Altered (FGA) 
The actual proportion of the genome that was altered in terms of its copy 
number was calculated as another reflection of the amount of genomic 
damage in samples from each clinicopathologic group. The FGA is 
calculated using the number of bases in all segments in each sample (i.e. 
the genome) as the denominator and number of bases in each sample that 
are copy number altered as the numerator. These were then compared 
between groups as with the breakpoints above. 
 
Figure 4-35: Comparison of FGA for non-metastatic primary tumours and 
metastatic primary tumours. 
 
The FGA for non-metastatic primary tumours and metastatic primary 
tumours (see Figure 4-35) were analysed using the Shapiro-Wilk test for 
normality. As it was not normally distributed the Mann-Whitney U test was 
then used to compare the means of these groups. The mean FGA of the 
metastatic primary tumours was highly significantly increased compared to 
the non-metastatic primary tumours (p = 0.0001). The FGA for non-
metastatic primary tumours was then compared to metastatic tumours 
associated with and without ECS (see Figure 4-36). The Mann Whitney test 
was used to compare these groups and found that both tumours associated 
with and without ECS had a significantly increased FGA compared to non-
metastatic primary tumours (p = 0.001 and p = 0.001, respectively). On 
comparing the mean FGA between the primary tumours associated with 
Node Negative   Node Positive 
Nodal Status 
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ECS and those not associated with ECS no significant difference was found 
(p = 0.673). 
 
Figure 4-36: Comparison of FGA from non-metastatic primary tumours to primary 
tumours associated with and without ECS. 
4.3 Discussion 
4.3.1 Tissue sampling 
When considering these results the source of the tissue is important. FFPE 
tissue has long been regarded as unsuitable for nucleic acid analysis. DNA 
from this tissue has been damaged by the process of formalin-fixation as 
well as the period of storage at room temperature (Iwamoto et al., 1996, 
Greer et al., 1991a, Greer et al., 1991b). The amount of DNA obtained from 
FFPE samples is likely to also be much lower than compared to fresh-frozen 
samples (Greer et al., 1991a, Greer et al., 1991b, Farrand et al., 2002). 
However, by appreciating these issues FFPE tissue can be used 
consistently. The effects of formalin-fixation on DNA include the formation of 
crosslinks that maintain morphology but inhibit denaturation and therefore 
inhibit the action of polymerases (Lu et al., 2010). Extraction techniques 
need to take this into account, as well as subsequent processing. Using 
NGS to produce copy number data allowed me to produce sequencing 
libraries from as little as 50 ng of extracted DNA.  
Node Negative  ECS Negative ECS Positive 
Nodal Status 
 149 
Additionally, the choice to use NGS technology allowed me to multiplex 40 
libraries per sequencing lane. This was essential to completing the project 
within grant budget as well as being well suited to the type of genomic 
analysis being planned in this study. Low-coverage sequencing such as this 
would not be appropriate for whole exome or whole genome sequencing 
(Zeng and Mortazavi, 2012). For copy number analysis it has been 
demonstrated using lung SCC and HNSCC samples to be consistent and 
reliable when compared to technical replicates at higher coverage (Wood et 
al., 2010, Gusnanto et al., 2014). Given that CNAs are often broad in cancer 
the resolution achievable multiplexing 40 samples per lane was deemed to 
be an appropriate depth (Taylor et al., 2008, Wood et al., 2010). It could be 
argued that very low frequency, minimal regions of copy number loss will be 
missed using low coverage sequencing, but as the original statistical 
projections suggested a minimum of 20 patients per group it would be 
difficult to draw strong conclusions from very low frequency CNAs in these 
small groups.  
The issue of tumour DNA content is important to understand. Laser 
microdissection is often regarded as the gold standard in achieving maximal 
tumour cell purity (Stoehr et al., 2003). However, attempts to use the PALM 
laser system within Leeds Institute of Cancer and Pathology were made 
unsuccessfully. Nonviable yields of DNA were achieved as well as issues 
with accurate alignment of the laser during use, which was out of service 
contract. This raised concern over the having to increase the number of 
cycles of PCR downstream during sequencing library preparation (with the 
resultant effect of introducing many PCR replicates to the sequencer). The 
rate of dissection was also extremely slow rate (one sample microdissection 
taking more than one day). It is well-established that non-laser dissection of 
tumour samples can be performed with minimal influences on tumour cell 
purity and nucleic acid profiles (de Bruin et al., 2005, Michel et al., 2003). As 
I was able to target the highest tumour cell content for dissection and 
estimate the subsequent ploidy and tumour DNA content from the copy 
number data I elected to abandon laser microdissection as a non-viable 
alternative. 
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Accuracy was ensured by taking a repeat 5 μm section of each sample after 
the 7 sections had been cut for DNA extraction. This was then stained with 
haematoxylin and eosin and examined by a consultant head and neck 
pathologist and the area of highest tumour cell content re-marked. This was 
used to confirm the accuracy of the area dissected for DNA by comparing it 
to a random section used for DNA extraction. This also served to confirm 
that the tumour had not been “cut through” by repeated sectioning.   
4.3.2 Advantages and disadvantages of NGS 
Several techniques are available to detect CNA. Older techniques include 
FISH and qRT-PCR. FISH has relatively low resolution, whilst qRT-PCR 
require specific primers, which may result in suboptimal precision as not all 
regions of the genome lend themselves to ideal primer design (Duan et al., 
2013, Hughes S, 2007).  
aCGH provides higher resolution than FISH, though this is dependent on the 
number of probes embedded in the array and therefore directly related to the 
cost per sample. To obtain a similar resolution to that achieved in my low 
coverage sequencing (800 kb) a microarray would cost approximately £600 
per sample (Agilent, UK). It only cost approximately £50 per sample to 
sequence these on the Illumina HiSeq platform. aCGH is well established 
and widely used, meaning that expertise is easily available. Its limitations are 
understood, including bias due to relatively lower sensitivity for detecting 
gains compared to losses and the fact only CNAs targeted by the array 
probes can be identified (Stankiewicz and Beaudet, 2007). Both aCGH and 
NGS can provide a genome-wide view of copy number status.  
Disadvantages of NGS include the fact it is a much more recent 
development and therefore expertise in both wet lab and bioinformatics 
analysis may not be as available. Though bias is avoided in terms of probes, 
the guanine-cytosine (GC) content of the input DNA affects sequencing 
reads. GC-poor or GC-rich regions have been reported to lead to uneven 
coverage of reads with relatively few reads in these parts of the genome 
(Chen et al., 2013). This needs to be accounted for and any analysis needs 
to normalise for this effect. An advantage of using CNAnorm is that it 
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automatically corrects for GC content, which has been shown to result in a 
more accurate estimation of CNA (Gusnanto et al., 2012).  
As NGS does not utilise targeted probes the resolution of CNA is dependent 
on the depth of sequencing. As sequencing reads are short and may contain 
errors, when attempting to reveal single nucleotide variants high depth 
sequencing is required to ensure accuracy. As I was not attempting to 
identify mutations I did not require high depth sequencing. High depth 
sequencing cannot overcome alignment issues with highly repetitive regions 
that are longer than the sequencing read. Using paired end reads (two reads 
separated by a known distance)  can provide confidence in aligning reads to 
repetitive regions shorter than the distance separating the paired ends (Sims 
et al., 2014).  
 
Figure 4-37: (a) shows the digital karyogram generated from the original ECS038-T 
FASTQ file (7,999,896 sequencing reads). (b) shows the digital karyogram 
created after the FASTQ file was divided into 8 (999,987 sequencing reads). 
 
Resolution of sequencing data can be reduced and manipulated post hoc in 
contrast to aCGH data. In order to examine the accuracy of CNA profile by 
sequencing depth a sample was selected (ECS038-T) for in silico analysis. 
ECS038 achieved 7,999,896 sequencing reads when run on the Illuina 
HiSeq 2500. This FASTQ file was then divided into 8 equal segments, 
(a) 
(b) 
      chr1        chr2        chr3      chr4      chr5    chr6    chr7  chr8  chr9  chr10 chr11 chr12      chr14          chr17     chr20 
 




essential reduced the number of reads for a single sample down to 999,987 
reads. Digital karyograms were created for these as for all other samples 
(see Figure 4-37). These images show strong similarity in CNA profile, 
demonstrating the accuracy of the depth of sequencing used in my study.  
In order to examine the consistency of breakpoint between the original and 
‘diluted’ sample the individual chromosome plots were further evaluated. An 
example of a chromosome containing multiple breakpoints is shown in Figure 
4-38. This was combined with the .bed file containing the genomic locations 
of the breakpoints (see Table 4-14). 
 
Figure 4-38: Individual chromosome plot of chr 11 (a) from the ECS038-T sample 
divided into 8 and (b) the full ECS038-T sample. 
  
 Genomic Locations 
 ECS038-T Full Sample ECS038-T_Divided into 8 
 Start End Start End 
chr11 1 49600001 1 49600001 
chr11 55200001 72800001 55200001 72800001 
chr11 73600001 96800001 73600001 96800001 
chr11 97600001 105600001 97600001 105600001 
chr11 106400001 124800001 106400001 124800001 
chr11 125600001 129600001 125600001 133600001 
chr11 130400001 133600001   
Table 4-14: Table listing precise genomic locations (breakpoints) of segments as 
identified in both the full ECS038-T sample and the ECS038-T sample divided 
into 8. 
 
ECS038_T_8b chr11 ECS038_T_full chr11 
Genomic Location (Mbp) of chr11 Genomic Location (Mbp) of chr11 
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As can be seen from the individual chromosome plot of chr 11 the overall 
CNA profile is very similar despite there being multiple breakpoints and 
segments present. The genomic locations are also very similar with 11/14 
breakpoints in the full sample being identical to the divided sample. 
However, one breakpoint is absent from the divided sample, meaning a 
small segment of loss from the distal end of 11q is not identified. This 
reflects the fact no reads contained in the divided sample aligned sufficiently 
around the distal breakpoint for this to be identified. It highlights the potential 
for CNAs to be missed at lower levels of sequencing. It is of interest that this 
breakpoint is close to the telomere of 11q which may also have affected the 
ability for the breakpoint to be identified as these regions are more repetitive 
and can present challenges in alignment of reads. It is also in a region where 
CNAs need to be regarded with caution regardless of depth of sequencing 
due to the nature of the repetitive genome in these regions.  
In total 174 breakpoints were present in the full sample and 134 in the 
divided sample. This also highlights the potential for CNA alterations to be 
missed with lower coverage sequencing. However when concordance of the 
divided sample was calculated for the original ECS038-T sample it was 
found to be high (95%). This suggests that whilst breakpoints may be 
missed the regions of gain and loss identified are still very consistent. This 
likely reflects the fact that breakpoints may be present along a copy number 
altered segment without change in overall copy number of adjacent 
segments. Intra-tumour heterogeneity can also increase the number of 
breakpoints present, whilst not affecting the overall copy number status 
being called as CNAs within smaller clonal populations may not reach the 
overall CNA call threshold, and therefore not affect the copy number status.  
4.3.3 CNAs in HNSCC 
Our understanding of HNSCC as a “genetic disease” has grown 
exponentially over the last three decades (Vogelstein and Kinzler, 2004). 
Regions of altered copy number potentially contain proto-oncogenes or 
tumour suppressor genes. Copy number can correlate with increased or 
reduced gene expression in both health and disease (McCarroll et al., 2006, 
Stranger et al., 2007, Sung et al., 2013).  
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Using a number of techniques (FISH, LOH analysis and aCGH) several 
recurrent chromosomal alterations have been identified in HNSCC. Some of 
these could be considered as “classical” (identified in multiple studies in 
HNSCC) including: loss of 3p, 4, 5q, 8p, 9p, 11, 13q and 18q. Gains of 3q, 
5p, 8q, 9q, 11q, 10q and 22q have also been reported (Bockmuhl et al., 
1996, Singh et al., 2001, Chen and Chen, 2008, Bockmuhl et al., 1998, 
Gollin, 2001). In considering the alterations seen in this study the sample 
groups must be considered in turn. 
4.3.3.1 CNAs associated with metastasis 
Using CNAnorm generated cumulative frequency karyograms a very similar 
profile between metastatic primary tumours and their matched metastases 
can be observed. This similarity is further demonstrated by the rates of 
concordance and correlation calculated between the metastatic primary 
tumour and the matching nodal metastasis. These figures do reveal that the 
DNA copy number signature of metastasis and parent tumour are not 
identical and that there is variation in their similarity. This is important in 
trying to identify a marker and gain understanding of the genomic changes 
associated with metastasis. If a marker is identifiable in the nodal metastasis 
– is it then identifiable in the primary tumour? 
There are relatively few studies using genome-wide approaches, reporting 
the genomic profile of cervical metastases in HNSCC. Kujawski et al 
analysed 19 pairs of laryngeal primary tumours and metastases using CGH 
(Kujawski et al., 1999). The majority of metastases were cervical nodes 
(90%) whilst the others were unspecified metastases. They found losses at 
8p, 9q and 13 were more frequent in metastases compared to the primary 
tumours.  
Bockmuhl et al analysed 34 metastatic HNSCC primary tumours and their 
lymph node metastases as well as 20 non-metastatic primary tumours using 
CGH (Bockmuhl et al., 2002). These were of mixed subsite with the majority 
being oropharynx and hypopharynx.  The proportion of oropharyngeal 
primary tumours is relevant as this introduces the potentially confounding 
factor of HPV-associated tumours being included in this cohort. They 
compared non-metastatic primary tumours to lymph node metastases. They 
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found few chromosomal regions in the pN0 primary tumours carried an 
excess of changes compared to the nodal metastases. Deletions of 5q34-
q35, 8p12-p22, 10p12, 10q21-qter, 11p14-p15, 11q23-qter and 14q21-qter 
and gains of 1q21-q22, 3q24-qter, 6q, 7q11.2, 12q12-q12 and 18p11.1 were 
associated with the nodal metastases.  
Patmore et al analysed and compared 23 paired primary tumour and lymph 
node metastases using CGH (Patmore et al., 2004). They found no 
overriding aberration in the nodal metastases, though gains of 6q (48% c.f. 
2%) and 22q (26% c.f. 9%) were found at higher frequencies. 
The discordance between studies could be due to several reasons. The 
generally low number of patients in these reports does limit conclusions as 
HNSCC is well recognised to be a genomically heterogeneous disease. The 
different analytical methods used in each study are important and indeed the 
underlying driver behind the development of GISTIC, which was not 
available at the time of the previous studies discussed. It is also possible 
that the aetiology of the tumours is a confounding factor. Alexandrov et al 
demonstrated trends in mutational signatures that were shared between 
tobacco smoking-associated cancer (lung, head and neck and liver) 
(Alexandrov et al., 2013). Though likely to be a minority, the unknown 
proportion of HPV-associated tumours in Bockmuhl et al’s studies could 
affect genomic findings (Bockmuhl et al., 2002). Patmore et al’s also study 
lacked non-metastatic primary tumours as a comparison (Patmore et al., 
2004). These studies were limited in terms of the number of patients 
included as well as the relatively low resolution of the conventional 
metaphase CGH technology available at the time. 
More recently Yoshioka et al used array-based CGH primary tumours and 
lymph node metastases from 15 OSCC patients and compared these 
profiles to 10 non-metastatic primary tumours (Yoshioka et al., 2013). This 
study used technology achieving similar resolution to that obtained using 
low-coverage NGS. They compared concordance rates of genomic 
breakpoints to assess clonality between primary tumour and matched 
metastases. By performing unsupervised hierarchical clustering they were 
able to identify 12 of 15 matched tumour-lymph node pairs, indicating the 
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genomic profile of the matched lymph node was most similar to the parent 
tumour in these cases. Their analysis suggests that similar clonal 
populations may predominate in primary tumours and their metastases but 
not exclusively. This concurs with my findings for both concordance and 
correlation of CNA between tumour-lymph node pairs. They also found gains 
at 7p, 8q and 17q were differentially detected in lymph node metastases  
suggesting these regions may be involved in metastasis. A limitation to this 
data is the lack of focal CNA analysis. 
The importance of subclonal populations and their relationship to the 
metastasis is highlighted in this work. A number of studies in different solid 
cancers have demonstrated that metastasis can arise from a non-dominant 
subclone within the primary tumour (Gronwald et al., 1999, Talmadge, 
2007). Other work has suggested that the metastatic subclone becomes 
dominant in the metastasis (Waghorne et al., 1988). As such obtaining 
genomic profiles of the actual metastasis is vital to obtain mechanistic 
information abut genomic changes which predispose to metastasis. The lack 
of homogeneous copy number profiles amongst the metastases in my study 
suggests that metastases are not mono-clonal, though it is reasonable to 
hypothesise that the metastatic clone is dominant. However, if metastasis 
occurs due to a minor subclone in the primary tumour this is an important 
concept to understand when looking for a biomarker for metastasis. 
An important potential confounding factor when considering the genomic 
profiles is the influence of the underlying aetiology. In the majority of these 
cases tobacco smoking is the obvious aetiological risk factor. Only 7 of 49 
patients (14%) with metastatic HNSCC had never smoked. All other patients 
were either current or ex-smokers. This clinical data is collected 
retrospectively from the PPM database so it limited in terms of drawing more 
detailed data of pack/years and arguably not as accurate as prospectively 
collected data. As all samples were from the oral cavity rather than the 
oropharynx, HPV is less likely to predominate and NGS was also used to 
simultaneously determine the HPV-status by calculating the precise viral 
load of each sample. 
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Comparison of CNAs associated with metastasis (as identified using GISTIC 
in my study) is made in Table 4-15.  The lack of concordance between 
studies is marked. Though perhaps attributable to the differing technologies 
and analytical methods used, it is also likely a reflection of the 
heterogeneous genomic nature of HNSCC. The small number of CNAs in 
these listed compared to the overall high number of aberrations seen across 
these tumours suggests that the differences between a metastatic and non-
metastatic tumour are relatively small.  
 An important variation in the use of GISTIC as compared to producing 
CNAnorm cumulative frequency plots is the use of a generic CNA calling 
threshold in GISTIC, whilst in developing the cumulative frequency plots 
individual thresholds were assigned to each sampled to account for variation 
in tumour DNA content and clonal heterogeneity. As such it may be that 
GISTIC is not as sensitive as visual inspection of the cumulative frequency 
plots. However, on comparing the metastatic primary tumours to their 
matched metastases, little difference is seen. This suggests that if a 
metastatic genomic signature is visible in the nodal metastasis it would be 
also be visible in the metastatic primary tumour.  
On comparing non-metastatic primary tumours to nodal metastases the 
differences are more marked. It also allowed CNAs present at significant 
levels in metastases to be excluded if they were also present at similar 
levels in non-metastatic primary tumours (e.g. gain of 3q26.2, present in 
26/49 (53%) of nodal metastases and 12/26 (48%) of non-metastatic primary 
tumours).  
In examining the genes contained within the altered regions in our studies it 
is important to remember that whilst many studies have demonstrated 
correlations between CNA and levels of gene expression they do not 
correlate universally nor is all altered gene expression uniquely mapped to 
DNA copy number (Bussey et al., 2006, Cheng et al., 2012, Lu et al., 2011, 
Yang et al., 2007, Myllykangas et al., 2008, Jarvinen et al., 2008, Xu et al., 
2010). Genes recurrently altered within the minimally altered regions may 
represent driver genes within this sample group. The fact that no gene was 
exclusively altered in all the samples of one group compared to another 
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does not preclude them being regarded as driver genes. Even lowly 
recurrent genes are important, particularly in attempting to identify genes 
important after early tumour development [Shah clonal and evolutional 
mutational spectrum Nature 2012].  
 



















































































Table 4-15: Comparison of CNAs associated with nodal metastases in this study 
and previous studies that compared metastases to primary tumours. 
Gain of 11q13.3-q13.2 was present in 22/49 (45%) of nodal metastases and 
only 2/26 (8%) of non-metastatic primary tumours. Gain of 11q13.3 is 
recognized to be a frequent CNA in HNSCC and has been associated 
strongly with metastasis (Sugahara et al., 2011). Within the genomic co-
ordinates for this minimally altered region, five genes were identified as of 
potential significance: CCND1, FGF3, FGF4, FGF19 and LRP5. CCND1 
encodes for cyclin D1 and previous HNSCC studies have suggested both a 
role in prognosis and predicting therapeutic response in relation to both 
expression of cyclin D1 and amplification of CCND1 (Feng et al., 2011, Zhou 
et al., 2009). CCND1 has been reported to be co-amplified with other genes 
such as CTTN (Rodrigo et al., 2009). This could reflect the fact that many 
CNAs tend to be large rather than focal. Fibroblast growth factors (FGF) 
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have been reported to important growth factor pathways in HNSCC cell lines 
(Marshall et al., 2011). FGF3 and FGF4 are considered to have a role in 
tumourigenesis in HNSCC and have been associated with metastasis 
(Muller et al., 1997). Interestingly, FGF3, FGF4 and FGF19 were reported by 
Huang et al to not be overexpressed in the presence of genomic copy 
number amplification and therefore suggested not to play a driver role in 
cancer, in contrast to a study in hepatocellular carcinoma cell lines which 
found a high correlation between overexpression of FGF19 and 11q13.3 
amplicon (Huang et al., 2006) (Sawey et al., 2011). LRP5 encodes a 
receptor involved in the WNT-signalling pathway, which has been identified 
as a key oncogenic pathway in cancer stem cells (CSCs) in several solid 
cancers with a potential role in self-renewal of HNSCC CSCs (de Sousa et 
al., 2011, Vermeulen et al., 2010, Monteiro et al., 2014, Da Forno et al., 
2008, Lee et al., 2014).  
Loss of 3p14.3-p14.1 was present in 35/49 (71%) of nodal metastases and 
10/26 (39%) of non-metastatic primary tumours. This was often co-deleted 
with another minimally altered region 3p26.3-p26.11. Allelic loss of 3p has 
been long recognised in HNSCC and associated with poorer survival, 
tobacco-related disease and nodal status (Dasgupta et al., 2002, Maestro et 
al., 1993, Gross et al., 2014). Within the genes identified at 3p14.3-p14.1, 
FHIT, represents the most well known tumour suppressor gene. In addition 
to being one of the largest known genes (~1.5 Mb) it also occurs at the most 
active common fragile chromosome region (FRA3B) (Pekarsky et al., 2002). 
It encodes for a histadine triad protein (diadenosine 5’,5”’-P1,P4-
tetraphosphate (Ap4A) hydrolase) and is thought to play a key role in purine 
metabolism, though its precise function is poorly understood (Pekarsky et 
al., 2002). FHIT expression has been found to be reduced or lost in oral, 
oesophageal, colon, cervical and breast cancer (Huebner and Croce, 2003). 
It has been associated with reduced survival in HNSCC (Dasgupta et al., 
2002). A recent study in lung cancer, using cell lines and murine models 
found that enforced expression of FHIT suppressed metastasis as well as 
inhibited epithelial-mesenchymal transition (thought to be a critical process 
during metastasis) (Suh et al., 2014). Though less common in non-
metastatic primary tumours, this gene deletion still occurs in 39% and 
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therefore is less useful as a discriminatory marker for metastasis (hence it’s 
exclusion from the CNA panel in section 4.2.4). It’s functions are also 
unlikely to be purely related to metastasis. This is highlighted by the fact that 
aberrant FHIT levels have been described in premalignant oral lesions using 
RT-PCR (Tanimoto et al., 2000). 
Loss of 11q23.1-q25 was present in 22/49 (45%) of nodal metastases and 
not found in non-metastatic primary tumours. Fifteen genes were identified 
after cross-referencing lists of interest, within this minimally altered region. 
TP53AIP1 is a p53 target, which produces 3 isoform transcripts which 
regulate mitochondrial membrane potential and the mitochondrial apoptotic 
pathways (Matsuda et al., 2002). As such this gene is a potential mediator of 
p53-dependent apoptosis, and overexpression of TP53AIP1 alone induces 
apoptosis. Given the near universal finding of TP53 mutation in the TCGA 
HNSCC subgroups report finding, decreased expression of this has been 
associated with lymph node metastasis and decreased survival in non-small 
cell lung cancer (Yamashita et al., 2008). In HNSCC this gene has not been 
explored specifically. This could represent a targetable event, as 
demonstrated by a study using a replication defective adenovirus Ad-
p53AIP1 (Jiang et al., 2010). This found infection of liver cancer (HepG2) 
cells  induced apoptosis and cell cycle arrest. Any functional role in 
metastasis specifically has not been elucidated yet. 
CHEK1 encodes for checkpoint kinase 1 which belongs to the Ser/Thr 
protein kinase family. This mediates cell cycle arrest in response to DNA 
damage. CHEK1 is regulated by ATR forming the ATR/CHEK1 pathway. 
Upregulation of this pathway has been reported in a subset of HNSCC and 
hypothesised to occur as a compensatory response to loss of the distal 11q 
(Sankunny et al., 2014). These findings have been associated to 
radioresistance in OSCC cell lines, allowing cells to avoid the cell-cycle 
checkpoint relating to DNA damage. Knocking down the ATR/CHEK1 
pathway has subsequently been demonstrated to increase radiosensitivity in 
vitro (Sankunny et al., 2014).  
EI24 is another proapoptotic p53-target gene that plays an important role in 
negatively controlling cell growth and division. Overexpression of EI24  
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induces apoptosis (Gu et al., 2000b, Gu et al., 2000a). Ectopic EI24 
expression has been shown to inhibit cell colony formation and to also 
induce apoptosis (Gu et al., 2000a). Though it’s precise mechanistic function 
is unclear recent evidence has shown that EI24 inhibits nuclear protein 
import via an importin β-binding-like domain. As such it can inhibit p53 
nuclear import demonstrating it is a key effector of TP53 (Lieu et al., 2014). 
Choi et al  demonstrated that EI24, in cell lines and murine models, acts as a 
negative regulator of TRAF2 signalling by inducing its degradation leading to 
NF-κB transcriptional activity (Choi et al., 2013). Decreased expression of 
EI24 induced EMT in epithelial cancer cells as well as increasing cell 
motility, invasiveness and resistance to apoptosis whilst overexpression 
resulted in the opposite characteristics (Choi et al., 2013). Choi et al also 
found that overexpression of EI24 and copy number gain of the EI24 gene 
correlated with invasiveness and metastasis in breast tumour clinical 
samples (Choi et al., 2013). 
The distal region of 11q clearly contains genes that interact with TP53. 
Given the already established high frequency of TP53 mutation in non-HPV 
associated HNSCC it is not surprising that this genomic loss is found 
frequently in HNSCC. As at least two of the genes are targets of p53 that 
appear to enhance its proapoptotic effects it is consistent that loss of distal 
11q would be associated with metastasis and hence a worse prognosis. 
4.3.3.2 CNA associated with ECS 
No CNA was found exclusively in metastases with ECS. Loss of 18q21.1-
q21.32 was found in 30/49 (59%) of nodal metastases and only 1/26 (4%) of 
non-metastatic primary tumours. Within the nodal metastases it was present 
in 9/22 (41%) of metastases without ECS and 21/27 (78%) of metastases 
with ECS. Three genes of potential interest were identified in this region 
(SMAD4, MALT1, PMAIP1). SMAD4 was originally identified as a tumour 
suppressor gene in pancreatic cancer, though subsequently has been 
identified in numerous solid cancers (Schutte et al., 1996, Hahn et al., 1996). 
It plays a key role in mediating signals in both the WNT-signalling pathway 
and the TGF-β signalling pathway (Nishita et al., 2000). SMAD4 forms 
complexes with other SMAD proteins which then regulate gene expression 
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of targets involved in cell death, proliferation and inflammation(Bornstein et 
al., 2009). TGF-βs are proteins encoded by the TGF-β superfamily of genes 
that regulate processes including cell proliferation, leucocyte infiltration, 
regulate the extracellular matrix. The components of this pathway are 
considered to act as tumour suppressors with SMAD4 being a common 
mediator to the signalling pathway (Korc, 2009).  A study using murine 
models found that SMAD4  deletion led to development of spontaneous 
HNSCC in 74% of mice. They also found in clinical samples decreased 
expression of SMAD4 in 86% of HNSCC tissue samples as well as in 67% of 
the adjacent morphologically normal buccal mucosa (Bornstein et al., 2009). 
Both of these findings suggested a key role for SMAD4 as a gatekeeper 
gene in HNSCC (Korc, 2009). Recently Liu et al reported that ablation of 
SMAD4 in murine models resulted in activation of the ERBB2 pathway (Liu 
et al., 2015a). Activation of this pathway has been shown to confer 
resistance to the EGFR antibody cetuximab in cell lines (Yonesaka et al., 
2011). Loss of SMAD4 has also been associated with metastasis and poor 
prognosis in colorectal cancer. It has been found to cause alteration of the 
BMP signalling pathway that causes it to be metastasis promoting in murine 
models (Voorneveld et al., 2014). An additional study by Liu et al found that 
in colon cancer cell lines with loss of SMAD4, inducing SMAD4 expression 
led to reduced migration and invasive ability, reducing VEGF-C secretion 
and lymphangiogenesis in mouse models (Liu et al., 2015b).  
Genes reported to have an association with ECS in HNSCC include EGFR 
and CCND1. Increased copy number was found to be significantly 
associated with 127 OSCC samples using FISH (Michikawa et al., 2011). 
SERPINE1 and SMA overexpression expression was found to be predictive 
of ECS in OSCC (81% sensitivity when both found to be upregulated) 
(Dhanda et al., 2014). Wang et al identified an 11-gene expression signature 
(GGH, MTFR1, CDHN3, PSRC1, SMIM3, CA9, IRX4, CPA3, ZSCAN16, 
CBX7 and ZFP3) significantly associated with ECS and associated with 
worse survival in histologically node negative patients (Wang et al., 2015). 
No correlations with these gene regions and ECS was found in my samples. 
In a small study of seven samples using qRT-PCR a three gene expression 
panel (CTTN, EEF1A1,  MMP9) was identified to be associated with ECS 
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(Zhou et al., 2006). Out of these, in my study, CTTN (at 11q13.3) was 
amplified in 14/27 (52%) of metastases with ECS and 8/22 (36%) of 
metastases without ECS. It is interesting that amongst these studies there is 
also little cross-over in identified associated genes looking for the same 
clinic-pathologic outcome. This could well be related to the differing 
methodologies across the three studies. The sample size could also affect 
consistency between studies. The different geographic origins of the studies, 
and the inferred underlying aetiologies of OSCC,  could influence trends in 
the genes identified. The recognised clonal heterogeneity of HNSCC could 
be responsible for the lack of concordance in gene expression signatures. It 
is also important to remember that metastasis is a complex process 
involving many cellular pathways and steps (Hanahan and Weinberg, 2000, 
Hahn and Weinberg, 2002). Combining this knowledge with the fact that 
recognised heterogeneity of HNSCC it is entirely possible that any genomic 
marker for such a diverse phenotype could be varied and wider than simply 
a small panel of genes. 
As no single CNA is exclusively found in all samples from one specific group 
and they often co-occur it is unlikely that these alone represent a reliable 
marker for lack of metastasis. They could however be combined with the 
presence of CNAs associated with metastasis to produce a more robust 
indicator of the presence of nodal metastasis. This is proposed in the 11-
CNA panel (see Table 4-13). When scoring each sample for this signature a 
significantly higher score was found in metastatic tumours compared to non-
metastatic primary tumours (p = 0.0001) but one non-metastatic primary 
tumour contained six markers from the panel and 6 metastatic primary 
tumours contained no markers. As such the signature does not discriminate 
entirely. This may well be due to both inter and intra-tumour genomic 
heterogeneity. It may also reflect the complex genomic interactions 
underlying cancer. Combining these factors could mean that using specific 
genomic markers will not result in a mutually exclusive marker. More 
detailed genomic analyses such as those performed by the head and neck 
sub-group of TCGA have failed to identify any new universal mutational 
signature for HNSCC (Cancer Genome Atlas, 2015). Gene expression 
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subtypes are yet to find a role in clinical decision making (Walter et al., 
2013).  
4.3.3.3 Comparison to TCGA HNSCC subgroup data 
The TCGA HNSCC subgroups data is available to the public in a post-
processed format. Clinical information was downloaded from the UCSC 
Cancer Genomics Browser (Zhu et al., 2009). This included all samples 
analysed by the TCGA HNSCC subgroup (n = 530). Samples IDs were 
obtained from this to identify oral cavity primary tumours that were HPV 
negative (n = 301). The pathological node positive and pathologically node 
positive samples out of this sub-cohort were then identified (N0, n = 132 and 
N+, n = 169). Segmented genomic data was then downloaded from the 
UCSC cancer genomic browser (N0, n = 116 and N+, n = 142). This data 
was then input to pheatmap (Raivo Kolde, Harvard USA), to generate 
genome wide heatmaps for both non-metastatic primary tumours and 
metastatic primary tumours. The frequency of CNAs identified in the panel 
associated with metastasis (see Table 4-13) was assessed using the 
downloaded TCGA data (see Table 4-16).  
A similar, consistent trend of increased frequency in metastatic tumours was 
seen in the TCGA HNSCC data. Loss of 11q23.1-q25 was not present in 
non-metastatic primary tumours in my samples but is present in 12/116 
(10%) of non-metastatic primary tumours in the TCGA data. This highlights 
the high level of inter-tumour heterogeneity and confirms that no CNA is 
uniquely exclusive to metastasis. The fact it was not identified in my samples 
is likely due to the smaller number of samples in my study. 
Similarly loss of 18q21.1-q21.32 was present in 25/116 (21%) of TCGA non-
metastatic primary tumours, but only 1/26 (4%) of these tumours in my 
samples. This again likely reflects the smaller number of samples in my 
study and heterogeneous nature of HNSCC. The overall similar trends in 
CNAs is reassuring that my data is not spurious given the robust 
methodology of the TCGA study. A heatmap was generated to visually 
assess the effectiveness of the CNA panel in selecting metastatic primary 




Cytoband TCGA cohort 
N0 (n = 116) 
TCGA cohort N+ 
(n = 142) 
Sethi cohort N0 
(n = 26) 
Sethi cohort N+ 
(n = 49) 
 Frequency % Frequency % Frequency % Frequency % 
+4p15.2-
p15.1 
3 3 9 6 1 4 5 10 
-4p15.1-
p14 
14 11 30 21 1 4 7 14 
-5q33.1-
q33.3 
16 14 40 28 4 15 18 37 
+7p12.1-
p11.2 
29 25 47 33 6 23 26 53 
-7q31.1-
q35 
7 6 16 11 1 4 7 14 
-8p23.3-
p22 
21 18 69 49 3 12 14 29 
-9p24.3-
p24.2 
15 13 50 35 3 12 15 31 
+9p21.1 12 10 29 20 1 4 9 18 
+11q13.3-
q13.2 
27 23 60 42 2 8 22 45 
-11q23.1-
q25 
12 10 45 32 0 0 22 45 
+13.q33-
q34 
9 8 21 15 1 4 9 18 
-15q26.2-
q26.3 
3 3 10 7 1 4 10 20 
+17q22-
q23.3 
5 4 12 9 3 12 15 31 
-18q21.1-
q21.32 
25 21 62 44 1 4 29 59 
Table 4-16: Comparison of frequency of CNA panel identified as associated with 
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Figure 4-39: Heatmap generated using CNA panel associated with metastasis 
using TCGA HNSCC subgroup data. Red denotes the presence of the CNA 
whilst white denotes the absence of the specific CNA. 
 
Inspection of the heatmap generated using the CNA panel suggests it does 
not separate metastatic vs. non-metastatic primary tumours as strongly as in 
my samples. The TCGA samples were then scored for the 
presence/absence of each CNA as previously (present = 1, absent = 0). The 
scores were analysed using the Shapiro-Wilk test for normality 
demonstrating they were not normally distributed. Therefore the mean 
scores for non-metastatic primary tumours and metastatic primary tumours 
were compared using the Mann Whitney test (see Figure 4-40). This found 
the mean score for metastatic primary tumours to be significantly higher (p = 
<0.0001). Though the mean scores is significantly different in each group 
this panel fails to discriminate completely between metastatic and non-


















































metastatic primary tumours. This may reflect the wide inter-tumour 
heterogeneity in HNSCC.  
 
 
Figure 4-40: Box-plot comparing CNA panel scores for metastatic and non-
metastatic primary tumours identified in the TCGA cohort. 
 
One potential confounding factor in using the TCGA data with pheatmap is 
the fact that a generic, group wide threshold was applied to their data, rather 
than an individual sample threshold as in my samples. This may increase 
the amount of background noise being included in the heatmap. However 
these samples were processed using GISTIC 2.0 by the TCGA group which 
utilises a generic threshold and as such it is not unreasonable to take this 
approach. Inspecting the group as a whole it was observed that canonical 
CNAs such as loss of 3p were present in appropriate proportions in each 
group.  
4.3.3.4 FGA as a biomarker for nodal status 
Taking a more generic view of genomic damage may represent a more 
useful method of stratifying patients risk. No difference was found in the 
mean number of segments in different groups. Using this a sole inference of 
genomic damage is actually a flawed approach as CNAs in HNSCC are 
generally broad. This means that large segments of the genome may be 
altered with relatively few breakpoints compared to another tumour where an 
increased number of smaller genomic regions are altered. This could a give 
Node negative  Node positive 
Nodal Status 
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a false impression that there are reduced genomic changes when in fact the 
converse is possible. Therefore using the FGA is likely to be a more reliable 
reflection of genomic damage. This approach has been found to predict 
survival in patients with metastatic colorectal carcinoma (Mehta et al., 2005). 
In different prognostic subtypes of breast cancer the FGA has been found to 
vary significantly (Jonsson et al., 2010). 
As the mean FGA in metastatic primary tumours was found to be 
significantly higher than in non-metastatic primary tumours (p = 0.0001) a 
further analysis was performed to attempt to determine a cut-off for this 
variable as a predictor for nodal status. An open access web application 
“Cutoff Finder” was used for this purpose as it provided multiple methods for 
different data types on one platform (Budczies et al., 2012). Using Fisher’s 
Exact text to calculate the significance of correlation between FGA and 
nodal status as a binary variable (N0 = 0, N+ve = 1) Cutoff Finder 
determined the optimal value to be 0.04. This generated a sensitivity of 98% 
but a specificity of 42.3% (see Figure 4-41).  
 
Figure 4-41: ROC for FGA as a marker for nodal metastases. 
 
Cutoff Finder also allowed analysis of the significance of correlation with 
survival. For disease-free survival it found a significant decrease in disease-
free survival using an FGA cut-off of 0.098, with a hazard ratio of 5.21 (1.2-
22.69) for an FGA > 0.098 (see Figure 4-42). For overall survival Cutoff 
FGA as a positive marker for nodal status 
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Finder identified a significant decrease in overall survival for patients with an 
FGA > 0.135 (p = 0.0059) (see Figure 4-43).  
 
 
Figure 4-42: Kaplan Meier plot demonstrating reduced disease free survival for 
patients with an FGA > 0.098 (p = 0.014). 
 
 
Figure 4-43: Kaplan Meier plot for overall survival demonstrating a significant 
decrease in patients with FGA > 0.1354 (p = 0.0059). 
 
The potential impact of intra-tumour heterogeneity is difficult to estimate. It is 
possible that the CNA signature or FGA could vary markedly dependent on 
the area of tumour sampled for DNA. Clonal heterogeneity has been 
demonstrated in studies sampling multiple topographically distinct areas of 
tumour in numerous cancers (McGranahan and Swanton, 2015). Proposed 
models of metastasis have suggested it could occur from relatively small 
Disease Free Survival (Months) 
Overall Survival (Months) 
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clonal populations with the primary tumour supporting the need to analyse 
metastases so as to identify any metastatic signature (Hynes, 2003). The 
similarity of nodal metastases to the primary tumour seen in this study 
suggests that this may not be the situation in every case and that the 
metastatic clone is often a significant population within the primary tumour. 
In future work it would be useful to evaluate the impact of this by using 
multiple sampling and comparing this to the genomic signatures obtained by 
taking one large, relatively untargeted sample. Indeed the clinical utility of 
genomic markers relies on the reproducibility and reliability of any signature 
identified. If these are limited by esoteric technical considerations, then the 
value of any purported signature is reduced. In taking any work forward to 
test a genomic signature the impact of intra-tumour heterogeneity must be 
taken into account.  
4.4 Conclusion 
In relation to the aims of this chapter: 
1. NGS CNA data was used to compare metastatic primary tumours to 
their matched nodal metastasis. This found that largely metastases 
were similar to their parent tumour, though not identical.  
2. In comparing CNA data between metastatic and non-metastatic 
primary tumours no single CNA is mutually exclusive in a single 
clinicopathologic group. A 14-CNA panel was identified as being 
significantly associated with metastasis. The FGA was found to also 
be significantly increased in metastatic primary tumours compared to 
non-metastatic tumours. These measures could be tested as a 
predictive marker for metastasis. 
3. When comparing  CNA data  between tumours associated with and 
without nodal ECS, a correlation was found between the presence of 
ECS and loss of 18q21.1-q21.32. Within this region the gene SMAD4 
represents a possible driver gene for this phenotype. 
 171 
Chapter 5  
Copy number analysis of OPSCC and comparison to viral 
load 
5.1 Introduction 
The association between HNSCC and high-risk human papillomavirus sub-
types (most commonly type 16) is well recognised (Gillison et al., 2008, Vidal 
and Gillison, 2008, Gillison and Lowy, 2004, Gillison, 2004). This association 
is predominantly in oropharyngeal SCC (OPSCC) with poorly differentiated, 
basaloid histological characteristics (Gillison, 2004). It is characterised by 
the detection of HPV DNA, RNA or expression of p16 protein (Venuti and 
Paolini, 2012). This subgroup of patients has been demonstrated in clinical 
trials to have a significantly better prognosis compared to patients with HPV-
negative tumours (Ang et al., 2010). In fact, HPV-status appears to be the 
single strongest prognosticator in OPSCC (Rischin et al., 2010, Fakhry et al., 
2008). The prevalence of HPV-positive OPSCC is increasing (Mehanna et 
al., 2013). The prognostic effect of HPV-status is not homogeneous. A small 
subset of HPV-positive OPSCCs has a poor treatment response and clinical 
outcome. The reasons for this are unclear and a reliable method for 
identifying these patients has not been established (Ang et al., 2010). The 
prevalence of HPV in head and neck cancer subsites outside the oropharynx 
appears low (< 10%, compared to ~60% of OPSCC) (Upile et al., 2014, 
Combes and Franceschi, 2014). The beneficial prognostic impact of HPV 
status also appears to be lost in subsites outside the oropharynx (Lassen et 
al., 2014). 
Targeted exome sequencing revealed a similar mutational burden of HPV-
positive and negative HNSCC but differences in the spectrum of mutations 
(including unique mutations in DDX3X, FGFR2/3) (Seiwert et al., 2015). 
Gene expression analysis has shown a different profile for HPV-positive and 
negative OPSCC, which may well explain the difference in response to 
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chemoradiation (Lohavanichbutr et al., 2009, Thibodeau et al., 2014). 
Surprisingly little overlap has been found in gene expression studies 
demonstrating that even HPV-positive HNSCC is a genomically 
heterogeneous disease (Weinberger et al., 2006, Slebos et al., 2006, 
Schlecht et al., 2007, Martinez et al., 2007). 
The low-coverage NGS approach taken to provide copy number profiles in 
my study (see Chapter 4) is much cheaper than mutational analysis or gene 
expression studies. It also works wells with FFPE-tissue. In addition to 
providing copy number data it also enables determination of the presence of 
any viral DNA sequences (Conway et al., 2012, Wood et al., 2012). By then 
relating the quantity of viral sequences detected to the depth of sequencing 
coverage the viral load can be determined (Conway et al., 2012). This 
method was used to determine the HPV-status of the OSCC samples 
included in my project. Briefly, the number of reads aligning to the human 
genome was used to calculate read depth in terms of reads per kilobase 
(Kb). Following this, the number of reads uniquely aligning to viral genomes 
was counted (this is proportional to the number of Kb viral sequence per 
human genome, and hence the number of viral genomes per human 
genome). Given a known number of human genome reads, the possible viral 
load that could be detected with 95% confidence is: 
(no. of viral reads x 6 x 109 bp diploid human genome) 
(7900 bp viral genome x number of human reads) 
There is a need for a reliable method of not just identifying HPV-positive 
HNSCC, but recognising those, which will benefit from the positive 
prognostic effect of HPV-status (i.e. those which are truly “HPV-driven”). 
This needs to be a swift and affordable test. The genomic signature of these 
tumours is still incompletely understood, and may well provide important, 
translational biomarkers. 
The Precancer Genomics group has previously performed low-coverage 
NGS on a group of HNSCC patients. Part of this group underwent 
determination of HPV-status by DNA-PCR and p16 immunohistochemistry 
(IHC) as well as NGS viral load calculation and was published by Conway et 
al (Conway et al., 2012). This paper concluded that NGS was comparable in 
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sensitivity and specificity to other methods for detecting HPV-status. Another 
study by Lechner et al performed targeted exome sequencing of OPSCC 
samples finding 100% concordance between sequencing and HPV status 
determined by p16 IHC and PCR (Lechner et al., 2013). By using the 
computational techniques I acquired in analysing the copy number profiles of 
my patient cohort I set out to evaluate if the copy number profile of HPV-
positive and negative OPSCC varied according to NGS-determined viral 
load.  
5.2 Aim 
The aim of this work was to: 
1. Produce a specific genome-wide CNV profile for HPV-positive 
OPSCC. 
2. To evaluate if there is a specific viral load at which this genomic 




5.3.1 Patient Groups 
Patients for this study were collected from the Precancer Genomics tissue 
bank database. The inclusion criteria for these patients were no history of 
previous HNSCC or radiation and a confirmed oropharyngeal SCC primary 
tumour.  In total 51 patients were identified (see Table 5-1). They included 13 
patients that were previously part of a larger separate study published by 
Conway et al, as part of the Precancer Genomics group, University of Leeds 
(Conway et al., 2012). They compared NGS to DNA-PCR and p16 IHC as a 





Base of tongue Tonsil Posterior wall 
of pharynx 
Soft palate 
No. of patients 23 13 4 11 
Table 5-1: Table of all OPSCC tumour subsites. 
 
These samples are detailed in Table 5-2. Each primary tumour from these 
patients underwent DNA extraction according to the same protocol 
described in Chapter 2.5. They were sequenced either on the Illumina 
Genome analyser II at 76-bp length reads multiplexing 10 samples per lane 
or the Illumina HiSeq 2500 at paired end 100 bp length reads. This produced 
approximately 0.033x – 0.33x coverage of the human genome. 
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5.3.2 Cumulative frequency karyograms 
The FASTQ files produced from these sequencing experiments were 
processed as described in Chapter 2.9. The CNAnorm cumulative frequency 
karyograms were generated for the zero viral load tumours and those with a 
viral load > 0 (see Figure 5-1). 
In comparing the cumulative CNA profiles for the oropharyngeal tumours 
with viral load of 0 (n = 31) and those with a viral load > 0 (n = 20), there are 
several striking differences (see Figure 5-1). Firstly there are fewer overall 
areas of chromosomal gain and loss seen in tumours with a viral load > 0, 





Figure 5-1: Cumulative frequency plots for the (a) Viral load = 0 group and (b) Viral 
load > 0 group. Regions of gain are represented in red and regions of loss in 
blue. 
 
Tumours with a viral load of 0 showed a far higher frequency of 3p loss 
(27/31 (87%)), with few tumours with a viral load > 0 (5/20 (25%)) 
demonstrating 3p loss. Loss of 9p is seen in 15/31 (48%) of tumours with no 
viral load and 1/20 (5%) of those with a viral load > 0. Loss of 18q is seen in 
Viral load = 0 














13/31 (42%) of tumours with no viral load and 3/20 (15%) of those with a 
viral load > 0. Other regions of CNA with a visually detectable difference 
between these two groups are shown in Table 5-3.  
 
 No of samples in each group (%) 
Region 0 Viral load group 
(n = 31) 
Viral load > 0 group 
(n = 20) 
- 3p 27 (87%) 5 (25%) 
- 4q 7 (23%) 1 (5%) 
+ 5p 12 (39%) 5 (25%) 
- 5q 10 (32%) 1 (5%) 
- 9p 15 (48%) 1 (5%) 
- 11p 11 (35%) 3 (15%) 
+ 12p 10 (32%) 2 (10%) 
+ 12q 6 (19%) 1 (5%) 
+ 15q 6 (19%) 1 (5%) 
- 18q 13 (42%) 3 (15%) 
+ 20p 12 (39%) 3 (15%) 
+ 20p 12 (39%) 3 (15%) 
+ 20q 8 (26%) 1 (5%) 
- 21q 12 (39%) 3 (15%) 
Table 5-3: List of differential CNA between the two viral load groups found on visual 
inspection of cumulative frequency karyograms. 
 
5.3.3 GISTIC focal analysis of oropharyngeal tumours with no 
detectable viral load and those with a detectable viral load 
GISTIC was used to analyse the same sample groups to produce a 
simultaneous focal and broad CNA. The input files for this were created as 
described in Chapter 2.9.2.3. The results of the focal analysis are shown in 
Figure 5-2 and Figure 5-3). From these analyses the focal amplification 
profiles can be seen to be largely similar between the two groups. It is 
important to remember that telomeric and centromeric regions are 
unreliable. Using the GISTIC focal plots alone suggested the tumours with 0 
viral load do possess two unique focal CNAs (gain of 15p15.1 and 8q23.3). 
However, examination of the sample karyograms revealed that these CNAs 
are found at differing rates in both groups. Gain of 15p.1 is found in 13/31 
(42%) of the 0 viral load group and 3/20 (15%) of the >0 viral load. Gain of 
8q23.3 was present 17/31 (55%) of 0 viral load tumours and 9/20 (45%) of 
the > 0 viral load group.  
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Figure 5-2: Genome-wide focal amplification plots for tumours with 0 viral load (a) 
and tumours with viral load >0 (b). The chromosomes are numbered along the 
y-axis. The bottom x-axis indicates the q-value with the green line marking the 
significance threshold at which the analysis was performed. The top x-axis 
shows the G-score for each CNA. 
 
Comparison of the focal deletion profiles for these two groups using GISTIC 
alone reveals a small number of differences. No focal deletions are unique to 
one group alone. Focal losses that are identified as significant by GISTIC in 
the tumours with 0 viral load only include loss of 4p16.2 (found in 16/31 
(52%) tumours with 0 viral load and 4/20 (20%) tumours with > 0 viral load), 
loss of 6p22.3 (found in 4 tumours with 0 viral load and 1 tumour with viral 
load > 0) and loss of 8p22 (found in 12/31 (39%) tumours with 0 viral load 
compared to 4/20 (20%) tumours with > 0 viral load).  
Focal deletions identified by GISTIC as being only in the tumours with viral 
load > 0 included loss of 6q26. However examination of the individual 
karyograms found loss of 6q26 in 7/31 (23%) tumours with viral load > 0 and 
4/20 (20%) with 0 viral load. Closer inspection of the wide peak boundaries 
of loss of 11q23.1 in tumours with > 0 viral load and 11q25 (identified by 
GISTIC in tumours with 0 viral load) found them to actually overlap. Deletion 
of the region 11q23.1-q25 occurred in 17/31 (55%) of 0 viral load tumours 
and 14/20 (70%) of the > 0 viral load group.  
0.25 10−1 10−2 10−4 10−6
































































































         
Figure 5-3:  Genome-wide focal deletion plots for tumours with 0 viral load (a) and 
tumours with viral load >0 (b). The chromosomes are numbered along the y-
axis. The bottom x-axis indicates the q-value with the green line marking the 
significance threshold at which the analysis was performed. The top x-axis 
shows the G-score for each CNA. 
 
Figure 5-4: Example of two adjacent focal deletions identified using GISTIC. The 0 
viral load group is on the left (a) and tumours with viral load >0 on the right 
(b). Inspection of the CNAnorm generated cumulative karyograms for the 
individual chromosomes allows the region of deletion to be seen to be actually 
overlapping the two foci. 
GISTIC suggests focal regions of potential interest. However, the wide peak 
boundaries for these remain large and GISTIC does not provide an accurate 
reflection of the frequency of these CNAs in one group relative to another. It 
also does not provide information on adjacent regions in different groups and 
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if wide peak boundaries overlap between groups. Though CNAnorm 
cumulative frequency karyograms provide some information on overlapping 
regions (see Figure 5-4), resolution is limited. Broad CNAs of similar or higher 
frequency to focal CNAs may obscure or completely mask the smaller 
altered region. To reliably identify the minimally altered regions an 
alternative is required. 
5.3.4 Evaluation of minimally altered regions between OPSCC 
tumours with 0 viral load and viral load > 0 
In order to try and identify potential candidate genes of interest it is 
necessary to identify the smallest region recurrently altered (the minimally 
altered region). By using open access software called pheatmap (Raivo 
Kolde, Harvard USA) and combining this with an R-based script called 
genomeHeat (Dr Henry Wood, Precancer genomics) I was able to create 
heatmaps for these samples, utilising the CNAnormout.txt files as input. This 
software provided greater resolution than the CNAnorm-generated 
cumulative frequency plots when attempting to identify the minimally altered 
region.  
Firstly, I instructed the software to create a heatmap of all samples allowing 
the software to cluster samples according to CNA profile (see Figure 5-5).  
Then, potential focal regions of interest were identified by visual inspection 
of the CNAnorm cumulative frequency karyograms. The chromosomal arms 
with the greatest differential frequency of CNA between the groups were 
selected. As demonstrated in Table 5-3 loss of 3p occurred with the highest 
frequency in the 0 viral load group (27/31 (87%)) and also with the largest 
difference in frequency when compared to the > 0 viral load group (25%). 
pheatmap allows generation of a sequential cluster heatmaps that can be 
used to gradually zoom in on the minimally altered region (see Figure 5-6). 
These images allow simultaneous assessment of the individual patients and 
frequency of the minimally altered region as well as the ability to identify 
samples according to viral load status. Due to the resolution and layout of 
the image focal CNAs of equivalent or lower frequency to broader CNAs are 




Figure 5-5: Heatmap of all OPSCC tumours generated by pheatmap. Regions of 
loss of one copy are in dark blue, loss of two or more copies in light blue. 
Regions of gain of one copy are in red and gain of two or more copies in 
orange. The chromosome some are numbered along the y-axis. Samples with 
0 viral load are represented by white along the top x-axis and samples with 
viral load >0 represented by green. 
 
Though the cumulative frequency karyograms were inspected to try and 
identify focal CNAs close correlation was found with the regions highlighted 
by GISTIC and therefore these were all included. Broader regions identified 
as on the CNAnorm-generated cumulative frequency karyograms were also 
assessed. CNAs were selected for attempted identification of minimally 
altered regions on the basis that they were present in at least 30% of 
samples in the group with the highest frequency and at least twice as 
frequently when compared to the other group. 
By progressively increasing the resolution of the heatmap and focusing on 
the smallest region that is recurrently altered, the genomic boundaries for 
this minimally deleted region amongst tumours with 0 viral load can be 
obtained. Using loss of 3p24.3 as an example: the wide peak boundaries 
provided by GISTIC for this are: chr3: 1-84,800,000. Using pheatmap, I was 
able to identify the actual minimally altered region to be within chr3: 





























40,000,000-79,200,000. This is still a relatively broad region but suggests 
the minimally altered region to be loss of 3p22.22-p12.3 and reduces the 


















Figure 5-6: (a) Heatmap of all OPSCC tumours based on chr 3p. Regions of loss of 
one copy are in dark blue, loss of two or more copies in light blue. Regions of 
gain of one copy are in red and gain of two or more copies in orange. The 
chromosome some are numbered along the y-axis. Samples with 0 viral load 
are represented by white along the top x-axis and samples with viral load > 0 
represented by green. The smallest, recurrently lost region in the 0 viral load 
group is highlighted between the black lines, whilst the smallest region lost in 
the > 0 viral load group is shown between the green lines. (b) Shows this 
region under higher resolution as obtainable using pheatmap 
Relatively broads regions may be of use as a marker, but provide a 
challenge when trying to identify the underlying key genes that are being 
affected by CNA. Gain of 5p15.1 was also identified by GISTIC as a focal 
CNA occurring at a statistically significant rate (q = 0.0589). The wide peak 
boundaries for this region provided by GISTIC were chr5: 6,400002-
24,000000. Using pheatmap to visualise initially chromosome 5, followed by 
5p (see Figure 5-7a & b) allowed identification of two minimally amplified 
regions within these wider boundaries. By increasing the resolution (see 
Figure 5-7c) the genomic windows at which these CNAs begin and end can 
be identified (5p15.31:7,200000-9,600,000 and 5p14.3: 20,000,000-
23,200,000).  
The boundaries of the minimally altered regions were then used to obtain the 
list of all genes within this region from the UCSC Genome Browser (Kent et 
al., 2002). This process was repeated for all selected regions (see Table 5-4), 




in an effort to specify the most common altered genes. These lists were then 
further analysed to identify genes of potential significance. 
(a)     (b) 
        
(c)	
	
Figure 5-7: (a) Heatmap of all OPSCC tumours based on chr 5. (b) Heatmap based 
on chr 5p with two recurrently gained regions marked in black and green (c) 
Heatmap at increased resolution to identify the exact windows representing 
the boundaries for the minimally altered regions. Regions of gain of one copy 
are in dark blue, loss of two or more copies in light blue. Regions of gain of 
one copy are in red and gain of two or more copies in orange. The 
chromosomes are numbered along the y-axis. Samples with 0 viral load are 
represented by white along the top x-axis and samples with viral load > 0 
represented by green. The smallest, recurrently lost regions in the 0 viral load 







All OPSCC Samples chr5 All OPSCC Samples chr5 800001-44000001 
All OPSCC Samples chr5 800001-44000001 




   No. of samples in each group (%) 
Region start end 0 viral load 
(n  = 31) 
> 0 viral load 
(n = 20) 
3p22.1-p12.3 40000000 79200000 27 (87) 7 (35) 
9p21.3-p21.2 20800001 25600001 16 (52) 1 (5) 
9p24.3-p24.1 2000000 4800001 16 (52) 1 (5) 
5q33.1-q33.2 150400001 153600001 12 (39) 1 (5) 
4p16.3-p16.1 2400000 10400000 16 (52) 4 (20) 
8p23.3-p21.1 800001 28800000 12 (39) 5 (25) 
18q21.1-22.1 44800001 62400000 14 (45) 2 (10) 
18q23.3-q23 70400001 76800000 13 (42) 4 (20) 
21q22.2-q22.3 42400001 47200001 15 (48) 3 (15) 
21q21.1-q21.3 23200001 28800001 10 (32) 2 (10) 
Amplifications 
Region start end 0 viral load > 0 viral load 
5p15.31 7200000 9600000 13 (42) 3 (15) 
5p14.3 20000000 23200001 15 (48) 5 (25) 
7p12.1-p11.2 53600001 56000000 8 (26) 3 (15) 
8q24.12-q24.13 120000001 128800001 17 (55) 8 (45) 
11q13.2-q13.4 68000001 70400001 12 (39) 5 (25) 
19q13.12-q13.2 36000001 41600001 14 (45) 6 (30) 
20p12.3-p12.1 7200001 12800001 13 (42) 1 (5) 
20q11.21-q11.23 32000001 35200001 10 (32) 4 (20) 
Table 5-4: List of minimally altered regions identified in 0 viral load and > 0 viral 
load tumour groups. 
 
5.3.5 Identification of genes and gene pathways 
After using the UCSC Genome Browser to obtain the lists of genes 
contained within all the minimally altered regions, these lists were then cross 
referenced against 13 list of genes known to be associated with HNSCC. 
These included 12 gene pathways from the Kyoto Encyclopaedia of Genes 
and Genomes (KEGG, http://genome.jp/kegg/), HNSCC cancer genes 
identified from the cancer gene census 
(http://cancer.sanger.ac.uk/cancergenome/projects/census/), and a list of 
genes gene identified by Stransky et al and the TCGA HNSCC subgroup as 
harbouring a statistically significant frequency of mutation in head and neck 
cancer (Stransky et al., 2011, Cancer Genome Atlas, 2015). 
The final gene lists are shown in Table 5-5. These represent genes that are 
copy number altered at a higher frequency in OPSCC tumours with 0 viral 
load compared to those with viral load > 0. The relatively low number of 
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genes identified in this stepwise process highlights the potential 








11q13.2-q13.4 LRP5, CCND1, FGF19, FGF4, FGF3 
12p12.3-p12.2 PIK3C2G, PLCZ1 
19q13.12-q13.2 PSENEN, RASGRP4, RYR1, MAP4K1, HNRNPL, DLL3, 
PAK4, AKT2, NUMBL 




3p22.1-p12.3 CTNNB1, SETD2, CDC25A, SHISA5, LAMB2, RHOA, 
CACNA2D2, CISH, MAPKAPK3, DUSP7, BAP1, TNNC1, 
PBRM1, CACNA1D, CACNA2D3, WNT5A, ERC2, FLNB, 
FHIT, PRICKLE2, MITF, FOXP1 
4p16.3-p16.1 PPP2R2C,  DRD5 
5q32-q33.2 CSF1R 
8p23.3-p21.1 ANGPT2, FGF20, PCM1, FGF17, PPP3CC, 
TNFRSF10B, STC1, PPP2R2A, ADRA1A, PTK2B, FZD3 
9p21.3-p21.2 IFNB1, IFNW1, IFNA21, IFNA4, IFNA7, IFNA10, IFNA16, 
IFNA17, IFNA14, IFNA5, IFNA6, IFNA13, IFNA2, IFNA8, 
IFNA1, IFNE, CDKN2A, CDKN2B 
9p24.3-p24.1  
18q21.1-22.1 SMAD2, SMAD4, MALT1, PMAIP1, PHLPP1, BCL2, 
SERPINB5, SERPINB4 
18q23.3-q23  
21q22.2-q22.3 TMPRSS2, U2AF1 
21q21.1-q21.3	 	
Table 5-5: Genes identified of potential significance in OPSCC within minimally 
altered regions. 
 
5.3.6 Analysis of pathways containing CNAs in tumours with 0 
viral load vs. > 0 viral load 
This was generated using the same pathways selected for cross-referencing 
the gene lists produced from the minimally altered regions (see section 
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5.3.5). The pathways enriched by CNAs in tumours with 0 viral load and > 0 
viral load are shown in Figure 5-8 and Figure 5-9).  
 
 
Figure 5-8: Number of genes cross-referenced to KEGG gene pathways and gene 
lists of potential significance in minimally altered regions (see table 6-4). 
 
The pathway containing the largest number of genes was the PI3K pathway. 
This is well recognised to be associated with proliferation, invasion and 
metastasis. Lui et al found this to be the most frequently mutated pathway in 
a study using whole exome sequencing of 151 HNSCC tumours (Lui et al., 
2013). The JAK/STAT pathway is widely recognised to be aberrant in 
haematological malignancy, but is also activated in HNSCC, where 
members of the pathway contribute to cell survival and proliferation (Lai and 































































































































































































contribute to tumour progression and signal poor prognosis 
(Leelahavanichkul et al., 2014).   
 
Figure 5-9: Total number of times a gene within each pathway was identified in 
tumours with 0 viral load (blue) and tumours with viral load > 0 (red). 
 
Comparison of the frequency of CNA of gene within specific pathways is 
made between the 0 viral load group and > 0 viral load tumours in Figure 5-9. 
This demonstrates a much higher frequency of copy number altered gene 
within the 0 viral load tumours. This is to be expected as the minimally 
altered regions are present at higher frequency in the 0 viral load group. No 
minimally altered regions occurred with greater frequency in the >0 viral load 
group. However, the pathways containing the highest frequency of copy 
number altered genes differs in the > 0 viral load group. 
The pathway most enriched by copy number altered genes in the >0 viral 



































































































































































































WNT signalling pathways. This concurs with Siewert et al, who found that 
PI3K signalling pathway aberrations were found in both HPV positive and 
negative tumours, whilst p53 signalling and cell-cycle pathway aberrations 
were found more commonly in HPV-negative tumours. It is important to 
remember that in their study, mutation analysis was used to compare altered 
networks and therefore used a specific software for this which is not suitable 
for copy number data, alone. 
5.3.7 GISTIC broad analysis of oropharyngeal tumours with no 
detectable viral load and those with a detectable viral load 
Using GISTIC to generate a simultaneous broad analysis of CNA in these 
two tumour groups produces heat maps (see Figure 5-10) with a similar 
profile to the cumulative frequency karyograms created using CNAnorm . 
 
    
Figure 5-10: Heatmaps generated by GISTIC for CNA in tumours with 0 viral load 
(a) and viral load > 0 (b). Regions of loss are represented by blue whilst 
regions of gain are red. 
 
Loss of 3p is seen as a more common event in tumours with 0 viral load as 
well as the other regions identified by CNAnorm. The advantage of using 
GISTIC generated heat maps in addition to CNAnorm cumulative frequency 
plots is the ability to see the group and the individual samples 
simultaneously. This allows regions that are of lost at a significant level at 

















































allows the inter-tumour heterogeneity of both groups to be visualised. They 
again suggest there is a reduced overall amount of CNA in the group of 
oropharyngeal tumours with a viral load > 0.  
5.3.8 Analysis of oropharyngeal tumours with intermediate viral 
load 
The groups above were divided purely on the basis of whether or not there is 
a detectable viral load using NGS. Those with 0 viral load were considered 
to represent an HPV-negative oropharyngeal tumour. Studies have shown 
NGS-determined viral load is highly concordant with other techniques such 
as PCR or IHC (Lechner et al., 2013, Conway et al., 2012). As can be seen 
in Table 5-2 there are a number of samples that had a low or barely 
detectable viral load. It was decided to analyse the samples with a viral load 
greater than 0 but no more than 20 as a separate group to those with a viral 
load greater than 20. This subgroup analysis was performed as the samples 
with a low viral load (> 0-20) were hypothesised to represent tumour that 
may not be driven by HPV and therefore possess a CNA profile similar to the 
0 viral load group. As not all patients deemed to be HPV positive using 
established methods are found to have the positive prognosis and treatment 
response associated with an HPV-positive tumour, this could hold value as 
an alternative method of stratifying patient risk clinically. This was firstly 
performed using cumulative karyograms producing using CNAnorm (see 
Figure 5-11). 
The CNA profiles for the intermediate viral load tumours and the high viral 
load tumours possess a lot of similarities as shown in Figure 5-11. 
Differences appear to be subtle, with no CNA being exclusively found in one 
group, or at a large differential level to the other group. Loss of 16q is 
observed in 5/12 (42%) of high viral load tumours and 2/8 (25%) of the 
intermediate viral load group. Gain of 7p is seen in 2/8 (25%) of the 
intermediate viral load tumours and only 1/12 (8%) of the high viral load 
tumours. Otherwise CNAs appear to occur at similar rates in both groups. 
This could well be due to the smaller number of patients in each group not 
allowing differences to be identified. It could also be due to the differences 
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between the groups being due to low frequency focal CNAs that require a 
different method to be identified (i.e. GISTIC). 
 
 
Figure 5-11: Cumulative frequency plots for tumours with viral load > 0-20 (a) and 
tumours with viral load > 20 (b). 
  
5.3.8.1 GISTIC focal analysis of intermediate viral load group 
GISTIC was used to analyse the same sample groups to produce a 
simultaneous focal and broad CNA. The input files for this were created as 
described in Chapter 2.9.2.3. The results of the focal analysis are shown in 
Figure 5-12 and Figure 5-13. In reviewing the GISTIC focal analysis it is 
important to remember the reduced number of patients in each group and to 
treat telomeric and centromeric CNAs with caution. 
 
Viral load > 0-20 


















The focal amplification profile of the intermediate viral load group (n = 8) is 
seen to be quite different to the group with viral load > 20 (n = 12) and 
actually has a greater similarity to the tumours with zero viral load (see 
Figure 5-2). The intermediate viral load group shares several focal 
amplifications identified at a significant level with the zero viral load group 
(gain of 3q26.3, 7q22.3, 8q24.12, 11q13.12). The tumours with viral load > 
20 are seen to contain gain of 20q11.2 at a significant level. In terms of focal 
deletions (see Figure 5-13) the intermediate viral load group is again seen to 
share CNAs with the zero viral load group (gain of 2q36.3, 13q13.2) and 
have little in common with the viral load > 20 tumours. However, the low 
frequency of any CNAs in the tumours with viral load > 20 may reflect the 
lower numbers of patients in this group and therefore the focal regions 
nominated by GISTIC need clarification by evaluating the minimally altered 
regions within these focal CNAs.  
 (a)     (b) 
           
Figure 5-12: Genome-wide focal amplification plots for OPSCC tumours with 
intermediate viral load > 0-20 (a) and > 20 (b). The chromosomes are 
numbered along the y-axis. The bottom x-axis indicates the q-value with the 






























































































         
Figure 5-13: Genome-wide focal deletion plots for OPSCC tumours with 
intermediate viral load > 0-20 (left) and > 20 (right).  
 
5.3.9 Evaluation of minimally altered regions in intermediate and 
high viral load groups 
Using the regions nominated by GISTIC and visual analysis of the CNAnorm 
karyograms, a number of focal CNAs were analysed to try and identify any 
minimally altered regions that may differentiate between intermediate or high 
viral load tumours. This analysis also included using pheatmap software as 
described in section 5.3.4 (see Table 5-6). As these groups were smaller, 
using the regions nominated by GISTIC was preferred rather than simple 
visual inspection, due to the fact that GISTIC performs statistical analysis of 
these regions, including adjusting the p-value for multiple testing (q-value) 
with the level of significance set at 0.25. The focal regions nominated by 
GISTIC met this criteria. 
When evaluating the minimally altered regions across the three groups there 
are few differences. No CNA is exclusively found in one group. Some do 
suggest that the intermediate viral load tumour shares similarities with the 0 
viral load tumours. Gain of 6q12.1-11.1 is found in 5/31 (16%) of 0 viral load 







































































































of tumours with viral load > 20. Loss of 6q26-q27 is also identified in 5/12 
(42%) of high viral load tumours but 1/8 (13%) of intermediate viral load 
tumours and 6/31 (19%) of 0 viral load tumours. Gain of 7q11.22-122.2 was 
present in 14/31 (45%) 0 viral load tumours and  3/8 (38%) intermediate viral 
load tumours but only 1/12 (8%) high viral load tumours. Gain of 7p12.3-
p11.2 is also seen in 8/31 (26%) of 0 viral load tumours, 2/8 (25%) of 
intermediate viral load tumours and 1/12 (8%) of the high viral load group. 
Loss of 3p21.31-p21.2 was found much more frequently in 0 viral load 
tumours compared to tumours with viral load > 0.  
When the intermediate and high viral load groups are compared, a similar 
frequency of loss of 3p is observed (27/31 (87%) in 0 viral load tumours, 3/8 
(38%) in intermediate viral load tumours and 4/12 (33%) in high viral load 
tumours). Loss of 3p has been associated with poor prognosis in HNSCC 
(Gross et al., 2014). The fact that it occurs at lower frequency in 0 viral load 
tumours is supportive of Gross et al’s findings as the prognosis for HPV-16-
associated OPSCC is generally improved compared to non-HPV-16-
associated OPSCC.  
Interestingly some CNAs were seen at a similar rate across all three groups 
including loss of 11q22.3-q23.2 9 present in 19/31 (61%) of 0 viral load 
tumours, 5/8 (63%) of intermediate viral load tumours and 10/12 (83%) of 
high viral load tumours. Gain of 8q24.12-q24.22 was seen in 17/31 (55%) of 
0 viral load tumours, 5/8 (63%) of the intermediate group and 6/12 (50%) of 
the high viral load tumours. These CNAs have been reported previously as 
frequently occurring in HNSCC (Bauer et al., 2008, Yong et al., 2014). This 
suggests that these CNAs relate to cancer mechanisms or attributes not 
specifically influenced by viral status. 
No CNAs (focal or broad) appear to differentiate well between the 







	 	 	 No. in each group (%) 
Cytoband start end 0 viral 
load 
n = 31 
> 0-20 
viral load 
n = 8 
> 20 viral 
load 
n = 12 
6q12.1-q11.1 55200001 63200001 5 (16) 1 (13) 3 (25) 
7q11.22-q22.2 67200000 111800000 14 (45) 3 (38) 1 (8) 
8q24.12-q24.22 119800000 132000000 17 (55) 5 (63) 6 (50) 
11q13.1-q13.4 64000001 70400001 11 (35) 2 (25) 3 (25) 
20q11.1-q11.23 28000000 35200001 10 (32) 3 (38) 2 (16) 
7p12.3-p11.2 47200001 56000000 8 (26) 2 (25) 1 (8) 
Deletions 
Cytoband start end n in 0 viral 
load 
n in >0-20 
viral load 
n in >20 
viral load 
2q35-q37.1 218400001 234400001 7 (23) 2 (25) 3 (25) 
2q37.2-q37.3 236800001 241600001 11 (35) 1 (13) 4 (33) 
6q15-q22.1 92800001 116800001 6 (19) 2 (25) 4 (33) 
7q36.1-q36.3 152000001 158400001 7 (23) 2 (25) 2 (16) 
10q26.13-q26.3 125600002 135534747 11 (35) 1 (13) 2 (16) 
11q22.3-q23.2 108000000 112800001 19 (61) 5 (63) 10 (83) 
13q32.3-q34 100800001 112800001 7 (23) 3 (38) 4 (33) 
3p21.31-p21.2 48000000 52000000 27 (87) 3 (38) 4 (33) 
6q26-q27 162400001 164800001 6 (19) 1 (13) 5 (42) 
14q32.2 96800001 99200001 7 (23) 2 (25) 4 (33) 
14q32.31-q32.33 101600001 104000001 6 (19) 1 (13) 5 (42) 
Table 5-6: List of minimally altered regions identified in 0 viral load, intermediate 
and high viral load tumour groups. 
 
5.3.10 Selection of CNA panel to differentiate OPSCC 
tumours with zero viral load from those with viral load >0 
Utilising the minimally altered regions identified in section 5.3.4, a selection 
were compiled as a panel of CNA markers to potentially separate OPSCC 
tumours with 0 viral load from those with a viral load >0 (see Table 5-7). This 
panel was then applied to all OPSCC tumours and a heatmap created as 
shown in Figure 5-14. 
Though this did not separate all tumours with 0 viral load, when applying a 
binary score of 1 for present to each minimally altered region and 0 for 
absence of specific gain or loss, a total score for each sample was 
generated. These scores were then analysed using the SPSS (Version 21, 
IBM Corp, Armonk NY). The Shapiro-Wilk test for normality was performed 
finding that data was not normally distributed (p = 0.004). The Kruksal-Wallis 
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test was then used to compare the mean scores across the three groups 
(see Figure 5-15) finding that the means scores for the 0 viral load tumours 
were significantly higher than the other groups (p = <0.001). When 
comparing the mean scores of the > 0-20 viral load and >20 viral load 
groups using the Mann Whitney U Test no significant difference was seen (p 
= 0.624).  
CNAs associated with 0 viral load 











Table 5-7: Panel of CNAs identified in OPSCC tumours associated with 0 viral load. 
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Figure 5-14: Heatmap to show all OPSCC samples when specifically assessed for 
the presence (red) or absence (white) of the minimally altered regions. 
 
Figure 5-15: Comparison of mean scores for the minimal CNA panel for the 3 
groups of viral load. 







5.3.11 Comparison of fraction of genome altered (FGA) 
The actual proportion of the genome altered in terms of copy number was 
calculated as a reflection of the underlying amount of altered genomic DNA 
in each group of tumours. The FGA is calculated using the number of bases 
in all segments in each sample as the denominator and number of bases in 
each sample that are copy number altered as the numerator. These were 
then compared between groups separated according to viral load. 
The FGA for OPSCC tumours with 0 viral load and those with viral load >20 
were analysed using the Shapiro-Wilk test for normality. As it was normally 
distributed the two-sample t-test was then used to compare the means of 
these groups (see Figure 5-16). The mean FGA of the tumours with 0 viral 
load (0.328) was found to be significantly higher than the mean FGA of 
tumours will viral load >0 (0.210, p = 0.006). 
 
 
Figure 5-16: Comparison of FGA for tumours with 0 viral load  and tumours with 
viral load >0. 
 
The FGA for the intermediate viral load group and tumours with viral load 
>20 were also calculated as above. The distribution of these samples was 
analysed for normality using the Shapiro-Wilk test for normality (see Figure 
5-17). This revealed neither group was normally distributed and thus the 







means were compared using the Mann-Whitney U test. The mean FGA of 
each group was not found to be significantly different (p = 0.910). 
 
 
Figure 5-17: Comparison of FGA of tumours with viral load >0-20 and tumours with 
viral load >20. 
 
5.4 Discussion 
5.4.1 CNAs associated with differing viral load in OPSCC 
Since Fearon and Vogelstein demonstrated the stepwise accumulation of 
genetic alterations occurring in parallel with colorectal tumourigenesis, 
cancer has been regarded as a disease of genomic origin (Fearon and 
Vogelstein, 1990). There are many ways of examining the cancer genome. 
CNV represents an important component of genetic damage and variation. It 
affects a greater fraction of the genome than mutations and has been used 
to identify novel oncogenes and provide biomarkers for prognostic sub-
groups (Curtis et al., 2012, Weir et al., 2007, Nielsen et al., 2008). Despite 
large genomic studies of HNSCC recently published, there is still a dearth of 
HPV-positive samples in these, for instance the TCGA cohort is 85% HPV 
negative (Cancer Genome Atlas, 2015).  
The association of 3p loss and OPSCC tumours with zero detectable viral 
load is of particular interest given the recent findings of the Cancer Genome 
         >0-20        >20 






Atlas (TCGA) HNSCC project. They reported loss of 3p (particularly in when 
associated with TP53 mutation) to be a strong marker for poor prognosis in 
HPV-16 negative tumours (Gross et al., 2014). In earlier work Stransky et al 
and Agrawal et al both found TP53 mutation to be an almost universal 
finding in HPV-16-negative tumours (Stransky et al., 2011, Agrawal et al., 
2011). Given the positive prognosis associated with the majority of HPV-16 
positive tumours it is entirely in keeping that loss of 3p should be largely 
absent from these patients.  
Interestingly gain of proximal 11q and loss of distal 11q is seen with similar 
frequency in the two groups. This has previously been associated with poor 
outcome in HNSCC, but was not discriminatory for HPV-16 status in these 
patients (Ambatipudi et al., 2011).  
In general, the HPV-16 negative tumours demonstrate a more “classical” 
CNV profile in terms of chromosomal changes associated with squamous 
cell carcinoma (e.g. loss of 3p, gain of 5p). The lack of the more typical 
alterations associated with SCC likely reflects the aetiology of these tumours 
and how it differs from the tobacco associated carcinogens.  
Seiwert et al used their targeted exome sequencing to infer copy number 
alteration using read depth analysis from 50 HPV-positive and 70 HPV-
negative mixed subsite HNSCC samples (Seiwert et al., 2015). As in my 
study, they found that 3p loss occurred primarily in HPV-negative tumours. 
They also presented a selection of 25 genes recognised in cancer and the 
incidence in HPV-positive and negative tumours (see Table 5-8). Of these 25 
genes, gains of EGFR and FGFR1 were observed only in HPV-negative 
tumours and highlighted by the study as of significance as driver genes of 
high translational value (Seiwert et al., 2015). In this study they were found 
in tumours with 0 viral load and those with viral load > 0, though at much 
lower frequency in tumours with a detectable viral load. It is of interest that 
there was a reduction in incidence of gain of EGFR from intermediate to high 
viral load. Gain of FGFR1 did not follow this trend but within Seiwert et al’s 
study this was only identified in 1/50 HPV negative samples (Seiwert et al., 
2015). Also concurring with Seiwert et al, gain of CCND1 was observed at a 
rate of 40% in tumours with 0 viral load and 20% in those with viral load > 0 
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(at a similar frequency in both the intermediate and high viral load tumours). 
Otherwise the remaining amplified genes highlighted by Seiwert et al occur 
in both 0 viral load tumours and tumours with viral load > 0. 
 
	 Gene Cytoband Frequency in tumours by viral 
load (%) 
   0 
n = 31 
> 0-20 
n = 8 
> 20 
n = 12 
Amplified EGFR 7p11.2 8 (26) 2 (25) 1 (8) 
	 FGFR1 8p11.23-
p11.22 
7 (23) 1 (13) 4 (33) 
REL 2p16.1 3 (10) 1 (13) 0 
BCL6 3q27.3 19 (61) 7 (88)  8 (67) 
AKT3 1q43-q44 7 (23) 2 (25) 3 (25) 
PIK3CB 3q22.3 13 (42) 5 (63) 8 (75) 
PIK3C2A 11p15.1 1 (3) 0 0 
PIK3CA 3q26.32 21 (68) 7 (88) 8 (75) 
TP63 3q28 20 (65) 7 (88) 8 (75) 
CCND1 11q13.3 13 (42) 3 (38) 1 (8) 
MYC 8q24.21 16 (52) 4 (50) 4 (33) 
MDM2 12q15 6 (19) 0 0 
Deleted ATM 11q22.3 13 (42) 6 (75) 7 (58) 
	 CDKN2A 9p21.3 16 (52) 0 1 (8) 
RB1 13q14.2 10 (32) 4 (50) 5 (42) 
TSC2 16q13.3 3 (10) 0 1 (8) 
CSF1R 5q32 9 (29) 0 1 (8) 
TP53 17p13.1 2 (6) 1 (13) 0 
UBR5 8q22.3 0 (0) 0 0 
SETD2 3p21.31 27 (87) 3 (38) 3 (25) 
NOTCH1 9q34.3 9 (29) 0 0 
SYNE2 14q23.2 2 (6) 1 (13) 4 (33) 
CHD5 1q36.31 6 (19) 0 1 (8) 
MYH6 14q11.2 3 (10) 0 3 (25) 
NF1 17q11.2 1 (3) 0 0 
Table 5-8: Prevalence of copy number altered genes highlighted by Seiwert et al 
(Seiwert et al., 2015). 
A number of deleted genes occur with greater frequency in tumours with 0 
viral load. These include loss of SETD2, CDKN2A, CSF1R, NOTCH1 and 
CHD5. Seiwert et al concurred with the finding that CDKN2A occurred 
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primarily in HPV-negative tumours, but found the other deleted genes at 
similar rates in both HPV-positive and negative tumours (Seiwert et al., 
2015). This could be due to the fact that their cohort consisted of mixed 
subsites, with only 20/70 of their HPV-negative cohort being oropharyngeal, 
though the majority of their HPV-positive tumours were oropharyngeal 
(47/51).  
The differences between my study and Seiwert et al’s may also be related to 
the combination of methods they used to determine viral status (DNA-PCR, 
p16 expression and presence of TP53 mutations).   
The advantages and disadvantages of different HPV-testing methods are 
debated. HPV-16 PCR can be accused of being prone to contamination or 
being overly sensitive. In-situ hybridisation can also detect a single copy of 
HPV-16 DNA (Smeets et al., 2007). The problem being that detection of any 
HPV-16 DNA at all does not necessarily mean the tumour is driven by this 
aetiological factor and therefore shares the positive prognosis bestowed by 
this. Immunohistochemistry suffers from inter-observer variation, as well as 
debate over grading of positivity, as well as its sensitivity (Smeets et al., 
2007).  
Examining Conway et al’s data (which compared viral load to the presence 
of DNA HPV-16 PCR), it can be seen that of 24 patients with 0 viral load 
100% concordance with a negative DNA-PCR results was found (Conway et 
al., 2012). Similarly, all patients with a viral load > 20 were reported to have 
a positive DNA-PCR result. In 4/6 patients with an intermediate viral load, a 
positive PCR result and 2 negative results were obtained. This suggests that 
the intermediate viral load patients are those in whom HPV DNA may be 
detectable but may well not be the primary aetiological factor behind the 
development of their OPSCC. This is an important finding as it allows 
discussion of specific terminology. Though the HPV-16 positive tumour is 
well-recognised, due to the variety of different tests available the “HPV-
driven tumour” cannot yet be reliably recognised. However the use of viral 
loads alone to group tumours could be improved by adding clinical outcome 
data for these tumours, which unfortunately was absent.  
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My study suggests that the genomic profile of OPSCC with an intermediate 
viral load may share similarities with tumours with 0 viral load or with viral 
load > 20. This could represent potential for use as a prognostic indicator if 
viral load could be linked to clinical outcome in the future. This is important in 
the debate over whether or not to de-escalate treatment regimes for those 
with HPV16-positive tumours. Hyper-sensitive methods of testing for HPV-16 
could lead to patients without a truly HPV-driven tumour having their 
treatment changed to a less aggressive protocol and potentially being placed 
at higher risk of recurrence/progression. 
However Seiwert et al’s study demonstrates that there is still considerable 
inter-tumour genomic heterogeneity (from both a mutational and copy 
number perspective) (Seiwert et al., 2015). Aside from TP53 there are no 
other unifying copy number or mutational aberrations found in one tumour 
type. This was similarly reported by the TCGA head and neck sub-group, 
exemplified by the novel recurrent alterations they reported in HPV-positive 
tumours being deletion of TRAF3 and amplification of E2F1 (Cancer 
Genome Atlas, 2015). Loss of TRAF3 only occurred in 5/36 (14%) samples, 
whilst gain of E2F1 was present in 7/36 samples (19%) (Cancer Genome 
Atlas, 2015). My study found this to be a particularly heterogeneous region 
with loss of TRAF3 in 6/20 (30%) tumours with viral load > 0 and 6/31 (19%) 
with 0 viral load. Gain of TRAF3 was present in two tumours with viral load 
>0 and four tumours with 0 viral load. Again, this may be related to the 
mixed subsites being included in the TCGA cohort (only 21/36 samples were 
oropharyngeal), or may simply reflect the heterogeneity of these tumours. 
Integration of HPV DNA into the host genome is well recognised as a likely 
key part of the carcinogenic process in HPV-associated cancers. Parfenov et 
al analysed 35 HPV-positive tumours from the TCGA cohort to determine the 
integration sites in this cohort (Parfenov et al., 2014). Of the 35 samples, 25 
cases had integration of the viral genome into the host identified. This was 
observed in up to 16 regions of the human genome (per sample), with 103 
genomic breakpoints. They found the majority (71%) of integrations occurred 
within a known gene or within 20kb of a gene. They also found that viral 
integration was associated with CNA of the integrated region in 82% of 
cases (Parfenov et al., 2014). After obtaining the list of genes associated 
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with viral integration I analysed my cohort of samples for CNA of genomic 
windows within or adjacent to these genes (see Table 5-9). 






n = 31 
> 0-20 
n = 8 
> 20 
n = 12 
  
Gain Loss Gain Loss Gain Loss 
RAD51B 14q24.1 6 3 1 1 1 4 
PRKRIR 11q13.5 6 12 0 3 0 6 
SERPINB4 18q21.33 3 14 0 2 1 0 
SERPINB7 18q21.33 3 14 0 2 1 0 
LOC100506023 1q25.1 5 1 2 0 3 0 
NR4A2 2q24.1 1 2 0 0 0 0 
DOLPP1 9q34.11 8 5 2 0 2 0 
CRAT 9q34.11 8 5 2 0 2 0 
LINC00111 21q22.3 0 15 1 2 1 1 
PLGRKT 9p24.1 4 15 1 1 2 0 
CD274 9p24.1 4 15 1 1 2 0 
ETS2 21q22.2 0 11 1 2 2 0 
ZBTB7C 18q21.1 4 0 2 1 1 0 
ARHGDIA 17q25.3 3 1 0 1 0 1 
CCDC39 3q26.33 21 0 6 0 9 0 
TTC14 3q26.33 21 0 6 0 9 0 
IQGAP1 15q26.1 4 3 1 1 0 0 
CEACAM19 19q13.31 13 0 2 1 3 0 
MAGI2 7q21.11 10 0 3 1 1 0 
TCTEX1D1 1p31.3 4 6 2 0 2 1 
TRPC4AP 20q11.22 10 1 2 1 2 0 
GRIK1 21q21.3 0 10 1 1 0 1 
PLCXD2 3q13.2 9 5 3 1 8 0 
EPSTI1 13q14.11 2 9 0 4 0 5 
DNAJC15 13q14.11 2 9 0 4 0 5 
LOC100506136 7q21.3 9 1 3 0 1 0 
TEAD1 11p15.3-p15.2 1 12 0 1 0 2 
ASIC2 17q11.2-q12 5 2 0 0 0 1 
Table 5-9: Frequency of copy number alteration in genomic windows containing or 
adjacent to genes identified at sites of HPV integration by Parfenov et al 
(Parfenov et al., 2014). Those genes found to have altered copy number in a 
higher proportion of tumours with viral load > 0 are highlighted in red. 
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CNA alteration was identified at almost all genes highlighted by Parfenov et 
al in both tumours with 0 viral load and tumours with viral load > 0 (Parfenov 
et al., 2014). NR4A2 was only found to be copy number altered in tumours 
with 0 viral load. This may reflect the smaller number of samples in my study 
or may result from the fact that this gene is smaller than the resolution 
achievable with my data (800 Kb). The fact that the majority of copy number 
alterations tend to be larger than a single genomic window would suggest 
that the sequencing resolution is adequate. However, smaller CNAs are not 
identifiable without higher resolution (greater depth of sequencing). Germline 
CNAs tend to be small and these may be of significance in the development 
of SCC as well as identifying those with a predisposition to harbouring HPV 
after infection and developing cancer in later life (Park et al., 2015). 
In only seven genes was the incidence of CNA found to be proportionally 
higher in the tumours with viral load > 0 (highlighted in red in Table 5-9).  All 
seven genes were found to be copy number altered in the 0 viral load group 
at slightly lower rates, which did not achieve a level of significance after 
examining the difference using Fisher’s Exact test. This suggests that 
though these genes have been associated with HPV integration they are 
also altered during carcinogenesis in tumours not caused by HPV. 
Parfenov et al reported an association specifically with copy number gain at 
viral integration sites. This trend was followed in this study. Overall, in the 0 
viral load tumours, there were 166 amplifications and 171 deletions of the 
genes in Table 5-9. In the tumours with viral load > 0 there were 95 
amplifications and 58 deletions. Both gain and loss were observed at most 
genes with deletions not observed at only 6 genes in the > 0 viral load 
group. These 6 genes were also found to be amplified in the 0 viral load 
group, demonstrating the heterogeneity to be found in both HPV-associated 
and non-HPV-associated OPSCC.  
5.4.2 Comparison to cervical squamous cell carcinoma 
HPV has been associated with cervical adenocarcinoma and squamous cell 
carcinoma since the early 1980s and to play a key role in the carcinogenesis 
of these cancers (Bosch et al., 2002). Given the common aetiological factor, 
comparison of the genomic changes in both OPSCC and cervical squamous 
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cell carcinoma (CSCC) is appropriate, bearing in mind the potentially 
significant differences between the two cancers. These include the fact that 
over 95% of oropharyngeal cancer  is histologically SCC, whilst it only 
comprises approximately 60% of cervical cancer (Vizcaino et al., 2000). 
HPV-negative cervical squamous cell carcinoma (CSCC) represents up to 
10% of CSCC, whilst approximately 35% of OPSCC is HPV-negative 
(Rodriguez-Carunchio et al., 2015). HPV-16 is associated with 62% of 
CSCC, with subtypes 18, 31, 33 and 45 making up the majority of the 
remainder (de Sanjose et al., 2010).  
The TCGA cervical cancer subgroup conducted whole exome sequencing of 
79 CSCC samples and inferred copy number data from the read depth of 
this data (Ojesina et al., 2014). All of these were HPV-positive. They utilised 
GISTIC 2.0 to provide broad and focal CNA analysis. Broad level alterations 
included gain of 3q, 1p, 1q, 20p, 20q, 14q, 5p, 19q and 8q as well as loss of 
3p, 4p, 13q, 3q, 4q, 11q, 17p, 11p, 6q, 8p and 6p (Ojesina et al., 2014). 
Focal CNAs are listed in Table 5-10. They demonstrate considerable 
similarity to the CNA alterations seen in HNSCC. Loss of 3p has been 
previously reported to be an early event in both HNSCC and CSCC, 
however in HNSCC it has specifically been associated with poorer outcome 
(Califano et al., 1996, Wilting et al., 2008, Gross et al., 2014). The fact that 
loss of 3p was observed in 50% of HPV-positive CSCC in the TCGA cohort 
is similar to the 35% (7/20) tumours with viral load > 0 in which 3p deletion 
was present and consistent with the improved outcome associated with both 
HPV-positive OPSCC and CSCC (Rodriguez-Carunchio et al., 2015, Ojesina 
et al., 2014, Fakhry et al., 2008). 
Several tumour suppressor genes have been identified on 3p, including 
FHIT, found specifically at 3p14.2, a common fragile site (Ingvarsson, 2005). 
This CNA was seen in 50% of CSCC, 87% of 0 viral load OPSCC and 35% 
of > 0 viral load OPSCC. FHIT has been associated with cellular pathways 
including apoptosis and cell cycle, in particular inhibiting p53 degradation by 
MDM2 (Watanabe et al., 2004). Decreased expression of FHIT has also 
been associated with poor prognosis in a number of cancers including 
HNSCC (Tai et al., 2004). The fact that deletion of this gene is found much 
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less frequently in OPSCC with viral load > 0 is consistent with the existing 
literature. 










































Table 5-10: List of focal amplifications and deletions identified in CSCC using 
GISTIC 2.0 by Ojesina et al (Ojesina et al., 2014). 
 
CDKN2A, found at 9p21.3, is also of particular interest. This encodes for 
p16, a tumour suppressor protein that plays a role in slowing cell cycle 
progression specifically from G1-phase to S-phase (Ruas et al., 1999). This 
gene is normally downregulated by the retinoblastoma tumours suppressor 
gene product (pRb). In HPV-associated OPSCC the E6 and E7 viral 
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oncoproteins are expressed. The E7 oncoprotein causes degradation of 
pRb, thereby promoting cell cycle progression. This results in p16 
overexpression in HPV-associated OPSCC (Langendijk and Psyrri, 2010).  
Deletion of 9p21.3 was observed in 16/31 (52%) of 0 viral load OPSCC and 
only 1/20 (5%) of OPSCC with viral load > 0. The TCGA cervical cancer 
subgroup did not identify loss of 9p21.3 in their CSCC cohort (Ojesina et al., 
2014). This is in keeping with the fact that all the TCGA CSCC cohort was 
HPV-positive. The fact that this gene was only deleted in 1/20 tumour with 
viral load > 0 is comparable to Seiwert et al who identified loss of CDKN2A 
in only 1/50 HPV-positive sample and 9/70 HPV-negative tumours (Seiwert 
et al., 2015). p16 overexpression has been reported in up to 100% of HPV-
positive HNSCC and 20% of HPV-negative HNSCC (Singhi and Westra, 
2010).  
Gain of 20p12.2 was identified in 13/31 (42%) of OPSCC tumours with 0 
viral load and 1/20 (5%) of tumours with viral load > 0. Evaluation of this 
region identified the gene JAG1, previously identified as a NOTCH ligand. 
Amplifications of NOTCH pathway genes including JAG1 have been recently 
reported to occur in 30% of HNSCC, though the prevalence in HPV-positive 
or negative HNSCC is not known (Sun et al., 2014). In cervical cancer 
activation of the NOTCH pathway has been suggested to occur via JAG1 
and has been associated with poorer outcome, though again not specifically 
with HPV-status (Yousif et al., 2015). The TCGA cervical cancer subgroup 
did not identify 20p12.2 as a focal amplification in their cohort (Ojesina et al., 
2014). This is consistent with the increased frequency of gain of JAG1 in 
OPSCC tumours with 0 viral load. JAG1 could represent further evidence for 
the therapeutic potential in targeting the NOTCH pathway, particularly in 
HPV-negative tumours. 
Another gene found to be more frequently deleted in tumours with 0 viral 
load was CSFR1, found at 5q32 (deleted in 9/31 (29%) of 0 viral load 
OPSCC and 1/20 (5%) tumour with viral load > 0). This region is not 
highlighted as a focal deletion by the TCGA cervical cancer subgroup, nor is 
broad level loss of 5q (Ojesina et al., 2014). CSF1R encodes for the colony-
stimulating factor 1 (CSF-1) receptor, which is thought to play a role in 
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recruiting tumour-infiltrating macrophages in cancer (Pixley and Stanley, 
2004). However, blockade of CSF1R signalling has been shown to enhance 
sensitivity to radiotherapy in murine models of prostate cancer (Xu et al., 
2013). HPV-positive OPSCC has been shown to have an improved 
response to chemoradiotherapy compared to HPV-negative OPSCC (Ang et 
al., 2010). This is in contrast to the findings that deletion of CSF1R occurred 
more frequently in OPSCC with 0 viral load, and may indicate that this 
pathway does not play a strong role in HPV-positive tumours. In support of 
this finding is a recent study analysing the relationship of tumour-associated 
macrophages and head and neck cancer relapse. They found that increased 
expression of marker of M2 macrophages (CD163) only correlated with 
clinical outcome (relapse) in HPV-negative tumours (Balermpas et al., 2014). 
The fact that CSF1R is deleted in only 9/31 (29%) of OPSCC tumour with 0 
viral load suggests this could be a potential therapeutic target and could be 
used a marker for treatment selection in a significant number of HPV-
negative tumours. 
5.4.3 Pathways containing copy number altered genes in 
tumours of differing viral load 
Analysis of pathways allows determination of potentially targetable options 
from this CNA data. The PI3K signalling pathway contained the most copy 
number altered genes from the OPSCC tumours with 0 viral load (see Figure 
5-9). This pathway is involved in many cellular functions crucial to tumour 
survival including cell growth, cell movement, metastasis and survival 
(Cantley, 2002). This in keeping with a study by Lui et al which used whole 
exome sequencing of 151 HNSCC samples and identified PI3K mutations in 
31% (46/151) (Lui et al., 2013). Only 3 of these tumours containing PI3K 
mutations were HPV-negative, though only 15 tumours out of the entire 
cohort (n = 151) were HPV-positive. Far more of the genes identified in the 
PI3K pathway were deleted in this series compared to the number of 
amplifications (22 genes deleted vs. 5 genes amplified). 42/51 OPSCC 
tumours were found to contain multiple copy number altered genes in the 
PI3K pathway analogous to Lui et al’s study, which found 22% of tumour 
containing PI3K pathway mutations, harboured multiple genetic alterations 
(Lui et al., 2013). Of the remaining tumour 3/51 contained no copy number 
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altered genes in the PI3K pathway and 6/51 contained only 1 gene. 
Interestingly, 5/6 tumours with only one gene had a viral load > 0, again 
suggesting this pathway represents greater therapeutic potential in HPV-
negative tumours.  
The MAPK signalling pathway contained the most genes found to be copy 
number altered within tumours with > 0 viral load (and the fourth most in 
tumours with 0 viral load) (see Figure 5-9). In humans there are at least 11 
members of the MAPK superfamily, all of which play an essential role in 
signal transduction in response to the extracellular environment 
(Leelahavanichkul et al., 2014). Although fewer genes overall were identified 
to belong to this pathway 46/51 tumours were found to contain copy number 
altered genes. Of the 4 tumours without any copy number altered MAPK 
pathway genes 3 were tumours with > 0 viral load. Despite this being the 
pathway that most copy number altered genes were identified in tumour with 
> 0 viral load there, there were more hits for these genes within tumours with 
0 viral load, indicating this is a significant pathway in both HPV-positive and 
negative tumours. Interestingly Lui et al found only 8.3% of tumours (12 of 
151) to contain mutations in this pathway, but another recent study found 
overexpression of p38α (a MAPK superfamily member) in 79% of 293 OSCC 
samples examined with IHC (Leelahavanichkul et al., 2014, Lui et al., 2013). 
They also found it to be a positive regulator of angiogenesis and 
lymphangiogenesis indicating that though mutations may be infrequent, this 
pathway is an important one in the context of HNSCC carcinogenesis. 
The JAK/STAT signalling pathway has been most extensively studied in 
haematologic malignancies, however it is recognised to be often activated in 
cancers of the upper aerodigestive tract, leading to increased cell survival, 
angiogenesis and immune system evasion (Lai and Johnson, 2010). 
Inhibition of this pathway has been shown to block cell invasion in HNSCC 
cell-line models (Lai et al., 2005). This pathway contained the second 
highest number of copy number altered genes in the 0 viral load tumours, 
whereas it contained the sixth highest number of genes within the tumours 
with viral load >0. Interestingly the regions with the greatest clusters of 
genes within the JAK/STAT pathway were found on 3p and 9p, both of which 
were more frequently deleted in tumours with 0 viral load (see Table 5-4 and 
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Table 5-5). 6/51 tumours were found to contain no copy number altered 
genes from the JAK/STAT pathway. Of these 5 were tumours with > 0 viral 
load. Combined with the fact that tumours with > 0 viral load contained far 
fewer hits for this pathway compared to the 0 viral load group (see Figure 
5-9), this suggests this pathway may represent greater therapeutic potential 
in HPV-negative tumours. A recent study by Bonner et al examining the use 
of an anti-JAK/STAT3 agent as a radiosensitiser in HNSCC cell-lines, in 
combination with Cetuximab (Bonner JA, 2015). This found a marked 
increase in apoptotic events, however these were reduced in the HPV-
positive cell-lines compared to the HPV-negative cell-lines.  
5.4.4 Indicators of overall genomic damage in tumours with 
differing viral load 
Stransky et al found the mutational burden to be higher in HPV-negative 
compared to HPV-positive tumours, whilst the TCGA reported a similar 
overall mutation rate (Cancer Genome Atlas, 2015, Stransky et al., 2011). 
This difference may relate to other clinical factors, for example Seiwert et al 
found a higher mutational burden in smokers versus nonsmokers (Seiwert et 
al., 2015). In my series the FGA was found to be significantly lower in the 
tumours with viral load > 0. This measurement allows inference of genomic 
damage, but correlation of this to clinical outcomes and smoking status 
would reveal any clinical utility of this measure in assigning viral status and 
prognosis. 
A similar analogy could be drawn from the frequency of copy number altered 
genes in pathways of potential significance (see Figure 5-9). Regardless of 
the difference in frequency of individual pathways the overall number of hits 
obtained for each pathway is considerably higher in tumours with 0 viral load 
compared to those with > 0 viral load. This suggests that the number of 
genomic CNAs in regions that are significant is higher in tumours with 0 viral 
load.  
5.4.5 Limitations 
The most important limitation to this study is the limited number of patients, 
particularly when attempting to analyse the tumours with intermediate viral 
load. Considerable inter-tumour heterogeneity is demonstrated in both 
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tumours with 0 viral load and those with viral load > 0 and this does require 
greater numbers of samples in order to try and elucidate reliable  patterns of 
genomic damage. Interestingly, however the heterogeneity does also 
suggest that no unifying genomic marker in HNSCC is present (excluding 
the almost universal presence of TP53 mutation in HPV-negative tumours). 
The challenges in obtaining large numbers of OPSCC samples are clearly 
demonstrated by the fact that these tumours form the minority of the TCGA 
head and neck cohort. HPV-positive OPSCC are even more difficult to study 
in large numbers, primarily because most of these are now treated non-
surgically. Therefore tissue samples are generally limited to small biopsies, 
which are not possible to replicate, as the patients rarely require repeat 
biopsy or surgery prior to receiving chemoradiation. My study does comprise 
one of the largest genomic studies of purely OPSCC samples. 
Another limitation in this cohort is the lack of detailed clinical information 
such as smoking status, which could be responsible for different CNAs. It is 
quite possible that specific CNAs may reflect a different clinicopathologic 
characteristic of these samples, rather than their HPV-status, as is 
suggested by the genomic analysis of OSCC conducted by the India 
Genome Project Team (India Project Team of the International Cancer 
Genome, 2013). Their samples originate in a region where betel nut chewing 
is common in contrast to the UK and US. They found mutations specific to 
their cohort such as USP9X, MLL4, ARID2, UNC13C, found in 10-20% of 
their cohort and found at a rate of less than 10% in the TCGA head and neck 
cohort (when analysing the TCGA data via cBIOPortal) (Cerami et al., 2012). 
Seiwert et al did report a significant association between smoking and 
mutations in TP53, CSMD3, RB1CC1, THSD7A (Seiwert et al., 2015). 
Though they did not report any association between smoking and CNA, this 
could be due to reducing numbers of patients in subgroup analyses. This 
can only be clarified by evaluating a larger number of patients including 
detailed clinical outcome data.   
With this approach to analysing CNA we are unable to identify copy-neutral 
(balanced) rearrangements. This is a potential area of interest being missed 
and one that is little explored in HNSCC. It is also possible that smaller 
CNAs are present that are not visible at the sequencing resolution utilised in 
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this study. The fact that most CNAs, even of minimally altered regions, tend 
to be several genomic windows would suggest that resolution is not an 
important limitation. However the considerable heterogeneity present 
between tumours also suggests that genomic patterns that are useful as 
markers or therapeutic targets may only be present in small numbers of 
patients, or even in a single patient. If this is approach is to be taken then 
higher resolution CNA analysis would be useful to identify any and all 
potentially targetable events, if this information were to be used to try and 
stratify treatment.  
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5.5 Conclusion 
This study used a low-cost form of NGS to provide genome-wide CNA 
analyses of FFPE OPSCC of specific HPV-16 viral loads. With reference to 
the specific aims of this chapter: 
1. Producing a CNA profile for HPV positive OPSCC. Though of limited 
size, this project contained numbers of OPSCC tumours with viral 
load > 0 comparable to publications produced by the TCGA head and 
neck sub-group and affiliated groups (Seiwert et al., 2015, Cancer 
Genome Atlas, 2015). This cohort identified a panel of CNAs 
associated with 0 viral load. The mean FGA in tumours with 0 viral 
load was also found to be significantly higher than those with a viral 
load > 0. 
2. In evaluating if there is a specific viral load at which this genomic 
profile becomes apparent my results suggested that these differences 
become less distinct in tumours of intermediate viral load. These 
tumours may represent a different clinical sub-group. A different 
pattern of copy number altered genes and potentially significant gene 
pathways were also identified in tumours of differing viral load, 
highlighting not just potential markers but that these therapeutic 
targets may be of greater significance in HPV-positive or negative 
tumours dependent on the pathway. The FGA of tumours with 
differing viral load was also found to be significantly different 
suggesting the overall genomic damage to HPV-positive OPSCC 
tumours is lower, and may also be related to the improved clinical 
outcomes in these patients. The need to include detailed clinical data 
for future studies on these genomic alterations is vital to providing 
greater translational significance.  
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Chapter 6  
MicroRNA profiling of HNSCC and matched cervical 
metastases to identify characteristics of metastatic and non-
metastatic HNSCC 
6.1 Introduction 
Cancer is thought to progress through the progressive accumulation of 
genetic and epigenetic changes that allow the cancerous cell to avoid 
normal cellular controls. Changes to the levels of transcription of a gene into 
mRNA are referred to as altered gene expression. Alterations in gene 
expression are well recognised across many cancer types.  In HNSCC, an 
important example of altered gene expression is shown by silencing of 
TP53, due to mutation or inactivation. This has been demonstrated in 
numerous studies to be the most common single gene to be affected across 
different studies of head and neck tumours (Califano et al., 1996, Leemans 
et al., 2011, Agrawal et al., 2011, Poeta et al., 2007). However, the gene 
expression profile of HNSCC is made up of hundreds of genes, with 
significant inter-tumour heterogeneity. Chung et al, identified four molecular 
subtypes of HNSCC (basal, atypical, mesenchymal and classical) using 
gene expression profiling of 60 tumours (Chung et al., 2004).  
Gene expression can be altered  at an epigenetic, transcriptional, post-
transcriptional, translation or post-translational level. miRNAs are a class of 
non-coding RNAs that regulate gene expression at the post-transcriptional 
level. Originally identified as “small temporal RNAs” that affected post-
embryological development in Caenorhabiditis elegans (Lee et al., 1993, 
Wightman et al., 1993). Although, only discovered in humans around 14 
years ago there has been a great deal of research into miRNAs in health 
and disease. It is estimated that the majority of coding genes are regulated 
by miRNAs (Lagos-Quintana et al., 2001, Friedman et al., 2009).  
 216 
Calin et al first reported a direct link between miRNAs and cancer, 
demonstrating loss of miR-15 and miR-16 in chronic lymphocytic leukaemia 
(Calin et al., 2002). miRNAs have been identified as playing roles in many 
different cancers since then. They have been found to be differentially 
expressed by normal and cancerous tissue and to reflect different tissues 
(Calin and Croce, 2006, Pichler and Calin, 2015). Studies have revealed 
miRNAs can have an oncogenic (referred to as oncomiRs) and/or a tumour 
suppressor effect (Sethi et al., 2014). In addition, a single miRNA has been 
shown to effect the expression of multiple target genes (Jansson and Lund, 
2012).  
Studies in HNSCC have demonstrated that aberrant expression of miRNAs 
is associated with tumourigenesis and chemoradiotherapy resistance (Sethi 
et al., 2014). miRNAs have also shown potential as a biomarker to stratify 
patient risk in a number of cancers (Mar-Aguilar et al., 2013, Mishra, 2014). 
In colorectal cancer miRNA profiles have been shown to discriminate 
between cancer that metastasised to lymph nodes and those, which 
metastasised to liver (Drusco et al., 2014). One drawback to profiling 
miRNAs is that our knowledge of them is evolving. Shortly after being first 
discovered in humans it was estimated that there might be over 100 miRNAs 
(Bartel, 2004). Over 1000 miRNAs have subsequently been catalogued in 
the miRNA database (miRBase, www.mirbase.org) with more being added 
every year (Griffiths-Jones, 2004). Therefore studies reliant upon array-
based technology are limited by the fact that they can only identify miRNAs 
that are present on the array. Using NGS to identify miRNAs allows all 
known miRNAs to be searched for as well as the fact that the data can be 
repeatedly interrogated for novel miRNAs without the cost or time involved in 
re-sequencing the sample.  
A challenge when working with RNA is the issue of degradation. It has long 
been regarded that RNA extracted from FFPE tissue is significantly 
degraded (Stanta and Schneider, 1991, Lewis et al., 2001). However 
miRNAs have been shown to be well preserved without degradation, even in 
archived FFPE tissue samples (Szafranska et al., 2008, Weng et al., 2010, 
Liu and Xu, 2011, Kolbert et al., 2013). This is thought to be due to the short 
length of miRNAs meaning they do not undergo degradation to smaller 
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components readily. In light of this, FFPE tissue archives hold great potential 
for research into miRNAs. 
Of particular interest is the fact that another study by Calin et al showed that 
miRNAs are frequently located at fragile genomic sites associated with CNA 
in cancer (Calin et al., 2004). Further studies in breast, colon, ovarian and 
prostate cancer have shown that miRNAs and miRNA-binding sites are 
significantly overrepresented in genomic regions with copy number gain and 
underrepresented in regions with copy number loss (Calin et al., 2004, 
Zhang et al., 2006). Zhang et al found that genomic alterations involving 
miRNAs were highly frequent in epithelial cancer and resulted in changes in 
miRNA expression. They also found that some deleted miRNAs were not 
under-expressed and therefore may be being rescued as part of the 
oncogenic process (Zhang et al., 2006). As a result integrating CNA and 
miRNA expression data could reveal important miRNAs that could be used 
as a biomarker for metastasis. 
6.2 Aim 
This study aimed to: 
1. Evaluate and compare the miRNA profile of metastatic primary 
tumours and a paired lymph node metastasis.  
2. It then compared non-metastatic primary tumours to the metastatic 
miRNA profile to identify any potential markers for nodal metastasis. 
 
6.3 Results 
6.3.1 Summary of patient cohort 
The patients included in this study were selected from the patient cohort 
identified in Chapter 3. The clinicopathologic characteristics of these groups 
were identical to those specified in Chapter 3 and 4 (see Table 6-1). Patients 
were selected to try and reduce heterogeneity. Inclusion criteria were oral 
tongue primary tumour, successful DNA extraction for CNA analysis, known 
current smoking status at the time of surgery. After discussion with Dr 
Alastair Droop (Bioinfomatics Research Fellow, University of Leeds). It was 
decided that a minimum of three patients in each group was necessary for 
the purposes of comparing miRNA profiles. From each patient, in addition to 
a sample from the primary tumour, a sample of normal epithelium was also 
used for RNA extraction and sequencing. The metastatic primary tumours 
had RNA extracted from a single paired lymph node metastasis (resulting in 
a total of 24 samples from nine patients). The overall number of patients was 
dictated by the desire to provide a matched normal sample as well as the 
overall cost of each sample.  
 
 T1-4 N0 T1-4 N1-3 No ECS T1-4 N1-3 with ECS 
Number of 
patients 
3 3 3 



















Table 6-1: Table to show the number of patients in each group and tissue samples used 
from each. 
 
All tissue blocks had a fresh 5 μm section stained with haematoxylin and 
eosin, examined by Professor Kenneth MacLennan or Dr Preetha Chengot 
(consultant head and neck histopathologists)  to mark the area of highest 
tumour cell content (in both primary tumours and lymph node metastases) 
as well as identify the normal epithelium on a separate tissue block to those 
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containing primary tumour. These areas were macrodissected and the total 
RNA (including miRNA) extracted as described in section Chapter 2.6. 
These were then all successfully processed to a small RNA sequencing 
library and multiplexed at 12 samples per lane on the Illumina HiSeq 2500 
on rapid mode. This was performed using 50 bp single end reads.  
6.3.2 miRNA sequencing (miRNASeq) of HNSCC primary tumours 
and matching nodal metastases 
6.3.2.1 Processing miRNASeq data for differential expression analysis 
The FASTQ files generated by the sequencer containing the raw sequencing 
read data were downloaded. Cutadapt was used to remove the adaptor 
sequences from the ends of each read (http://code.google.com/p/cutadapt/). 
Open access software, CAP-miRSeq (Comprehensive Analysis Pipeline – 
microRNA Sequencing), was then used to process the data (Sun et al., 
2014). This automatically aligned the trimmed reads to the human reference 
genome (University of California Santa Cruz version GRCh37/hg19, 
http;//genome.ucsc.edu). After trimming all reads less than 17 bp in length 
were removed. All RNA types contained in the sequencing library were 
quantified and even data on single nucleotide variants in the coding regions 
of miRNAs was available. CAP-miRSeq generated raw count data for each 
uniquely mapped miRNA and performed normalisation of these for the 
number of aligned reads per sample. 
CAP-miRSeq then implemented another open access software package 
called edgeR (Bioconductor, US) to perform further normalisations steps. 
These include scaling of the libraries for the number of aligned reads per 
sample as well as the dispersion of reads in each sample. It then generated 
differential expression data according to the clinicopathologic groups defined 
(Robinson et al., 2010).  
6.3.2.2 Analysis of read counts  
Due to the highly specific nature of the sequencing performed, using the 
overall coverage of the sequencing performed is a somewhat misleading 
measurement, in isolation. Small RNA sequencing targets small reads (17 – 
22 bp) and has a limited number of overall targets (only those registered as 
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Homo sapiens miRNAs in miRBase) (Griffiths-Jones, 2004).  An average of 
5,078,953 (range: 2,199,736 – 10,395,214) sequencing reads were obtained 
for each sample. Of these an average of 3,598,699 reads (range: 1,478,161 
– 7,798,540)  aligned to the human reference genome, GRCh38 (UCSC, 
California, USA). On average 1,706,371 (range: 525,093 – 4,513,312) 
aligned to the Homo sapiens miRNAs registered in miRBase, version 21 
(Griffiths-Jones, 2004). Of the reads aligned to miRBase there were on 
average 526 miRNAs (range: 322 – 714) with at least 5x coverage per 
sample.  
6.3.2.3 Comparison of miRNASeq profile of nodal metastases to 
matched metastatic primary tumours 
Gene expression has been shown to vary by tissue type and amongst 
individuals (Whitney et al., 2003, Cobb et al., 2005, Palmer et al., 2006). In 
order to evaluate how similar nodal metastases were to their matching 
primary tumour, the normalised mature miRNA expression was used to 
compare metastatic primary tumours to their matched metastases. 
Pearson’s product moment correlation was calculated comparing each nodal 
metastasis to each metastatic primary tumour using R (Vienna, Austria) 
(Team, 2015).  
Overall this found that the correlation between metastatic primary 
and matched nodal metastasis was high, ranging from 0.74–0.99 
(see  
 
Table 6-2). However the matching tumour-metastasis pair often did not have 
the highest correlation. In only 2/6 pairs did the matched metastasis have 
the highest correlation. In the other 4 pairs another metastasis had a higher 
correlation. This could reflect the fact that gene expression varies between 
individuals and is affected by behaviours such as smoking or diet (Jaenisch 
and Bird, 2003, Landi et al., 2008). It could also be due to the fact that cells 
within the metastasis are subject to different environmental pressures and 
develop different expression profiles secondary to this. The similarity 
between metastatic primary tumours and nodal metastases may also reflect 
there are similar changes in miRNA expression involved in the progression 
of cancer across all of the samples. This variation between different 
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individuals may have obscured the variation due to carcinogenesis or the 
metastatic process and represent a confounder in these comparisons. 
 
 
Figure 6-1: Pearson's product moment correlation on comparing ECS033 nodal 
metastasis (ECS033_L) to itself and every other nodal metastasis and 
metastatic primary tumour. Correlation with itself is 100%, whilst correlation 
with its matched metastatic primary tumour (ECS033_T) is 87%. The highest 
correlation (97%) was found to be with the metastatic primary tumour for 
patient ECS084.  
 
In order to reduce the background noise produced by the variation in miRNA 
expression found in different individuals, paired analyses comparing each 
nodal metastasis and metastatic primary tumour to its matching normal 
epithelium were performed. This was done using CAP-miRSeq with the 
significance threshold of 0.25 for the p-value adjusted for multiple testing of 
each miRNA found to be differentially expressed.  
 
Correlation of miRNA expression 





   
   
   
   
   









Table 6-2: Correlation of normalised mature miRNA expression between metastatic primary tumours and nodal metastases. Tumour-






























1.00 0.87 0.89 0.93 0.85 0.98 0.90 0.88 0.94 0.79 0.95 0.99 
ECS033
_T 
0.87 1.00 0.97 0.97 0.87 0.88 0.97 0.94 0.86 0.96 0.94 0.84 
ECS040
_L 
0.89 0.97 1.00 0.97 0.92 0.89 0.96 0.94 0.88 0.94 0.96 0.86 
ECS040
_T 
0.93 0.97 0.97 1.00 0.88 0.94 0.96 0.92 0.91 0.91 0.96 0.92 
ECS054
_L 
0.85 0.87 0.92 0.88 1.00 0.86 0.84 0.81 0.88 0.79 0.92 0.83 
ECS054
_T 
0.98 0.88 0.89 0.94 0.86 1.00 0.88 0.84 0.98 0.78 0.96 0.98 
ECS055
_L 
0.90 0.97 0.96 0.96 0.84 0.88 1.00 0.99 0.84 0.97 0.93 0.86 
ECS055
_T 
0.88 0.94 0.94 0.92 0.81 0.84 0.99 1.00 0.79 0.97 0.91 0.83 
ECS060
_L 
0.94 0.86 0.88 0.91 0.88 0.98 0.84 0.79 1.00 0.74 0.95 0.95 
ECS060
_T 
0.79 0.96 0.94 0.91 0.79 0.78 0.97 0.97 0.74 1.00 0.86 0.74 
ECS084
_L 
0.95 0.94 0.96 0.96 0.92 0.96 0.93 0.91 0.95 0.86 1.00 0.95 
ECS084
_T 
0.99 0.84 0.86 0.92 0.83 0.98 0.86 0.83 0.95 0.74 0.95 1.00 
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The miRNA profile for metastatic primary tumours was compared to that of 
the matching normal epithelium. The miRNA profile of metastatic primary 
tumours (n = 6) was then compared to the matched normal epithelium (n = 
6).  Across these sample 1026/2578 miRNAs were not detected in any 
sample. Comparing the two groups in pairs, in total, 186 miRNAs were 
identified as significantly differentially expressed (adjusted p-value = < 0.25) 
between metastatic primary tumours and matched normal (see Table 6-3). 
For brevity only the top ten in each analysis is shown, the full lists of each 
differential expression analysis are in Appendix 8.5. 
 
 log Fold 
change 
p-value Adjusted p-value 
hsa-miR-375 -8.02 2.09E-39 5.40E-36 
hsa-miR-196b-5p 5.27 2.14E-17 2.75E-14 
hsa-let-7c-5p -3.45 2.22E-16 1.90E-13 
hsa-miR-615-3p 7.54 4.29E-15 2.76E-12 
hsa-miR-196a-5p 5.44 9.14E-14 4.71E-11 
hsa-miR-1247-5p -3.54 1.82E-10 7.82E-08 
hsa-miR-99a-5p -3.09 3.33E-10 1.22E-07 
hsa-miR-1910-5p 4.23 1.08E-09 3.47E-07 
hsa-miR-150-5p -2.50 3.80E-09 9.81E-07 
hsa-miR-125b-5p -2.41 4.00E-09 9.81E-07 
Table 6-3: Top 10 significantly differentially expressed miRNAs between metastatic 
primary tumours and matched normal epithelium (adjusted p-value = < 0.25). 
 
The miRNA profiles from nodal metastases (n = 6) were then compared to 
the matching normal epithelium (n = 6) using CAP-miRSeq. In total, 2578 
miRNAs were screened for across the samples. Of these, 1070 miRNAs 
were not detected in any sample. Overall 131 miRNAs were identified as 
significantly differentially expressed between the nodal metastases and 
matched normal (see Table 6-4).  
On cross-referencing these two lists of differentially expressed miRNAs, 95 
were found to be duplicated in both (with concordant change in expression). 
This demonstrates that a large proportion of differentially expressed miRNAs 
are common to both metastatic primary tumours and nodal metastases. The 
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fact that the miRNA signatures are not identical is in keeping with the fact 
that HNSCC tumours are made up of molecularly heterogeneous clonal 
populations. It is also consistent with the hypothesis (maintained from the 
comparison of CNA profiles in Chapter 4) that the metastatic clonal 
population is more likely to be dominant within the nodal metastasis tissue 
and therefore less prone to sampling mixed clonal populations.  
 
 
 log Fold 
change 
p-value Adjusted p-value 
hsa-miR-375 8.82 6.66E-32 1.72E-28 
hsa-miR-196a-5p -5.93 2.23E-25 2.87E-22 
hsa-miR-133b 7.44 2.68E-19 2.30E-16 
hsa-miR-1 6.59 6.04E-18 3.89E-15 
hsa-miR-615-3p -7.83 2.06E-17 1.06E-14 
hsa-miR-133a-3p 7.15 2.85E-17 1.22E-14 
hsa-miR-196b-5p -4.57 9.76E-17 3.28E-14 
hsa-miR-135a-5p 6.24 1.02E-16 3.28E-14 
hsa-miR-206 7.76 6.61E-14 1.89E-11 
hsa-let-7c-5p 3.35 1.05E-13 2.72E-11 
Table 6-4: Top 10 list of significantly differentially expressed miRNAs (adjusted p-
value = < 0.25) between nodal metastases and matched normal epithelium. 
 
On this basis, in order to try and identify a molecular profile associated with 
metastasis it is necessary to sample and analyse the metastatic tissue rather 
than just the metastatic primary tumour. The molecular markers identified 
should then be cross-referenced against non-metastatic primary tumours to 
try and eliminate miRNAs associated with cancer development rather than 
the metastatic process. 
 
6.3.2.4 Comparison of the miRNASeq profile of non-metastatic primary 
tumours to nodal metastases 
A paired analysis of the miRNA profiles of non-metastatic primary tumours (n 
= 3) was then compared to that of the matching normal epithelium (n = 3). 
Across these samples 1221 miRNAs were not detected in any sample.  
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Overall 69 miRNAs were identified as significantly differentially expressed 
(adjusted p-value = < 0.25) between non-metastatic primary tumours and the 
matching normal (see Table 6-5).  
 
 log Fold 
change 
p-value Adjusted p-value 
hsa-miR-1269a 12.80866958 7.52E-17 1.94E-13 
hsa-miR-615-3p 8.538011515 2.23E-13 2.88E-10 
hsa-miR-1269b 11.44791655 3.48E-11 2.99E-08 
hsa-miR-1910-5p 4.231464778 6.29E-09 4.06E-06 
hsa-miR-196a-5p 4.921079066 4.54E-08 2.34E-05 
hsa-miR-431-5p 3.691385296 7.32E-07 0.000314334 
hsa-miR-29c-3p -2.365685094 5.00E-06 0.001782227 
hsa-miR-4713-5p 4.017179645 5.53E-06 0.001782227 
hsa-miR-139-5p -2.979490344 6.49E-06 0.001859884 
hsa-miR-4521 -3.095342054 1.57E-05 0.004049336 
Table 6-5: Top 10 significantly differentially expressed miRNAs between non-
metastatic primary tumours and matched normal epithelium (adjusted p = < 
0.25). 
 
This list of differentially expressed miRNAs was cross-referenced against the 
miRNAs identified in nodal metastases (see Table 6-4). Duplicates were 
removed to identify miRNAs specifically associated with metastasis rather 
than carcinogenesis. The unique differentially expressed miRNAs in nodal 
metastases are more likely to be associated with the metastatic process. 
This identified 97 miRNAs whose differential expression was uniquely 
associated with metastasis (see Table 6-6).  
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 log Fold 
change 
p-value Adjusted p-value 
hsa-miR-133b 7.44 2.68E-19 2.30E-16 
hsa-miR-1 6.59 6.04E-18 3.89E-15 
hsa-miR-133a-3p 7.15 2.85E-17 1.22E-14 
hsa-miR-206 7.76 6.61E-14 1.89E-11 
hsa-let-7c-5p 3.35 1.05E-13 2.72E-11 
hsa-miR-99a-3p 2.91 4.94E-11 1.06E-08 
hsa-miR-99a-5p 3.39 9.21E-11 1.83E-08 
hsa-miR-125b-2-3p 2.54 7.71E-09 1.24E-06 
hsa-miR-208b-3p 6.52 1.50E-08 2.15E-06 
hsa-miR-21-5p -2.46 1.71E-08 2.32E-06 
Table 6-6: Top 10 differentially expressed miRNAs uniquely associated with 
metastasis. 
In order for miRNAs to be of potential patient benefit as a biomarker for 
metastasis, it is necessary to be able to identify them within the primary 
tumour. Therefore, the list of miRNAs uniquely associated with metastasis 
(see Table 6-6) was cross-referenced against the differentially expressed 
miRNAs identified in metastatic primary tumours (see Table 6-3). This 
identified 63 miRNAs in common to both lists that could therefore be of 
potential use as a marker for metastasis within the primary tumour (see 
Table 6-7). 




hsa-let-7c-5p -3.45 2.22E-16 1.90E-13 
hsa-miR-99a-5p -3.09 3.33E-10 1.22E-07 
hsa-miR-125b-5p -2.41 4.00E-09 9.81E-07 
hsa-miR-99a-3p -2.93 5.17E-08 9.11E-06 
hsa-miR-4776-5p -5.59 4.17E-07 4.88E-05 
hsa-miR-6842-3p 4.79 6.22E-07 6.68E-05 
hsa-miR-10b-5p -2.38 8.11E-07 8.36E-05 
hsa-miR-885-5p -4.95 1.54E-06 0.000153 
hsa-miR-31-3p 3.42 2.00E-06 0.0001913 
hsa-miR-21-5p 2.36 3.92E-06 0.000337 
 
Table 6-7: Top 10 differentially expressed miRNA associated with metastasis that 
are identifiable within the metastatic primary tumour (adjusted p = < 0.25). 
 227 
6.3.2.5 Comparison of miRNASeq profile of nodal metastases with and 
without ECS 
Paralleling the analysis of CNA performed in Chapter 4 a further breakdown 
of the metastatic samples was made. In order to try and identify any miRNAs 
whose differential expression was associated with ECS the nodal 
metastases were divided into those with and without ECS. A paired analysis 
was performed comparing the miRNA profiles of nodal metastases with ECS 
(n = 3) to matching normal epithelium. This identified 131 differentially 
expressed miRNAs, meeting the significance threshold of < 0.25 for the p-
value adjusted for multiple testing (see Table 6-8).  
 log Fold 
change 
p-value Adjusted p-value 
hsa-miR-133a-3p 7.90 2.54E-27 6.55E-24 
hsa-miR-208b-3p 8.25 4.21E-19 5.42E-16 
hsa-miR-1 6.31 2.07E-17 1.77E-14 
hsa-miR-375 8.04 4.79E-16 3.09E-13 
hsa-miR-615-3p -7.89 3.47E-15 1.79E-12 
hsa-miR-133b 7.59 7.14E-15 3.07E-12 
hsa-miR-206 8.66 1.74E-13 6.39E-11 
hsa-miR-196a-5p -5.26 2.68E-13 8.62E-11 
hsa-miR-196b-5p -4.48 3.07E-11 8.78E-09 
hsa-miR-135a-5p 6.00 7.24E-11 1.87E-08 
Table 6-8: Top 10 significantly differentially expressed miRNAs when comparing 
nodal metastases with ECS to matching normal epithelium (adjusted p = < 
0.25). 
 
A similar paired analysis was performed comparing the miRNA profiles of 
nodal metastases without ECS (n = 3) to matching normal epithelium. This 
identified 32 differentially expressed miRNAs using the significance 
threshold of < 0.25 for the adjusted p-value (see Table 6-9). These two lists 
were then cross-referenced. Duplicates were removed to leave miRNAs 
whose differential expression was more likely to be associated with ECS 
rather than metastasis. The remaining miRNA list was then cross-referenced 
against the list of differentially expressed miRNAs identified on comparing 
non-metastatic primary tumours to matching normal epithelium (see Table 
6-5).  
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 log Fold 
change 
p-value Adjusted p-value 
hsa-miR-375 9.30 2.55E-22 6.56E-19 
hsa-miR-196a-5p -6.86 3.27E-11 4.21E-08 
hsa-miR-3168 11.09 4.43E-08 3.80E-05 
hsa-miR-211-5p 7.45 2.16E-07 0.000139519 
hsa-miR-135a-5p 6.39 3.39E-07 0.000174653 
hsa-miR-133b 6.74 4.56E-07 0.000195749 
hsa-miR-615-3p -7.87 6.56E-07 0.000224872 
hsa-miR-196b-5p -4.86 6.98E-07 0.000224872 
hsa-miR-21-3p -4.21 8.87E-07 0.000254178 
hsa-miR-99a-5p 3.97 1.10E-06 0.000283051 
Table 6-9: Top 10 significantly differentially expressed miRNAs when comparing 
nodal metastases without ECS to matching normal epithelium (adjusted p = < 
0.25). 
 
 Log Fold 
change 
p-value Adjusted p-value 
hsa-miR-208b-3p 8.25 4.21E-19 5.42E-16 
hsa-miR-206 8.66 1.74E-13 6.39E-11 
hsa-miR-133a-5p 7.78 1.54E-10 3.31E-08 
hsa-miR-99a-3p 3.22 3.14E-09 5.40E-07 
hsa-miR-561-5p 4.28 4.68E-08 7.10E-06 
hsa-miR-499a-5p 3.90 1.71E-07 2.45E-05 
hsa-miR-146b-5p -3.09 2.46E-07 3.34E-05 
hsa-miR-455-3p -2.85 4.99E-07 6.44E-05 
hsa-miR-2355-5p -3.42 1.32E-06 0.000149568 
hsa-miR-10a-5p -3.10 2.27E-06 0.000244115 
Table 6-10: Top 10 significantly differentially expressed miRNAs associated with 
ECS. 
 
Duplicates were again removed to avoid miRNAs associated with 
carcinogenesis alone. This approach discovered 81 differentially expressed 
miRNAs potentially associated with ECS (see Table 6-10).  
An attempt was then made to validate the miRNASeq findings using the 
Nanostring nCounter miRNA assay and replicating the sequencing data 
analyses.  
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6.3.3 nCounter miRNA assay profiling of HNSCC primary 
tumours and matched nodal metastases 
The Nanostring nCounter expression profiling system is a relatively recent 
innovation. It uses hybridisation-based technology that can detect specific 
nucleic acid molecules from very low amounts of input material. It avoids the 
need for reverse transcription or PCR-based cDNA amplification (as is 
required in the preparation of miRNA sequencing libraries). Multiplexed 
probes are hybridised to specific transcripts and generate fluorescent 
signals, which are counted for each miRNA. Raw molecular counts are 
obtained (Geiss et al., 2008, Tam et al., 2014). Advantages of this 
technology include the reduced manipulation of input RNA, avoiding PCR 
amplification cycles. It only allows testing of 813 miRNAs simultaneously and 
therefore not all sequencing findings can be validated. The assay used is 
also unable to identify potentially novel miRNAs. It has also been shown to 
have a high correlation with miRNA sequencing and microarray-generated 
data from both cell lines and human tissue (Kolbert et al., 2013, Knutsen et 
al., 2013, Tam et al., 2014). It was therefore selected as a method of 
confirming miRNA expression profile generated from NGS. 
The same RNA sample from each patient sample used to create miRNA 
sequencing libraries (see Table 6-1) was used to obtain 150 ng of input RNA 
for the Nanostring nCounter miRNA Assay. This was performed with Bruno 
Steinkraus and Tudor Fulga (Weatherall Institute of Molecular Medicine, 
Oxford), one of only two centres in the UK to have a Nanostring nCounter 
system.  
The raw molecular count data was then processed using a software package 
called nSolver (Nanostring, Seattle USA) specifically designed to perform 
quality control and normalisation steps. This analysed the internal positive 
and negative controls to ensure that ligation worked appropriately. It also 
performed normalisation of the raw count data to five housekeeping genes 
included in the assay cartridge. This normalised count data was then input to 




6.3.3.1 Correlation of nCounter and miRNASeq profiles 
In an effort to compare the two technologies (NGS and Nanostring nCounter 
assay) a correlation analysis of the expression levels detected by both was 
performed. 
The nCounter miRNA assay contained probes for 813 mature miRNAs. It 
provides raw molecular counts for these as an output. After normalisation 
was performed as above the list of miRNAs was ranked by count. The 
normalised sequencing read counts for the same 813 miRNAs generated 
from the miRNASeq FASTQ files were also ranked by count. This was 
performed for each sample (n = 24).  
 
Figure 6-2: Plot of log counts (expression level) of each miRNA for both miRNASeq 
and nCounter for the sample ECS026_N, rho = 0.533 (p = <0.000001). 
 
 Each list of counts was then tested for normality using the Shapiro-Wilk test. 
These were all found to be not normally distributed. As such, the log counts 
for all 813 miRNAs on each platform were plotted against each other and 
correlation analysed using Spearman’s rank correlation coefficient (rho). An 
example of this is shown in Figure 6-2 for the sample ECS026_N. For this 
sample rho = 0.533, indicating a moderate correlation. This process was 
repeated for all samples (see Appendix 8.4 for all correlation scatterplots). 
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For all samples the correlation coefficients varied from 0.481–0.647, 







ECS026_N 0.533 <0.000001 
ECS026_T 0.589 <0.000001 
ECS029_N 0.566 <0.000001 
ECS029_T 0.612 <0.000001 
ECS033_L 0.573 <0.000001 
ECS033_N 0.540 <0.000001 
ECS033_T 0.647 <0.000001 
ECS040_L 0.608 <0.000001 
ECS040_N 0.593 <0.000001 
ECS040_T 0.581 <0.000001 
ECS042_N 0.576 <0.000001 
ECS042_T 0.547 <0.000001 
ECS054_L 0.559 <0.000001 
ECS054_N 0.509 <0.000001 
ECS054_T 0.556 <0.000001 
ECS055_L 0.589 <0.000001 
ECS055_N 0.532 <0.000001 
ECS055_T 0.573 <0.000001 
ECS060_L 0.481 <0.000001 
ECS060_N 0.562 <0.000001 
ECS060_T 0.562 <0.000001 
ECS084_L 0.592 <0.000001 
ECS084_N 0.606 <0.000001 
ECS084_T 0.572 <0.000001 
Table 6-11: List of Spearman's correlation coefficients calculated for all tissue 
samples (n = 24). 
The correlation scatterplots indicate that both miRNASeq and nCounter fail 
to detect miRNAs that are reported to have a detectable expression level in 
the other platform, though this number is higher in miRNASeq. This does not 
appear to reflect a greater sensitivity of NGS for low abundance of miRNAs 
but rather each platform has a greater propensity to detect a different 
spectrum of miRNAs. A previous analysis by Kolbert et al compared 
correlation of miRNA expression levels across a number of platforms (NGS, 
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microarray, qRT-PCR and nCounter) (Kolbert et al., 2013). This reported a 
very strong correlation (r = 0.935) between NGS and nCounter miRNA 
detected expression levels when utilising FFPE tissue. When a subset of 
miRNAs (37) from each platform was compared to qRT-PCR the nCounter 
platform demonstrated the highest correlation, but even this was only 
moderate (r = 0.481). Kolbert et al concluded that the choice of platform 
would depend upon pragmatic factors such as aim of project, finance and 
time given the commonly interrogated miRNAs were generally similar 
amongst the platforms (Kolbert et al., 2013). Though my correlation 
coefficients were lower than Kolbert et al, this may reflect variation in tissue 
type as they examined lung tissue (Kolbert et al., 2013). They also only 
examined two sample of FFPE tissue and therefore represent a much 
smaller group. My results suggest that the nCounter miRNA assay is a 
reasonable choice of technique to use to attempt to validate the miRNASeq 
data. However, lack of validation by nCounter should not preclude highly 
significant miRNAs identified using miRNASeq data from being considered 
in future studies using alternative technology (e.g. microarrays). They also 
highlight the fact that miRNASeq can screen from over double the number of 
miRNAs that the nCounter assay can. Therefore miRNAs not validated by 
nCounter data that are absent from the assay probes should also be 
considered for investigation in future studies. 
6.3.3.2  Comparison of nCounter and miRNA profiles of nodal 
metastases and matched normal epithelium 
The nCounter miRNA profile of nodal metastases was compared to matched 
normal epithelium, using the significance threshold of < 0.25 for the p-value 
adjusted for multiple testing. Forty-five miRNAs were found to be 
differentially expressed (see Table 6-12).  
Of the 45 significantly differentially expressed miRNAs identified using 






p-value Adjusted p-value 
hsa-miR-206 7.47 2.25E-22 1.85E-19 
hsa-miR-133a 6.64 8.12E-14 3.34E-11 
hsa-miR-375 6.00 5.07E-12 1.39E-09 
hsa-miR-424-5p -4.89 3.04E-11 6.24E-09 
hsa-miR-21-5p -3.35 7.06E-09 1.16E-06 
hsa-miR-99a-5p 2.78 2.56E-08 3.51E-06 
hsa-miR-503 -4.47 5.99E-08 7.03E-06 
hsa-miR-455-5p -4.37 1.22E-07 1.25E-05 
hsa-miR-1246 -5.21 2.91E-07 2.66E-05 
hsa-miR-455-3p -4.37 9.26E-07 7.61E-05 
Table 6-12: Top 10 nCounter generated significantly differentially expressed 
miRNAs between nodal metastases and matched normal epithelium. 
 
Figure 6-3: Plot of log fold changes generated for 25 miRNAs common to 
differential expression analysis between lymph node metastases and matched 
normal epithelium. 
The lists of the 25 miRNAs common to both platforms were ranked in order 
of log fold change (see Table 6-13) and again plotted against each other (see 
Figure 6-3). Spearman’s correlation coefficient was 1.0 (p = < 0.000001), 
suggesting a very strong for miRNAs when identified at a significant level 
(adjusted p-value < 0.25). This again reassures that the nCounter miRNA 
assay is a reasonable choice of technique to try and confirm miRNASeq 
data. 
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Mature miRNA miRNASeq log 
Fold change 
Mature miRNA nCounter log 
fold change 
hsa-miR-375 8.82 hsa-miR-206 7.47 
hsa-miR-206 7.76 hsa-miR-133a 6.64 
hsa-miR-133b 7.44 hsa-miR-375 6.00 
hsa-miR-1 6.59 hsa-miR-204-5p 3.20 
hsa-miR-204-5p 3.40 hsa-miR-1 3.13 
hsa-miR-99a-5p 3.39 hsa-miR-203 2.79 
hsa-miR-378i 2.55 hsa-miR-99a-5p 2.78 
hsa-miR-100-5p 2.07 hsa-miR-133b 2.55 
hsa-miR-125b-5p 2.04 hsa-miR-376c 2.14 
hsa-miR-378a-3p 1.82 hsa-miR-125b-5p 1.81 
hsa-miR-23b-3p 1.39 hsa-miR-23b-3p 1.80 
hsa-miR-130b-3p -1.11 hsa-miR-378a-3p 1.76 
hsa-miR-421 -1.14 hsa-miR-378i 1.76 
hsa-miR-455-5p -1.64 hsa-let-7c 1.63 
hsa-miR-135b-5p -1.67 hsa-miR-100-5p 1.41 
hsa-miR-450a-5p -1.78 hsa-miR-29c-3p 1.24 
hsa-miR-424-5p -1.79 hsa-miR-125a-5p -1.31 
hsa-miR-7-5p -1.83 hsa-miR-135b-5p -1.50 
hsa-miR-146b-5p -1.96 hsa-miR-193b-3p -1.99 
hsa-miR-455-3p -2.12 hsa-miR-630 -2.12 
hsa-miR-21-5p -2.46 hsa-miR-132-3p -2.22 
hsa-miR-31-5p -2.52 hsa-miR-130b-3p -2.28 
hsa-miR-1246 -3.40 hsa-miR-155-5p -2.32 
hsa-miR-196b-5p -4.57 hsa-miR-7-5p -2.34 
hsa-miR-196a-5p -5.93 hsa-miR-28-5p -2.49 
Table 6-13: Table of 25 significant miRNAs (adjusted p-value < 0.25) common to 
differential expression analysis performed with miRNASeq and nCounter 
generated data. This compared each lymph node metastasis to matched 
normal epithelium. The miRNAs are ranked in order of log fold change. 
 
The list of 25 miRNAs common to both platforms demonstrates that, though 
the correlation of expression is moderate to strong, when miRNAs are 
identified on both platforms, they are detected at similar levels. Though there 
are differences in the rank order according to fold change there is 
consistency in the direction of fold change (increased or decreased 
expression. Again suggesting the nCounter assay to be a practical choice of 
validation technique. 
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6.3.3.3 Comparison of nCounter miRNA profiles of non-metastatic 
primary tumours to nodal metastases 
The nCounter miRNA profiles of non-metastatic primary tumours were then 
compared to their matched normal epithelium. All 800 miRNA probes were 
detectable in at least one of the samples. This identified 27 differentially 
expressed miRNAs (see Table 6-14).  
 




hsa-miR-221-3p 2.28 2.94E-08 2.42E-05 
hsa-miR-4286 2.38 5.17E-07 2.12E-04 
hsa-miR-29c-3p -2.05 3.16E-06 8.66E-03 
hsa-miR-424-5p 5.28 1.59E-05 3.27E-03 
hsa-miR-183-5p 3.75 5.98E-05 9.83E-03 
hsa-miR-182-5p 3.70 8.49E-05 0.012 
hsa-miR-455-3p 3.96 0.000104869 0.012 
hsa-miR-375 -5.35 0.000157489 0.016 
hsa-miR-485-3p 4.05 0.000203723 0.018 
hsa-miR-199b-5p -1.54 0.000273739 0.02 
Table 6-14: Top 10 nCounter generated significantly differentially expressed 
miRNAs (adjusted p-value = < 0.25) between non-metastatic primary tumours 
and matched normal epithelium. 
 
 Log Fold 
change 
p-value Adjusted p-value 
hsa-miR-206 7.47 2.25E-22 1.85E-19 
hsa-miR-133a 6.64 8.12E-14 3.34E-11 
hsa-miR-99a-5p 2.78 2.56E-08 3.51E-06 
hsa-miR-196b-5p -3.89 4.87E-06 3.33E-04 
hsa-miR-944 -3.57 1.65E-05 0.0010 
hsa-miR-31-5p -3.14 3.88E-05 0.0022 
hsa-miR-196a-5p -3.47 4.80E-05 0.0026 
hsa-let-7c 1.63 8.08E-05 0.0040 
hsa-miR-146b-5p -4.75 8.38E-05 0.0040 
hsa-miR-28-5p -2.49 0.000119114 0.0054 
Table 6-15: Top 10 differentially expressed miRNAs identified using nCounter data 
as uniquely associated with metastasis (p = < 0.25). 
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The two lists of differentially expressed miRNAs (see Table 6-12 and Table 
6-14) were then cross-referenced to remove duplicates. This allowed 
miRNAs uniquely associated with metastasis to be identified. This 
highlighted 30 differentially expressed miRNAs unique to the nodal 
metastases (see Table 6-15).  
 
6.3.3.4 Validation of miRNASeq data miRNAs associated with 
metastasis 
The list of 30 differentially expressed miRNAs uniquely associated with 
metastasis (see Table 6-14) identified using the Nanostring nCounter miRNA 
assay was then compared to the 97 identified using miRNASeq (see Table 
6-6).  
Using this method the nCounter data validated 12 miRNAs whose differential 
expression was uniquely associated with metastasis in these samples (see 
Table 6-16). 
It should be noted that 32/97 differentially expressed miRNAs associated 
with metastases identified using miRNASeq were not contained in the 
nCounter miRNA probeset, and therefore could not be validated using this 
technique. These represent miRNAs potentially associated with nodal 
metastasis. 
The average sequencing read count across the patient samples for the 
differentially expressed miRNAs only detected by miRNASeq (n = 85) was 
calculated. The median of these was 274 (mean: 80,803, range: 6 – 
2,683,169). The average sequencing read count across the patient samples 
for the miRNAs common to both analyses (n = 12) was then calculated. The 
median of these was 21,408 (mean: 50,733, range: 66 – 270,827). The large 
difference in median read count suggests that low abundance miRNAs may 
be less likely to be detected by the nCounter assay, though the fact that 
there are miRNAs with relatively high read counts not identified as 
differentially expressed by nCounter indicates that low abundance is not the 
only reason that some miRNAs were not validated. 
 
 237 
 Log Fold 
change 
p-value Adjusted p-value 
hsa-miR-206 7.47 2.25E-22 1.85E-19 
hsa-miR-133a-3p 6.64 8.12E-14 3.34E-11 
hsa-miR-99a-5p 2.78 2.56E-08 3.51E-06 
hsa-miR-31-5p -3.14 3.88E-05 0.0022 
hsa-let-7c-3p 1.63 8.08E-05 0.0040 
hsa-miR-146b-5p -4.75 8.38E-05 0.0040 
hsa-miR-125b-5p 1.81 0.000193726 0.0079 
hsa-miR-1 3.13 0.000243149 0.0095 
hsa-miR-23b-3p 1.80 0.000359254 0.012 
hsa-miR-7-5p -2.34 0.00051702 0.016 
hsa-miR-133b 2.55 0.001873921 0.048 
hsa-miR-130b-3p -2.28 0.002028861 0.049 
Table 6-16: miRNAs uniquely associated with nodal metastases validated by 
nCounter miRNA assay. 
 
6.3.3.5 Validation of miRNASeq metastatic markers identifiable in 
metastatic primary tumours 
The differentially expressed miRNAs uniquely associated with metastasis 
identified using the nCounter assay (see Table 6-15) were then compared to 
the miRNAs identified as differentially expressed in the metastatic primary 
tumours. Duplicates were highlighted as potential miRNA markers of 
metastasis. These were then cross-referenced against the miRNA markers 
identified in metastatic primary tumours using miRNASeq data (see Table 
6-7). Using this approach seven miRNAs were validated by the nCounter 
data as being miRNA markers of metastasis identifiable in the primary 
tumours (see Table 6-17). 
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 Log Fold 
change 
p-value Adjusted p-value 
hsa-miR-125b-5p -2.13 1.22E-08 1.11E-06 
hsa-miR-130b-3p 4.24 2.01E-08 1.65E-06 
hsa-miR-99a-5p -2.67 3.23E-08 2.04E-06 
hsa-miR-146b-5p 3.82 7.63E-07 3.92E-05 
hsa-miR-23b-3p -2.04 9.02E-06 3.70E-04 
hsa-miR-7-5p 2.71 0.000450381 0.013 
hsa-miR-31-5p 3.09 0.001232828 0.029 
Table 6-17: miRNA markers for metastasis identifiable in the primary tumour, 
validated by nCounter data. 
 
6.3.3.6 Comparison of nCounter miRNA profiling of nodal metastases 
with and without ECS 
In parallel with previous sections the nCounter generated miRNA profiles of 
nodal metastases with ECS (n = 3) were compared to matching normal 
epithelium. This identified 29 differentially expressed miRNAs. The nCounter 
generated miRNA profiles of nodal metastases without ECS (n = 3) was then 
compared to matching normal epithelium. These two lists were then cross-
referenced. Duplicates were removed (leaving miRNAs only associated with 
metastases with ECS). This revealed 15 differentially expressed miRNAs. 
These were then cross-referenced against the nCounter generated 
differentially expressed miRNAs in non-metastatic primary tumours (see 
Table 6-14). Duplicates were removed (to remove miRNAs associated with 
carcinogenesis rather than ECS). This approach identified 11 differentially 
expressed miRNAs associated with ECS (see Table 6-18). On comparing this 
list to the differentially expressed miRNAs associated with ECS identified 
from miRNASeq data (see Table 6-10). In this way nCounter failed to validate 
any miRNAs associated with ECS found using miRNASeq data.  
Of the miRNAs highlighted by miRNASeq as associated with ECS (n = 81) 
only 47 were present on the nCounter miRNA assay probeset. The failure to 
validate the sequencing data in this situation may be due to the fact not all 
miRNAs were tested for in the nCounter assay. The small sample size in this 
study may also be why no common pattern of expression can be seen. 
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 Log Fold 
change 
p-value Adjusted p-value 
hsa-miR-1 4.80 6.56E-13 1.80E-10 
hsa-miR-204-5p 4.98 1.18E-05 0.0013 
hsa-miR-378g 4.68 4.54E-05 0.0046 
hsa-miR-630 -3.09 0.000320469 0.023 
hsa-miR-23b-3p 2.73 0.000722914 0.042 
hsa-miR-381 3.98 0.000812441 0.044 
hsa-miR-663b -4.19 0.001002273 0.045 
hsa-miR-518b 3.12 0.002070728 0.074 
hsa-miR-299-5p 3.33 0.003122911 0.11 
hsa-miR-30c-5p 2.94 0.007869778 0.23 
hsa-miR-133b 3.12 0.008340578 0.23 
Table 6-18: List of nCounter generated differentially expressed miRNAs associated 
with ECS (after comparison to non-metastatic primary tumours). 
 
The median sequencing read count of miRNAs associated with ECS 
identified by the nCounter assay (n = 11) was 382 (mean: 10,804, range: 0–
70,438). For those only identified by miRNASeq and present on the 
nCounter assay (n = 47) the median read count was 617 (mean: 16,683, 
range: 14–270,827). The fact that the median sequencing read count was 
higher in those miRNAs not highlighted by nCounter data suggests that low 
abundance of miRNA is not the sole reason that they were not identified by 
this assay.  
 
 
6.3.3.7 Integrating CNA and miRNAs associated with metastasis 
Identification of miRNAs whose pattern of expression correlates to  copy 
number change could highlight miRNAs of additional use as markers for 
metastasis. Known genes targets of these miRNAs could also be of interest 
in future studies of the metastatic process or as additional markers. In order 
to discover any such miRNAs the log-fold change of differentially expressed 
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miRNAs was plotted against the genomic copy number of the genomic loci 
of each miRNA.  
 
Mature miRNA Precursor miRNA Cytoband 
hsa-miR-125b-5p hsa-mir-125b-2 21q21.1 
hsa-mir-125b-1 11q24.1 
hsa-miR-99a-5p hsa-mir-99a 21q21.1 
hsa-miR-133b hsa-mir-133b 6p12.2 
hsa-mir-206 hsa-mir-206 6p12.2 
hsa-miR-23b-3p hsa-miR-23b 9q22.32 
hsa-miR-1 hsa-mir-1-1 20q13.33 
hsa-mir-1-2 18q11.2 
hsa-miR-133a-5p hsa-mir-133a-1 18q11.2 
hsa-mir-133a-2 20q13.33 
hsa-let-7c-5p hsa-let-7c 21q21.1 
hsa-let-7c-3p hsa-let-7c 21q21.1 
hsa-miR-146b-5p hsa-mir-146b 10q24.32 
hsa-miR-7-5p hsa-mir-7-1 9q21.32 
hsa-mir-7-2 15q26.1 
hsa-miR-7-3 19p13.3 
hsa-miR-130b-3p hsa-mir-130b 22q11.21 
hsa-mir-31-5p hsa-mir-31 9p21.3 
  Table 6-19: List of validated differentially expressed miRNAs associated with 
metastasis, with corresponding precursor miRNAs and genomic position. 
 
Understanding the biogenesis of miRNAs was key to attempting this 
analysis. miRNAs are encoded as longer transcripts called primary miRNAs. 
These are subsequently processed to precursor-miRNAs (approximately 60-
100 nt in length). These are stem-loop structures that are cleaved in the 
cytoplasm to eventually form the mature miRNA. As such, a mature miRNA 
does not have a corresponding genomic location but a precursor-miRNA 
does.  
Mature miRNAs may be coded for by multiple precursor-miRNAs. This 
means that simply attempting to match the mature miRNAs to areas of 
genomic CNA is not possible; the precursor-miRNAs must be used to map 
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genomic locations, and then interpret which mature miRNAs are descended 
from them. 
Firstly the list of validated differentially expressed miRNAs associated with 
metastasis (see Table 6-16) was obtained. The potential precursor-miRNAs 
for each mature miRNA were identified as well as the corresponding 
genomic locations (see  Table 6-19).  
The normalised sequencing counts of these precursor-miRNAs were 
combined with the segmented genomic copy number files for each nodal 
metastasis as input for a python script called miRNA_CNA (Dr Henry Wood, 
Precancer Genomics). This plotted the log fold change against the 
corresponding copy number ratio for each miRNA. This was performed 
comparing each nodal metastasis (n = 6) to its matching normal epithelium 
(see Figure 6-4). 
By inspecting each plot the miRNAs whose expression correlated to their 
corresponding genomic loci  copy number were then discovered from these 
plots i.e. overexpression correlating with genomic loci copy number gain and 
underexpression correlating with genomic loci copy number loss. 
As with the CNA analysis the individual threshold for calling CNAs for each 
sample needed to be accounted for. This was not possible on the expression 
vs. copy number ratio plots and required visual inspection of each sample’s 
individual chromosomal karyogram, generated using CNAnorm (Gusnanto et 
al., 2012). This allowed the location of each precursor-miRNA to be 





























































Copy number ratio 
Copy number ratio Copy number ratio 
Copy number ratio Copy number ratio 
Copy number ratio 
0.8       0.9          1.0         1.1        1.2 
Copy number ratio 
0.8           0.85         0.9          0.95        1.0 
Copy number ratio 
  0.95      1.0     1.05       1.1       1.15     1.2  
Copy number ratio 
  0.8     0.9     1.0    1.1   1.2    1.3      1.4    1.5  
Copy number ratio 
  0.7   0.75    0.8    0.85   0.9    0.95    1.0  
Copy number ratio 




Figure 6-5: Example of using individual chromosomal karyograms to evaluate copy 
number status of each precursor-miRNA. This example shows how only one 
of the precursor-miRNAs for the underexpressed mature product (hsa-miR-
125b-5p) has a correlating copy number status. 
 
Copy number loss in association with underexpression of miRNAs was 
observed more frequently than copy number gain and 
miRNAs (see  
 
Table 6-21 and Table 6-22). All 6 nodal metastases contained between 1–4 
correlating underexpressed mature-miRNAs, compared to only 3/6 
containing 1–2 correlating overexpressed miRNAs. Overall, the correlation 
between expression levels and copy number status was low. For each 
patient the correlation between fold change and copy number ratio of 
potential precursor miRNA was calculated using Spearman’s correlation 
Genomic Location (Mbp) 
Genomic Location (Mbp) 
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coefficient. This varied from -0.585 - 0.004 (see Table 6-20). For two patients 
(ECS060 and ECS084) a statistically significant, strong negative correlation 
was indicated (p = 0.022 and 0.041). For the remaining four patients no 




ECS060 -0.585 0.022 
ECS084 -0.532 0.041 
ECS033 -0.309 0.262 
ECS040 -0.228 0.413 
ECS055 -0.055 0.846 
ECS054 0.004 0.99 
Table 6-20: List of Spearman's correlation coefficient of precursor miRNA 
expression and copy number ratio (significance level set at p = 0.05). 
 
Amongst the mature-miRNAs whose underexpression correlates with 
genomic copy number loss, hsa-miR-125b-5p is consistently identified in 
each nodal metastasis. It is encoded by two pre-cursor miRNAs, hsa-miR-
125-1 and hsa-miR-125-2). These are located at 21q21.1 and 11q24.1 
respectively (see Figure 6-5). At least one of these precursor-miRNAs was 
located in a deleted region and in one case (ECS084_L) both precursors 
were deleted. The expression of hsa-miR-99a-5p correlated to copy number 
loss of its precursor (hsa-miR-99a located at 21q21.1) in 3/6 nodal 
metastases.  
It would be reasonable to hypothesise that the higher the number of 
precursors known to be associated with the mature miRNA the more likely 
this is to be to be associated with a corresponding CNA. However, hsa-miR-
7-5p is known to be a potential product of three precursor miRNAs (hsa-miR-
7-1, hsa-miR-7-2, hsa-miR-7-3) with three different genomic loci (9q21.32, 
15q26.1 and 19p13.3). Therefore, potentially this had 18 genomic locations 
(3 in 6 samples) that could correlate to copy number status. This only 
correlated overexpression with copy number gain in 2 samples (in 3 






Table 6-21: List of under expressed miRNAs whose genomic loci correlates to regions of copy number loss in nodal metastases. 
 
ECS033 ECS040 ECS054 ECS055 ECS060 ECS084 









hsa-mir-7-1 Nil Nil Nil Nil 
    hsa-mir-7-3       
    hsa-mir-
31-5p 
hsa-mir-31       
Table 6-22: List of overexpressed miRNAs whose genomic loci correlates to regions of copy number gain in nodal metastases. 
ECS033 ECS040 ECS054 ECS055 ECS060 ECS084 


























































miRNAs whose expression correlate with genomic CNA, make up the 
minority of even the small number of validated miRNAs associated with 
metastasis. They represent potential markers for metastasis but also can 
provide insight into the metastatic process.  
miRNAs whose dysregulation is independent of CNA are also of interest as 
a marker for metastasis, which can be used in addition to copy number. 
Amongst the nodal metastases, miRNAs whose expression is independent 
of CNA would include hsa-miR-206 and hsa-miR-146b-5p. 
6.4 Discussion 
6.4.1 Tissue sampling 
The transcriptional profile of cells will depend on their specific tissue type. As 
the level of expression of any gene is effectively unknown until the RNA 
sample is profiled it is important to obtain as pure a source tissue sample as 
possible. In order to try and achieve the highest purity of tumour cells, 
haematoxylin and eosin slides of my samples were marked by a consultant 
head and neck histopathologist with the specific remit of marking the areas 
of highest tumour cell content (i.e. not less that 80%).  
Using a laser has been shown to achieve high levels of target cell purity from 
heterogeneous cell populations (Emmert-Buck et al., 1996, Espina et al., 
2006, Morrogh et al., 2007). As this method was not available to me due to 
technical problems with the laser (see Chapter 4.3.1), tissue dissection was 
performed using the marked slides as a template for the target area for RNA 
extraction. A further 5 μm slide was cut immediately following the 7 x 10 μm 
slides cut for extraction. This section was stained with haematoxylin and 
eosin and marked by the histopathologist to ensure the target area of tumour 
had not altered. This quality control step was particularly important in smaller 
samples to ensure that the tumour had not been cut-through.  
In terms of preserving tissue samples for prolonged periods, formalin fixation 
has long been the preferred method due to maintenance of morphology and 
the compatibility with innumerable immunohistochemical tests. For molecular 
analysis, the formalin fixation process and long term storage of these 
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samples represent causes of degradation of nucleic acids. RNA 
fragmentation occurs during the time between harvesting the sample and 
fixation as well as during the fixation process and may also occur if the 
samples are stored at high temperatures (Werner et al., 2000, von Ahlfen et 
al., 2007). miRNAs have been demonstrated to be well preserved in 
archived FFPE tissue samples, though there is some evidence that tissue 
samples subject to extended storages times (over 11 years) may suffer from 
degradation of miRNAs expressed at low levels (Szafranska et al., 2008). As 
all tissue samples being used in my study were less than 10 years old and 
my aim was to study miRNAs FFPE samples were appropriate and 
obtainable. However, a study by von Ahlfen et al did find that formalin-
fixation had a negative effect on PCR performed on RNA (von Ahlfen et al., 
2007). This was performed on mRNA rather than miRNA. The fact that 
mRNA from FFPE tissue is degraded may be the cause of this effect, as well 
as noting they did not assess miRNAs. As PCR is an integral part of creating 
small RNA libraries this could have lead to bias in the results.  
RNA is also subject to degradation by RNases which are almost ubiquitous 
(Houseley and Tollervey, 2009). In order to try and combat this RNase 
decontamination was performed before, during and after any handling of 
RNA in the laboratory.   
6.4.2 Nucleic acid manipulation 
As detailed in the methods the extracted RNA undergoes manipulation in 
preparation for both sequencing input and the nCounter assay. During small 
RNA library preparation key steps include the ligation of 3’ and 5’ adaptors 
followed by reverse transcription, PCR amplification and size selection. 
There is no step for depletion of ribosomal RNA. This was attempted during 
optimisation of the library preparation protocol but was found to deplete the 
input RNA to the extent that no viable library was then produced. This may 
have been related to the fact that the library protocol required a minimum of 
1 μg input RNA. This was not always achievable and therefore the input 
amount was titrated down to 500 ng successfully. When ribosomal depletion 
was performed with the reduced input amount of RNA no viable library was 
obtained. As over 80% of total cellular RNA is ribosomal this represents a 
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significant contaminant to the RNA sample (Lodish H, 2000). The adaptors 
are highly specific for the chemical structure of miRNAs but the 
fragmentation of larger RNAs may confound this specificity. Another 
potential source of error is introduced with PCR. This can occur due to 
editing errors during the DNA-polymerase-catalysed enzymatic copying and 
errors due to thermally-induced DNA damage during temperature changes 
associated with PCR cycling (Pienaar et al., 2006). 
 The nCounter miRNA assay preparation protocol did not include any PCR 
though annealing and hybridisation of tags and probes is performed at 
varying temperatures, which could introduce error from thermal DNA 
damage. The nCounter protocol also required less than 10% of the input 
amount of total RNA and no ribosomal depletion was performed. These 
could mean that the target miRNAs were in such low abundance as to 
potentially introduce error.  
6.4.3 Profile of sequenced RNA 
In terms of the differently types of RNA identified in each sample, miRNA 
represented the majority of the sequenced library. On average 60% (range: 
51 – 71%) of aligned sequencing reads in each sample were miRNAs.  This 
represented by far the largest proportion of aligned reads in any sample, 
confirming the effectiveness of both the RNA extraction and library 
preparation techniques. Other types of small RNA identified in the sample 
included long noncoding RNA (lincRNA), ribosomal RNA (rRNA), 
mitochondrial RNA, mitochondrial transfer RNA, small nucleolar RNA, and 
small nuclear RNA (see Figure 6-6).  
On average, over 25% of each sample’s aligned reads were made up of 
non-miRNAs, with the largest proportion being linc-RNAs followed by rRNA. 
Attempts were made to optimise the Illumina Small RNA protocol by 
performing rRNA depletion prior to commencing the library protocol. This 
resulted in a non-viable concentration of library being produced and 
therefore had to be abandoned. This may have been related to the reduced 





Figure 6-6: Average content of aligned reads in each sample processed for small 
RNA sequencing. 
 
It is unlikely that the other types of RNA could be successfully removed 
without compromising the miRNA content as the RNA was from an FFPE 
tissue source and therefore degraded. Longer chains of RNA were therefore 
fragments to smaller chains and difficult to remove effectively on the basis of 
size alone. The adaptors in the Illumina protocol were highly specific for the 
3’-hydroxyl group on miRNAs and Figure 6-6 demonstrates that they are 
effective at targeting miRNAs from a sample containing a mix of RNA types. 
6.4.4 Intra-tumour heterogeneity 
As discussed in Chapter 4, intra-tumour heterogeneity is an important 
consideration when attempting any molecular analysis. It has been 
demonstrated clearly in genomic studies of a number of solid cancers 
(Gerlinger et al., 2014, Gerlinger et al., 2012).  
Wood et al used deep targeted sequencing and copy number sequencing to 
demonstrate tumour evolution through clonal populations in HNSCC. They 
demonstrated through multiple sampling of both a nodal metastasis and the 
primary tumour from the same patient that two distinct subclonal populations 
were identifiable in the metastatic primary tumour, one of which gave rise to 
the metastasis (Wood et al., 2015). This supports the hypothesis behind 











group of clonal populations of cancerous cells (Almendro et al., 2013, Zhang 
et al., 2013, Gotte et al., 2005). The metastatic clone may not necessarily be 
the dominant clone within the primary tumour, but is more likely to be 
dominant within the metastatic tissue (Hong et al., 2015).  
The low number of differentially expressed miRNAs between primary tumour 
and matched metastasis could be due to clonal population sampling 
difference. However it may also be due to ongoing evolution occurring at the 
two sites. The molecular changes required for oncogenesis are not sufficient 
for metastasis to be successful, demonstrated by the reporting of murine 
models of cancer that do not automatically develop metastases (Minna et al., 
2003). However, the molecular aberrations at the primary tumour may allow 
escape of the metastatic cell, but further evolution may be required for the 
metastatic clone to thrive at its new site. Regardless, markers for metastasis 
are more likely to be identifiable when utilising metastatic tissue.  
For this reason the nodal metastases were interrogated for differentially 
expressed miRNAs. To try and remove confounding miRNAs that are 
involved with carcinogenesis rather than metastasis the differentially 
expressed miRNAs associated with non-metastatic primary tumours were 
then removed from the analysis.   
6.4.5 miRNA Nomenclature 
One important aspect of the rapidly expanding and evolving research base 
in miRNAs is the corrections to nomenclature that have had to be made as 
our insight into their biogenesis and function has increased. Unchanged 
parameters include the first three letter (hsa) which indicate species (Homo 
sapiens) and the numbering of miRNAs, (e.g. hsa-miR-99) which is 
sequential. Specific precursors are indicated by suffix number (e.g. has-miR-
99-1). Suffixes made of letters denote related mature sequences (e.g. hsa-
miR-99a, hsa-miR-99b).  
Suffixes denoting 3p or 5p indicate which arm of the hairpin-shaped 
precursor structure the mature sequence originated from (e.g. hsa-miR-99a-
5p). Previously, nomenclature attempted to represent which of these arms 
represented the predominant product from the precursor miRNA by 
assigning the miRNA name without suffix and the opposing arm product 
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indicated with the suffix ‘*’. This was retired in miRBase version 17 for clarity 
and due to this being an area that has evolved markedly as knowledge 
about origin, sequence and predominance of miRNAs has changed and 
continues to change. With each update of miRBase miRNA names are 
changed and novel ones added. It was important this was acknowledged 
and traced to ensure accurate literature searches.  
miRiadne is an online tool specifically for this purpose and enables tracking 
of changes in nomenclature to enable swift, reliable referencing (Bonnal et 
al., 2015). Each miRNA was input into miRiadne to allow identification of 
previous names for each miRNAs. For example, has-miR-99a-5p was 
previously registered in miRBase as has-miR-99a until version 18.0 (2011). 
In this version, the suffix -5p was added and  the use of ‘*’ in nomenclature 
was replaced. This is particularly important to understand when surveying 
the literature.  
6.4.6 miRNAs associated with metastasis 
The potential of miRNAs as a biomarker for clinicopathological outcome is 
highlighted by a recent study  by Hur et al that identified a four miRNA 
signature associated with liver metastasis in colorectal cancer (Hur et al., 
2015). In my study 12 miRNAs were validated by nCounter data as 
associated with metastasis (see Table 6-16).  
Of there, eight were underexpressed in the nodal metastasis, relative to 
normal epithelium. Interestingly, four of these were overexpressed in the 
matched metastatic primary tumours (see Figure 6-7). 
It is recognised that a single miRNA may have a wide variety of effects, 
mediating both upregulation and downregulation of different target genes 
(Valinezhad Orang et al., 2014). The changing levels of expression relative 
to the states of tumour and metastasis highlight the complexity of potential 




Figure 6-7: Plot of log fold-change of each validated miRNA associated with 
metastasis, from normal to tumour to metastasis. 
 
The most highly significant (p = 1.85E-19) differentially expressed was has-
miR-206. This was overexpressed in the metastatic primary tumours but 
underexpressed in the nodal metastases. Downregulation of miR-206 has 
been observed in a number of other cancers (Yan et al., 2009, Song et al., 
2009, Vickers et al., 2012). In gastric carcinoma cells loss of miR-206 was 
described, particularly in those with high metastatic potential (Zhang et al., 
2015). The same study also demonstrated that miR-206 levels were 
significantly  decreased in metastatic lymph nodes compared to metastatic 
primary tumours. Transfection of a miR-206 inhibitor in  gastric carcinoma 
cells with high metastatic potential was shown to increase cell migration and 
invasion (Zhang et al., 2015). The transcription factor, PAX3 was confirmed 
to be a direct target of mir-206, in gastric cancer cells. Overexpression of 
PAX3 correlated positively with MET expression and predicted poor 























The MET signalling pathway is essential for normal embryological 
development but has been implicated in carcinogenesis and epithelial-
mesenchymal transition (EMT), a key step in tumour invasion and the 
metastatic process (Mazzone and Comoglio, 2006). It is a member of the 
receptor protein tyrosine kinase family. Overexpression of MET has been 
reported widely in HNSCC, as has a correlation with poor prognosis and 
nodal metastasis (Xu and Fisher, 2013). Over-activation of the MET pathway 
has also been implicated in anti-EGFR therapy (cetuximab) resistance (Lau 
and Chan, 2011).  
Similarly, in hepatocellular carcinoma cells NOTCH3 was revealed to be a 
target of miR-206. NOTCH3 is a member of the Notch family of 
transmembrane receptors, whose signalling is involved in regulating cell 
differentiation and senescence (Cui et al., 2013). Downregulation of 
NOTCH3 was observed in response to overexpression of miR-206 resulting 
in an increase in cell cycle arrest, apoptosis and cellular migration (Liu et al., 
2014).  
Alteri et al demonstrated that CCND1 was a major target of miR-206, and 
that miR-206-mediated repression of cyclin D1 is directly coupled to growth 
inhibition of cancer cell-lines (Alteri et al., 2013). Cyclin D1 promotes 
progression through the G1 phase of the cell cycle and inhibits the 
retinoblastoma protein (Du et al., 2013). RAS-mediated pathways induce 
transcription of cyclin D1 (Hitomi and Stacey, 1999). RAS proteins also play 
essential roles in signalling pathways that regulate cell proliferation. They 
are mutated in up to 20% of all cancers (Downward, 2003). As such cyclin 
D1 lies at the junction of a number of key signalling pathways in cancer. 
Specifically in HNSCC, cyclin D1 is overexpressed in up to 70% of HNSCC 
(Thomas et al., 2005). It has also been associated with occult nodal 
metastases and poor prognosis in HNSCC (Capaccio et al., 2000).  
miR-206 has been observed to be downregulated in supraglottic carcinoma, 
though no relation to metastasis was made (Zhang et al., 2014). This is the 
first report that it is underexpressed in relation to nodal metastases in 
HNSCC. The fact that its expression was slightly elevated in the matching 
primary tumours of these metastases may indicate a tumour suppressive 
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role prior to metastasis, and that this non-metastatic clone was sampled in 
the primary tumour. It may also be due to the differing primary tumour 
subsite evaluated. It may also be related to the fact that in Zhang et al’s 
studies, metastatic and non-metastatic tumours were included (Zhang et al., 
2014). As such, miR-206 represents a valid potential target in HNSCC. 
However its role as a biomarker may be limited as it was not identified 
amongst the metastatic primary tumour as significantly differentially 
expressed. It may have a role as a serum biomarker, which is yet to be 
explored. 
miR-125b-5p has also been identified as playing a tumour suppressor role in 
a number of cancers. In Ewing’s sarcoma and cervical cancer, miR-125b-5p 
was found to be underexpressed, as well as targeting the PI3K/AKT/mTOR 
signalling pathway (Li et al., 2014, Cui et al., 2012). Li et al discovered the 
oncogene PIK3CD to be suppressed by overexpression of miR-125b-5p in 
Ewing sarcoma cells(Li et al., 2014). PIK3CD is a key regulator of the 
PI3K/AKT/mTOR signalling pathway, which is an essential cell cycle 
mediator. PI3Ks are a family of enzymes that have been linked to regulating 
cell growth, differentiation, apoptosis, proliferation and migration (Engelman, 
2009). Lui et al found this pathway contained the highest frequency of 
mutations in a series of 151 HNSCCs undergoing whole-exome sequencing, 
illustrating dysregulation of this pathway to be a common aberration in 
HNSCC (Lui et al., 2013). However, in breast cancer cells, miR-125b 
overexpression was found to be associated with metastasis in cell lines and 
murine models. miR-125b-5p was shown to upregulate α-SMA and vimentin, 
which lead to increased metastatic potential and mesenchymal cell 
characteristics (consistent with EMT) (Tang et al., 2012).  
In HNSCC, decreased expression of miR-125b-5p has been reported in 
HNSCC studies of mixed subsite (Wong et al., 2008b, Kikkawa et al., 2010). 
In my study it was shown to be underexpressed in metastatic primary 
tumours and to be consistently underexpressed in matching nodal 
metastases. The fact that it was validated as identifiable in the primary 
tumours highlights the potential for this as a marker for metastasis. 
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miR-130b-3p was found to be over expressed in both metastatic primary 
tumours and matching nodal metastases. It has previously been reported to 
be upregulated in colorectal, renal cell and endometrial carcinoma (Wu et 
al., 2012a, Colangelo et al., 2013, Li et al., 2013). In endometrial cancer, it 
was associated with EMT via effects on DICER1 (Li et al., 2013). Colangelo 
et al identified increased levels of miR-130b-3p in association with more 
advanced tumour stage and peroxisomal proliferator activated receptor 
gamma (PPARgamma) as a direct target (Colangelo et al., 2013). This 
belongs to the family of nuclear hormone receptors and regulates lipid and 
glucose metabolism(Krishnan et al., 2007). Via this target, deregulation of 
PTEN, E-cadherin and VEGF was demonstrated (Colangelo et al., 2013). 
These are key mediators in invasion and metastasis. PTEN has been shown 
to play a tumour suppressor role in HNSCC and 30% of HNSCC exhibit 
decreased expression of this (Squarize et al., 2013). This is unsurprising 
given it is a member of the PI3K/AKT/mTOR pathway. 
The upregulation of miR-130b-3p observed in my study is consistent with 
previous studies profiling miRNAs in HNSCC (Cao et al., 2013, Sethi et al., 
2014). It has also been reported as upregulated in plasma of patients with 
colorectal cancer undergoing chemotherapy and predictive of non-
responders to treatment (Kjersem et al., 2014). This draws attention to the 
potential for miRNAs as predictive markers for metastasis.  
miR-99a-5p was underexpressed in both metastatic primary tumours and 
nodal metastases. The change was greater in the nodal metastases, though 
this may be due to mixed clonal sampling in the primary tumours, rather than 
reflective of an actual cellular change. Previous studies in HNSCC have 
found downregulation of miR-99a contributes to survival of OSCC cells and 
forced restoration resulted in suppression of cell proliferation and migration 
(Chen et al., 2012, Yan et al., 2012).  
Yan et al demonstrated that mTOR was directly targeted by miR-99a-5p in 
OSCC cell lines (Yan et al., 2012). Overexpression of miR-99a-5p was also 
shown to downregulated expression of mTOR. This role for miR-99a-5p was 
also been demonstrated in breast cancer cells, with some evidence that 
miR-99a-5p can reverse the breast cancer stem cell phenotype via the 
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PI3K/AKT/mTOR signalling pathway (Yang et al., 2014). Similarly, in cervical 
cancer cells miR-99a-5p was shown to inhibit proliferation and invasion via 
the mTOR pathway (Wang et al., 2014). This pathway interaction is 
consistent with the report that as part of a three microRNA signature miR-
99a-5p predicted response to anti-EGFR therapy (given that EGFR can 
activate the PI3K pathway via phosphorylation of ERBB3) (Cappuzzo et al., 
2014).  
hsa-miR-146b-5p was overexpressed in both metastatic primary tumours 
and nodal metastases at similar levels of fold change. This has previously 
been recognised to be overexpressed in oral and pharyngeal SCC tissue 
samples (Xiao et al., 2012, Lajer et al., 2012). This study is the first to report 
an association with metastasis in HNSCC.  
In thyroid cancer cells, over-expression of hsa-miR-146b-5p was found to 
directly target the 3’ untranslated region of SMAD4, inhibiting expression 
levels. Geraldo et al identified the TGF-β-signalling pathway as the route by 
which this occurred (Geraldo et al., 2012). SMAD4 originally identified as a 
tumour suppressor gene in pancreatic cancer has since been recognized to 
play a key role mediating both the WNT-signalling and TGF-β-signalling 
pathway (Hahn et al., 1996, Nishita et al., 2000). These pathways regulate 
processes included cell proliferation, survival, migration and polarity as well 
as immune regulation (Anastas and Moon, 2013, Massague, 2008). In 
HNSCC SMAD4 deletion was found to lead to spontaneous HNSCC in 
murine models, with a high proportion (86%) of HNSCC tissue samples 
showing decreased expression of SMAD4 (Bornstein et al., 2009). SMAD4 is 
located in 18q21.1-q21.32, a region found to be lost in 59% of nodal 
metastases and only 4% of non-metastatic primary tumours in which copy 
number sequencing was performed in Chapter 4. Integrating CNA and 
miRNA expression data like this provides further evidence for a significant 
role for SMAD4 in metastasis and suggests potential for hsa-miR-146b-5p 
as a marker. 
hsa-miR-23b-3p was observed to be underexpressed in both metastatic 
primary tumours and nodal metastases. miR-23b-3p has been found to have 
differing oncogenic and tumour suppressor effects in different studies. 
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Pellegrino et al demonstrated an inverse correlation between expression and 
breast cancer metastases and tumour growth in vivo (Pellegrino et al., 
2013). However, Jin et al found suppression of miR-23b-3p led to 
upregulation of tumour suppressor protein and  reduced growth and 
metastasis in vivo (Jin et al., 2013). In renal cell carcinoma and glioma miR-
23b-3p has been shown to have an oncogenic role whilst in pancreatic and 
bladder cancer it has been shown to have tumour suppressor effects 
(Donadelli et al., 2014). 
In bladder cancer increased miR-23b-3p expression positively correlated 
with improved patient survival. ZEB1, a key oncogenic moderator of EMT, 
was found to be a direct target of miR-23b-3p (Majid et al., 2013, Sayan et 
al., 2009). Increased expression of ZEB1 has been identified in HNSCC 
stem-cell-like cell lines and inhibition of this in murine models reduced 
tumour growth and metastasis (Chu et al., 2013). ZEB1 has also been 
shown to repress transcription of miR-200, which leads to 
immunosuppression of tumour-infiltrating lymphocytes (CD8(+) T-cells) and 
metastasis (Chen et al., 2014).  
In HNSCC, miR-23b-3p has been reported to be upregulated and 
downregulated in HNSCC tissue from a range of subsites (Scapoli et al., 
2010, Childs et al., 2009, Ramdas et al., 2009). These apparently conflicting 
roles may reflect the mixed tumour subsites included in previous studies. It 
may also be due to the fact that miR-23b-3p appears to mediate a number of 
pathways and given the intertumour heterogeneity of HNSCC, in different 
tumours different pathways are dysregulated as part of carcinogenesis. A 
larger, homogeneous cohort may reveal more about the role of this miRNA 
in HNSCC and potential use as a marker. 
hsa-miR-7-5p was overexpressed in metastatic primary tumours and nodal 
metastases. This is consistent with previous studies that profiled HNSCC 
tissue samples, from oral, oropharyngeal and hypopharyngeal subsites 
(Kikkawa et al., 2010, Rentoft et al., 2011, Ramdas et al., 2009, Maclellan et 
al., 2012). This miRNA has been shown mediate the PI3K/AKT/mTOR 
pathway in lung, breast and prostate cancer (Webster et al., 2009, Kefas et 
al., 2008). It directly targets the 3’ UTR of the EGFR mRNA, inhibiting 
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expression of this and other subsequent downstream molecules (Kalinowski 
et al., 2014). This suggests a tumour suppressor function for has-miR-7-5p 
in these cancers, contrary to the fact several studies found it to be 
upregulated in HNSCC. A study using HNSCC cell lines found upregulation 
of miR-7 resulted in decreased expression of EGFR, and that exogenous 
miR-7 inhibited tumour growth (Kalinowski et al., 2012). As such this may 
have limited use as a marker for metastasis given conflicting evidence for its 
function role and expression levels in HNSCC. 
hsa-miR-31-5p was consistently upregulated in metastatic primary tumours 
and nodal metastases. This is another miRNA whose expression level 
appears to be cancer-type specific. It has been reported to be 
overexpressed in hepatocellular and colorectal carcinoma whilst 
underexpression has been observed in breast and ovarian cancer (Bandres 
et al., 2006, Motoyama et al., 2009, Wong et al., 2008a, Yan et al., 2008, 
Schaefer et al., 2010). Numerous studies in HNSCC have reported 
overexpression of has-miR-31-5p in tissue samples and cell lines (Xiao et 
al., 2012, Kozaki et al., 2008, Liu et al., 2010b). Upregulation of miR-31 was 
found to predict the presence of lymph node metastases in patients with lung 
adenocarcinoma (Meng et al., 2013). Liu et al found miR-31-5p increased 
oncogenicity of HNSCC cell lines and increased tumour growth in murine 
models via the hypoxia-inducible factor (HIF) signalling pathway (Liu et al., 
2010b). In a separate study they found that plasma levels of hsa-miR-31-5p 
were elevated in OSCC patients and that these levels decreased markedly 
after tumour resection (Liu et al., 2010a). This miRNA has not been reported 
to be related to metastasis in HNSCC previously, Liu et al’s work 
demonstrates how markers identified in tissue could translate to less 
invasive tests.  
6.4.7 Genes and gene pathways affected by miRNAs 
Literature searches performed on each validated miRNA highlighted 
recurrently involved pathways. However, performing an analysis of pathways 
affected by miRNAs is challenging as a single miRNA can affect hundreds of 
genes and there is still a relative paucity of data on miRNA targets in specific 
diseases. To formally assess recurrent pathways, an online tool specifically 
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designed to provide access to up to date data called DIANA-miRPath 
version 2.0 was used (Vlachos et al., 2012). This incorporated TarBase, the 
largest manually curated database of experimentally validated miRNA gene 
interactions (Vlachos et al., 2015). The validated miRNAs associated with 
metastasis were each input into DIANA-miRPath and the resultant pathways 
evaluated. 
The number of genes known to be targeted by each miRNA ranged from 18 
– 1012 (see Table 6-23).  The large differential likely reflects the lack of 
research into individual miRNAs targeting, rather than a definitive functional 
difference. Using 15 cell signalling pathways known to be relevant to cancer, 
the number of miRNAs associated to each pathway by DIANA-miRPath was 
counted (see Figure 6-8). The pathway with the highest frequency of miRNA 
hits was the MAPK signalling pathway (n = 12). This was closely followed by 
the PI3K/AKT, calcium and apoptosis signalling pathways. The distribution of 
hits amongst pathways contrasted with the similar analysis performed in 
Chapter 4, where there was a sharp drop off in hits. This is due to the fact 
that a single miRNA affects multiple pathways and appears to have a wider 
range of potential effects than a single gene. The pathways with a lower 
frequency of miRNA hits include NOTCH and Hedgehog signalling pathway 
(n = 3 and 1, respectively). This may simply reflect a lack of functional 
research in genes in these pathways or the relative number of genes known 
in each pathway.  
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6.4.8 Integrating genomic CNA and miRNA expression data 
On interrogating miRNA data for associated copy number changes it is 
essential to remember that a mature miRNA has no genomic location. It is 
derived from a precursor-miRNA, which does have a genomic location. 
However, a single mature miRNA may be derived from multiple precursor 
miRNAs. The precursor-miRNAs may be at different genomic locations. 
CAP-miRSeq utilises a software package called miRDeep2 (Berlin, 
Germany) as part of its algorithm to align sequencing reads to miRBase and 
also to calculate the number of reads for each precursor-miRNA (Friedlander 
et al., 2008). This is calculated on the basis that each of the RNA products 
generated after the precursor-miRNA is cleaved by DICER (the 3’ and 5’ 
product) has a certain probability of being sequenced. miRDeep maps 
sequenced RNA reads to both the genomic position of the predicted 
precursor as well as the reads that correspond to the DICER cleavage 
products (that make up the precursor-miRNA) (Friedlander et al., 2008). In 
this way CAP-miRSeq is able to assign reads to the most statistically likely 
precursor-miRNA. Where it is unable to decide it will divide read evenly 
amongst the multiple precursor-miRNAs allowing each to be assessed 
equally. This appeared to happen more commonly when the precursor-
miRNAs had adjacent genomic locations, reducing the potential impact of 
uncertainty in assignation of precursor-miRNA. 
In this way each precursor-miRNA associated with the 12 validated mature 
miRNAs linked to metastasis were plotted against the genomic copy number 
ratio of their genomic location. Two upregulated (hsa-miR-125b-5p, hsa-
miR-99a-5p) and one downregulated (hsa-miR-7-5p) were recurrently 
associated with copy number gain and loss respectively. Only one was 
consistently associated with CNA in every sample (hsa-miR-135b-5p) 
suggesting that the expression of this miRNA is directly related to copy 
number status of its precursor miRNA.  
The fact that miRDeep2 uses statistical probability to assign the reads to 
corresponding precursor-miRNAs means that they may potentially be prone 
to error or bias in the sequencing. Where miRDeep2 is unable to identify the 
specific precursor-miRNA it evenly divides the sequencing reads for the 
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mature miRNA between the precursors available. This is a useful failsafe 
position as it allows each precursor to be considered as potentially 
responsible for the expression of the mature miRNA, but makes it impossible 
to decide which is most likely. This did not occur in any of the precursors 
associated with metastasis. This indicates that sufficient reads of the mature 
miRNAs and products of cleavage of the precursor-miRNA were present to 
allow identification of the most likely candidate. 
hsa-miR-130b-3p and hsa-miR-23b-5p only correlated their expression 
levels with copy number status of their precursor-miRNAs in a single sample 
each. As such these miRNAs could hold potential as a marker for metastasis 
in addition to the CNA marker identified in Chapter 4.  
The effect of deleted or amplified miRNAs on the expression of their target 
genes can only be assessed by evaluating the gene expression profile of the 
same RNA samples. A previous study by Wu et al found that copy number 
altered miRNAs tend to target a higher number of gene than average (Wu et 
al., 2012b). Given the fact that a single miRNA can both upregulate and 
downregulate different genes, and can influence the expression of many 
genes means that the potential targets and effects are great in number.  
Taking the additional step of adding mRNA expression data to this existing 
CNA and miRNA data could reveal a great deal about the mechanisms 
controlling the metastatic process.  
My study suggests strongly that, in general, copy number status does not 
dictate expression levels of miRNAs in metastasis in head and neck cancer. 
A recent study in colorectal cancer tissue samples evaluated the relationship 
between CNA and miRNA expression levels (Gasparini, 2013). This similarly 
found only 2 miRNAs had altered copy number status. The relationship 
between copy number status and miRNA expression may also be consistent 
in health and disease as another recent study evaluated 5 haemopoetic cell 
lines using microarrays and found little correlation between copy number 
and miRNA expression (Veigaard and Kjeldsen, 2014). 
Though hsa-miR-125b-5p consistently correlated expression to copy number 
status it is important to remember the inter-tumour heterogeneity of HNSCC. 
This was clearly shown by the CNA profiling performed in chapter 4 and 5. A 
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larger number of tumours, with multiple sampling performed per tumour, 
would need to be interrogated to confirm the consistent nature of this 
relationship. It was not possible to assess the available TCGA data for the 
expression levels of the miRNAs identified in my study as they only currently 
provide miRNA read count data for tumours and not for the matched normal, 
prohibiting a like-for-like analysis. 
6.5 Conclusion 
With regards to the specific aims of this chapter: 
1. NGS and nCounter generated data was used to compare the miRNA 
profiles of nodal metastases to non-metastatic primary tumours and 
identified 12 miRNAs whose differential expression was associated 
with metastasis.  
2. The matching metastatic primary tumours were then used to identify 
those miRNAs that may have use as predicting metastasis from 
primary tumour tissue. A panel of seven miRNAs were identified as 
potential markers for metastasis. Integrating genomic CNA data and 
miRNA expression data revealed that the expression of very few 






Chapter 7  
Discussion 
7.1 Introduction 
Metastasis is a potentially catastrophic event for patients with cancer. The 
majority of deaths from cancer are due to metastatic disease. Models of 
metastasis vary from the linear progression model, wherein a stepwise 
accumulation of genomic abnormalities leads to the metastatic clone, to the 
parallel progression model, where tumour cells leave the primary tumour 
before the acquisition of the definitive malignant phenotype and undergo 
further evolution at the site of metastasis (Klein, 2009). Incontrovertible proof 
does not exist for any model. Regardless of which is preferred, all support 
the hypothesis that the primary tumour consists of metastatic and non-
metastatic clonal populations.  
Intra-tumour heterogeneity has been demonstrated in a wide range of solid 
cancer including HNSCC (McGranahan and Swanton, 2015, Wood et al., 
2015). Relatively few studies have performed comparative analysis of 
primary tumours with matched metastases. Previous studies have shown 
metastasis may arise from a non-dominant clone within the primary tumour 
and that the metastatic subclone becomes dominant in the metastasis 
(Gronwald et al., 1999, Talmadge, 2007, Waghorne et al., 1988).  
7.2 Comparison of copy number profile of metastatic primary 
tumours to metastases 
Very few studies have compared genomic profiles of metastatic tissue to 
matched primary tumour as well as a cohort non-metastatic tumours. 
Yoshioka et al found 12/15 tumour-metastasis pairs of OSCC were 
identifiable using unsupervised hierarchical clustering of genomic 
breakpoints, concurring with our findings (Yoshioka et al., 2013). Bockmuhl 
et al utilised concordance and “similarity scores” based on chromosomal 





allowed identification of up to 24/34 paired samples, though the cohort 
consisted of mostly oropharyngeal and hypopharyngeal tumours (24/34) 
(Bockmuhl et al., 2002).   
My study demonstrated that the CNA profiles of nodal metastases and their 
matching primary tumour are not identical. In 37/49 cases the paired 
metastasis had the closest concordance of CNA profile to its primary tumour. 
Similar levels of correlation were found between nodal metastases and 
matching primary tumours (in 40/49 cases was the metastases the closest 
correlate to its paired tumour). The differences between primary tumour and 
metastasis support the notion that in order to identify molecular changes 
associated with metastasis, it is essential to use metastatic tissue. 
It would have been revealing to use multiple samples of both the primary 
tumours and the nodal metastases, as well as including samples from all 
nodal metastases where there was more than one present. This could have 
allowed greater insights into the effect of intra-tumour heterogeneity. A more 
recent study in non-small cell lung cancer found wide variation in somatic 
mutations between primary tumours and metastases. Vignot et al found 94% 
concordance for recurrent, presumed driver mutations compared to 63% for 
likely passenger mutations (Vignot et al., 2013). Using whole exome 
sequencing or transcriptome sequencing could be revealing in future work in 
HNSCC but presents considerably higher costs. In order to gain a better 
insight into tumour evolution the concept of multi-region sampling could be 
taken down to a single cell level. This could be combined with the relatively 
lower cost approach of low-coverage sequencing to provide CNA data to 
show the evolution of metastatic HNSCC. 
7.3 Identification of CNA associated with metastasis 
Comparison of the CNA profile of nodal metastases to non-metastatic 
primary tumours demonstrated a number of differences, though no single 
CNA was exclusively present in all samples of one group.  The CNA 
associated with metastasis identified in this and previous HNSCC studies 
are listed in Table 7-1. Some of the most striking CNAs associated with 
metastasis in my study included gain of 11q13.3-q13.2 (present in 45% of 





p14.1 (present in 71% of metastases and 39% of non-metastatic primary 
tumours) and loss of 11q23.1-q25 (present in 45% of metastases and 0% of 
non-metastatic primary tumours). The high frequency of alterations on 11q in 
nodal metastases highlighted genes that interact with TP53 (TP53AIP1 and 
EI24) which are little explored in HNSCC.  
The low level of concordance between the studies shown in Table 7-1 is of 
concern when attempting to identify a copy number signature for metastasis. 
HNSCC represents a genomically heterogeneous group of tumours. Though 
my study had the highest number of samples (49 tumour-metastasis pairs 
and 26 non-metastatic primary tumours) the low number of samples across 
the studies means any purported marker may be limited in its application to 
a larger cohort.  
Another limitation to my study is the resolution of sequencing. Though cost-
effective the low-coverage sequencing approach taken achieved a genomic 
resolution of 800 kb. This means any CNA smaller than this would not be 
discernible in my data. There is no universal definition of what a focal copy 
number alteration is. GISTIC 2.0 used the cut off of < 98% of the 
chromosomal arm as the upper limit for focal CNAs, with alterations smaller 
than this included in the analysis. Numerous studies in different  solid 
cancers have utilised the definition of < 3 Mb in length as the cut off for focal 
CNA (Brosens et al., 2010, Jones et al., 2008, Leary et al., 2008, Parsons et 
al., 2008, Weir et al., 2007). Genes vary in their length from 0.2 kb to 2.5 Mb 
(Strachan T, 1999). In my study CNAs spanning a single genomic window 
(800 kb) were rare, though there is no way to tell if smaller CNAs were being 
missed.  
After identifying a 14-CNA marker for metastasis in Chapter 4 (see Table 4-
13), this was then tested against copy number data downloaded from TCGA 
HNSCC cohort. Though the difference in scores for this marker was 
significantly different (p = < 0.001) between metastatic and non-metastatic 
primary tumours it was not able to discriminate completely between 
metastatic and non-metastatic tumours. This likely reflects the high level of 
inter-tumour heterogeneity in HNSCC. This limits the applicability of CNA 





processed using a generic CNA threshold as opposed to my data, which 
was analysed to assign each sample an individual threshold. This may have 
affected the accuracy of the CNA calls. However, generic thresholds are 
used widely in CNA analysis including in software packages such as GISTIC 
2.0 and as such any translational marker should arguably withstand this. 
 



















































































Table 7-1: Comparison of CNAs associated with nodal metastases in this study and 
previous studies that compared metastatic tissue to primary tumours. 
 
Future work should focus on the characteristics of the genes identified from 
this data, including immunohistochemistry analysis as well as functional 
analysis of the upregulation and downregulation of these genes in vitro 







7.4 Evaluation of CNA profile of metastasis with and without ECS 
Though the presence of lymph node metastasis does have a detrimental 
impact on patient outcomes in HNSCC, the presence of ECS remains the 
most significant negative prognosticator, reducing overall survival by up to 
70% (Shaw et al., 2010, Jose et al., 2003). No single CNA was found 
exclusively in metastases with or without ECS. Loss of 18q21.1-q21.32 was 
found in 30/49 (59%) nodal metastases and 1/26 (4%) non-metastatic 
primary tumours. It further identified in 21/27 (78%) metastases with ECS 
compared to 9/22 (41%) metastases without ECS. Three genes of potential 
interest were identified in this region (SMAD4, MALT1, PMAIP1) . SMAD4 
has been highlighted as performing a tumour suppressor function in 
pancreatic cancer originally (Hahn et al., 1996, Schutte et al., 1996). Since 
then, loss of SMAD4 has been observed to lead to spontaneous head and 
neck tumour development in murine models (Bornstein et al., 2009). 
Decreased expression of SMAD4 was reported in HNSCC tissue samples as 
well as the morphologically normal adjacent mucosa (Korc, 2009). The fact 
that it is underexpressed in adjacent mucosa suggests that loss of function 
of this gene is an early event in HNSCC, as this tissue represents part of the 
“cancerised field” in patients with HNSCC (Slaughter et al., 1953, Braakhuis 
et al., 2003). Previous work has also demonstrated that TP53 mutations are 
identifiable in morphologically normal mucosa in HNSCC (Wood et al., 2015, 
Escher et al., 2009). Being an early event does not preclude it from being an 
important event in metastasis, particularly in the setting of the parallel 
progression theory of metastasis. Examining for loss of SMAD4 in precancer 
could reveal it to be an early marker for risk of malignant transformation and 
metastasis. 
Relatively few studies have examined a molecular marker for ECS in 
HNSCC. Increased copy number of EGFR and CCND1 was observed in 
OSCC tissue using FISH (Michikawa et al., 2011). Overexpression of 
SERPINE1 and SMA has been found to be predictive of ECS with a high 
sensitivity (81%) but lower specificity (50%) (Dhanda et al., 2014). Wang et 
al identified a an 11-gene expression signature associated with ECS (Wang 
et al., 2015). Similarly to genomic copy number studies searching for 





between studies. This may be affected by the number of patients included in 
each study and therefore affected by the inter-tumour heterogeneity. As all 
these studies were based upon a single tissue sample, intra-tumour 
heterogeneity may be affecting the ability to identify a consistent marker 
associated with ECS.  
SMAD4 may represent a driver gene in not just HNSCC but specifically with 
the development of ECS. The low number of potential driver genes identified 
is also reflected in other cancers such as lung and colorectal carcinoma. 
Tomasetti et al found only 3 sequential mutations were required for the 
development of cancer in these two types (Tomasetti et al., 2015).  
Future work attempting to elucidate a marker for ECS may required a more 
integrated approach utilising mutation, copy number and transcriptomic 
profiling. However, it may also reflect that the underlying molecular 
processes resulting in the ECS phenotype are too varied to identify a simple 
marker for all patient with ECS. Therefore a larger number of samples that 
allow molecular sub-groups to be identified within metastases with ECS may 
be of value. However, it should be noted that with precise histopathological 
categorisation significant subgroups of cancer samples can be selected and 
genomic alterations tracked to these sub groups. Shain et al used targeted 
exome sequencing within a group of 37 primary melanomas and their 
adjacent precursor lesion to identify driver mutations that track the evolution 
of melanoma. This was only possible using precise histological classification 
of each tissue-type sampled along with detailed clinical characterisation of 
each patient (Shain et al., 2015). 
7.5 Fraction of genome altered (FGA) in metastasis 
CNAs affect a larger proportion of the genome than any other type of genetic 
alteration (Zack et al., 2013). In interpreting and visualising the genome and 
CNAs it is possible to evaluate the actual length of the genome that is 
affected by CNA. As such, attempts have been made to assess any 
relationship between the fraction of genome altered (FGA) and 
clinicopathologic outcomes in patients with cancer. In prostate cancer, this 
was prognostic for prostate cancer relapse and metastasis (Hieronymus et 





different values of FGA to be associated with differing histological subtypes 
of breast cancer (e.g. triple negative vs. estrogen receptor positive vs. 
estrogen receptor negative) (Jonsson et al., 2010). 
In my study, the mean FGA of metastatic primary tumours was found to be 
significantly higher than non-metastatic primary tumours (p = 0.0001), 
though no difference was found between tumours associated with and 
without ECS. Further analysis identified the cut off for this to be an FGA of 
0.04 that identified metastatic primary tumours with a sensitivity of 98% and 
specificity of 42.3%. 
No previous studies have examined this aspect of CNA burden in HNSCC. 
FGA as a marker for metastasis is appealing as it removes subjective 
interpretation of the copy number profile of a sample and provides a single 
figure as a result. It also is less likely to be affected by the genomic 
resolution of sequencing or array as the effect of small alterations in the 
exact breakpoint will not substantially change the overall proportion of 
genome that is copy number altered. Therefore extremely small CNAs that 
are obscured by broader CNA when performed a group-wide analysis are 
less likely to impact on this result. However, the potential for false positives 
is considerable with a specificity of 42.3%. It may also be affected by clonal 
sampling and therefore future work could evaluate this.  
An FGA > 0.098 and  > 0.125 was also associated with a significant 
decrease in disease-free survival and overall survival respectively (p = 0.014 
and p = 0.0059 respectively). This could hold potential for stratifying patients 
into those that could benefit from multimodal therapy. Neoadjuvant 
chemotherapy has been found to be of limited overall benefit in HNSCC 
(Garden, 2014). FGA could identify patients, at the point of primary tumour 
biopsy, that are at increased risk of recurrence and decreased survival. 
These patients could then be stratified into clinical trials to determine those 
that may benefit from more aggressive treatment regimes. 
7.6 Evaluation of CNA profile of OPSCC and viral load 
The association between OPSCC and HPV is well established though 
incompletely understood (Gillison et al., 2008, Vidal and Gillison, 2008, 





sequencing have revealed a similar mutational burden of both HPV-positive 
and negative HNSCC tumours, with characteristic differences in the 
spectrum of mutations. The most striking of these being a low incidence of 
TP53 mutations in HPV-positive tumours, whilst it is almost universally 
present in HPV-negative tumours (Stransky et al., 2011, Agrawal et al., 
2011, Seiwert et al., 2015). Both have been suggested to be genomically 
heterogeneous. NGS has been shown to be an effective method of detecting 
HPV-DNA and determining viral load (Conway et al., 2012, Lechner et al., 
2013).  
My study identified a panel of 19 CNAs associated with 0 viral load (see 
Table 5-6). When scoring each tumour for the presence/absence of these 
CNAs, the mean score of tumours with 0 viral load was found to be 
significantly higher than tumours with a viral load >0 (p = <0.0001). No 
difference in scores was found between tumours with intermediate and high 
viral loads, suggesting that viral load alone does not dictate the nature of the 
genomic alterations associated with OPSCC.  
Seiwert et al analysed 50 HPV-positive and 70 HPV-negative mixed subsite 
HNSCC samples, revealing considerable inter-tumour genomic 
heterogeneity (Seiwert et al., 2015). Copy number altered genes associated 
with HPV-negative tumours included EGFR, FGFR1, CCND1 and CDKN2A. 
My study concurred with these findings. Loss of SETD2, CSF1R, NOTCH1 
and CHD5 were also observed with greater frequency in tumours with 0 viral 
load in my samples, though Seiwert et al identified these at similar rates in 
HPV-positive and negative tumours (Seiwert et al., 2015). The differences 
between studies could be related to the fact Seiwert et al’s tumours were of 
mixed subsites (20/70 HPV-negative and 47/51 HPV positive being 
oropharyngeal) or they could simply reflect the inter-tumour heterogeneity of 
these tumours (Seiwert et al., 2015). 
The viral load was calculated using the number of reads obtained per 
sample and the number of reads that aligned to the viral genome. A potential 
confounding factor to this could be the coverage of the sequencing. As this 
provided a maximum resolution of 800 kb per sample it is possible that viral 





0 viral load when they actually had a low level of viral DNA present. Another, 
criticism of this study could be the lack of another method of determining 
HPV status of each sample in addition to NGS (e.g. p16 
immunohistochemistry). This could have provided an alternative method of 
grouping copy number profiles and evaluating differences. However previous 
work by Conway et al demonstrated that low coverage sequencing had 
100% sensitivity compared to DNA PCR or p16 IHC (Conway et al., 2012). 
This indicates that detection of viral DNA using NGS correlated highly with a 
positive PCR or IHC test. This suggests that the depth of sequencing was 
adequate to detect low levels of viral DNA.  In order to glean more 
translational information from the impact of viral load, clinical outcome data 
including survival and recurrence would be essential for any future work, 
ideally of a greater number of patients to add power to any sub-groups of 
viral load. 
7.7 Fraction of genome altered (FGA) in OPSCC according to viral 
load 
The FGA was again evaluated as a reflective marker of viral load. This was 
found to be significantly lower in tumours with viral load >0 (p = 0.006). This 
is an interesting genomic marker as it requires less visual assessment of 
each individual karyogram compared to using a panel of CNAs. It also 
provides a bottom line figure which is attractive as a translational marker. 
However it is not a definitive binary divider  between these two tumour 
groups, similarly to the CNA panel for metastatic and non-metastatic primary 
tumours. If this was related to clinical outcomes such as survival or 
recurrence it may be of use in differentiating HPV-positive tumours that are 
associated with a beneficial prognosis and treatment response. Future work 
could specifically evaluate this. 
The importance of FGA has not been reported previously in OPSCC but 
Stransky et al did report they found the mutational burden of HPV-negative 
HNSCC to be higher than HPV-positive (Stransky et al., 2011). Mroz and 
Rocco developed a measure of intra-tumour heterogeneity based on whole 
exome sequencing of tumour and matched normal DNA called Mutant Allele 





the mutant allele fraction of tumour-specific mutations and assigns a score 
for heterogeneity. They found that higher intra-tumour heterogeneity 
(measured by MATH) was related to worse outcome in a series of 74 
HNSCC patients (Mroz et al., 2013). This series of patients was primarily 
HPV-negative (63/74). They went on to examine 305 TCGA HNSCC patients 
(36 of which were HPV-positive). They found MATH scores were 
significantly lower in HPV-positive tumours (p = 0.004) (Mroz et al., 2015). 
The effect of intra-tumour heterogeneity must be considered in future work 
evaluating the validity of FGA. Subclonal CNAs containing in heterogeneous 
tumour samples may not reach the CNA threshold set for the sample. As 
such the FGA for the sample would not necessarily be increased. This is a 
potential flaw in applying FGA. Multi-region sampling of each tumour may 
assist with identifying this and accounting for heterogeneity. Mroz et al’s 
findings suggest that in HPV-positive tumours, heterogeneity would 
potentially have less of an effect than in HPV-negative tumours (Mroz et al., 
2015). Calculating an average of multiple samples may increase the ability 
of FGA to separate tumours by HPV-status or by patient outcome. 
7.8 Identification of miRNAs associated with metastasis 
My study utilised RNA from six nodal metastases and three non-metastatic 
primary tumours along with matching normal epithelium from all nine 
patients to identify miRNAs associated with metastasis. To increase the 
likelihood of these not just being associated with carcinogenesis  the miRNA 
profile of the metastatic primary tumours was used to discover the 
differentially expressed miRNAs only associated with nodal metastases. 
These findings were initially discovered using NGS and validated using the 
nCounter miRNA assay.  
Twelve miRNAs were found to be associated with metastasis (see Table 6-
17). Of these eight were also identifiable in the metastatic primary tumour 
(see Table 6-18). Though the full function of these miRNAs is still poorly 
understood, collectively they represent a great potential as metastatic 
markers in tumour tissue and have been demonstrated as detectable in the 
serum of other cancers, such as hsa-miR-130b-3p in the plasma of patients 





Though many studies have attempted to comprehensively profile miRNAs in 
HNSCC, there is a high level of heterogeneity in the miRNAs identified 
(Sethi et al., 2014). Part of this is likely due to the fact that there was a steep 
increase in the number of miRNAs registered in miRBase from its inception 
(<100) to today (1881) (Griffiths-Jones, 2004). The fact that every year novel 
miRNAs means that array-based methods of detecting miRNAs are limited 
to searching only for the probes present. miRNASeq offer the advantage of 
simply sequencing all small RNA sequences present in the sample. These 
can then be re-aligned to each updated version of miRBase as it is 
produced, essentially “future-proofing” the data against the discovery of 
novel miRNAs. 
Few studies have actually utilised tissue from nodal metastases in profiling 
miRNAs in HNSCC. As demonstrated with the copy number analysis 
performed in Chapter 4, it is necessary to use this tissue to reliably identify 
any potential markers or targets that are specifically associated with 
metastasis. Fletcher et al found hsa-miR-205 to be overexpressed in 12 
metastatic HNSCC primary tumours and their matching nodal metastases, 
using qRT-PCR (Fletcher et al., 2008). This miRNA has also been found to 
be underexpressed in HNSCC in a separate study (Fletcher et al., 2008). It 
was not identified as significantly differentially expressed in my study using 
both miRNASeq and nCounter approaches. This could reflect inter-tumour 
heterogeneity or the complexity of miRNA function and the epigenetic 
influences on their behaviour, which are poorly understood. 
The Nanostring nCounter expression profiling system offered the ability to 
profile and therefore attempt to validate a large number of miRNAs (800) 
rather than select a smaller number to attempt to validate with another 
method such as qRT-PCR. It also avoided any PCR cycles as part of the 
preparation of the RNA, which is another source of potential error. Recent 
studies have shown it to have a high correlation to miRNASeq and 
microarray generated data (Kolbert et al., 2013, Tam et al., 2014). Analysis 
of the sequencing counts of the miRNAs there were and were not validated 
by nCounter data found no significant difference between them suggesting 
that sensitivity to low abundance miRNAs was not the reason they were not 





involves 12 cycles of PCR amplification may contribute to miRNAs detected 
by sequencing but not by nCounter data.  
The most important limitation to the work was the limited number of patients 
included. Given the inter-tumour heterogeneity demonstrated by the copy 
number analysis performed in Chapter 4 and 5 it is likely that the miRNA 
profiles of HNSCC will be similarly heterogeneous. It should be noted that 
32/97 miRNAs identified using miRNASeq data were not present on the 
nCounter miRNA probeset, meaning they could not be validated using this 
technique and therefore represent miRNAs still potentially associated with 
metastasis. These could potentially be investigated in future work using 
custom-made probeset or alternative techniques. 
7.9 Integration of miRNA and CNA data 
In the final analysis I attempted to correlate the expression of miRNAs 
associated with metastasis to copy number changes. A low level of 
correlation was found overall. One miRNA (hsa-miR-125b-5p) was 
consistently identified to be underexpressed in each nodal metastasis. At 
least one of its precursor-miRNAs was also located at a site of genomic loss 
in each metastasis. Though other miRNAs were identified in specific 
samples to correlate expression to copy number, no other miRNA was found 
share this correlation in every metastasis.  
Given the association of miRNAs to fragile genomic locations in other 
cancers this low level of correlation between expression and CNA strongly 
suggests that genomic copy number does not dictate expression of miRNAs 
in metastasis in HNSCC (Calin et al., 2004, Zhang et al., 2006). This 
concurs with a study examining the expression of miRNAs in colorectal 
cancer (N. Gasparini, 2013). However miRNAs that are not associated with 
CNAs hold potential for use as part of a marker that integrates different 
molecular components (e.g. genomic CNA and specific miRNAs). Future 
work including more samples could explore this. Gross et al found loss of 3p 
correlated to poorer patient survival in HNSCC. This effect was synergistic 
with TP53 mutation and hsa-miR-548k expression (Gross et al., 2014). If 
metastatic nodal tissue was evaluated in a similar way an integrated marker 





Again this work is limited by the fact only small numbers of patients were 
included. Combined with the inter-tumour heterogeneity, any marker needs 
to be tested in a larger cohort of samples. Though the tumour and metastatic 
RNA was extracted from the same tissue blocks as the DNA was obtained 
from for copy number analysis, it was not obtained from the same tissue 
sample. This could introduce variation due to intra-tumour heterogeneity and 
affect the correlation identifiable from comparing these data. This could be 
accounted for in future work by utilising kits that allow dual-extraction of DNA 
and RNA from a single tissue sample (e.g. the QIAgen AllPrep 
DNA/RNA/miRNA Universal kit). 
7.10 Reflections 
Though a great deal was learnt during the course of this research, on 
reflection there are several aspects that could have been enhanced with the 
benefit of hindsight. Ideally the patients would have been recruited 
prospectively with detailed clinical information being collected 
contemporaneously. This is particular importance with respect to smoking or 
tobacco use. Accurate clinical data can only be reliably collected 
prospectively using a predetermined set of parameters. Detailed information 
can allow sub-groups to be evaluated, even within relatively small groups of 
heterogeneous tumours 
Attempting to integrate the host response to cancer by obtaining data such 
as the presence of tumour infiltrating lymphocytes and using additional 
samples including blood and saliva would be of great interest. Correlating 
the host response to genomic characteristics could reveal novel markers. 
Screening blood and saliva for both genomic (e.g. circulating tumour DNA) 
or immunological (e.g. immune cells) markers would enable non-invasive 
biomarkers to be recognised. 
Blood may also represent a valuable alternative to using morphologically 
normal epithelium. As the “normal” epithelium was obtained from the 
excision specimen it is still within the potentially cancerised field and may 





It would also have been of benefit to try and account for the effect of intra-
tumour heterogeneity. By utilising multiple, topographically separate tissue 
samples from each individual tumour and nodal metastasis, the real utility of 
any marker can be evaluated. It would also have been of great interest to 
evaluate each metastasis (in patients with more than one) and ascertain 
whether the same clonal population was responsible for each metastasis. 
When attempting to guide biological therapies it is of limited gain to only 
target one of the clonal populations present and capable of invasion and 
metastasis.   
 
7.11 Conclusion 
In general my work has revealed genomic differences between metastatic 
and non-metastatic HNSCC. It has also revealed differing profiles and levels 
of genomic damage between OPSCC with and without a detectable viral 
load. miRNAs associated with metastasis were also identified, though little 
correlation was found between miRNA expression and genomic CNA.  
Potentially translational elements of this include a panel of CNAs associated 
with metastatic primary OSCC tumours and a panel associated with OPSCC 
with 0 viral load. Statistically significant differences in the FGA of metastatic 
primary tumours as well as OPSCC with and without detectable viral load 
were also found and could hold potential for future clinical use. Greater 
numbers of samples needs to be assessed for these elements as well as the 
evaluation of the miRNAs associated with metastasis and potential 
integration of these markers. These genomic features could be combined 
with traditional histopathological techniques to give an integrated 
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8.2 Clinicopathologic Data 
ECS Code pT Stage pN Stage ECS+/- Tumour 
thickness (mm) 






ECS001 pT2 pN0 N0 5 Well Oral tongue No Yes No 
ECS002 pT1 pN1 ECS- 12 Well Oral tongue Yes No No 
ECS003 pT2 pN2b ECS- 12 Poor Oral tongue Yes Yes No 
ECS004 pT2 pN0 N0 3.5 Mod Oral tongue Yes No Yes 
ECS005 pT1 pN2b ECS- 8 Mod Oral tongue Yes No No 
ECS006 pT2 pN2b ECS+ 25 Mod Oral tongue No No No 
ECS007 pT1 pN0 N0 8 Mod Oral tongue Yes No No 
ECS008 pT1 pN1 ECS- 3.6 Mod Oral tongue No No No 
ECS009 pT2 pN1 ECS- 3 Mod Oral tongue No No Yes 
ECS013 pT2 pN1 ECS- 14 Mod Oral tongue Yes Yes No 
ECS014 pT1 pN1 ECS- 2.5 Poor Oral tongue No No No 
ECS015 pT3 pN0 N0 10 Well Oral tongue No No No 
ECS016 pT2 pN1 ECS+ 10 Mod Oral tongue No No No 
ECS017 pT2 pN0 N0 6 Mod Oral tongue No No No 
ECS018 pT2 pN2b ECS+ 15 Well Oral tongue No No No 
ECS019 pT1 pN0 N0 - Well Oral tongue No No No 
ECS020 pT1 pN0 N0 - Well Oral tongue No No No 
ECS021 pT1 pN0 N0 - Poor Oral tongue Yes No No 
ECS022 pT1 pN0 N0 5 Well Oral tongue No No No 
ECS023 pT1 pN0 N0 3.1 Mod Oral tongue No No No 
ECS024 pT1 pN0 N0 6 Mod Oral tongue No No No 
ECS025 pT1 pN0 N0 3 Poor Oral tongue No No No 
ECS026 pT1 pN0 N0 16 Well Oral tongue No No No 
ECS027 pT1 pN0 N0 5 Mod Oral tongue No No No 
ECS028 pT1 pN0 N0 8 Mod Oral tongue Yes No No 




ECS030 pT1 pN0 N0 - Well Oral tongue No No No 
ECS031 pT1 pN0 N0 3 Well Oral tongue No No No 
ECS032 pT! pN0 N0 6 Well Oral tongue No No No 
ECS033 pT1 pN1 ECS- 9.5 Poor Oral tongue No No No 
ECS034 pT1 pN1 ECS- 4 Poor FOM/Oraltongue Yes Yes No 
ECS035 pT2 pN1 ECS+ 27 Poor Oral tongue Yes No Yes 
ECS036 pT1 pN2b ECS+ - Mod Oral tongue Yes No No 
ECS038 pT1 pN2b ECS+ 8 Poor Oral tongue Yes No No 
ECS039 pT1 pN2b ECS+ 14 Mod Oral tongue No No No 
ECS040 pT1 pN2a ECS+ 11 Poor Oral tongue Yes Yes No 
ECS041 pT1 pN1 ECS- 14 Poor Oral tongue Yes Yes No 
ECS042 pT2 pN0 N0 21 Poor Oral tongue Yes No No 
ECS043 pT2 pN0 N0 12 Mod Oral tongue No No No 
ECS044 pT2 pN0 N0 16 Poor Oral tongue Yes No No 
ECS045 pT2 pN0 N0 14 Mod Oral tongue No No No 
ECS047 pT2 pN0 N0 21 Well Oral tongue No No No 
ECS048 pT2 pN0 N0 12 Well Oral tongue Yes No No 
ECS049 pT2 pN1 ECS- 9 Poor Oral tongue Yes No No 
ECS050 pT2 pN1 ECS- 14 Poor FOM/Oral 
tongue 
Yes Yes No 
ECS053 pT1 pN2b ECS+ 12 Poor Oral tongue Yes Yes Yes 
ECS054 pT1 pN1 ECS- 22 Poor Oral tongue Yes No No 
ECS055 pT2 pN1 ECS- 25 Poor Oral tongue No No No 
ECS056 pT2 pN2b ECS- 10 Mod Oral tongue No Yes No 
ECS057 PT2 pN2b ECS- - Well Oral tongue Yes Yes No 
ECS059 pT2 pN1 ECS+ 11 Mod Oral tongue No No No 
ECS060 pT2 pN2b ECS+ - Well Oral tongue Yes Yes No 
ECS061 pT2 pN2a ECS+ 32 Mod Buccal Yes No No 
ECS062 pT2 pN2b ECS+ 14 Well Oral tongue No No No 




ECS064 pT3 N0 N0 12 Well Oral tongue Yes No No 
ECS065 pT3 pN1 ECS- 32 Well Oral tongue No No No 
ECS066 pT3 pN2b ECS+ 45 Mod Oral tongue Yes No No 
ECS067 pT3 pN2b ECS+ 15 Poor FOM/Oral 
tongue 
Yes No Yes 
ECS068 pT3 pN2c ECS+ - Mod Oral tongue Yes No No 
ECS069 pT3 pN3 ECS+ 28 Well Oral tongue No No No 
ECS070 pT2 pN2b ECS- - Poor Oral tongue No Yes No 
ECS071 pT2 pN2b ECS+ - Poor Oral tongue Yes Yes Yes 
ECS073 pT4a pN2c ECS+ 40 Poor Oral tongue Yes Yes No 
ECS075 pT2 pN2b ECS+ 7 Mod Oral tongue Yes No No 
ECS076 pT2 pN2b ECS+ 5 Poor FOM/Oral 
tongue 
Yes Yes Yes 
ECS078 pT2 pN1 ECS- 8 Mod FOM/Oral 
tongue 
No Yes Yes 
ECS079 pT3 pN1 ECS- 11 Well FOM/Oral 
tongue 
No No No 
ECS080 pT4a pN2b ECS- 8.4 Well Alveolar Yes No No 
ECS081 pT3 pN2a ECS+ 18 Well Buccal Yes Yes No 
ECS082 pT2 pN2b ECS+ 9 Mod Buccal No No No 
ECS083 pT1 pN2b ECS- 15 Poor FOM Yes No No 
ECS084 pT4a pN3 ECS+ 12 Poor FOM No Yes No 
ECS085 pT4a pN2c ECS+ - Well Oral tongue Yes Yes Yes 
ECS087 pT4a pN2b ECS+ 11 Poor FOM Yes No No 
Table 8-1: Histopathologic details of patient samples. 
 








Recurrence? Site? Distant 
mets? 
Alive/Dead 
ECS001 50yr 2mth No 14 14 No - No Dead 




ECS003 75yr 0mth Yes 60 60 No - No Alive 
ECS004 52yr 7mth Yes 60 60 No - No Alive 
ECS005 60yr 7mth Yes 15 15 No - No Dead 
ECS006 52yr 11mth Yes 2 3 No - Yes Dead 
ECS007 53yr 5mth No 53 53 - - No Alive 
ECS008 72yr 9mth No 52 52 No - No Alive 
ECS009 64yr 9mth No 7 12 Yes Neck Yes Dead 
ECS013 66yr 8mth No 47 47 No - No Alive 
ECS014 52yr 3mth No 47 47 No - No Alive 
ECS015 90yr 2mth No 46 46 No - No Alive 
ECS016 75yr 8mth Yes 43 43 No - No Alive 
ECS017 84yr 11mth No 43 43 No - No Alive 
ECS018 84yr 6mth Yes 42 42 No - No Alive 
ECS019 47yr 2mth No 111 111 No - No Alive 
ECS020 52yr 10mth No 111 111 No - No Alive 
ECS021 58yr 5mth Yes 90 90 No - No Alive 
ECS022 48yr 9mth No 91 91 No - No Alive 
ECS023 48yr 9mth No 16 30 No - No Dead 
ECS024 65yr 4mth No 89 89 No - No Alive 
ECS025 54yr 0mth No 85 85 No - No Alive 
ECS026 56yr 8mth No 91 91 No - No Alive 
ECS027 67yr 3mth No 97 97 No - No Alive 
ECS028 61yr 0mth No 80 80 No - No Dead 
ECS029 53yr 6mth No 102 102 No - No Alive 
ECS030 74yr 8mth Yes 72 72 No - No Alive 
ECS031 67yr 0mth No 80 80 No - No Alive 
ECS032 61yr 1mth No 37 37 No - No Dead 
ECS033 39yr 11mth Yes 17 22 No - Yes Dead 




ECS035 80yr 6mth No 2 4 Yes Local No Dead 
ECS036 80yr 7mth Yes 4 4 Yes Neck No Dead 
ECS038 77yr 1mth Yes 2 5 Yes Neck No Dead 
ECS039 55yr 6mth Yes 2 7 Yes Neck No Dead 
ECS040 54yr 10mth Yes 36 36 No - No Dead 
ECS041 70yr 11mth Yes 81 81 No - No Alive 
ECS042 68yr 7mth No 66 66 No - No Alive 
ECS043 56yr 1mth Yes 93 93 No - No Alive 
ECS044 59yr 7mth Yes 70 70 No - No Alive 
ECS045 71yr 0mth No 92 92 No - No Alive 
ECS047 70yr 0mth Yes 22 22 No - No Dead 
ECS048 47yr 0mth No 18 31 Yes Oral and Neck Yes Dead 
ECS049 53yr 8mth Yes 77 77 No - No Alive 
ECS050 57yr 1mth Yes 72 72 No - No Alive 
ECS053 66yr 4mth Yes 2 67 Yes Neck No Alive 
ECS054 56yr 11mth Yes 66 66 No - No Alive 
ECS055 60yr 8mth Yes 28 28 No - No Dead 
ECS056 57yr 1mth Yes 63 63 No - No Dead 
ECS057 60yr 1mth Yes 8 8 No - - Dead 
ECS059 67yr 11mth No 2 2 No - No Dead 
ECS060 52yr 3mth Yes 52 52 No - No Dead 
ECS061 64yr 0mth Yes 32 38 No - Yes Dead 
ECS062 71yr 6mth Yes 6 9 Yes Neck No Dead 
ECS063 74yr 3mth Yes 9 9 No - No Dead 
ECS064 79yr 3mth No 8 18 Yes Oral, Neck No Dead 
ECS065 72yr 10mth No 5 5 No - No Dead 
ECS066 83yr 5mth Yes 5 5 No - No Dead 
ECS067 56yr 7mth Yes 34 34 No - No Alive 




ECS069 77yr 10mth Yes 4 5 Yes Oral and Neck No Dead 
ECS070 54yr 3mth Yes 59 59 No - No Alive 
ECS071 36yr 4mth Yes 4 4 No - Yes Dead 
ECS073 56yr 11mth Yes 5 5 No - No Dead 
ECS075 47yr 2mth No 1 1 No - No Dead 
ECS076 60yr 1mth Yes 25 46 Yes pyriform fossa No Dead 
ECS078 62yr 11mth Yes 40 40 No - No Alive 
ECS079 77yr 10mth Yes 4 4 No - No Dead 
ECS080 60yr 2mth Yes 54 54 No - No Alive 
ECS081 61yr 4mth Yes 6 7 Yes Oral and Neck No Dead 
ECS082 56yr 3mth Yes 1 2 Yes Oral and Neck No Dead 
ECS083 43yr 1mth Yes 47 47 No - No Alive 
ECS084 44yr 1mth No 5 8 Yes Neck No Dead 
ECS085 54yr 1mth No 0 1 Yes Oral and Neck No Dead 
ECS087 61yr 1mth Yes 2 10 Yes Neck No Dead 




8.3 Digital karyograms for all OSCC primary tumours and 
lymph node metastases 
Primary tumours are denoted by the suffix ‘–T’ and metastases by ‘–L’. 
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8.5 miRNA Differential expression tables 
 
miRNASeq nCounter 








hsa-miR-375 8.83 1.72E-28 hsa-miR-206 7.47 1.85E-19 
hsa-miR-196a-5p -5.93 2.87E-22 hsa-miR-133a 6.64 3.34E-11 
hsa-miR-133b 7.44 2.30E-16 hsa-miR-375 6.00 1.39E-09 
hsa-miR-1 6.59 3.89E-15 hsa-miR-424-5p -4.89 6.24E-09 
hsa-miR-615-3p -7.84 1.06E-14 hsa-miR-21-5p -3.36 1.16E-06 
hsa-miR-133a-3p 7.15 1.22E-14 hsa-miR-99a-5p 2.78 3.51E-06 
hsa-miR-196b-5p -4.58 3.28E-14 hsa-miR-503 -4.47 7.03E-06 
hsa-miR-135a-5p 6.24 3.28E-14 hsa-miR-455-5p -4.37 1.25E-05 
hsa-miR-206 7.77 1.89E-11 hsa-miR-1246 -5.21 2.66E-05 
hsa-let-7c-5p 3.36 2.72E-11 hsa-miR-455-3p -4.37 7.61E-05 




hsa-miR-99a-3p 2.91 1.06E-08 hsa-miR-196b-5p -3.89 3.33E-04 
hsa-miR-99a-5p 3.39 1.83E-08 hsa-miR-944 -3.58 1.05E-03 
hsa-miR-1247-5p 2.74 5.24E-08 hsa-miR-31-5p -3.15 2.28E-03 
hsa-miR-211-5p 6.11 1.28E-07 hsa-miR-196a-5p -3.47 2.63E-03 
hsa-miR-125b-2-3p 2.55 1.24E-06 hsa-let-7c 1.63 4.05E-03 
hsa-miR-139-5p 2.48 2.03E-06 hsa-miR-146b-5p -4.75 4.05E-03 
hsa-miR-208b-3p 6.53 2.15E-06 hsa-miR-28-5p -2.50 5.44E-03 
hsa-miR-21-5p -2.46 2.32E-06 hsa-miR-183-5p -2.55 6.76E-03 
hsa-miR-378i 2.56 2.73E-06 hsa-miR-125b-5p 1.82 7.96E-03 
hsa-miR-3168 9.60 1.47E-05 hsa-miR-1 3.14 9.52E-03 
hsa-miR-1246 -3.40 1.84E-05 hsa-miR-155-5p -2.33 1.07E-02 
hsa-miR-133a-5p 6.67 3.95E-05 hsa-miR-23b-3p 1.81 1.28E-02 
hsa-miR-1269a -5.98 3.95E-05 hsa-miR-18a-5p -3.00 1.53E-02 
hsa-miR-450b-5p -2.37 1.20E-04 hsa-miR-7-5p -2.34 1.70E-02 
hsa-miR-4776-5p 5.52 1.97E-04 hsa-miR-450a-5p -3.06 1.84E-02 
hsa-miR-378c 1.94 2.11E-04 hsa-miR-203 2.80 2.23E-02 
hsa-miR-125b-5p 2.05 2.25E-04 hsa-miR-135b-5p -1.50 2.81E-02 
hsa-miR-196a-3p -5.39 4.59E-04 hsa-miR-182-5p -2.51 4.48E-02 
hsa-miR-31-5p -2.52 4.59E-04 hsa-miR-378a-3p 1.76 4.69E-02 
hsa-miR-455-3p -2.13 5.74E-04 hsa-miR-378i 1.76 4.69E-02 
hsa-miR-6842-3p -4.36 6.22E-04 hsa-miR-133b 2.55 4.81E-02 
hsa-miR-561-5p 3.32 7.33E-04 hsa-miR-125a-5p -1.31 4.91E-02 
hsa-miR-1910-5p -3.34 7.85E-04 hsa-miR-130b-3p -2.29 4.91E-02 
hsa-miR-204-5p 3.41 1.00E-03 hsa-miR-193b-3p -1.99 5.52E-02 
hsa-miR-21-3p -3.02 1.13E-03 hsa-miR-630 -2.12 9.00E-02 
hsa-miR-378a-3p 1.82 1.13E-03 hsa-miR-100-5p 1.42 9.21E-02 
hsa-miR-7705 -2.54 1.23E-03 hsa-miR-181b-5p -3.51 9.23E-02 
hsa-miR-378f 2.54 1.28E-03 hsa-miR-181d -3.51 9.23E-02 
hsa-miR-1251-5p	 5.05	 1.40E-03	 hsa-miR-132-3p	 -2.23	 1.06E-01	
hsa-miR-424-3p -2.43 1.61E-03 hsa-miR-204-5p 3.21 1.26E-01 
hsa-miR-10a-3p -2.60 1.61E-03 hsa-miR-1180 -2.75 1.34E-01 
hsa-let-7c-3p 2.77 1.63E-03 hsa-miR-663b -2.75 1.44E-01 
hsa-miR-1247-3p 3.03 2.38E-03 hsa-miR-29c-3p 1.24 1.56E-01 
hsa-miR-100-5p 2.08 2.54E-03 hsa-miR-376c 2.15 2.33E-01 
hsa-miR-424-5p -1.79 2.82E-03    
hsa-miR-301b -2.09 3.30E-03    
hsa-miR-30a-5p 1.62 3.30E-03    
hsa-miR-136-3p 2.42 3.35E-03    
hsa-miR-31-3p -2.67 3.48E-03    
hsa-miR-203a 3.21 3.48E-03    
hsa-miR-203b-5p 4.34 3.86E-03    
hsa-miR-381-3p 3.42 4.13E-03    
hsa-miR-3129-3p -2.91 4.71E-03    
hsa-miR-378a-5p 1.77 5.41E-03    




hsa-miR-455-5p -1.64 8.23E-03    
hsa-miR-146b-5p -1.97 1.10E-02    
hsa-miR-454-3p -1.44 1.18E-02    
hsa-miR-135b-5p -1.68 1.47E-02    
hsa-miR-92b-3p -1.50 1.65E-02    
hsa-miR-4485 1.85 1.75E-02    
hsa-miR-2355-5p -2.27 2.05E-02    
hsa-miR-30a-3p 1.54 2.17E-02    
hsa-miR-23b-3p 1.40 2.22E-02    
hsa-miR-146b-3p -1.48 2.22E-02    
hsa-miR-450a-5p -1.78 2.64E-02    
hsa-miR-301a-3p -1.43 2.79E-02    
hsa-miR-10a-5p -1.88 3.11E-02    
hsa-miR-338-5p 1.72 3.38E-02    
hsa-miR-503-5p -2.67 3.51E-02    
hsa-miR-940 -2.08 3.99E-02    
hsa-miR-1271-3p -4.00 4.34E-02    
hsa-miR-378d 1.66 4.64E-02    
hsa-miR-4510 2.78 4.64E-02    
hsa-miR-183-3p -1.92 4.67E-02    
hsa-miR-615-5p -4.08 4.67E-02    
hsa-miR-335-3p -1.49 4.77E-02    
hsa-miR-96-5p -1.46 5.12E-02    
hsa-miR-4705 3.21 5.22E-02    
hsa-miR-431-3p 2.52 5.44E-02    
hsa-miR-3065-3p 1.82 5.44E-02    
hsa-miR-5089-3p 3.64 6.12E-02    
hsa-miR-7-5p -1.84 6.12E-02    
hsa-miR-3687 -2.60 6.12E-02    
hsa-miR-671-5p -1.54 7.14E-02    
hsa-miR-1301-3p -2.07 7.14E-02    
hsa-miR-4652-5p -3.73 7.28E-02    
hsa-miR-421 -1.15 7.31E-02    
hsa-miR-101-3p 1.39 7.41E-02    
hsa-miR-27b-3p 1.19 7.44E-02    
hsa-miR-542-5p -1.61 7.75E-02    
hsa-miR-149-5p 1.22 8.50E-02 	 	 	
hsa-miR-1266-5p 3.41 8.87E-02 	 	 	
hsa-miR-136-5p 2.05 9.14E-02 	 	 	
hsa-miR-139-3p 2.65 9.64E-02 	 	 	
hsa-miR-1290 -2.20 9.90E-02 	 	 	
hsa-miR-203b-3p 1.86 1.02E-01 	 	 	
hsa-miR-499a-5p 2.37 1.04E-01 	 	 	
hsa-miR-454-5p -1.54 1.15E-01 	 	 	




hsa-miR-130b-3p -1.11 1.31E-01 	 	 	
hsa-miR-125b-1-3p 1.25 1.41E-01 	 	 	
hsa-miR-148a-5p 1.33 1.41E-01 	 	 	
hsa-miR-4662a-5p -1.96 1.43E-01 	 	 	
hsa-miR-370-5p -3.44 1.44E-01 	 	 	
hsa-miR-422a 1.85 1.45E-01 	 	 	
hsa-miR-4326 -1.56 1.45E-01 	 	 	
hsa-miR-4741 -3.61 1.58E-01 	 	 	
hsa-miR-598-3p 1.40 1.71E-01 	 	 	
hsa-miR-885-5p 2.25 1.72E-01 	 	 	
hsa-miR-4284 3.09 1.72E-01 	 	 	
hsa-miR-29c-5p 1.35 1.80E-01 	 	 	
hsa-miR-486-5p 1.43 1.85E-01 	 	 	
hsa-miR-570-3p -2.80 1.86E-01 	 	 	
hsa-miR-487b-3p 1.70 1.86E-01 	 	 	
hsa-miR-3196 -2.36 1.86E-01 	 	 	
hsa-miR-3129-5p -3.49 1.92E-01 	 	 	
hsa-miR-411-5p 1.85 1.93E-01 	 	 	
hsa-miR-331-5p -1.38 2.00E-01 	 	 	
hsa-miR-22-5p -1.19 2.07E-01 	 	 	
hsa-miR-519a-3p -3.13 2.07E-01 	 	 	
hsa-miR-1908-5p -2.72 2.07E-01 	 	 	
hsa-miR-193b-5p -1.76 2.08E-01 	 	 	
hsa-miR-18a-3p -1.40 2.10E-01 	 	 	
hsa-miR-1291 1.23 2.18E-01 	 	 	
hsa-miR-887-3p 1.36 2.22E-01 	 	 	
hsa-miR-199b-5p 1.36 2.28E-01 	 	 	
hsa-miR-30e-3p 1.04 2.36E-01 	 	 	
hsa-miR-515-5p -3.24 2.37E-01 	 	 	
hsa-miR-10b-5p 1.31 2.39E-01 	 	 	
Table 8-3: Differentially expressed miRNAs between nodal metastases and 
matched normal epithelium. 
 
miRNASeq nCounter 








hsa-miR-1269a 12.81 1.94E-13 hsa-miR-221-3p 2.28 2.42E-05 
hsa-miR-615-3p 8.54 2.88E-10 hsa-miR-4286 2.38 2.13E-04 
hsa-miR-1269b 11.45 2.99E-08 hsa-miR-29c-3p -2.05 8.67E-04 
hsa-miR-1910-5p 4.23 4.06E-06 hsa-miR-424-5p 5.28 3.28E-03 
hsa-miR-196a-5p 4.92 2.34E-05 hsa-miR-183-5p 3.75 9.83E-03 
hsa-miR-431-5p 3.69 3.14E-04 hsa-miR-182-5p 3.70 1.16E-02 
hsa-miR-29c-3p -2.37 1.78E-03 hsa-miR-455-3p 3.96 1.23E-02 




hsa-miR-139-5p -2.98 1.86E-03 hsa-miR-485-3p 4.05 1.86E-02 
hsa-miR-4521 -3.10 4.05E-03 hsa-miR-199b-5p -1.54 2.25E-02 
hsa-miR-195-5p -2.28 4.35E-03 hsa-miR-378a-3p -2.12 2.53E-02 
hsa-miR-183-5p 2.83 5.08E-03 hsa-miR-378i -2.12 2.53E-02 
hsa-miR-196b-5p 4.44 1.50E-02 hsa-miR-455-5p 3.68 4.37E-02 
hsa-miR-182-5p 2.56 1.50E-02 hsa-miR-331-3p 3.49 4.37E-02 
hsa-miR-3929 5.07 1.50E-02 hsa-miR-503 3.96 4.37E-02 
hsa-miR-450a-5p 2.83 1.58E-02 hsa-miR-450a-5p 3.37 4.37E-02 
hsa-miR-21-3p 2.55 1.74E-02 hsa-miR-1246 3.90 5.49E-02 
hsa-miR-503-5p 3.19 1.85E-02 hsa-miR-139-5p -3.74 6.70E-02 
hsa-miR-1246 2.83 1.85E-02 hsa-miR-135b-5p 1.48 8.66E-02 
hsa-miR-9-5p 2.69 2.54E-02 hsa-miR-1206 3.16 1.04E-01 
hsa-miR-34c-5p 2.30 2.73E-02 hsa-miR-34c-5p 4.38 1.06E-01 
hsa-miR-212-3p 2.85 2.73E-02 hsa-miR-96-5p 2.40 1.48E-01 
hsa-miR-542-3p 2.62 2.73E-02 hsa-miR-21-5p 2.66 1.48E-01 
hsa-miR-381-3p -1.95 2.73E-02 hsa-miR-222-3p 1.28 1.48E-01 
hsa-miR-1251-5p -4.30 2.96E-02 hsa-miR-324-5p 2.21 1.74E-01 
hsa-miR-212-5p 3.22 3.91E-02 hsa-miR-421 2.94 1.78E-01 
hsa-miR-485-3p 2.31 4.11E-02 hsa-miR-144-3p -1.25 1.95E-01 
hsa-miR-101-5p -2.03 4.25E-02 hsa-miR-145-5p -1.55 1.95E-01 
hsa-miR-301b 2.34 4.25E-02    
hsa-miR-424-3p 2.35 4.25E-02    
hsa-miR-497-5p -2.11 4.48E-02    
hsa-miR-183-3p 2.23 4.48E-02    
hsa-miR-450b-5p 2.53 4.96E-02    
hsa-miR-34b-3p 2.79 5.58E-02    
hsa-miR-3607-3p -2.04 5.70E-02    
hsa-miR-542-5p 2.08 6.02E-02    
hsa-miR-323a-3p 2.22 6.02E-02    
hsa-miR-34b-5p 1.93 7.41E-02    
hsa-miR-378i -2.04 7.41E-02    
hsa-miR-378a-3p -1.78 9.07E-02    
hsa-miR-6510-3p -2.28 9.07E-02    
hsa-miR-92b-3p 1.64 9.36E-02    
hsa-miR-1197 3.39 9.57E-02    
hsa-miR-100-5p -1.78 9.58E-02    
hsa-miR-4664-3p 3.74 9.58E-02    
hsa-miR-516a-5p 4.81 9.61E-02    
hsa-miR-767-5p 4.66 9.75E-02    
hsa-miR-375 -3.83 1.10E-01    
hsa-miR-101-3p -1.58 1.23E-01    
hsa-miR-3065-5p -1.83 1.23E-01    








hsa-miR-135a-5p -5.67 1.35E-01    
hsa-miR-211-5p -3.55 1.39E-01    
hsa-miR-937-3p 3.13 1.43E-01    
hsa-miR-378a-5p -1.89 1.45E-01    
hsa-miR-758-3p 1.93 1.47E-01    
hsa-miR-380-3p 2.91 1.59E-01    
hsa-miR-424-5p 1.96 1.59E-01    
hsa-miR-548i 4.91 1.59E-01    
hsa-miR-942-5p -2.29 1.61E-01    
hsa-miR-204-5p -3.83 1.65E-01    
hsa-miR-105-3p 4.17 1.65E-01    
hsa-miR-3938 4.85 1.77E-01    
hsa-miR-199b-5p -1.41 1.98E-01    
hsa-miR-1247-5p -1.75 1.98E-01    
hsa-miR-512-3p 3.35 2.23E-01    
hsa-miR-4443 4.03 2.35E-01    
hsa-miR-338-5p -1.75 2.42E-01    
Table 8-4: Differentially expressed miRNAs between non-metastatic primary 
tumours and matched normal epithelium. 
 
miRNASeq nCounter 








hsa-miR-375 -8.03 5.40E-36 hsa-miR-375 -6.29 2.38E-14 
hsa-miR-196b-5p 5.27 2.75E-14 hsa-miR-424-5p 6.43 4.60E-14 
hsa-let-7c-5p -3.45 1.90E-13 hsa-miR-1180 5.09 5.67E-10 
hsa-miR-615-3p 7.54 2.76E-12 hsa-miR-421 4.71 1.12E-09 
hsa-miR-196a-5p 5.44 4.71E-11 hsa-miR-503 5.75 3.02E-09 
hsa-miR-1247-5p -3.54 7.82E-08 hsa-miR-21-5p 3.04 7.16E-09 
hsa-miR-99a-5p -3.10 1.22E-07 hsa-miR-196b-5p 4.87 1.08E-08 
hsa-miR-1910-5p 4.23 3.47E-07 hsa-miR-663b 4.93 6.32E-07 
hsa-miR-150-5p -2.51 9.81E-07 hsa-miR-125b-5p -2.13 1.11E-06 
hsa-miR-125b-5p -2.42 9.81E-07 hsa-miR-130b-3p 4.24 1.65E-06 
hsa-miR-424-3p 3.08 9.81E-07 hsa-miR-455-5p 4.57 1.71E-06 
hsa-miR-125b-2-3p -3.15 1.24E-06 hsa-miR-4286 3.16 1.71E-06 
hsa-miR-503-5p 4.43 6.50E-06 hsa-miR-99a-5p -2.67 2.04E-06 
hsa-miR-99a-3p -2.94 9.11E-06 hsa-miR-944 4.10 4.10E-06 
hsa-miR-1269a 6.81 9.11E-06 hsa-miR-196a-5p 4.29 1.59E-05 
hsa-miR-424-5p 2.74 9.11E-06 hsa-miR-146b-5p 3.82 3.92E-05 
hsa-miR-135a-5p -5.02 9.85E-06 hsa-miR-18a-5p 4.09 3.98E-05 
hsa-miR-1246 3.69 1.38E-05 hsa-miR-1246 4.33 5.34E-05 
hsa-miR-211-5p -5.66 1.44E-05 hsa-miR-450a-5p 3.71 2.26E-04 
hsa-miR-450b-5p 2.84 2.32E-05 hsa-miR-23b-3p -2.04 3.71E-04 




hsa-miR-4776-5p -5.60 4.88E-05 hsa-miR-150-5p -2.18 2.49E-03 
hsa-miR-450a-5p 2.54 6.68E-05 hsa-miR-135b-5p 1.89 5.65E-03 
hsa-miR-6842-3p 4.79 6.68E-05 hsa-miR-455-3p 3.75 6.09E-03 
hsa-miR-10b-5p -2.38 8.36E-05 hsa-miR-708-5p 3.01 6.47E-03 
hsa-miR-885-5p -4.95 1.53E-04 hsa-let-7c -1.45 1.18E-02 
hsa-miR-31-3p 3.42 1.91E-04 hsa-miR-630 3.01 1.32E-02 
hsa-miR-139-5p -2.25 2.59E-04 hsa-miR-7-5p 2.71 1.32E-02 
hsa-miR-21-3p 3.25 3.10E-04 hsa-miR-26b-5p -1.52 1.69E-02 
hsa-miR-21-5p 2.36 3.37E-04 hsa-miR-181b-5p 2.95 1.72E-02 
hsa-miR-6510-3p -3.59 5.04E-04 hsa-miR-181d 2.95 1.72E-02 
hsa-let-7c-3p -3.39 8.32E-04 hsa-miR-9-5p 3.29 1.72E-02 
hsa-miR-203a -4.57 8.60E-04 hsa-miR-151a-3p 1.67 2.54E-02 
hsa-miR-18a-3p 2.44 8.60E-04 hsa-miR-93-5p 1.38 2.96E-02 
hsa-miR-23b-3p -1.77 9.84E-04 hsa-miR-31-5p 3.09 2.97E-02 
hsa-miR-4705 -4.78 1.06E-03 hsa-miR-1915-3p 3.01 2.97E-02 
hsa-miR-1468-5p -2.36 1.61E-03 hsa-miR-28-5p 2.20 3.16E-02 
hsa-miR-3196 3.87 2.26E-03 hsa-miR-204-5p -2.90 3.16E-02 
hsa-miR-455-5p 1.76 2.52E-03 hsa-miR-320e 2.37 3.96E-02 
hsa-miR-6723-5p 5.12 2.52E-03 hsa-miR-4488 1.76 4.91E-02 
hsa-miR-31-5p 2.50 2.88E-03 hsa-miR-199b-5p -1.46 5.18E-02 
hsa-miR-7705 2.48 3.68E-03 hsa-miR-125a-5p 1.25 5.18E-02 
hsa-miR-2355-5p 2.52 4.65E-03 hsa-miR-664-3p -1.74 5.18E-02 
hsa-miR-934 5.13 5.11E-03 hsa-miR-497-5p -2.78 5.18E-02 
hsa-miR-25-5p 2.19 5.48E-03 hsa-miR-195-5p -1.64 5.24E-02 
hsa-miR-15b-3p 2.19 5.48E-03 hsa-miR-4508 2.95 6.21E-02 
hsa-miR-671-5p 2.05 6.04E-03 hsa-miR-139-5p -2.27 6.21E-02 
hsa-miR-1268b 2.44 6.45E-03 hsa-miR-30c-5p -1.96 6.27E-02 
hsa-miR-3168 -7.45 6.45E-03 hsa-miR-34c-5p 2.80 6.60E-02 
hsa-miR-3176 2.20 6.45E-03 hsa-miR-183-5p 2.24 6.60E-02 
hsa-miR-196a-3p 4.90 6.84E-03 hsa-miR-96-5p 2.27 6.92E-02 
hsa-miR-940 2.30 7.03E-03 hsa-miR-451a -1.61 7.48E-02 
hsa-miR-3117-3p 2.61 7.03E-03 hsa-miR-185-5p 1.53 7.94E-02 
hsa-miR-26a-5p -1.66 7.26E-03 hsa-miR-25-3p 1.10 9.96E-02 
hsa-miR-511-3p 2.29 7.26E-03 hsa-miR-518b -2.11 1.13E-01 
hsa-miR-339-5p 1.60 8.09E-03 hsa-miR-221-3p 1.39 1.25E-01 
hsa-miR-708-5p 1.62 8.53E-03 hsa-let-7i-5p 1.14 1.25E-01 
hsa-miR-542-3p 2.13 8.59E-03 hsa-miR-29c-3p -1.18 1.30E-01 
hsa-miR-125a-5p -1.49 9.09E-03 hsa-miR-155-5p 1.74 1.33E-01 
hsa-miR-431-5p 2.10 9.93E-03 hsa-miR-600 2.01 1.34E-01 
hsa-miR-663b 3.98 1.06E-02 hsa-miR-342-3p -1.11 1.35E-01 
hsa-miR-1251-5p -4.61 1.11E-02 hsa-miR-106b-5p 1.15 1.44E-01 
hsa-miR-148a-3p -1.55 1.15E-02 hsa-miR-19a-3p 1.23 1.48E-01 
hsa-miR-130b-3p 1.52 1.16E-02 hsa-miR-29a-3p 1.00 1.48E-01 
hsa-miR-1268a 2.38 1.16E-02 hsa-miR-187-3p 2.01 1.48E-01 




hsa-miR-3677-3p 2.57 1.36E-02 hsa-miR-26a-5p -0.95 1.57E-01 
hsa-miR-455-3p 1.76 1.36E-02 hsa-miR-130a-3p 1.04 1.58E-01 
hsa-miR-3691-5p 3.40 1.36E-02 hsa-miR-331-3p 2.48 1.59E-01 
hsa-miR-129-5p 2.69 1.60E-02 hsa-miR-22-3p 0.99 1.69E-01 
hsa-miR-1247-3p -2.97 1.99E-02 hsa-miR-520f 1.54 1.71E-01 
hsa-miR-1301-3p 2.15 2.25E-02 hsa-miR-106a-5p 0.91 1.81E-01 
hsa-miR-561-5p -2.07 2.51E-02 hsa-miR-17-5p 0.91 1.81E-01 
hsa-miR-7-5p 2.38 2.59E-02 hsa-miR-4532 2.07 1.81E-01 
hsa-miR-18a-5p 1.60 2.72E-02 hsa-miR-135a-5p -2.72 1.81E-01 
hsa-miR-4485 -1.80 2.72E-02 hsa-miR-1234 1.68 1.82E-01 
hsa-miR-106b-5p 1.26 2.91E-02 hsa-miR-450b-5p 1.50 1.85E-01 
hsa-miR-2355-3p 2.50 2.99E-02 hsa-miR-542-3p 1.55 1.85E-01 
hsa-miR-30a-5p -1.36 3.09E-02 hsa-miR-1290 1.60 1.85E-01 
hsa-miR-1307-3p 1.29 3.13E-02 hsa-miR-126-3p -0.91 2.28E-01 
hsa-miR-100-5p -1.54 3.24E-02 hsa-miR-182-5p 2.06 2.32E-01 
hsa-miR-27b-3p -1.47 3.50E-02 hsa-miR-193b-3p 1.74 2.37E-01 
hsa-miR-4510 -2.69 3.52E-02 hsa-miR-376c -1.51 2.40E-01 
hsa-miR-136-3p -1.43 3.52E-02 hsa-miR-520h 1.51 2.40E-01 
hsa-miR-4521 -2.54 3.69E-02    
hsa-miR-542-5p 1.79 3.75E-02    
hsa-miR-195-5p -1.48 3.79E-02    
hsa-miR-29c-3p -1.29 3.79E-02    
hsa-miR-92b-3p 1.25 3.79E-02    
hsa-miR-301b 2.51 3.85E-02    
hsa-miR-381-3p -1.95 3.97E-02    
hsa-miR-148a-5p -1.59 4.83E-02    
hsa-miR-1271-3p 3.99 4.84E-02    
hsa-miR-1296-5p 1.52 4.84E-02    
hsa-miR-96-5p 1.45 4.98E-02    
hsa-miR-30e-3p -1.24 5.04E-02    
hsa-miR-4741 3.97 5.04E-02    
hsa-miR-19a-3p 1.48 5.75E-02    
hsa-miR-664a-3p -1.51 5.75E-02    
hsa-miR-486-5p -1.93 5.75E-02    
hsa-miR-22-5p 1.70 5.75E-02    
hsa-miR-6753-3p 3.90 5.85E-02    
hsa-miR-3619-5p 3.89 6.29E-02    
hsa-let-7a-5p -1.24 6.37E-02    
hsa-miR-1287-5p 1.96 6.43E-02    
hsa-miR-1908-5p 2.79 6.53E-02    
hsa-miR-1180-3p 1.54 7.25E-02    
hsa-miR-550a-5p 2.11 7.25E-02    
hsa-miR-2467-5p 2.06 7.47E-02    
hsa-miR-3934-5p 1.77 7.70E-02    




hsa-miR-520f-3p 3.69 8.40E-02    
hsa-miR-4707-3p 2.72 8.66E-02    
hsa-miR-345-3p 3.80 8.66E-02    
hsa-miR-615-5p 3.92 8.66E-02    
hsa-miR-1305 2.52 8.87E-02    
hsa-miR-877-3p 3.74 8.89E-02    
hsa-miR-3687 2.48 8.89E-02    
hsa-miR-139-3p -3.21 8.89E-02    
hsa-miR-6854-5p 3.69 8.89E-02    
hsa-miR-3129-3p 2.28 8.89E-02    
hsa-miR-3162-3p 3.69 8.89E-02    
hsa-miR-937-3p 1.91 9.16E-02    
hsa-miR-4677-5p 3.39 9.16E-02    
hsa-miR-1273e 3.79 9.16E-02    
hsa-miR-550a-3-5p 2.07 9.21E-02    
hsa-miR-1307-5p 1.11 9.29E-02    
hsa-miR-378a-3p -1.14 1.02E-01    
hsa-miR-449b-5p 2.75 1.04E-01    
hsa-miR-126-3p -1.04 1.07E-01    
hsa-miR-454-3p 1.40 1.07E-01    
hsa-miR-5008-3p 2.68 1.07E-01    
hsa-miR-4652-5p 3.86 1.07E-01    
hsa-miR-675-5p 2.67 1.07E-01    
hsa-miR-16-1-3p 1.98 1.08E-01    
hsa-miR-548aq-5p 3.60 1.11E-01    
hsa-miR-378i -1.36 1.11E-01    
hsa-miR-4516 2.24 1.13E-01    
hsa-miR-4746-5p 2.05 1.18E-01    
hsa-miR-758-3p 1.94 1.20E-01    
hsa-miR-4671-3p 2.78 1.26E-01    
hsa-miR-146b-5p 1.17 1.29E-01    
hsa-miR-26b-5p -1.23 1.30E-01    
hsa-miR-619-5p 1.83 1.35E-01    
hsa-miR-570-3p 2.93 1.36E-01    
hsa-miR-3653 -2.32 1.40E-01    
hsa-miR-4798-5p 3.22 1.44E-01    
hsa-miR-135b-5p 1.77 1.44E-01    
hsa-miR-331-5p 1.39 1.44E-01    
hsa-miR-30a-3p -1.10 1.53E-01    
hsa-miR-4443 2.27 1.55E-01    
hsa-miR-215-5p -1.42 1.55E-01    
hsa-miR-199b-5p -0.99 1.57E-01    
hsa-miR-335-3p 1.31 1.63E-01    
hsa-miR-128-3p 1.03 1.63E-01    




hsa-miR-5089-5p -3.13 1.64E-01    
hsa-miR-193b-5p 1.62 1.65E-01    
hsa-miR-519a-3p 3.36 1.68E-01    
hsa-miR-451a -1.39 1.68E-01    
hsa-miR-3613-5p 2.14 1.78E-01    
hsa-miR-185-3p 1.55 1.78E-01    
hsa-miR-187-5p 3.30 1.78E-01    
hsa-miR-663a 3.32 1.89E-01    
hsa-let-7i-3p 1.18 1.89E-01    
hsa-miR-590-5p 1.98 1.97E-01    
hsa-miR-138-5p 2.21 2.01E-01    
hsa-miR-4713-5p 2.33 2.01E-01    
hsa-miR-219b-5p 3.26 2.01E-01    
hsa-miR-5582-3p 3.28 2.01E-01    
hsa-miR-941 1.07 2.05E-01    
hsa-miR-454-5p 1.48 2.13E-01    
hsa-miR-34c-5p 1.05 2.13E-01    
hsa-let-7g-5p -0.94 2.16E-01    
hsa-miR-3145-3p 3.19 2.16E-01    
hsa-miR-584-3p 3.19 2.17E-01    
hsa-miR-301a-3p 1.23 2.23E-01    
hsa-miR-487b-3p -1.23 2.27E-01    
hsa-miR-106b-3p 0.96 2.27E-01    
hsa-miR-3065-3p -1.25 2.27E-01    
hsa-miR-150-3p -1.62 2.30E-01    
hsa-miR-642a-3p 2.55 2.31E-01    
hsa-miR-192-5p -0.89 2.32E-01    
hsa-miR-491-5p 1.54 2.32E-01    
hsa-miR-129-1-3p 3.64 2.40E-01    
hsa-miR-3129-5p 3.14 2.42E-01    
Table 8-5: Differentially expressed miRNAs between metastatic primary tumours 
and matched normal epithelium. 
 
miRNASeq nCounter 








hsa-miR-133a-3p 7.90 6.55E-24 hsa-miR-206 8.33 4.35E-19 
hsa-miR-208b-3p 8.26 5.42E-16 hsa-miR-133a 7.81 1.03E-14 
hsa-miR-1 6.32 1.77E-14 hsa-miR-1 4.80 1.80E-10 
hsa-miR-375 8.05 3.09E-13 hsa-miR-375 5.60 5.09E-04 
hsa-miR-615-3p -7.89 1.79E-12 hsa-miR-424-5p -5.07 1.07E-03 
hsa-miR-133b 7.59 3.07E-12 hsa-miR-99a-5p 3.48 1.39E-03 
hsa-miR-206 8.66 6.39E-11 hsa-miR-204-5p 4.98 1.39E-03 




hsa-miR-196b-5p -4.48 8.78E-09 hsa-miR-503 -4.23 1.80E-02 
hsa-miR-135a-5p 6.01 1.87E-08 hsa-miR-1246 -4.07 2.03E-02 
hsa-let-7c-5p 3.78 2.48E-08 hsa-miR-630 -3.10 2.39E-02 
hsa-miR-133a-5p 7.79 3.31E-08 hsa-miR-455-5p -4.36 3.35E-02 
hsa-miR-1246 -4.42 3.74E-08 hsa-miR-196b-5p -4.05 4.19E-02 
hsa-miR-204-5p 3.64 4.35E-07 hsa-miR-23b-3p 2.74 4.24E-02 
hsa-miR-99a-3p 3.23 5.40E-07 hsa-miR-381 3.98 4.45E-02 
hsa-miR-381-3p 3.68 9.62E-07 hsa-miR-378a-3p 2.36 4.58E-02 
hsa-miR-561-5p 4.28 7.10E-06 hsa-miR-378i 2.36 4.58E-02 
hsa-miR-499a-5p 3.91 2.45E-05 hsa-miR-31-5p -2.86 4.58E-02 
hsa-miR-146b-5p -3.09 3.34E-05 hsa-miR-663b -4.19 4.58E-02 
hsa-miR-455-3p -2.85 6.44E-05 hsa-miR-944 -3.66 5.52E-02 
hsa-miR-6510-3p 3.23 1.11E-04 hsa-miR-29c-3p 2.07 5.52E-02 
hsa-miR-2355-5p -3.42 1.50E-04 hsa-miR-455-3p -4.09 6.02E-02 
hsa-miR-125b-2-3p 2.59 1.50E-04 hsa-miR-4286 -2.57 7.40E-02 
hsa-miR-10a-5p -3.11 2.44E-04 hsa-miR-518b 3.12 7.40E-02 
hsa-miR-378i 2.80 2.55E-04 hsa-miR-299-5p 3.34 1.07E-01 
hsa-miR-21-5p -2.98 2.55E-04 hsa-miR-421 -3.02 1.45E-01 
hsa-miR-99a-5p 2.73 2.59E-04 hsa-let-7c 1.92 1.69E-01 
hsa-miR-378c 2.33 5.01E-04 hsa-miR-30c-5p 2.95 2.33E-01 
hsa-miR-1247-3p 3.46 5.25E-04 hsa-miR-135b-5p -1.74 2.33E-01 
hsa-miR-3607-3p 3.60 6.16E-04 hsa-miR-133b 3.13 2.36E-01 
hsa-miR-1247-5p 2.64 6.72E-04    
hsa-miR-31-3p -3.13 8.24E-04    
hsa-miR-211-5p 4.30 9.05E-04    
hsa-miR-1269a -6.23 9.62E-04    
hsa-miR-4770 4.13 1.29E-03    
hsa-miR-135b-5p -2.30 1.44E-03    
hsa-miR-450b-5p -2.24 1.61E-03    
hsa-miR-365a-5p -3.08 1.84E-03    
hsa-miR-96-5p -2.32 2.19E-03    
hsa-miR-139-5p 2.50 2.79E-03    
hsa-miR-1251-5p 6.00 2.84E-03    
hsa-let-7c-3p 3.26 3.24E-03    
hsa-miR-1910-5p -3.27 3.48E-03    
hsa-miR-3129-3p -3.76 3.77E-03    
hsa-miR-136-3p 2.31 4.77E-03    
hsa-miR-4776-5p 5.64 4.86E-03    
hsa-miR-378f 3.00 5.03E-03    
hsa-miR-1301-3p -3.07 5.11E-03    
hsa-miR-193b-5p -2.60 5.41E-03    
hsa-miR-582-3p 2.79 5.75E-03    
hsa-miR-7-5p -2.60 8.30E-03    
hsa-miR-455-5p -1.93 9.17E-03 	 	 	




hsa-miR-378d 2.21 9.80E-03 	 	 	
hsa-miR-31-5p -2.57 1.03E-02 	 	 	
hsa-miR-941 -2.09 1.16E-02 	 	 	
hsa-miR-10a-3p -2.65 1.26E-02 	 	 	
hsa-miR-7705 -2.55 1.37E-02 	 	 	
hsa-miR-301b -1.90 1.40E-02 	 	 	
hsa-miR-454-3p -1.82 1.40E-02 	 	 	
hsa-miR-193b-3p -2.14 1.43E-02 	 	 	
hsa-miR-4662a-5p -2.89 1.43E-02 	 	 	
hsa-miR-101-3p 2.05 1.55E-02 	 	 	
hsa-miR-4640-3p -5.33 2.45E-02 	 	 	
hsa-miR-335-3p -2.05 2.58E-02 	 	 	
hsa-miR-619-5p -2.64 3.01E-02 	 	 	
hsa-miR-378a-3p 2.00 3.69E-02 	 	 	
hsa-miR-92b-3p -1.87 4.15E-02 	 	 	
hsa-miR-183-5p -2.68 4.15E-02 	 	 	
hsa-miR-130b-3p -1.64 4.26E-02 	 	 	
hsa-miR-146b-3p -1.75 4.54E-02 	 	 	
hsa-miR-4429 5.28 4.65E-02 	 	 	
hsa-miR-5701 2.25 4.87E-02 	 	 	
hsa-miR-3065-3p 2.06 4.97E-02 	 	 	
hsa-miR-1276 -3.26 5.28E-02 	 	 	
hsa-miR-6842-3p -3.63 5.63E-02 	 	 	
hsa-miR-146a-5p -2.07 5.63E-02 	 	 	
hsa-miR-3679-5p -5.21 5.73E-02 	 	 	
hsa-miR-421 -1.49 5.97E-02 	 	 	
hsa-miR-503-5p -2.84 5.99E-02 	 	 	
hsa-miR-431-3p 2.68 6.00E-02 	 	 	
hsa-miR-1271-3p -4.82 6.95E-02 	 	 	
hsa-miR-584-5p -1.73 8.65E-02 	 	 	
hsa-miR-4521 2.83 9.30E-02 	 	 	
hsa-miR-22-5p -1.67 9.30E-02 	 	 	
hsa-miR-212-3p -2.07 9.42E-02 	 	 	
hsa-miR-5089-3p 4.43 9.54E-02 	 	 	
hsa-miR-542-5p -1.99 9.61E-02 	 	 	
hsa-miR-125b-5p 1.71 9.66E-02 	 	 	
hsa-miR-203b-5p 4.46 9.85E-02 	 	 	
hsa-miR-3653 2.52 9.85E-02 	 	 	
hsa-miR-424-5p -1.64 9.96E-02 	 	 	
hsa-miR-422a 2.39 1.00E-01 	 	 	
hsa-miR-512-3p -3.46 1.00E-01 	 	 	
hsa-miR-183-3p -2.32 1.00E-01 	 	 	
hsa-miR-4713-5p -3.10 1.02E-01 	 	 	
hsa-miR-5096 -1.99 1.05E-01 	 	 	




hsa-miR-1290 -2.48 1.18E-01 	 	 	
hsa-miR-450a-5p -1.91 1.19E-01 	 	 	
hsa-miR-187-3p 1.97 1.21E-01 	 	 	
hsa-miR-3687 -2.79 1.24E-01 	 	 	
hsa-miR-1262 3.32 1.25E-01 	 	 	
hsa-miR-424-3p -2.04 1.25E-01 	 	 	
hsa-miR-5700 -4.85 1.27E-01 	 	 	
hsa-miR-25-5p -1.73 1.30E-01 	 	 	
hsa-miR-431-5p -1.69 1.31E-01 	 	 	
hsa-miR-141-5p -1.61 1.33E-01 	 	 	
hsa-miR-671-5p -1.83 1.33E-01 	 	 	
hsa-miR-615-5p -4.66 1.33E-01 	 	 	
hsa-miR-365a-3p -1.57 1.37E-01 	 	 	
hsa-miR-365b-3p -1.57 1.37E-01 	 	 	
hsa-miR-296-3p 2.12 1.48E-01 	 	 	
hsa-miR-4652-5p -4.56 1.48E-01 	 	 	
hsa-miR-18a-5p -1.70 1.60E-01 	 	 	
hsa-miR-4326 -2.01 1.61E-01 	 	 	
hsa-miR-6509-5p -4.44 1.62E-01 	 	 	
hsa-miR-194-3p 4.19 1.68E-01 	 	 	
hsa-miR-598-3p 1.69 1.77E-01 	 	 	
hsa-miR-4449 1.61 1.88E-01 	 	 	
hsa-miR-30a-5p 1.52 1.94E-01 	 	 	
hsa-miR-501-3p -1.38 2.03E-01 	 	 	
hsa-miR-548a-3p -3.12 2.06E-01 	 	 	
hsa-miR-4775 -1.82 2.21E-01 	 	 	
hsa-miR-203b-3p 2.43 2.25E-01 	 	 	
hsa-miR-105-3p -4.49 2.25E-01 	 	 	
hsa-miR-21-3p -1.96 2.40E-01 	 	 	
hsa-miR-149-5p 1.37 2.43E-01 	 	 	
hsa-miR-30a-3p 1.62 2.43E-01 	 	 	
hsa-miR-9-3p -4.17 2.48E-01 	 	 	
hsa-miR-136-5p 1.85 2.48E-01 	 	 	
Table 8-6: Differentially expressed miRNAs between nodal metastases with ECS 
and matched normal epithelium. 
 
miRNASeq nCounter 








hsa-miR-375 9.30 6.56E-19 hsa-miR-1246 -9.64 2.68E-20 
hsa-miR-196a-5p -6.86 4.21E-08 hsa-miR-375 6.34 1.98E-05 
hsa-miR-3168 11.10 3.80E-05 hsa-miR-21-5p -3.87 1.43E-04 
hsa-miR-211-5p 7.46 1.40E-04 hsa-miR-146b-5p -5.37 5.70E-04 




hsa-miR-133b 6.75 1.96E-04 hsa-miR-181b-5p -4.66 7.36E-04 
hsa-miR-615-3p -7.87 2.25E-04 hsa-miR-181d -4.66 7.36E-04 
hsa-miR-196b-5p -4.86 2.25E-04 hsa-miR-18a-5p -4.52 1.46E-03 
hsa-miR-21-3p -4.22 2.54E-04 hsa-miR-455-5p -4.38 2.58E-03 
hsa-miR-99a-5p 3.97 2.83E-04 hsa-miR-93-5p -1.70 3.10E-03 
hsa-miR-133a-3p 5.66 3.07E-04 hsa-miR-28-5p -3.74 3.10E-03 
hsa-miR-1 7.27 7.61E-04 hsa-miR-296-5p -4.30 3.10E-03 
hsa-let-7c-5p 2.76 8.37E-03 hsa-miR-125a-5p -1.77 3.70E-03 
hsa-miR-6510-3p 3.35 9.02E-03 hsa-miR-503 -4.79 3.70E-03 
hsa-miR-100-5p 2.62 1.75E-02 hsa-miR-99a-5p 2.06 4.30E-03 
hsa-miR-203a 3.33 2.15E-02 hsa-miR-455-3p -4.64 5.26E-03 
hsa-miR-196a-3p -6.18 6.16E-02 hsa-miR-183-5p -3.58 7.65E-03 
hsa-miR-139-3p 4.86 7.13E-02 hsa-miR-106b-5p -1.54 1.10E-02 
hsa-miR-4776-5p 5.24 7.65E-02 hsa-miR-196a-5p -4.05 1.10E-02 
hsa-miR-4770 -6.62 8.98E-02 hsa-miR-182-5p -4.24 1.10E-02 
hsa-miR-6842-3p -5.68 8.98E-02 hsa-miR-155-5p -3.01 1.10E-02 
hsa-miR-21-5p -2.14 9.65E-02 hsa-miR-143-3p -5.35 1.43E-02 
hsa-miR-125b-5p 2.19 9.65E-02 hsa-miR-221-3p -1.65 1.58E-02 
hsa-miR-1247-5p 2.67 9.65E-02 hsa-miR-34c-5p -4.38 2.81E-02 
hsa-miR-31-5p -2.63 1.46E-01 hsa-miR-203 2.67 2.81E-02 
hsa-miR-1269a -5.91 1.46E-01 hsa-miR-421 -3.78 2.81E-02 
hsa-miR-187-3p -2.61 1.74E-01 hsa-let-7e-5p -1.33 3.33E-02 
hsa-miR-125b-2-3p 2.31 1.74E-01 hsa-miR-2682-5p -3.82 3.33E-02 
hsa-miR-424-3p -3.04 1.74E-01 hsa-miR-454-3p -3.72 4.03E-02 
hsa-miR-139-5p 2.27 2.41E-01 hsa-miR-206 4.75 4.18E-02 
hsa-miR-940 -3.73 2.41E-01 hsa-miR-130a-3p -1.26 4.78E-02 
hsa-miR-141-3p 2.11 2.41E-01 hsa-miR-450a-5p -3.43 5.35E-02 
	 	 	 hsa-miR-25-3p -1.23 6.00E-02 
	 	 	 hsa-let-7c 1.34 6.28E-02 
	 	 	 hsa-miR-324-5p -2.73 6.28E-02 
	 	 	 hsa-miR-196b-5p -3.69 6.28E-02 
	 	 	 hsa-miR-133a 4.15 6.72E-02 
	 	 	 hsa-miR-96-5p -3.00 8.45E-02 
	 	 	 hsa-miR-944 -3.45 8.54E-02 
	 	 	 hsa-miR-132-3p -2.87 8.71E-02 
	 	 	 hsa-miR-31-5p -3.55 8.71E-02 
	 	 	 hsa-let-7i-5p -1.22 9.91E-02 
	 	 	 hsa-miR-548ah-5p -3.19 9.99E-02 
	 	 	 hsa-miR-106a-5p -1.18 1.01E-01 
	 	 	 hsa-miR-17-5p -1.18 1.01E-01 
	 	 	 hsa-miR-1290 -2.74 1.10E-01 
	 	 	 hsa-miR-15b-5p -1.27 1.51E-01 
	 	 	 hsa-miR-181a-5p -1.21 1.51E-01 
	 	 	 hsa-miR-15a-5p -1.15 1.51E-01 




	 	 	 hsa-miR-19b-3p -1.07 1.57E-01 
	 	 	 hsa-miR-7-5p -2.39 2.05E-01 
	 	 	 hsa-miR-130b-3p -2.37 2.07E-01 
	 	 	 hsa-miR-1180 -3.14 2.12E-01 
	 	 	 hsa-miR-331-3p	 -2.43	 2.35E-01	
	 	 	 hsa-miR-125b-5p	 1.46	 2.35E-01	
Table 8-7: Differentially expressed miRNAs between nodal metastases without 
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